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BACKGROUND AND PURPOSE  
Prostaglandin E2 (PGE2) is an inflammatory mediator synthesized by the brain constitutive 
cyclooxygenase (COX) enzyme, whose activity is blocked by the nonsteroidal anti-
inflammatory drugs (NSAIDs). PGE2 binds to G protein-coupled EP1-4 receptors (EP1 to Gq, 
EP2 and EP4 to Gs, and EP3 to Gi/o). Activation of EP receptors by PGE2 has been shown to 
modulate the synaptic transmission and neuronal activity in various brain regions, such as in 
the hippocampus, the hypothalamus, and the periaqueductal grey. One of the areas that 
expresses EP2, EP3, and EP4 receptors is the LC, the main noradrenergic nucleus in the brain, 
which is involved in the regulation of the sleep-wake cycle, arousal, cognition, pain, and reward 
behavior. To date, the role of EP receptors in regulating the neuronal activity of LC 
noradrenergic cells has not been elucidated. Therefore, our main aim was to pharmacologically 
characterize the EP2, EP3, and EP4 receptors in the rat LC by recording the firing activity of 
LC cells by electrophysiological techniques in vitro. We also studied the interaction between 
the prostanoid and the opioid systems by live time-lapse calcium imaging in the mice 
preBötzinger complex (preBötC), the central inspiratory pattern generator. It has been shown 
that preBötC inspiratory neurons express µ-opioid receptors (MOR) and respond to PGE2. 
Thus, administration of PGE2 increases the frequency of sighs and induces gasps under hypoxic 
circumstances, while opioid receptor agonists produce respiratory depression through their 
action in the preBötC. However, the possible interaction between both systems to induce major 
respiratory disturbances remains to be studied.  
 
EXPERIMENTAL APPROACH  
In the first, second, and third studies, we characterized the effects of EP2, EP3, and EP4 
receptor agonists by single-unit extracellular electrophysiological techniques in rat brain slices 
of the LC. For this purpose, we perfused agonists of EP receptors in the absence and presence 
of selective EP receptor antagonists or different modulators of EP receptor signaling 
mechanisms. In the fourth study, we tested the effect of PGE2 and the MOR agonist DAMGO 
and their combination by live time-lapse calcium imaging on preBötC organotypic slices from 
both wild-type mice (WT) and mice lacking the EP3 receptor (Ptger3-/-).  
 
 
KEY RESULTS  
STUDY I 
The EP3 receptor agonist sulprostone (0.15 nM – 1.28 µM), the endogenous PGE2 (0.31 nM – 
10.2 µM), and the PGE1 analogue misoprostol (0.31 nM – 2.56 µM) inhibited the firing rate of 
LC neurons in a concentration-dependent manner (EC50=15 nM, 51 nM, and 110 nM, 
respectively). The EP3 receptor antagonist L-798,106 (10 µM), but not the EP2 (PF-04418948, 
10 µM) or EP4 (L-161,982, 10 µM) receptor antagonists, caused a more than 8-fold rightward 
shift in the concentration-effect curves for the EP3 receptor agonists. The sulprostone-induced 
effect was attenuated by the Gi/o-protein blocker pertussis toxin (PTX, 500 ng ml-1) and the 
inhibitors of inwardly rectifying potassium channels (GIRK) BaCl2 (300 µM) and SCH-23390 
(15 µM).  
STUDY II 
The EP2 receptor agonist butaprost (0.01-10 μM) and the prostacyclin (PGI2) analog 
treprostinil (0.03-10 µM) increased the firing rate of LC neurons in a concentration-dependent 
manner (EC50=0.45 µM and 0.54 µM; Emax=74.3% and 81.3%; respectively). The selective 
EP2 receptor antagonist PF-04418948 (10 nM), but not the EP3 (L-798,106, 10 nM) or EP4 
(L-161,982, 10 nM) receptor antagonists, hindered the excitatory effect of butaprost and 
treprostinil. Furthermore, extracellular sodium replacement and a Gβγ blocker (gallein, 20 μM) 
prevented the butaprost-induced increase in the firing activity of LC cells. However, the 
excitatory effect caused by butaprost was not reduced by a PKA activator (8-Br-cAMP, 1 mM) 
or a PKA inhibitor (H-89, 10 μM). This effect was not modified by synaptic blockade or by 
inhibitors of the Gαs subunits (NF449, 10 µM), hyperpolarization-activated cyclic nucleotide-
gated (HCN) channels (ZD7288, 30 µM), transient receptor potential (TRP) channels (2-APB, 
30 µM), and Kir6.2 channels (glibenclamide 3 µM). 
STUDY III 
The EP4 receptor agonists rivenprost (0.01 nM – 1 µM) and TCS 2510 (0.20 nM – 2 µM) 
increased the firing rate of LC cells in a concentration-dependent manner (EC50=1.43 nM and 
18.0 nM; Emax=83.7% and 98.4%; respectively). The selective EP4 receptor antagonist L-
161,982 (30 and 300 nM) hindered the excitatory effect caused by rivenprost and TCS 2510, 
whereas the EP2 (PF-04418948, 300 nM) or EP3 (L-798,106, 300 nM) receptor antagonists 
did not reduce it. Furthermore, extracellular sodium replacement and a Gαs blocker (NF449, 10 
μM) prevented the rivenprost-induced stimulation of neuronal activity. However, the excitatory 
 
 
effect caused by rivenprost was not attenuated by a PKA activator (8-Br-cAMP, 1 mM) or a 
PKA inhibitor (H-89, 10 µM), nor was it reduced by a phosphatidylinositol 3-kinase (PI3K) 
blocker (wortmannin, 100 nM), a PKC inhibitor (chelerythrine, 10 µM) or a Gβγ signaling 
blocker (gallein, 20 µM). Furthermore, previous administration of the EP2 receptor agonist 
butaprost (1 µM) did not occlude the excitatory effect caused by rivenprost, suggesting that 
EP2 and EP4 receptors may not share the same signaling pathway to stimulate LC neurons. 
STUDY IV 
DAMGO (0.5 and 5 µM) or PGE2 (10 and 100 nM) reduced the Ca2+ transient frequency of 
the whole cell population and respiratory neurons of the preBötC in WT. Notably, in Ptger3-/- 
mice, the inhibitory effect of PGE2 on Ca2+ transient frequency was absent, and the effect 
caused by DAMGO (5 μM) was delayed on time comparing to WT mice. This result suggests 
an interaction between the prostanoid and the opioid systems. Moreover, application of 
DAMGO in the presence of PGE2 did not further reduce the Ca2+ oscillatory activity, which 
suggests that they probably share a common signaling pathway. Indeed, the phosphodiesterase 
4 blocker rolipram (5 µM) and the GIRK channel blocker SCH-23390 (15 µM) prevented both 
DAMGO- and PGE2-induced reduction in Ca2+ oscillatory activity, suggesting a mutual 
dependency on the cAMP pathway and GIRK channels. Finally, both DAMGO and PGE2 
reduced the cellular connectivity and synchronicity and increased the segregation into local cell 
clusters. The effects of DAMGO on the network connectivity and topology were abolished by 
rolipram and SCH-23390, whereas the effect of PGE2 was partially hindered by rolipram.  
 
CONCLUSIONS AND IMPLICATIONS  
Firing activity of LC neurons is regulated in an inhibitory manner by EP3 receptors, 
presumably by a Gi/o protein and GIRK-mediated mechanism. In addition, activation of EP2 or 
EP4 receptors may excite LC noradrenergic neurons through a Gβγ and Gαs-dependent 
regulation of sodium currents. On the other hand, PGE2 inhibits the preBötC cellular activity 
and interferes with the opioid-induced respiratory depression. Given the role of the LC and the 
preBötC in the regulation of nociception and its affective component, as well as in the induction 
of fever, anxious states, and the inspiratory pattern, the presence of the prostanoid system in 
these brain areas may constitute a suitable target for the treatment of neuropsychiatric or 
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Prostaglandins are associated with the immune system, as they are released in response to 
harmful stimuli and constitute the main immune messenger across the blood-brain barrier 
(BBB)1. Furthermore, common painkillers exert an anti-inflammatory effect by blocking the 
synthesis of prostaglandins. However, several pieces of evidence broaden the role of 
prostaglandins as brain mediators under non-inflammatory conditions, considering they are 
found constitutively present in the brain2 and integrate a part of the glial-neuronal signaling3,4. 
Additionally, prostaglandins modulate the neuronal activity5, which raises the question of 
whether they are key mediators within the central nervous system (CNS).  
1.1 PROSTANOIDS 
Prostanoids, as a subclass of eicosanoids, are lipid compounds involved in many physiological 
and pathophysiological processes, including vasodilation, reproduction, and inflammation6. 
They are comprised by the prostaglandins, prostacyclins (PGI2), and thromboxanes (TX; such 
as the TXA2) (Figure 1.1). Prostaglandins were first isolated in 1935 from the prostate gland 
and seminal fluid by M.W. Goldblatt and U.S. von Euler7. The most widely synthesized 
prostaglandin in mammals is the prostaglandin E2 (PGE2)8,9, although other types, such as the 
prostaglandin D2 (PGD2) or prostaglandin F2α (PGF2α) also have important physiological roles.  
1.1.1 Synthesis, transport, and metabolism 
Prostanoids are synthesized and immediately released, without being stored10. Then, they work 
in an autocrine or paracrine manner11, in part limited by their short half-life12. For these reasons, 
the content of PGE2 is determined by its synthetic and degradative enzymatic activity11.  
PGE2 is synthesized from membrane phospholipids, which are converted into arachidonic acid 
(AA) by the phospholipase A2 (PLA2) enzyme. Then, the AA can be transformed by the 
cyclooxygenase enzyme (COX) into an unstable precursor of prostanoids; the prostaglandin 






Figure 1.1. Illustrative drawing of PGE2 synthesis from membrane phospholipids14. NSAIDs block the synthesis 
of prostanoids. 
The rate-limiting enzyme for the synthesis of prostaglandins is the COX enzyme, which 
enzymatic activity is blocked by common painkillers or nonsteroidal anti-inflammatory drugs 
(NSAIDs), such as ibuprofen or naproxen (Figure 1.1). There are mainly two COX subtypes, 
COX-1 and COX-2, although a third subtype COX-3 has been described as a splice variant of 
the COX-115. All the subtypes are constitutively present in the CNS16,17, although the COX-2 
is considered to be an inducible enzyme in the rest of the body. Specifically, COX-2 has been 
found active in the spinal cord18–20, locus coeruleus (LC)21, paraventricular hypothalamic 
nucleus22, hippocampus, and cerebral cortex10,23. At the cellular level, COX-1 is mainly 
expressed in microglia and endothelial cells, while COX-2 is localized in postsynaptic 
dendrites and excitatory terminals24. PGE2 is primarily synthesized by the COX-2, as shown 
by a reduction in brain PGE2 concentration due to selective COX-2 blockers25,26 or mice 
lacking COX-227. In fact, mice lacking COX-1 show higher concentration of PGE2 due to a 
compensatory upregulation of COX-228. Therefore, these data indicate that COX-2 is involved 
in the synthesis of PGE2 on basal conditions. 
As abovementioned, other enzymes take part in the synthesis of PGE2, including the PLA2 and 
the PGES. The former is expressed predominantly in neurons of the medulla oblongata, pons 
and epiphysis, and glial cells of the choroid plexus29. It is localized in dendritic spines30, and 
when released to the extracellular medium, it can promote the transcellular generation of PGE2 
by the neighboring cells31. On the other hand, the PGES isozymes are classified into cytosolic 
(cPGES) and microsomal PGES (mPGES-1 and mPGES-2). In basal conditions, brain 
constitutive mPGES is found in endothelial cells, astrocytes and choroid plexus32. However, 
upon immune stimulation, mPGES-1 and COX-2 coexpression is upregulated in the 
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vasculature22,32,33, and as a consequence, the production of PGE2 increases almost 
immediately33–35. Thus, inflammatory signals, including the cytokines interleukin IL-1β36–38 
and tumor necrosis factor α (TNFα)39, are the principal inducers of the PGE2 formation. 
Endogenous synthesis of PGE2 can also be stimulated upon regular synaptic activity10, as seen 
after administration of a 5-HT2A/2C receptor agonist in the LC40 or a CB1 receptor agonist in 
the hippocampus41.  
Once synthesized in the cytoplasm, PGE2 becomes anionic at physiologic pH, so it needs to be 
actively transported by the prostaglandin transporter (PGT)42,43 and organic anion transporter 
(OAT)44. This active transport mechanism is also responsible for the clearance of PGE2, which 
half-life is 3.4 min in the cerebrospinal fluid (CSF)12 and 16.3 min in the cerebral cortex45. 
PGE2 undergoes a final elimination by the cytoplasmic prostaglandin 15 dehydrogenase46, 
whose activity in the choroid plexus is very low at adult stages47. Therefore, it seems likely that 
PGE2 crosses the BBB in its intact form through the specific transporters and then undergoes 
peripheral metabolism45, mostly in liver and lungs47. 
1.1.2 Prostanoid receptors: distribution and signaling transduction pathways 
PGE2 targets eicosanoid prostanoid (EP) receptors, which are members of the G protein-
coupled receptor superfamily principally located on the cell membrane48, although they have 
also been found in the cytoplasm and perinuclear regions49–52. Upon ligand binding, the G 
protein forms a complex with the receptor, which conformational change dissociates the Gα 
subunit from the Gβγ dimer. Both Gα and Gβγ can activate downstream proteins to amplify the 
signal transduction53. Four subtypes of G protein-coupled EP receptors have been cloned so 
far: EP1, EP2, EP3, and EP4. 
In the brain, EP1 receptor mRNA expression is almost restricted to Purkinje cells of the 
cerebellum, whereas one of the lowest expression levels in the brain is found in the brainstem54. 
EP1 receptor couples to Gq protein, and its activation leads to an influx of extracellular 
calcium55. However, coupling to Gi/o as a secondary pathway has also been proposed56. 
In situ hybridization signal for EP2 mRNA is predominantly found in the hippocampus, 
amygdala, and hypothalamus. By contrast, in the brainstem, the signal for EP2 mRNA is 
scarcely present and almost exclusively found in the LC, where it shows a moderate signal57. 
EP2 receptor couples to Gs protein and its stimulation results in an adenylate cyclase activation 
and increase of cAMP concentration (Figure 1.2)58, which in turn activates the protein kinase 
A (PKA) and/or the hyperpolarization-activated, cyclic nucleotide-gated cationic (HCN) 
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channels59. Phylogenetically, the EP2 receptor shows higher homology with the PGI2-IP and 
PGD2-DP1 receptors than with other EP receptors, such as the EP4 receptor (Figure 1.2)60 with 
which it only shares the 31% of the amino acid identity61.  
EP3 mRNA expression is widely shown across the CNS62. In particular, an intense mRNA 
signal is found in the median preoptic nucleus of the hypothalamus, substantia nigra, LC, raphe 
nuclei, nucleus of the solitary tract (NTS), and ventrolateral medulla62–64. In these regions, such 
as the LC, inflammatory signals like IL-1β do not further upregulate the EP3 expression63, 
since it is already prominent. The EP3 receptor has a neuronal preference62,65,66, even though 
cultured glial cells also show some expression67 possibly in response to excitotoxicity68. Apart 
from the cellular membrane, the EP3 receptor has been detected at the nuclear level in cerebral 
endothelial cells, which activation induces the transcription of the endothelial nitric oxide 
synthase50,51. Furthermore, several splicing isoforms (EP3α, EP3β, and EP3γ) have been 
described in mice, rats, and humans69–74, with the EP3α isoform being the most prominently 
expressed69,75. EP3 receptors mainly couple to Gi/o protein, but since the splicing isoforms differ 
in the C-terminal69,72, coupling to the G protein and constitutive activity can vary. Indeed, EP3α 
and EP3γ have constitutive activity in receptor overexpressing cultured cells (Figure 1.2)76,77 
and EP3γ can also couple to Gs78.  
EP4 mRNA signal is most abundant in the supraoptic nucleus, followed by the posterior 
hypothalamus, the LC and the cerebellum, and to a lesser extent in the dorsal raphe and NTS57. 
These areas are activated in response to an acute inflammatory insult, as demonstrated by 
higher c-Fos immunoreactivity, which suggests that the EP4 receptor signaling is involved57. 
In contrast to the EP2 receptor, the EP4 has a long C-tail that allows its desensitization and 
recycling (Figure 1.2)79,80. EP4 receptor mainly couples to Gs protein, which activation by an 
agonist leads to cAMP formation61. However, an additional Gi/o protein-dependent pathway 
has been described, with the subsequent involvement of the phosphatidylinositol 3-kinase 




Figure 1.2. A) Different types of prostanoids and their specific receptors. B) Phylogenetic tree of prostanoid 
receptors60. C) PGE2-EP receptors and their associated G-protein coupling, signaling transduction, desensitization 
ability, and constitutive activity61. 
1.1.3 Physiological and pathophysiological roles of the prostanoid system  
The prostanoid system serves as a mediator in the inflammatory response to toxic compounds 
or traumatic injuries. In the first instance, the toxicity derives from either biological or 
xenobiotic substances; including drugs, microorganisms, and health conditions (e.g., ischemia 
or Alzheimer’s disease). In the second instance, traumatic injuries promote the release of 
prostaglandins that might compromise the well-being by producing pain.  
Some drugs and toxic compounds such as fluoxetin83, amphetamines84, alcohol85 or 
carrageenan11 may produce an inflammatory state, also in the brain. In response to either pro-
inflammatory drugs or threatening pathogens, like those containing the component of the 
bacterial wall lipopolysaccharide (LPS), immune cells respond by releasing a cascade of 
signaling molecules. These include the cytokines IL-1β, IL-6 or TNF-α, and prostaglandins, 
which serve to attract other cells to the site of inflammation by vasodilation or to spread the 
signal throughout the body6,86. The cytokines, however, are too bulky and hydrophilic to cross 
the BBB, so they promote prostaglandin entrance87 or prostaglandin synthesis in the brain 
vascular cells22 and CSF88. Once PGE2 is synthesized, its local release adjacent to hypothalamic 
neurons89,90 can trigger inflammatory fever by binding to EP3 receptors (Figure 1.3)5,91,92. 
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Therefore, prostaglandins are lipid inflammatory mediators that coordinate the immune-to-
brain signaling1.  
 
Figure 1.3. Representation of how peripheral inflammation can trigger fever by PGE2 synthesis in endothelial 
cells of the brain that are close to the median preoptic nucleus of the hypothalamus (MnPO)92. 
Prostaglandins are closely related to blood vessels, not only because they can be synthesized 
in the endothelium in response to inflammatory signals, but also because PGE2 has a role in 
neurovascular coupling. Neurons synthesize and release PGE2 upon neuronal activation to 
adapt the supply of O2 and glucose from blood vessels by EP2 and EP4-dependent 
vasodilation23. As a consequence, signaling via the EP2 receptor could have neuroprotective 
effects in cerebral ischemia93. Conversely, activation of EP3 receptors has deleterious effects 
in stroke and excitotoxicity94 due to vasoconstriction, and it further increases the blood pressure 
by its action in the rostral ventrolateral medulla (RVLM)95 and hypothalamic paraventricular 
nucleus96. Likewise, inhibitory EP3 receptors hinder the breathing pattern generation97 and the 
response to hypoxic events98, leading to sighs and gasps, particularly in neonates (Table 1.1)99. 
With regard to additional pathophysiological events in the brain, PGE2 has been linked to 
psychiatric and neurologic disorders. Depression and inflammation are closely related as 
depressed patients have higher levels of plasmatic cytokines6. Furthermore, LPS-induced PGE2 
synthesis leads to a depressive-like behavior100, and thereby, COX-2 inhibitors can be effective 
against depression6. In addition, PGE2 may be involved in many neurologic disorders as 
showed by the increased levels of PGE2 in CSF (Table 1.1). Patients of Alzheimer’s disease 
have higher COX-2 mRNA levels in the brain16 and higher PGE2 levels in CSF compared to 
controls (Table 1.1)101. Furthermore, PGE2 impairs the long-term hippocampal plasticity102 and 
increases the expression of the β-amyloid precursor protein, which deposition is thought to 
contribute to Alzheimer’s neuropathology103. 
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Disease PGE2 levels in CSF 
Alzheimer's disease 
Increased by 5 fold in early Alzheimer's disease but declined with 
progressive cognitive impairment 
Amyotrophic lateral 
sclerosis 
Increased by 2 to 10 fold 
Creutzfeldt-Jakob 
disease 
Increased by 6 fold in patients with sporadic, familial forms or variant 
Creutzfeldt-Jakob disease 
Ischemic stroke Increased by 2 fold during initial 72 h 
HIV-associated 
dementia 
Increased by 40% in all HIV-seropositive patients and positively correlated 
with the degree of cognitive impairment 
Hypoxic-ischemic 
encephalopathy 
Increased PGE2 metabolite in newborns with hypoxic-ischemic 
encephalopathy and positively correlated with severity and outcome 
Table 1.1. PGE2 levels in CSF from human patients with neurologic diseases compared to controls (Adapted 
from 101,104). 
Regarding nociception, PGE2 contributes to hyperalgesia and allodynia (increased pain 
perception to both noxious and non-noxious stimuli, respectively). This sensitization is 
observed after both peripheral and central activation of EP receptors. Thus, intraplantar 
administration of PGE2 results in hyperalgesia105 at least due to EP4 receptor activation106. 
Under inflammatory conditions, the EP4 receptor is upregulated in the dorsal root ganglion 
(DRG)107, ultimately promoting the excitatory nociceptive signal transmission80,82. By contrast, 
this EP4-dependent sensitization can be counteracted by DRG EP3 receptor activation108. 
Concerning central activation of EP receptors, spinal intrathecal administration of PGE2 
produces hyperalgesia109,110 and allodynia111 via an EP2 receptor-dependent blockade of 
glycinergic inhibitory transmission in the spinal cord112. Furthermore, selective activation of 
EP1, EP2, and EP3 receptors in the periaqueductal gray matter (PAG) decreases the nociceptive 





The brainstem, located in the caudal part of the brain, is the most primitive part of the CNS116 
and composed of the midbrain, the pons, and the medulla oblongata. It coordinates many 
primary and autonomic functions. For example, the LC regulates nociception, wakefulness, 
and arousal states, among others. It was not until the time of the French revolution that those 
vital functions of the brainstem became apparent, including breathing117. The respiratory 
rhythm, necessary to supply the organism with O2, is generated by the preBötzinger complex 
(preBötC), but it is finely tuned by chemosensitive areas or emotional states118. Although both 
the LC and preBötC differ in morphology, they share numerous features. For instance, both 
express pain-related receptors (substance P-NK, PGE2-EP3) and μ-opioid receptors 
(MOR)97,119–121 and are involved in the regulation of breathing. Furthermore, both regions are 
anatomically connected. Thus, LC neurons receive excitatory afferents from the preBötC122,123 
and may provide excitatory input to the respiratory rhythm generator124–126. 
1.2.1 Locus coeruleus 
1.2.1.1 Anatomy of the LC 
The LC (A6) is the richest noradrenaline (NA)-containing nucleus in the CNS and the main 
site for NA synthesis116. It is a pontine nucleus first described by Reil in 1809, although its 
name was proposed by Wenzel and Wenzel in 1812127, meaning “blue spot” in Latin as this 
was the nucleus in fresh tissue. The color is caused by the polymerization of NA into 
melanin128. The LC is located bilaterally on the lateral border of the 4th ventricle, surrounded 
by the mesencephalic nucleus of the trigeminal nerve (Me5) and the medial parabrachial 
nucleus (MPN) (Figure 1.4)129. Rostro-caudally, the LC measures around 480 μm and contains 




Figure 1.4. Coronal view of the rat brain showing the location of the LC near the 4th ventricle. A zoomed area 
shows a NA neuron filled with biocytin. The dark area (TH immunoreactivity) delineates the LC (Adapted from 
130,131).  
The vast majority of the neurons are noradrenergic and contain tyrosine hydroxylase (TH), 
defining a compact and homogeneous nucleus116. Despite its uniformity, the cells within the 
nucleus display some degree of specialization. First, two types of NA neurons can be 
distinguished by staining with Nissl and for dopamine-β-hydroxylase (DBH): large multipolar 
and small fusiform cells, with the latter composing of about the 25% of the neurons, 
predominantly found in the dorsal part of the LC (Figure 1.5)129,132. Second, a subset of NA 
neurons co-releases either galanin or neuropeptide Y (Figure 1.5)133, although vasopressin, 
corticotropin-releasing factor, enkephalin, and tachykinin peptides can also be found. Third, 
LC neurons projecting to the prefrontal cortex show higher firing rate (FR), and higher 
expression of voltage-gated sodium channels (Nav) and ionotropic glutamate receptors (Figure 
1.5) than those projecting to the motor cortex134. Finally, the differences are expressed in 
behavioral tests, as specific activation of LC neurons projecting to the prefrontal cortex results 
in anxiety, whereas activation of LC neurons projecting to the spinal cord leads to 
antinociception135,136. Apart from neurons, the LC contains glial cells, which can be 
electrotonically coupled to neurons137 or modulate the neuronal discharge by gliotransmitters, 




Figure 1.5. Schematic representation of LC neuronal specialization in terms of morphology (A), receptor 
expression (B), and projection target (C). (D) A simplified sagittal view of the anatomical inputs to the LC. (E) 
Integration of several inputs from different brain regions in the LC133. (See abbreviation list for further details).  
a)   	
    
A single LC-NA neuron receives input from 9-15 different brain areas133 (Figure 1.5). The 
main brain regions projecting to the LC are the nucleus prepositus hypoglossi (PrH) and the 
nucleus lateral paragigantocellularis (LPGi), both in the rostral medulla139, which send 
GABAergic or glutamatergic inputs, respectively. The LC also receives inputs from areas 
involved in cardiorespiratory control and autonomic functions, including the rostral 
ventrolateral medulla, NTS, parafacial respiratory group/retrotrapezoid nucleus (pFRG/RTN) 
and preBötC122. In particular, the preBötC contains a neuronal subpopulation that excites NA 
neurons in the LC123. Other areas sending projections to the LC are the noradrenergic A5 
nucleus, the Kölliker-Fuse nucleus, and the contralateral LC, together with the serotonergic 
dorsal raphe and the GABAergic pericoeruleus area in the pons122,140. Similarly, the PAG and 
the dopaminergic ventral tegmental area (VTA) in the midbrain also connect with the LC 
(Figure 1.5)141.  
b) Efferent projections from the LC 
LC neurons are the major source of NA in the CNS142, so they send projections to virtually all 
brain regions, except the basal ganglia143 (Figure 1.6). Moreover, the neocortex and the 
hippocampus receive NA inputs exclusively from the LC144. As a consequence of this 
innervation to different brain areas, LC contributes to memory formation145, modulates 
different behaviors, and coordinates responses to stress and arousal146 (Figure 1.6). For 
example, upon NA release from the LC, α1 and β1 adrenoceptor activation in cholinergic 
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neurons of the cortex promotes an awakening state, and meanwhile, α2 adrenoceptor inhibits 
the activity of GABAergic neurons (Figure 1.6). Thus, they have an overall awakening output 
on the cortex133.  
 
Figure 1.6. LC neurons send broad innervation to virtually the whole brain. (A) Tonic and phasic firing modes 
differentially modulate behavior. (B) Differences in receptor expression at targeted neurons determine the final 
action of NA133. 
1.2.1.2 Physiology of the LC: intrinsic properties and regulation of NA cells 
LC neurons fire spontaneous action potentials ranging from 0.5 to 5 Hz in vitro147, and up to 7 
Hz in vivo148. Electrophysiologically, LC neurons are characterized by a resting membrane 
potential of -55 to -65 mV, a threshold for spike generation of -55 mV147, a slow, broad action 
potential waveform (1-2 ms), and a quiescence period after generation of burst discharges144.  
A remarkable characteristic of LC neurons is the pacemaker activity, which implies that in the 
absence of any stimulus or synaptic activity, they discharge spontaneous action potentials149 
followed by interspike intervals. Such intervals consist of an afterhyperpolarization and a slow 
depolarization147, involving voltage-dependent Na+ and K+ currents in neonatal mice150,151 and 
an additional calcium-activated potassium channel in adult rats152,153. The pacemaker activity 
is also controlled by cAMP concentration and PKA activation149. Furthermore, LC neurons 
show pacemaker synchronous activity (i.e., electrotonic coupling), subject to developmental 
changes154 and attributed to gap junctions in pericoerulear neuronal dendrites155, and between 
neurons and glia137. This synchronous activity may contribute to harmonizing the activity of 
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the entire nucleus in response to sensory inputs156. However, when the electrotonic coupling is 
weak, the synchrony depends basically on the firing frequency157.   
LC neurons discharge in tonic and phasic modes. The former is regular, and the latter is 
composed of a brief burst followed by an inhibition133 (Figure 1.6). Importantly, a change in 
the firing mode anticipates the behavioral response144. Thereby, stimulation of both tonic and 
phasic modes increase wakefulness, but only the tonic mode stimulates locomotion and 
anxiety-like behavior133,146. In contrast, the phasic mode is associated with focused attention144. 
LC discharge activity is linearly correlated with the release of NA144. For instance, cAMP-
mediated increase in the neuronal activity158 leads to an equivalent enhancement of the NA 
efflux159 and cortical excitability in just a few milliseconds160.  
Neurotransmitters can modify the spontaneous neuronal LC activity. First, the quantal 
somatodendritic release of NA from the LC leads to neuronal hyperpolarization by α2 
autoreceptors that open Gi/o protein-coupled inwardly rectifying potassium channels (GIRK), 
which serves as a negative feedback161–164. Akin to the α2 adrenoceptor, NA cells are modulated 
by Gi/o protein-coupled MOR, which activation results in a decrease of a cAMP-dependent Na+ 
current158, and a Gβγ-dependent opening of GIRK channels165–167. Other inhibitory inputs to the 
LC are mediated by activation of specific receptors for the neurotransmitters GABA168 or 
serotonin169, along with the neuropeptides galanin, neuropeptide Y, and somatostatin170. In 
sharp contrast, neuronal stimulation can be driven by glutamate, which binds to ionotropic 
NMDA or non-NMDA receptors or, to a lesser extent, to metabotropic receptors171. Additional 
excitatory effects on the neuronal activity can be driven by the vasoactive intestinal peptide 
(VIP), which binds to VPAC receptors and activates an inward sodium current via 
cAMP/PKA172,173. Further excitatory responses can be triggered by binding of cannabinoids174, 
imidazolines175, orexins176, thyrotropin-releasing hormone177, substance P (SP), and 
corticotropin-releasing factor170 to specific membrane receptors. Finally, gliotransmitters such 
as ATP or L-lactate can also promote neuronal excitability138,178. 
In addition to synaptic neurotransmitters, LC cells can respond to specific trophic factors 
present in the CSF (neurotrophic nerve growth factor) due to its convenient location on the 
dorsolateral wall of the 4th ventricle179 or to LPS administered both intraperitoneally (i.p.)180 or 
locally in the CNS. Hence, when LPS is microinjected into the LC, a prolonged excitation is 
observed, which is dependent on IL-1181 and mPGES-1182. In addition, LPS upregulates mRNA 
expression of IL-1β, TNFα183, and microglial COX-2184. Moreover, when the IL-1 receptor 
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antagonist is microinjected into the LC, the neuronal activity decreases185, suggesting a possible 
tonic excitation and a role for cytokines in LC neuronal signaling.  
1.2.1.3 Functional implications and pathophysiological aspects of the LC-NA system 
Anatomical and physiological properties of LC neurons determine the performance of the 
entire system. The LC finely tune brain functions, and its dysregulation may play a key role in 
many pathophysiological conditions. 
a) Sleep cycle and arousal. Optogenetic photostimulation of LC neurons induces cortical 
excitability and, thus, sleep-to-wake transition146. During sleep, on the contrary, LC 
activity stops due to tonic GABAergic inhibition186. Alteration of the noradrenergic 
neurotransmission could lead to sleep disorders. For instance, in pain-related sleep 
disorders (e.g., sciatic nerve ligation) increased cortical levels of NA and enhancement 
of wakefulness have been observed187. 
 
b) Attention. LC neuronal discharge in phasic mode improves attentional shift to the target 
stimuli188, whereas its optogenetic silencing impairs the cognitive flexibility due to 
poorer attentional shift189. In addition, alteration of the cAMP/CREB signaling pathway 
in the LC produces attention-deficit/hyperactivity disorder (ADHD)-resembling 
symptoms190. 
 
c) Anxiety. Excessive activity of LC neurons projecting to the prefrontal cortex136 and 
amygdala191 results in anxiety-like behavior. This effect is mediated by the β receptor, 
and for this reason, its pharmacological blockade mitigates anxiety symptoms192. 
 
d) Nociception. The LC constitutes a part of the descending modulatory pathway. Thus, 
stimulation of spinally projecting LC neurons produces antinociception to a thermal 
stimulus135,136, to a peripheral inflammatory hyperalgesia193,194, and to a hind paw 
pinch195 through spinal α2 adrenoceptors196. On the other hand, persistent inflammatory 
pain increases the release of endogenous opioids, which downregulates MOR in LC 
neurons197.  
 
e) Learning and memory. LC neurons send widespread projections to learning-involved 
areas, some of which require the β adrenoceptor for memory consolidation143 and a 
proper microglial function198. Hence, LC neuronal activation enhances hippocampal 
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memory persistence, particularly in response to novel199 and aversive stimuli200. In 
contrast, during Alzheimer disease, the loss of up to 50% of LC neurons201 makes the 
human LC to shrink in volume202. Subsequently, hippocampal microglia is blunted, and 
thereby, it fails to clear amyloid-β deposition198.  
 
f) Autonomic functions. LC promotes sympathetic activity and diminishes 
parasympathetic activity by innervating preganglionic neurons145,203. These effects 
result in higher blood pressure138, heart rate increase203, pupil dilation, and reduction in 
salivation145.   
 
g) Body temperature. Lesioning the LC completely blocks the development of LPS- and 
PGE2-induced fever204. Furthermore, LC neurons respond to thermal stimuli205 and 
LPS-induced fever with the apparent involvement of the serotonergic 5-HT2A 
receptor206 and nitric oxide (NO)207. The latter is also thought to play a role in the 
hypoxia-induced hypothermia and hyperventilation208.  
 
h) Breathing control. The LC constitutes one of the putative central chemosensory 
brainstem nuclei, along with the pFRG/RTN, NTS, and LPGi209. LC neurons respond 
not only to peripheral chemoreceptor stimulation210 but also directly to hypercapnia. 
The rise of CO2 levels increases the firing rate of LC neurons by closing the GIRK 
channels211 and opening the L-type calcium channels212 and TRP channels213. The gap-
junctions are also believed to be involved since their blockade impair the LC 
chemosensitivity214. Thus, LC lesion blunts the response to hypercapnia215. Most LC 
neurons fire synchronously with the respiratory rhythm216, and thereby, increased 
activity of LC neurons results in an increase of breathing frequency124 via the α1 
adrenoceptor217. In fact, NA has an overall excitatory effect on the breathing behavior126 
because it excites the pFRG/RTN218 and the inspiratory-generator preBötC219, whereas 
it depresses the Bötzinger complex (BötC)-inspiratory inhibition220. Moreover, the LC 
is necessary for the maturation of the brainstem respiratory network221 as the LC 
chemosensitivity index is higher in neonates222. Thus, dysfunctional LC performance 
has been associated with respiratory depression217,222, Rett syndrome, and sudden infant 
death syndrome (SIDS)127,168,223. Furthermore, in Parkinson’s disease, the central 





i) Inflammation. The LC is vulnerable to inflammation. First, single i.p. injection of  LPS 
increases NA content in the LC225 and c-fos immunoreactivity182,226, which is greatly 
reduced in mPGES1-/- mice182. In contrast, chronic LPS exposure produces a loss of 
NA cells in the LC227,228 and an increase of IL-1β levels in the brainstem228. 
Furthermore, NA has a potent anti-inflammatory effect on astrocytes and microglia, 
which leads to a decrease in cytokine signaling and an increase in brain-derived 
neurotrophic factor198,229,230. Accordingly, degeneration of LC-NA neurons potentiates 
LPS-induced astrocytosis231,232.  
 
j) Opiate tolerance and withdrawal. Acute opioid administration inhibits LC neuronal 
activity158, which turns into an excitatory effect upon chronic exposure233 due to cellular 
tolerance234. Furthermore, this increased activity of LC neurons is partly responsible 
for the opioid withdrawal syndrome156, which is attenuated with an EP3 receptor 





1.2.2 PreBötzinger complex 
1.2.2.1 Anatomy of the preBötC 
The preBötzinger complex (preBötC) is a cluster of neurons located in the ventrolateral 
medulla oblongata that contains the kernel for breathing rhythmogenesis235. Several reasons 
support the involvement of the preBötC in driving the inspiratory breathing. First, optogenetic 
excitation of preBötC neurons increases the respiratory frequency236, whereas unilateral lesion 
in vivo induces a sigh behavior and bilateral loss of preBötC neurons produces erratic breathing 
and pathological responses to changes in O2 concentration237. Second, the oscillatory activity 
is maintained in slices, where the preBötC population activity can simulate eupneic and sigh 
patterns238. Furthermore, inspiratory neurons discharge in phase with the rhythmic motor 
output measured on the hypoglossal XII nerve239 and laser ablation of these inspiratory neurons 
impair breathing rhythm in slices240. In conclusion, the preBötC is both necessary and sufficient 
for generating the respiratory rhythm241. 
The preBötC lies within the rostral ventrolateral medulla (RVLM)242 and its core is located 
0.43 mm (between 0.35 - 0.5 mm) posterior to the caudal border of the VII motor nucleus in 
neonatal mice (Figure 1.7)243 immediately ventral to the nucleus ambiguus244. The preBötC 
constitutes a part of the ventral respiratory group, along with the Bötzinger complex and the 
rostral and caudal part of the ventral respiratory group, which in turn, comprises the ventral 
respiratory column (VRC) in conjunction with the pFRG/RTN (Figure 1.7)245. 
 
Figure 1.7. Outline of the breathing brainstem anatomy in coronal slices (a; left), in horizontal view (a; right) and 
parasagittal section (b)245. (See abbreviation list for further details). 
The preBötC is a highly heterogeneous region, broadly composed of glial cells, and 
glycinergic, GABAergic, and glutamatergic neurons239. Since no motoneurons are present, the 
neuronal population is composed of interneurons246 that derive from Dbx1-expressing 
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progenitors247, which are only apparent during embryonic development248. Among neurons, 
only 15% of the glutamatergic neurons show intrinsic oscillatory bursting239, and their selective 
laser ablation precludes the breathing rhythm in slices240. Additionally, these glutamatergic 
neurons express SP-NK1 receptor and somatostatin-SST receptors121,247,249,250, whereas most 
GABAergic cells fail to express the NK1 receptor121. NK1 receptor located at postsynaptic sites 
is prevailing in the preBötC121,251. Thus, markers for NK receptors are frequently used to 
identify and localize the preBötC119. SP terminals innervating the preBötC assemble excitatory 
synapses251, and accordingly, SP administration increases the neuronal burst frequency via 
NK1 receptor252. In addition to the NK receptor, some rhythmogenic glutamatergic neurons 
express MOR119,253. Thus, opioid administration into the preBötC abolishes the breathing 
rhythm, causing respiratory depression253,254. Therefore, the preBötC has been considered 
essential for the opioid-induced respiratory depression255. 
a) Afferent projections to the preBötC 
PreBötC NK1R+ neurons are innervated by excitatory glutamatergic256 and inhibitory 
GABAergic or glycinergic inputs257. Some glutamatergic afferents originate in the 
pFRG/RTN258, and some have shown to form SP and enkephalin-mediated synapses251. 
Enkephalin terminals are thought to come from the RVLM or NTS 251. On the other hand, 
GABAergic SST+ arising from the NTS and parabrachial nuclei250 send inhibitory inputs to the 
preBötC, together with the expiratory Bötzinger complex (BötC), which inhibits the inspiratory 




Figure 1.8. A general overview of the complex connectivity among regions of the breathing brainstem that 
generate inspiratory output245. 
c) Efferent projections from the preBötC  
Both excitatory SST+ and inhibitory glycinergic neurons in the preBötC send parallel 
projections to the same brain regions involved in breathing modulation: the contralateral 
preBötC, BötC, ventral respiratory column, pFRG/RTN, NTS, Kölliker-Fuse, PAG259,260 and 
post-inspiratory complex (PiCo)261 (Figure 1.9). Interestingly, a few suprapontine regions are 
innervated by the preBötC, including the thalamus, lateral and dorsomedial hypothalamus, and 
lateral preoptic area, suggesting a role for breathing in higher-order functions260. Moreover, a 
subset of excitatory neurons, expressing both cadherin-9 and Dbx1 (Cdh9+/Dbx1+), send 
projections to the LC (Figure 1.9), and its selective ablation leads to calm behaviors123. The 
synchronized activity of both sides of the preBötC246,262 and the hypoglossal XII motor 
output239,263 (Figure 1.10) is attributable to the commissural innervation239, which shapes the 
inspiratory rhythm240.   
 
Figure 1.9. Anatomical sagittal scheme for the parallel excitatory and inhibitory efferences arising from the 
preBötC. Note the excitatory Cdh9 connexion between the preBötC and the LC260. (See abbreviation list for further 
details). 
1.2.2.2 Physiology of the preBötC: intrinsic properties and physiological regulation 
The preBötC primary function is to generate the breathing pattern260, as confirmed by the 
disrupted breathing and apneas following preBötC neuronal ablation both in vivo and in 
vitro240,264,265. Furthermore, more than 80% of neurons and glial cells in the preBötC fire in 
synchrony with the inspiratory phase of breathing239,241 (Figure 1.10), and accordingly, both 
optogenetic photostimulation236 or inhibition266 modifies the rhythm. Finally, activation of 
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astrocytes within the preBötC anticipates the neuronal inspiratory burst246,267, so that both 
neurons and astrocytes are functionally coupled268. 
The majority of the respiratory neurons in the preBötC are inspiratory (80%) (Figure 1.10), 
implying that they fire in phase with the preBötC population269,270. However, 5% of the 
neuronal population in the preBötC are inhibited during inspiration, and those are expiratory 
neurons (Figure 1.10). In addition, the preBötC contains post-inspiratory neurons that are also 
inhibited during inspiration but experience a post-inspiratory rebound269. Finally, 11% of the 
population are non-respiratory neurons that fire tonically regardless of the inspiratory 
activity269 (Figure 1.10).  
Among the inspiratory neurons, 24% have pacemaker activity, defined as maintained rhythmic 
burst after synaptic blockade271. The pacemaker activity is mainly dependent on a persistent 
sodium current, and to a lesser extent to a calcium-activated non-specific cation current, which 
is also sensitive to hypoxia271. Nevertheless, pacemaker activity should not be a binary 
classification, there is instead, a spectrum of firing patterns272. 
 
Figure 1.10. (A) Reconstruction of a preBötC-containing slice with the electrophysiological characteristics of its 
neurons. The left image at the bottom represents examples of Ca2+ imaging traces for two neurons and synchronous 
inspiratory activity recorded on the hypoglossal nerve root (ʃXII) (Adapted from 273). (B) Different neuronal 
subtypes in the preBötC and their representative histograms of activity269. 
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Despite the cellular diversity of the preBötC270, the synchronicity and connectivity among 
different cells are thought to play a fundamental role in constituting the neuronal “group 
pacemaker”262,274. Ultimately, in order to harmonize the rhythm of both sides of the 
preBötC246,262, the network rhythmogenesis depends on a non-NMDA synaptic 
transmission241,262 together with the electrical coupling270,275. Furthermore, preBötC neurons 
organize into clusters276 interconnected by hubs and resembling the small-world topology97 
(Figure 1.11), by which neighboring cells in a network are connected with a regular pattern and 
some random rewiring277,278. These networks are defined by the parameters mean clustering 
coefficient (σ) and shortest path length (λ), where σ is the number of nodes that are also 
neighbors of each other and λ is the minimum number of nodes that must be passed to travel 
from one node to another (Figure 1.11). As a consequence of this neural circuit, the signal of a 
few neurons is amplified into a burst of a whole population279 and finally transmitted to the XII 
motoneurons by electrical coupling275. 
 
Figure 1.11. (A) Representation of a regular ring lattice by which all nodes or hubs are connected by edges. 
Distance weight shows a higher strength of close edges, and progressive random rewire creates a small-world 
network. (B) σ and λ as a function of the rewiring probability (p) (adapted from 280). C) Illustration of ten cells, in 
which some cells are connected due to a high correlation coefficient (c1) defined by their synchronous activity, 
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compared to low correlated cells (c2). (D) The small-world network combines features of both regular and random 
networks, with high σ and short λ. A decrease in the σ implies increased randomness of the network (adapted from 
278). 
The generation of the respiratory rhythm is thought to be driven by the alternation of activity 
between the inspiratory (preBötC) and the expiratory (pFRG/RTN) function281 (Figure 1.8). At 
rest, however, the expiration is passive282, so a triple oscillator theory has been proposed272, by 
which the ventilation is induced due to the inspiratory activity of the preBötC and the post-
inspiratory of the PiCo261. In contrast, the pFRG/RTN only generates active expiration to 
induce ventilatory movements282 in the event of high metabolism272, hypercapnia4,97, or the 
absence of preBötC activity282. 
1.2.2.3 Physiological and pathophysiological aspects of preBötC 
The preBötC is capable of reacting to hypoxia283 in order to adapt the inspiration to the need 
for O2. The preBötC activity in vitro shows a population burst, and an additional pattern 
resembling sighs238, so it may be plausible that the preBötC generates different respiratory 
patterns118. Then, during hypoxic events, the preBötC reacts by increasing the frequency of 
sighs238, which have essential functions, as they expand the lungs, induce arousal, and reshape 
the breathing network118.  
The preBötC is sensible to inflammation, as PGE2 increases the frequency of sighs, induces 
gasps under hypoxic conditions99, and increased the apnea frequency38, through inhibitory EP3 
receptors97. Furthermore, babies with severe hypoxic-ischemic encephalopathy have higher 
PGE2 metabolite levels in CSF104, and sudden infant death syndrome victims show structural 
and functional alterations of the preBötC284.  
Also, the preBötC has been defined as crucial in the opioid-induced respiratory 
depression254,255. NK1 receptor-expressing neurons in the preBötC respond to opioids119,254 via 
MOR285, which activation produces a Gi/o-protein-dependent286 decrease of cAMP 
production287,288 and opening of GIRK channels289,290. As a result, the breathing rhythm 
decreases253, and that could have severe consequences291. Neonates can be particularly 
sensitive to opioid-induced respiratory depression as their brainstem has high MOR binding 
density292. MOR signaling is also involved in analgesia, so the analgesic effect cannot be 
isolated from the respiratory depression293,294. Moreover, after chronic opioid treatment, it is 
easier to develop tolerance (i.e., loss of pharmacologic response) to opioid-induced analgesia 
than to the respiratory depression295,296. Thus, tolerance culminates in dose escalation and 








2 HYPOTHESIS AND OBJECTIVES 
Prostaglandins, as inflammatory molecules spreading across the BBB1, are released in response 
to blood inflammatory signals in the vicinity of the neurons, where they can modulate the 
neuronal activity5. First, prostaglandins stimulate the nociceptive transmission by increasing 
the excitability of nociceptive112,297–299 and spinal neurons300 or by further decreasing the 
nociceptive threshold in the PAG115,301, and ultimately promoting hyperalgesia109 and 
allodynia111. Secondly, fever is triggered by the activation of EP3 receptors, which inhibits 
median preoptic neurons5 and disinhibits the thermogenic pathway (for review see Blomqvist 
and Engblom92). Finally, prostaglandins regulate autonomic functions by increasing the 
neuronal activity of the NTS302, control the release of oxytocin and vasopressin by exciting 
supraoptic neurons through EP4 receptors303, or modify the synaptic transmission in the 
neocortex via EP3 or in the hippocampus via presynaptic EP2 receptors26,304,305. Moreover, 
PGE2 may serve as a gliotransmitter to activate hypothalamic neuroendocrine neurons3 and the 
respiratory network4,97. Hence, prostaglandins might act as lipid signaling molecules between 
brain cells. In summary, prostaglandins can modulate neuronal discharge activity in different 
brain areas3,26,302–304,306,307, including those involved in inflammation and nociception5,92,115,305.  
 
The LC, the main noradrenergic nucleus in the brain, is susceptible to inflammation. First, LPS 
or PGE2 produce fever via a pathway that includes the LC, as the thermogenic response to these 
signals is reduced in LC-lesioned rats204. Second, LPS administration produces neuroadaptive 
effects in the LC, including a strong rise in c-fos immunoreactivity180,182, loss of TH 
immunoreactivity227,228, increased expression of IL-1β and TNF-α183,308, and increased NA 
content225. Third, microinjection of IL-1β, TNF-α, and LPS modifies the LC firing 
activity181,185 and ultimately leading to activation of the LC descending pathways and reduction 
in the development of hyperalgesia193,194, since NA has antinociceptive193,194 and anti-
inflammatory actions229,309. Accordingly, LC-NA neurons synthesize anti-inflammatory 
mediators310, and its deterioration during stress311 or Alzheimer’s disease202 can aggravate the 
inflammatory response and increase amyloid-β deposition198,232. Thus, suggesting that the LC 
plays a role in neurodegenerative diseases145,312, as shown in a Parkinson’s disease model, 
where the LC reestablishes the chemosensitivity to hypercapnia due to the impaired function 




Notably, LC neurons are not only sensitive to inflammation in general but to prostaglandins in 
particular. First, LC neurons possess the enzymatic machinery necessary to synthesize 
prostaglandins; including constitutive COX-2, and mPGES121,182. Thus, NSAIDs, by blocking 
the synthesis of prostanoids, attenuate the activation of LC neurons in response to nociception 
and inflammation180,313,314. Second, the EP2, EP3, and EP4 receptor mRNA is found in the LC 
by in situ hybridization57,62,63,120 and the EP3 receptor protein by immunoreactivity64 and 
double immunofluorescence65. Furthermore, it is likely that during inflammatory conditions, 
there is a bias towards the EP4 receptor signaling in catecholaminergic neurons57. Third, EP3 
receptor activation in the LC reduces c-fos mRNA and opioid-withdrawal syndrome120,315. 
Additionally, presynaptic EP3 receptors mediate the inhibition of NA release in the main 
projection areas of the LC, including the cortex, hippocampus, and hypothalamus316–320.  
 
Taken together, this evidence suggests an interaction between the prostaglandin system and the 
LC concerning inflammation, nociception, fever, and neurodegeneration. To date, however, 
the role of EP receptors in the regulation of the LC neuronal activity has not been studied. 
 
On the other hand, the release of endogenous opioids counteracts the effect of nociceptive 
signals321. Due to their potent analgesic effect, opioids are widely used in the clinic, with the 
major drawback of producing potentially lethal respiratory depression291 and dependence322. 
The main target of opioids in the respiratory brainstem is the inspiratory pattern generator 
preBötC, which is considered essential in the opioid-induced respiratory rate depression254,255. 
Furthermore, preBötC inspiratory neurons express MOR119,254 and κ-opioid receptor (KOR) 
RNA248. Thus, opioids act postsynaptically on preBötC neurons by decreasing the inspiratory 
frequency in slices119, but producing a quantal slowing in en bloc or in vivo preparations, due 
to the complex configuration of the breathing brainstem323. The underlying mechanism 
involves a Gi/o protein-dependent286 opening of GIRK channels290 and decrease of cAMP 
formation287,288 leading to neuronal hyperpolarization119. 
 
Apart from being inflammatory messengers, the prostaglandins produce respiratory depression 
by interfering with the breathing rhythm generation324, as demonstrated by the fact that i.c.v. 
administration of PGE2 leads to irregular breathing and apneas98,325 via the EP3 receptor38. 
Furthermore, PGE2 metabolite concentration in neonatal CSF correlates positively with 
asphyxia and the outcome of hypoxic-ischemic encephalopathy104. Additionally, in the 
preBötC, the brainstem central pattern generator, PGE2 lowers the calcium transient frequency 
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of the network97 and increases the sigh frequency and gasp tendency99. However, the possible 
synergy between PGE2 and opioids to induce major respiratory disruption, e.g., during 
infections and surgery, remains to be elucidated. 
 
In sum, the global aim of this study was to characterize the effect of prostanoid agonists on the 
LC neuronal activity and to elucidate its underlying mechanism. Furthermore, we aimed to 
study the interaction between the prostaglandin and opioid systems in the inspiratory pattern 
generator preBötC. The specific objectives of the present study were: 
 
I. To characterize the functional role of the prostaglandin E2 EP3 receptors in the rat LC 
by single-unit extracellular recording in vitro. For this purpose, we studied the effect of 
various EP3 receptor agonists on the spontaneous firing activity of NA cells, and we 
evaluated the underlying signaling mechanism in the LC. 
 
II. To determine the role of the EP2 receptors in the rat LC by single-unit extracellular 
recording in vitro. Accordingly, the effect of EP2 receptor agonists and different 
blockers of the signaling mechanism were tested on the spontaneous firing activity of 
LC cells. 
 
III. To investigate the function of EP4 receptors in the rat LC by single-unit extracellular 
recordings in vitro. For this reason, the effect of EP4 receptor agonists and signaling 
inhibitors were examined. 
 
IV. To study the interaction between the effect of PGE2 and opioids on the Ca2+ transient 
frequency and cellular connectome of the inspiratory pattern generator preBötC in 





3 MATERIALS AND METHODS 
3.1 MATERIALS 
3.1.1 Animals 
Adult male Sprague-Dawley rats (200-300 g) bred in the animal facility of the University of 
the Basque Country were used for the electrophysiological experiments. The animals were kept 
under controlled environmental conditions (22 ºC, 12-h light/dark cycle, humidity of 65 – 70%) 
and with food and water ad libitum.  
For calcium imaging studies, postnatal day 3 – 4 (P3 – P4) C57BL/6J mice were used as wild 
type (WT). Additionally, a knockout mouse strain (B6.E14Tg2a-Ptger3tm1Unc) was derived 
from the WT by deleting the EP3 receptor gene (Ptger3). Phenotypically, the Ptger3-/- mice 
have higher body weight and increased nocturnal activity326. 
All experimental procedures were conducted in accordance with the Directive 2010/63/EU of 
the European Parliament and of the Council of 22 September 2010 on the protection of animals 
used for scientific purposes and with the institutional guidelines for animals used in research 
(Animal Care and Use Committee of the University of the Basque Country or Sweden). All the 
efforts were made to minimize animal suffering and to reduce the number of animals used 
according to the Three Rs: Replace, Reduce, and Refine. 
3.1.2 Drugs and reagents 
Drugs and reagents used in this thesis are shown in alphabetical order in Table 3.1. 
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Pertussis toxin Bacterial toxin that 
catalyzes ADP-
ribosylation of G-
proteins Gi, Go and Gt 
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H2O 104 mM 5 min 
VIP Neuropeptide agonist 
of VIP and PACAP 
receptors 
Bachem H2O 500 nM 5 min 
Wortmannin PI3K inhibitor Tocris DMSO 100 nM 20 min 





Most drugs were prepared as stock solutions in miliQ water and stored at -20 ºC until the day 
of the experiment, when they were finally diluted in artificial cerebrospinal fluid (aCSF). Some 
other drugs were dissolved in DMSO (Table 3.1) to a final concentration in the perfusion fluid 
<0.1%, which does not affect the firing activity of LC neurons in vitro327. Except for PGE2 and 
treprostinil, all the EP agonists were purchased pre-dissolved in the corresponding solvent 
according to Table 3.1, and the final concentration of the solvents in the perfusion fluid was 
<0.03%. The composition of the aCSF for the electrophysiological studies was (in mM): NaCl 
130, KCl 3, NaH2PO4 1.25, glucose 10, NaHCO3 20, CaCl2 2, MgSO4 2 saturated with 95% 
O2/ 5% CO2 for a final pH of ~7.34. In some experiments, 80% of the NaCl was equiosmolarly 
substituted for trizma hydrochloride (TRIS) to a final concentration of NaCl 26 mM328,329. For 
the calcium imaging study, PGE2 was dissolved in absolute ethanol, and a slightly different 
aCSF was used (in mM); NaCl 124, KCl 3, NaH2PO4 1.1, glucose 10, NaHCO3 26, CaCl2 2, 
MgSO4 2 and also saturated with 95% O2/ 5% CO2. 
3.2 METHODS 
3.2.1 Electrophysiological procedures 
3.2.1.1 Brain slice preparation 
Rats were anesthetized with chloral hydrate (400 mg kg-1, i.p.) and decapitated. The brain was 
rapidly extracted after decapitation and placed in an ice-cold aCSF (4ºC), where NaCl was 
substituted by sucrose (252 mM) to improve neuronal viability330. Coronal brainstem sections 
of 500-600 μm thickness containing the LC were cut using a vibratome (FHC Inc. USA) with 
a Valet blade (World Precision Instruments, Inc. USA). The facial nerve and the IV ventricle 
were used for anatomical references. The slices were allowed to recover from the slicing for 
60-90 min in a glass beaker covered with a lid and bubbled with 95% O2/ 5% CO2. After the 
recovery period, the slices were transferred into a custom-made modified Haas-type interface 
chamber, including a polypropylene mesh covered with cellulose paper (Sigma-Aldrich 
Química, Spain) and lens paper (Olympus Optical Spain S.A. Spain) on which the tissue was 
placed. The slice was continuously perfused with oxygenated aCSF at a flow rate of 1.5 ml 
min-1. Drugs dissolved in aCSF were applied by a polyethylene tube system manually 




3.2.1.2 Uni-extracellular recording technique 
Single-unit extracellular recordings of LC neurons were made as previously described 331. 
 Recording electrode preparation. The recording electrode, an Omegadot glass 
micropipette, was prepared with a horizontal pipette puller (Sutter Instruments Co., USA). 
The micropipette tip was shaped by adjusting the parameters of heat and speed of the puller. 
Then, the electrode was filled with sodium chloride (50 mM) using a Yale spinal needle 
(0.5 x 90 mm, 25 G, Beckton Dickinson S.A., Spain) coupled to a Sartorious cellulose filter 
(0.20 μm, Filtros Anoia S.A., Spain). Once filled, the tip was broken to a diameter of 2 – 5 
μM for a final resistance of 3 – 5 MΩ. 
 
 Recording of uni-extracellular electrical activity of LC neurons. The electrode 
was positioned, under a binocular microscope (C011, Olympus Optical Spain, S.A., Spain), 
into the recording area, i.e., the LC. This nucleus was visually identified as a dark oval area 
on the lateral borders of the central gray and the IV ventricle, anterior to the genu of the 
facial nerve. The electrode was lowered at 4 μm intervals using a micropositioner (6000-
ULN, Burleigh Instruments, Canada). Noradrenergic cells were identified by their 
spontaneous and regular discharge activity, slow firing rate, and long-lasting biphasic 
positive-negative waveforms153. As illustrated in Figure 3.1, the extracellular signal was 
filtered through a high-input impedance headstage (HS-2A, Axon Instruments, USA) and 
amplified (x 10) together with a pre-amplifier (Axoclamp-2A, Axon Instruments, USA). 
Then, the signal was further filtered and amplified by a high input impedance amplifier 
(Cibertec S.A., Spain). After that, an oscilloscope (Hameg Instruments, Germany) and an 
audio-analyzer (Cybertec S.A., Spain) were used to monitor the signal. Individual (single-
unit) neuronal spikes were isolated from the background noise with a window discriminator 
(Cibertec S.A., Spain) and finally, the firing rate was analyzed by a PC-based custom-made 
software (HFCP®, Cibertec S.A., Spain), which generated consecutive histogram bars 
representing the accumulated number of spikes in 10 s. To maintain the slice at a 
physiological temperature (33-34 ºC), a thermoregulatory system was used (Cybertec S.A., 





Figure 3.1. Scheme for electrophysiological signal processing and recording. 
3.2.2 Calcium time-lapse imaging in organotypic slice cultures 
3.2.2.1 Organotypic slice cultures preparation 
Organotypic slice cultures containing the preBötC were used for study IV. One of the 
advantages of employing organotypic slice cultures is the flattening of the tissue, without 
changing the cytoarchitecture, which leads to improved optical conditions increasing calcium 
time-lapse imaging performance97,252. The brainstem organotypic cultures were obtained from 
P2-P5 mice pups, which further provide optimal imaging conditions, due to less glial coverage 
than in adult slices332. As previously described elsewhere97, pups were decapitated and the brain 
was dissected in a dissection medium (55% Dulbecco’s modified Eagle’s medium, 0.3% 
glucose, 1% HEPES buffer and 1% penicillin-streptomycin). The brain was sectioned into 300 
μm-thick transverse slices by using a McIlwain Tissue Chopper (Ted Pella, Inc., Redding, CA, 
USA). Slices were selected based on anatomical descriptions of previous reports243,333 and 
washed by moving them to brain slice medium (55% Dulbecco’s modified Eagle’s medium, 
32.5% Hank’s balanced salt solution, 0.3% glucose, 10% fetal bovine serum, 1% HEPES buffer 
and 1% Antibiotic-Antimycotic [Invitrogen, UK]). Subsequently, they were carefully placed 
on insert membranes (Millicell Culture Plate Inserts; Millipore, Billerica, MA, USA), which 
had been coated with poly-L-lysine (0.3 ml; 0.1 mg ml-1, Sigma-Aldrich, St. Louis, USA) and 
ultimately inserted into six-well plates. Finally, brain slice medium (1 ml) was placed 
underneath the membrane, allowing the slices to be on the liquid/gas interphase to permit a 
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correct oxygenation334 by the Stoppini method335. The slice cultures were kept in an incubator 
(37˚C, 5% CO2), and the medium was changed every second day. The brainstem slices were 
kept for 7 – 21 days in vitro (DIV) before live imaging experiments.  
3.2.2.2 Calcium time-lapse imaging 
For Ca2+ imaging, Fluo-8 AM (AAT Bioquest, Inc., USA) was added to a solution of pluronic 
acid 1% in DMSO (Invitrogen, UK). The final concentration in aCSF was 10 µM. In order to 
localize the preBötC, tetramethylrhodamine-conjugated substance P (TMR-SP; Biomol, 
Oakdale, NY, USA) was used at a final concentration of 3 µM in aCSF. The TMR-SP solution 
was placed on top of the brainstem slice and was incubated for 10 min (37˚C, 5% CO2 
atmosphere). The TMR-SP solution was then replaced with 1 ml of the 10 µM Fluo-8 solution, 
which was in turn incubated for 30 min (37˚C, 5% CO2). Before imaging, the slice was washed 
with aCSF for 1-5 min (37˚C, 5% CO2). During time-lapse imaging, slices were kept in an open 
chamber perfused with aCSF (1.5 ml min-1) by a peristaltic pump. A Chamlide Inline Heater 
(Live Cell instruments, Seoul, Korea, cat no. IL-H-10) was used to set the temperature to 32ºC 
and a Chamlide AC-PU chamber (Live Cell instruments, Seoul, Korea, cat no. ACPU25) for 
perfusion. The aCSF was constantly bubbled with 5% CO2 and 95% O2. Images were captured 
by using a Zeiss AxioExaminer D1 microscope equipped with 20x and 40x water immersion 
objectives (N.A. 1.0), a Photometrics Evolve EMCCD-camera and filter sets 38HE (Zeiss) and 
et560/hq605 (Chroma, Bellows Falls, VT, USA). For live imaging, a frame interval of 0.5 s 
was used. Exposure time was set to 100 ms. Testing drugs were dissolved in aCSF prior to 
application and added to the chamber by using a continuous flow system. When the effect of 
SCH-23390 was tested, it was added to the Fluo-8 solution for the 30-minute incubation. For 
each experiment, a baseline period with aCSF (5 min) was followed by drug application. The 
drug concentrations employed in this investigation are in accordance with those used in 
previous studies in slices97,99,336,337. 
Table 3.3. Summary of the studies, regions, and techniques used in this thesis. 
Studies Region Technique Animals Slices 
I-III Locus coeruleus Extracellular 
electrophysiology 
Sprague-Dawley adult rats Acute 
IV preBötzinger 
complex 
Calcium time lapse 
imaging 






3.2.3 Pharmacological procedures 
3.2.3.1 Pharmacological characterization of EP3 receptors in rat LC neurons 
To study the effect of EP3 receptor agonists on the firing rate of LC neurons, we perfused 
increasing concentrations of the EP1/EP3 receptor agonist sulprostone (0.31 nM – 1.28 µM, 
2x), PGE2 (0.31 nM – 10.2 µM, 2x) or the PGE1 analog misoprostol (0.31 nM – 2.56 µM, 2x). 
Concentrations were based on previous studies in brain slices318,338. Each concentration of the 
EP receptor agonists was perfused for enough time to reach the maximal effect (1 min).  
To identify the subtype of EP receptor involved in the effect of sulprostone, PGE2, and 
misoprostol, concentration-effect curves for these agonists were performed in the presence of 
different EP receptor-selective antagonists. First, for sulprostone, the EP2 receptor antagonist 
PF-04418948 (3 and 10 µM), the EP3 receptor antagonist L-798,106 (3 and 10 µM), and the 
EP4 receptor antagonist L-161,982 (3 and 10 µM) were used at the concentrations previously 
reported339. Next, for PGE2 and misoprostol, the EP3 receptor antagonist L-798,106 at 10 μM 
was used, along with a combination of the aforementioned EP2 and EP4 receptor antagonists 
at 10 μM. All the antagonists were perfused for 30 min before performing the concentration-
effect curves for the EP receptor agonists.  
Based on its pharmacological profile, sulprostone was selected to further characterize the 
molecular mechanism underlying EP3 receptor activation. To study the involvement of Gi/o 
proteins, concentration-effect curves for sulprostone were made after overnight incubation of 
the slices with the irreversible inhibitor of Gi/o proteins pertussis toxin (PTX, 500 ng ml-1, 18 
h) in an oxygenating glass beaker at room temperature, in line with preceding studies340. In 
order to verify that PTX had effectively blocked the Gi/o protein, the effect of the Gi/o-coupled 
MOR agonist ME was tested. Thus, only cells with a reduced inhibitory effect of ME (<80%) 
were considered to perform the concentration-effect curves for sulprostone. In those cells, 
proper drug perfusion was assessed with GABA (1 mM, 1 min) 
To confirm the involvement of GIRK channels, which are described to be activated by Gi/o 
proteins166, concentration-effect curves for sulprostone were performed in the presence of the 
GIRK blocker BaCl2 (300 µM, 15 min) or the selective GIRK2 gating inhibitor SCH-23390 
(15 µM, 30 min) at the concentrations previously used211,336. 
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3.2.3.2 Pharmacological characterization of EP2 receptors in rat LC neurons 
To characterize the effect of EP2 receptor agonists in LC neurons, we perfused increasing 
concentrations of the EP2 receptor agonist butaprost free acid (10 nM – 10 μM, 3x) and the 
synthetic PGI2 analog treprostinil, which has a high affinity for the EP2 receptor (30 nM – 10 
µM, 3x), based on other studies93. Each concentration of the EP2 receptor agonists was 
perfused for at least 10 min. To verify the specificity of the agonists for the EP2 receptor, the 
EP2 receptor antagonist PF-04418948 (3 and 10 nM) was used according to preceding 
reports341–343. A combination of the EP3 receptor antagonist L-798,106 (10 nM) and the EP4 
receptor antagonist L-161,982 (10 nM) was also used to study the selectivity of the EP2 
receptor agonists for the EP3 and EP4 receptors. All the antagonists employed were perfused 
for 30 min before performing the concentration-effect curves for the EP2 receptor agonists.  
Butaprost was used for subsequent characterization of the molecular mechanism involved in 
EP2 receptor activation. A mechanism described for excitatory responses of LC neurons 
consists of a cAMP/PKA-induced opening of a non-selective cation current327. Then, to 
investigate the involvement of sodium current in the butaprost-mediated effect, a low sodium-
containing aCSF was prepared by replacing 80% of the NaCl equiosmolarly with Trizma 
hydrochloride/base (TRIS), and then the effect of butaprost was tested329. To further describe 
the involvement of sodium currents, we checked whether the transient receptor potential (TRP) 
ion channels213 might contribute to butaprost effect by using the nonselective TRP blocker 2-
APB (30 µM, 10 min). Finally, to discard the activation of other channels that may mediate 
excitatory effects in the LC neurons344, we examined the effect of butaprost in the presence of 
the ATP-sensitive potassium channel (Kir6.2) specific blocker glibenclamide (3 μM, 15 min).  
To test whether the sodium current was induced by a rise in the cAMP levels and the resultant 
activation of the PKA, we performed an occlusion experiment with the non-hydrolyzable cell-
permeable cAMP analog 8-Br-cAMP (1 mM, 8 min)173. Thus, in case the EP2 receptor 
activation depends on the cAMP/PKA pathway, administration of a saturating concentration 
of 8-Br-cAMP would occlude the subsequent effect of butaprost. In addition, the cAMP/PKA-
dependency was further determined by testing butaprost in the presence of the PKA inhibitor 
H-89 (10 μM, 20 min)345 or the HCN channel blocker ZD7288 (30 μM, 20 min)346.  
Then, we evaluated the possible activation of ion channels in a cAMP/PKA-independent 
manner. For this purpose, we tested whether the Gαs protein would intermediate in the effect of 
butaprost by application of the blocker of the Gαs-dependent signaling NF449 (10 µM, 30 
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min)347. In these assays, VIP (0.5 μM, 5 min) administration was used as a positive control to 
confirm that NF449 was effectively blocking the Gαs protein, as previously reported in LC 
neurons172. Finally, to assess the involvement of the Gβγ subunits, the effect of butaprost was 
tested in slices previously incubated with gallein (20 µM) in an aluminum foil-covered glass 
beaker for 120 min348.  
In order to study the involvement of presynaptic mechanisms in the effect caused by EP2 
receptor activation, butaprost was applied in the presence of the GABAA channel blocker 
picrotoxin (100 μM), the non-NMDA ionotropic glutamate receptor antagonist CNQX (30 
μM), the NMDA receptor antagonist d-AP5 (100 μM), and the non-selective metabotropic 
glutamate receptor antagonist RS-MCPG (500 μM)349,350. All mentioned drugs were bath 
perfused for at least 10 min before and during testing the effect of butaprost. 
3.2.3.3 Pharmacological characterization of EP4 receptors in rat LC neurons  
To characterize the effect of EP4 receptor agonists in LC neurons, we perfused increasing 
concentrations of the EP4 receptor agonist rivenprost (0.01 nM – 1 µM, 3x) and TCS 2510 
(0.20 nM – 2 μM, 3x) for at least 8 min each concentration, based on previous studies351. To 
pinpoint the EP receptor involved in the observed effect upon rivenprost administration, the 
EP4 receptor antagonist L-161,982 (3, 30, and 300 nM), the EP2 receptor antagonist PF-
04418948 (300 nM), and the EP3 receptor antagonist L-798,106 (300 nM) were used. All the 
antagonists were perfused for 30 min before performing the concentration-effect curves for the 
EP4 agonists.  
To investigate the molecular mechanism involved in EP4 receptor activation, we used a similar 
approach to the pharmacological characterization of the EP2 receptor (see section 3.2.3.2 for 
further details). First, low-sodium aCSF (TRIS 80%) and the TRP channel blocker 2-APB (30 
µM, 10 min) were employed to test the involvement of sodium currents. Secondly, 8-Br-cAMP 
(1 mM, 8 min) and H-89 (10 μM, 20 min) were used to study the connection with the 
cAMP/PKA pathway.  
Considering the similarities between the effects of EP2 and EP4 receptor activation, we 
performed an occlusion experiment in the presence of a submaximal concentration of butaprost 
(1 µM, 15 min) to examine the possible convergence of both signaling pathways. 
 
 39 
In addition, the effect of rivenprost was tested in the presence of the Gαs blocker NF449 (10 
µM, 30 min) or the Gβγ blocker gallein (20 µM, 120 min) to further characterize the G-protein 
subunits involved (see section 3.2.3.2 for further details). 
Finally, since the EP4 receptor has been described to couple to the PI3K and PKC signaling 
pathways81,352,353, the PI3K inhibitor wortmannin (100 nM, 20 min) and the cell-permeable 
PKC inhibitor chelerythrine (10 μM, 30 min) were used at previously tested 
concentrations354,355.   
Except otherwise stated, all mentioned drugs were bath perfused for at least 10 min before and 
during testing the effect of rivenprost. 
 
Table 3.2. Prostanoid receptor binding profiles for the employed agonists and antagonists. Specific binding was 
determined using displacement radioligand binding to HEK cell membranes expressing the EP receptors. The 
values represent the inhibition constant (Ki) in nM, whereas those with an asterisk (*) represent the IC50. 
 Ki (nM)       













PGE2 22 6.8 0.9 1.1 119 356 
Sulprostone 94 >100000 0.7 43600  356 
Misoprostol 11935 34 7.9 23  357 
Butaprost 38700 65 11815 15700  356 
Treprostinil 212 3.6 2505 826 4.4 358 
Rivenprost 10000 620 56 0.7   359 








PF-04418948 >10000* 16* >10000* >33300*   341 
L-798,106 >8400 >9200 0.2 >3200  361 
L-161,982 61000 58000 7000 32   362 
        
3.2.3.4 Influence of PGE2 on opioid-induced respiratory depression 
For the study IV, we hypothesized that the PGE2-induced irregular breathing would enhance 
the opioid-induced respiratory depression to cause major breathing disruption. In order to 
characterize the possible influence of PGE2 on opioid-induced respiratory depression, PGE2 at 
10 and 100 nM was used along with the MOR agonist DAMGO at 0.5 and 5 μM. To verify 
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that the effect of DAMGO was caused by the activation of MOR, the opioid receptor antagonist 
naloxone (5 μM, 10 min) was used. In addition, the implication of GIRK channels was studied 
by incubation with the GIRK2 gating inhibitor SCH-23390 (15 µM, 30 min). Finally, the 
involvement of the cAMP pathway was determined by the administration of rolipram (5 μM, 
10 min), an inhibitor of the cAMP degradative enzyme phosphodiesterase 4 (PDE4), at the 
concentrations previously used288. 
3.2.4 Data analysis and statistics 
3.2.4.1 Electrophysiology 
In electrophysiological experiments, the neuronal firing rate (FR) was collected in 10 s bin 
frequency histograms, where each bar represents the accumulated neuronal discharges in 10 
seconds (spikes 10 s-1). The inhibitory effect of [Met]enkephalin (ME, 0.8 µM, 1 min) was 
used as a control for the perfusion system (Figure 3.2), and to test the efficacy of some blockers 
that would presumably inhibit the effect of ME, such as the pertussis toxin, barium or SCH-
23390. The effect of prostanoid agonists could not be washed out easily. Thus, the effect (E) 
was calculated as the percentage of reduction/increase of firing rate from the baseline, 
according to the following equation: 
㨖⑌ܫ⑍ ᩛ 㨗㨣㨻㨽㨰  㨗㨣㨻㨺㨾㨿㨗㨣㨭㨬㨾㨬㨷
᧛  ڴڴڵ
Where:  
- E is the inhibitory/excitatory effect of the drug in percentage. 
- FRbasal is the average firing rate for 60 s at the beginning of the recording or immediately 
before the prostanoid receptor agonist administration. 
- FRpre is the average firing rate for 60 s immediately before drug application. 
- FRpost is the average firing rate after drug application, with the time of calculation 
depending on the kinetics of the drug effect as follows: 
 For ME application: average firing rate for 90 s, ruling out the first 40 s after 
switching to the drug solution (dead volume) (see Figure 3.2). 
 For EP3 receptor agonists: average firing rate for 60 s, ruling out the first 60 s 
after switching to the drug solution (dead volume) (see Figure 3.2). 
 For GABA application: average firing rate for the time of complete inhibition. 
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 For the EP2 and EP4 receptor agonists: average firing rate for 60 s, once it 
reached a plateau of firing rate (see Figure 3.3). 
 
Figure 3.2. Representative example of the firing rate of an LC neuron showing the inhibitory effect of ME (0.8 
μM) and sulprostone (2.5 and 5 nM). The vertical bars are the number of spikes accumulated every 10 s, whereas 
the horizontal lines represent the period of drug application. 
 
Figure 3.3. Representative example of the firing rate of an LC neuron showing the excitatory effect of butaprost 
(BUT, 1 μM), where the vertical bars are the number of spikes accumulated every 10 s, and the horizontal line 





To construct concentration-effect curves for the EP receptor agonists, increasing 
concentrations of the agonist were perfused (2 – 3x), until the maximal effect was reached. 
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Where: 
- E is the effect induced by each concentration of the agonist. 
- A is the concentration of the agonist (nM or μM). 
- Emax is the maximal effect (constrained to 100% in the case of the inhibitory effects, 
as no further inhibition could be recorded after the complete silencing of the neuron). 
- EC50 is the concentration of the agonist needed to elicit a 50% of the maximal effect. 
- n is the slope factor of the concentration-effect curve. 
 
EC50 values from individual experiments were finally converted to negative logarithm values 
(pEC50, M) to adjust them to a normal Gaussian distribution363 for further statistical analysis. 
 
Competitive antagonists compete with the agonist for the same binding site on the receptor 
and are their respective concentration and affinity which determines the prevalence of one or 
another. Ideally, increasing the concentration of the agonist would favor its action and the 
maximal effect will be reached. In a semi-logarithmic representation of the concentration-
effect curve, the presence of a competitive antagonist produces a parallel rightward shift in 
the concentration-effect curve for the agonist (Figure 3.4), indicating that a higher 
concentration of the agonist is required to obtain the same amount of effect. Supposing that 
the maximal effect is not reached in the presence of the antagonist under equilibrium 
conditions, the antagonist most likely behaves in a non-competitive manner (Figure 3.5).  
 
In addition to the concentration, the antagonist affinity value (pKB) dictates the outcome of 
the agonist-antagonist interaction. The pKB is the negative logarithm of the equilibrium 
dissociation constant of the antagonist-receptor complex (KB). When the antagonist causes a 
twofold shift in the concentration-effect curve for the agonist, the pKB is usually referred to 
as pA2 (see below). A few methods could be used to determine the pKB of a given antagonist. 
The most common one, the Gaddum/Schild, compares the whole curve shift. Additionally, if 
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more than three concentrations of the antagonist were employed, the EC50 displacement could 
be expressed graphically as the Schild plot, where the slope must be equal to one for 
competitive antagonists (Figure 3.4). If that is not the case, then a non-competitive binding 
could be assumed, and the affinity value could be derived by plotting double equieffective 
concentrations of the agonist in the absence and presence of the antagonist, in the so-called 
Gaddum method (Figure 3.5). 
 
In the first case, the Gaddum/Schild equation allows the global fitting of the curves364. In this 
method, control experiments in the absence of the antagonist were averaged into a theoretical 
curve, which was compared to each individual experimental curve obtained in the presence 




- Top and Bottom is the highest and lowest asymptote of the curves. 
- logEC50 is the logarithm of EC50 in the absence of the antagonist. 
- n is the slope. 
- S is the Schild slope, which was constrained to one. 
- [B] is the concentration of antagonist. 
- pA2 is the negative logarithm of the [B] that produces a 2-fold shift in the agonist 
EC50 by a factor of 2. When less than three different concentrations of the antagonist 
were employed, the term pA2 was substituted by pKB. 
 
pKB values for individual experiments were then grouped by the concentration of the 
antagonist, where a mean was extracted and compared statistically. Considering the pKB 
values should not depend on the concentration of the antagonist, the pKB values can then be 
pooled and averaged to yield a mean pKB365. However, when differences among the pKB 
values were found depending on the antagonist concentration (Table 3.3), the Schild analysis 
was used as an additional pKB estimation.  
 
The Schild analysis is based on the dextral displacement caused by the competitive antagonist 
in the concentration-effect curve for the agonist, which defines a concentration ratio (CR) as 




㨷㨺㨲⑌㨔㨣  ⑍ڵ ᩛ 㨷㨺㨲␡㨓␡  㨷㨺㨲㨜￈ 
 
Where: 
- [B] is the concentration of the antagonist (in M). 
- KB is the equilibrium dissociation constant of an antagonist from the receptor (in M). 
 
From the equation, it could be deduced that when the antagonist doubles the EC50 of the 
concentration-effect curve for a given agonist (CR = 2) (Figure 3.4), then log[B] would equal 
logKB. Therefore, the pA2 is the negative logarithm of the antagonist concentration that 
causes a 2-fold shift in the concentration-effect curve for the agonist. The linear relationship 
between log (CR – 1) and log[B] could be drawn in a Schild plot (Figure 3.4), where the pA2 
is the intercept of the x-axis when the ordinate value is zero (Figure 3.4). One of the 
advantages of the pA2 is that it is independent of the agonist concentration366.  
 
 
Figure 3.4. A) Simulated concentration-response curves showing the effect of an agonist in the absence (○) and 
presence (●) of an antagonist. The rightward shift implies that a concentration of the agonist needed to reach 
the EC50 (K) is higher in the presence of an antagonist (K’). Further, a concentration ratio (CR) could be 
established as the ratio of equieffective agonist concentrations367. B) Example of a Schild plot extracted from 





























Sulprostone + L-798,106 
3 µM 5.61 ± 0.15 - - 
10 µM 5.93 ± 0.12 - - 
Misoprostol + L-798,106 10 µM 5.91 ± 0.14 - - 
PGE2 + L-798,106 10 µM 6.26 ± 0.05* - - 
EP2 
Butaprost + PF-04418948 
3 nM 8.45 ± 0.18 - - 
10 nM 8.34 ± 0.25 - - 
Treprostinil + PF-04418948 10 nM - - 
8.34 (95% CI: 
8.29 – 8.38) 
EP4 
Rivenprost + L-161,982 
3 nM 8.84 ± 0.13 8.69 (95% CI: 
15.96 – 7.92) 
slope: 0.39 
(95% CI: 0.05 
– 0.72) 
- 
30 nM 7.94 ± 0.24† - 
300 nM 7.40 ± 0.08† - 
TCS 2510 + L-161,982 300 nM - - 
7.69 (95% CI: 
7.61 – 7.76) 
Values are expressed as mean ± SEM or 95% CI. *P < 0.05 when compared to the pKB values obtained with 
sulprostone or misoprostol as the standard agonist (one-way ANOVA followed by a Bonferroni’s post hoc test). 
†P < 0.05 when compared to the pKB values obtained with the different concentrations of the antagonist (one-way 




On the other hand, when the Schild slope differs from unity, the generated pA2 cannot be 
considered an estimate of the pKB. Thus, either the system had not reached the equilibrium 
conditions, or the antagonists are non-competitive. In both cases, the maximal effect can 
decrease. However, in the presence of a non-competitive antagonist, high receptor reserve (very 
efficacious agonists that only need a fraction of the total receptor population to elicit the 
maximal response) may result in a parallel shift of the concentration-effect curve with no 
depression in the Emax367,369. In the case of non-competitive antagonists, the affinity 
measurement was obtained from the Gaddum method by plotting double equieffective 
concentrations of the agonist in the absence (ordinates) and presence (abscissae) of the 
antagonist (Figure 3.5). The concentrations were extracted from the theoretical concentration-
effect curves for the agonist. Then, the equilibrium dissociation constant is calculated by: 
㨜￈ ᩛ￦ ␡㨓␡ϑ⑌㨾㨷㨺㨻㨰   ⑍ڵ
 
Figure 3.5. A) Concentration-effect curve for an agonist in the absence and presence of a non-competitive 
antagonist, which causes a decrease in the agonist maximal effect. B) Double reciprocal plot of equieffective 
concentrations in the presence and absence of a non-competitive antagonist. 
 
Statistical analysis was performed by the software GraphPad Prism (5.01 for Windows), SPSS 
statistics (22.0.0.1 for Windows) and Microsoft Excel 2016 (16.0.4639.1000 for Windows). 
Data were expressed as the mean ± standard error of the mean (SEM) of n number of 
experiments. For statistical evaluation, a paired Student’s t-test was used when the effects 
before and after the drug application were compared within the same cell or an unpaired 
Student’s t-test when two independent groups were compared. Comparison among more than 
two experimental conditions was made by one-way analysis of variance (ANOVA) followed 
by a Dunnett’s post hoc test or Bonferroni’s Multiple Comparison test only if F achieved the 
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necessary level of statistical significance (i.e., P < 0.05) and there was no significant variance 
inhomogeneity. Dunnett’s method is used for comparison with a control group and 
Bonferroni’s test for comparison among all the groups. The threshold for considering statistical 
significance was set at P = 0.05, and only one level of probability was reported. 
3.2.4.2 Calcium Time Lapse Imaging 
Ca2+ imaging time traces were analyzed with a recently published method278,370. Regions of 
interest (ROI) were marked for all cells based on the standard deviation of fluorescence 
intensity over time, using a semiautomatic, adapted ImageJ script kindly provided by Dr. John 
Hayes (The College of William and Mary, Williamsburg, VA, USA, 
http://physimage.sourceforge.net/). For each frame, the mean intensity value within each ROI 
was measured using ImageJ, along with their coordinates. Then, the fluorescence signals were 
normalized to baseline values. Synchronized activity between cells was measured by the 
Pearson correlation with a custom-made script in MATLAB (version 9.2.0.538062 R2017a; 
MathWorks, Natick, MA, USA) and by the mic2net toolbox278 (version 6.12; MathWorks). 
The calculated pair-wise correlation coefficients resulted in a correlation matrix that was 
converted to an adjacency matrix by applying a cut-off level. The cut-off level was selected by 
calculating the mean of the 99th percentile of correlation coefficients for a set of experiments 
with scrambled signals. Scrambling was performed by randomly translating all traces in the 
time-domain. The network structure was visualized by plotting a line between pairs of cells, 
where the color of the lines was proportionate to the correlation coefficient. The degree of 
connections within a network (connectivity) was defined as the number of cell pairs with a 
correlation coefficient larger than the cut-off value divided by the total number of cell pairs. 
PreBötC cells are organized in a small-world structure97 formed by hubs or nodes connected in 
clusters and allowing high connectivity efficiency with a minimal connection cost371. The 
information travels from one node to another, so that the parameter mean shortest path length 
(λ) could be defined as the minimum number of nodes that must be passed in between. In 
addition, the mean clustering coefficient (σ) is the number of neighbors of a node that are also 
neighbors of each other. Finally, as the small-world parameter (γ) equals σ/λ278 these networks 
are defined by short distance λ and high σ (For further details see figure 1.11 in the introduction 
section). The parameters were calculated by using the MATLAB BGL library 
(http://www.mathworks.com/matlabcentral/fileexchange/10922) and compared to the 
corresponding randomized networks. For each ROI a baseline fluorescence was determined 
(F0), which was used to normalize the change in fluorescence as ΔF/F0, where ΔF=F1-F0, 
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being F1 is the specific fluorescence intensity at a specific time point, and F0 is the average 
intensity of 30 s before and after F1. A previously published toolbox was used for the frequency 
analysis of time traces by the Fourier transform372. Data were further processed in GraphPad 
Prism 5.01 (GraphPad Software, Inc., USA) to create the figures. 
Since the preBötC is constituted by a heterogeneous population of cells and some of them were 
found insensitive to DAMGO283, the cells were sorted out into two groups depending on their 
behavior within the first 5 minutes of drug application. The behavior was defined as either 
decreased or increased Ca2+ oscillation frequency compared to control. This analysis allowed 
the proportion of cells that were affected by the drug in a certain way to be calculated. Then, 
the behavior of single cells could be followed.  
Experiments were excluded based on the following criteria: low dye loading, the total number 
of cells per slice less than 20, standard deviation (SD) at the control period higher than the 50% 
of the mean frequency, and peaks of maximum amplitude in the Fourier transform of calcium 
oscillation signal above 200 mHz.  
For statistical evaluation, a paired Student’s t-test was used when the effects before and after 
the drug application were compared within the same cell or an unpaired Student’s t-test when 
two independent groups were compared. Comparisons among more than two experimental 
conditions by one-way analysis of variance (ANOVA) followed by a Dunnett’s post hoc for 
comparison with a control group and only if F achieved the necessary level of statistical 
significance (i.e., P < 0.05) and there was no significant variance inhomogeneity. All 
calculations for the statistical tests were conducted with Microsoft Excel 2016 (16.0.4639.1000 
for Windows), LibreOffice Calc (6.0.7.3 for Ubuntu), and GraphPad Prism (5.01 for 
Windows). In all cases, P < 0.05 was considered statistically significant. Data are presented as 
mean ± SD.  
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4 RESULTS  
4.1 STUDY I – INHIBITION OF RAT LOCUS COERULEUS NEURONS VIA 
PROSTAGLANDIN E2 EP3 RECEPTOR: PHARMACOLOGICAL 
CHARACTERIZATION IN VITRO 
The results of this study are going to be submitted to the British Journal of Pharmacology. The 
written version of the manuscript has been attached in the section of accompanying 
manuscripts. 
Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons 
 
EP3 receptors are expressed in catecholaminergic neurons of the brain, including the LC65. 
To investigate the effect of EP3 receptor activation on the firing rate of LC neurons, we 
performed concentration-effect curves for sulprostone, an EP3 receptor agonist that shows 
more than 300-fold higher affinity for the EP3 receptor than for the EP1 receptor357. 
Increasing concentrations of sulprostone (1.25 – 320 nM, 2x, 1 min each) inhibited the 
neuronal activity of LC cells in a concentration-dependent manner with an EC50 value of 14.8 
nM (Figures 4.1A and C; Table 4.1). Complete inhibition of the firing rate of noradrenergic 
cells was achieved at the highest concentration of sulprostone used (20 – 320 nM) and 
persisted for 265 ± 53 s on average (n = 9). 
 
In order to study the EP receptor involved in the sulprostone-induced inhibitory effect, 
concentration-effect curves for sulprostone (0.15 nM – 1.28 µM) were performed in the 
presence of the EP3 receptor antagonist (L-798,106), the EP2 receptor antagonist (PF-
04418948) or the EP4 receptor antagonist (L-161,982) at 3 and 10 µM. Perfusion with L-
798,106 (3 µM) for 30 min did not change the firing rate of LC neurons, but reduced the 
steepness of the concentration-effect curve for sulprostone (Figure 4.1C; Table 4.1). 
Moreover, a higher concentration of L-798,106 (10 μM, 10 min) reduced by 17.7 ± 3.8 % the 
firing rate of LC neurons (n = 6, P < 0.05 compared to baseline) and shifted by 8 fold to the 
right the concentration-effect curve for sulprostone (Figures 4.1B and C; Table 4.1). The 
apparent affinity of L-798,106 for the EP3 receptor (pKB) was calculated to be 5.77 ± 0.10 




In contrast, the EP2 receptor antagonist PF-04418948 (3 µM) failed to cause significant 
changes in the firing rate or any rightward shift in the concentration-effect curve for 
sulprostone (Figure 4.2B; Table 4.1). Indeed, unexpectedly, the highest concentration of PF-
04418938 (10 µM) produced a 4-fold leftward shift in the concentration-effect curve for 
sulprostone (Figures 4.2A and B; Table 4.1). Similar to the EP2 receptor antagonist, 
perfusion with the EP4 receptor antagonist L-161,982 (3 and 10 µM) failed to change the 
firing rate or to shift to the right the concentration-effect curve for sulprostone (Figures 4.2C 
and D; Table 4.1). Altogether, these results indicate that the inhibitory effect of sulprostone 
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Figure 4.1. Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons in the absence or 
presence of the EP3 receptor antagonist L-798,106. (A, B) Representative examples of firing rate recordings of 
two LC neurons showing the effect of increasing concentrations of sulprostone in the absence (A) and presence 
of L-798,106 (10 µM) (B). The vertical lines represent the number of spikes recorded every 10 s and the 
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horizontal bars the period of drug application. (C) Concentration-effect curves for sulprostone in control (filled 
squares) and in the presence of L-798,106 (3 µM, open circles or 10 µM, filled circles). The horizontal axis 
shows the sulprostone concentration on a semi-logarithmic scale. The vertical axis expresses the reduction in 
firing rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at each sulprostone 
concentration obtained from n number of experiments. The lines through the data are the theoretical curves in 
each group constructed from the mean of the individual concentration-effect curve parameters, as estimated by 












































































































Figure 4.2. Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons in the presence of 
the EP2 receptor antagonist PF-04418948 or the EP4 receptor antagonist L-161,982. (A, B) Representative 
examples of firing rate recordings of two LC neurons showing the effect of increasing concentrations of 
sulprostone in the presence of PF-04418948 (10 µM) (A) or L-161,982 (10 µM) (B). (C, D) Concentration-
effect curves for sulprostone in control (filled squares) and in the presence of PF-04418948 (3 µM, open 
triangles or 10 µM, filled triangles) (C) or L-161,982 (3 µM, open diamonds or 10 µM, filled diamonds) (D).  
The horizontal axis shows the sulprostone concentration on a semi-logarithmic scale. The vertical axis expresses 
the reduction in firing rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at 
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each sulprostone concentration obtained from n number of experiments. The lines through the data are the 
theoretical curves in each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions. 
 
 
Table 4.1.  Basal firing rate and concentration-effect curve parameters for the inhibitory action of the EP3 receptor 
agonist sulprostone on LC neurons in the absence (control) or in the presence of the EP3 (L-798,106), EP2 (PF-
04418948), and EP4 (L-161,982) receptor antagonists. 
 _________________________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) pEC50 (M) (EC50, nM) Slope factor  n 
 _________________________________________________________________________________  
Sulprostone 
 Control  0.84 ± 0.07 7.83 ± 0.08 (14.8) 2.39 ± 0.37 9 
 + L-798,106 3 µM 0.64 ± 0.11 7.49 ± 0.09 (32.4) 1.39 ± 0.16* 6 
  10 µM 0.87 ± 0.22 6.89 ± 0.11* (128) 1.07 ± 0.12* 6 
 + PF-04418948 3 µM 0.66 ± 0.11 7.63 ± 0.15 (23.5) 1.89 ± 0.14 6 
  10 µM 0.58 ± 0.08 8.49 ± 0.10* (3.25) 1.61 ± 0.21 5 
 + L-161,982 3 µM 0.64 ± 0.11 8.05 ± 0.11 (8.93) 1.92 ± 0.36 5 
  10 µM 0.71 ± 0.12 8.08 ± 0.11 (8.34) 1.49 ± 0.11 5 
 _________________________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Maximal effect values were 
100% in all cases. pEC50 is the negative logarithm of the concentration needed to elicit 50% of the maximal effect. 







Effect of PGE2 and the PGE1 analog misoprostol on the firing rate of LC neurons 
 
To study whether the endogenous PGE2 and the PGE1 synthetic analog misoprostol mimic 
the inhibitory effect observed with sulprostone on the firing rate of LC cells, we performed 
concentration-effect curves for PGE2 and misoprostol. PGE2 (0.31 nM – 1.28 µM, 2x, 1 min 
each) concentration-dependently inhibited the firing rate of LC neurons with the EC50 being 
110 nM (Figures 4.3A and C; Table 4.2). Likewise, misoprostol (0.31 – 320 nM, 2x, 1 min 
each) inhibited the neuronal activity of LC cells with an EC50 of 50.7 nM (Figures 4.4A and 
C; Table 4.2).  
 
Perfusion with the EP3 receptor antagonist L-798,106 (10 µM) displaced by 19 and 9 fold, 
respectively, to the right the concentration-effect curves for PGE2 (0.31 nM – 10.2 µM) and 
misoprostol (0.31 nM – 2.56 µM) (both n = 5, P < 0.05; Figures 4.3B and C, 4.4B and C; 
Table 4.2). When PGE2 was used as the standard agonist, the pKB value for L-798,106 was 
higher (pKB = 6.26 ± 0.05; n = 5, P < 0.05, one-way ANOVA followed by Bonferroni’s 
Multiple Comparison test) than that with sulprostone (see above). However, the pKB value 
estimated for L-798,106 with misoprostol (pKB = 5.91 ± 0.14; n = 5, P > 0.05) was not 
different from that obtained with sulprostone. On the other hand, administration of a 
combination of the EP2 receptor antagonist PF-04418948 (10 µM) and the EP4 receptor 
antagonist L-161,982 (10 µM) caused a more than 6-fold leftward shift in the concentration-
effect curve for PGE2 (n = 5, P < 0.05; Figure 4.3C; Table 4.2). However, both antagonists 
in combination did not produce any shift in the concentration-effect curve for misoprostol 
(Figures 4.4C; Table 4.2). Finally, none of these antagonists changed the slope of the 
concentration-effect curves. As a whole, these results suggest that the endogenous ligand 
PGE2 and the PGE1 analog misoprostol inhibit the activity of LC neurons, preferentially 
through the EP3 receptor. In addition, administration of the EP2 and EP4 receptor antagonists 






























































































Figure 4.3. Effect of PGE2 on the firing rate of LC neurons in the absence or presence of the EP3 receptor 
antagonist L-798,106 or a combination of the EP2 receptor antagonist PF-04418948 and the EP4 receptor 
antagonist L-161,982. (A, B) Representative examples of firing rate recordings of two LC neurons showing the 
effect of increasing concentrations of PGE2 in the absence (A) and presence of L-798,106 (10 µM) (B). The 
vertical lines represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (C) Concentration-effect curves for PGE2 in control (filled squares) and in the presence of L-
798,106 (10 µM, filled circles) or PF-04418948 and L-161,982 (10 µM each, half-filled diamonds). The 
horizontal axis shows the PGE2 concentration on a semi-logarithmic scale. The vertical axis expresses the 
reduction in firing rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at each 
PGE2 concentration obtained from n number of experiments. The lines through the data are the theoretical 
curves in each group constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. Note that the concentration-effect curve for PGE2 is shifted to the right by 















































































Figure 4.4. Effect of misoprostol on the firing rate of LC neurons in the absence or presence of the EP3 receptor 
antagonist L-798,106 or a combination of the EP2 receptor antagonist PF-04418948 and the EP4 receptor 
antagonist L-161,982. (A, B) Representative examples of firing rate recordings of two LC neurons showing the 
effect of increasing concentrations of misoprostol in the absence (A) and presence of L-798,106 (10 µM) (B). 
The vertical lines represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (C) Concentration-effect curves for misoprostol in control (filled squares) and in the presence of 
L-798,106 (10 µM, filled circles) or PF-04418948 and L-161,982 (10 µM each, half-filled diamonds). The 
horizontal axis shows the misoprostol concentration on a semi-logarithmic scale. The vertical axis expresses 
the reduction in firing rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at 
each misoprostol concentration obtained from n number of experiments. The lines through the data are the 
theoretical curves in each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions. Note that the concentration-effect curve for misoprostol is 




Table 4.2.  Basal firing rate and concentration-effect curve parameters for the inhibitory action of the EP3 receptor 
agonists PGE2 and misoprostol on LC neurons in the absence (control) or in the presence of the EP3 (L-798,106) 
or a combination of the EP2 (PF-04418948) and EP4 (L-161,982) receptor antagonists. 
 _________________________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) pEC50 (M) (EC50, nM) Slope factor  n 
 _________________________________________________________________________________  
PGE2 
 Control  0.76 ± 0.10 6.96 ± 0.20 (110) 1.92 ± 0.36 5 
 + L-798,106 10 µM 0.87 ± 0.14 5.68 ± 0.05* (2098) 2.55 ± 0.47 5 
 + PF-04418948 10 µM   
     L-161,982 10 µM 0.83 ± 0.24 7.78 ± 0.19* (16.6) 1.07 ± 0.06 5 
Misoprostol 
 Control  0.80 ± 0.12 7.30 ± 0.13 (50.7) 1.85 ± 0.30 5 
 + L-798,106 10 µM 0.67 ± 0.11 6.34 ± 0.12* (455) 1.36 ± 0.28 5 
 + PF-04418948 10 µM   
     L-161,982 10 µM 0.72 ± 0.11 7.31 ± 0.12 (49.5) 1.76 ± 0.33 5 
 _________________________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Maximal effect values were 
100% in all cases. pEC50 is the negative logarithm of the concentration needed to elicit 50% of the maximal effect. 










Molecular mechanisms involved in the effect of EP3 receptor agonists on the firing rate of 
LC neurons 
 
The EP3 receptor has been shown to be coupled to Gi/o protein373 and GIRK channels374. 
Thus, to identify the molecular mechanisms involved in the EP3 receptor-mediated inhibition 
of firing rate of LC cells, we performed concentration-effect curves for sulprostone (0.31 nM 
– 1.28 µM, 2x) in slices incubated for 18 h with the irreversible Gi/o protein blocker pertussis 
toxin (PTX, 500 ng ml-1). In order to confirm that PTX had effectively blocked the Gi/o 
protein, only cells with a reduced inhibitory response (inhibition <80% of basal firing rate) 
to the Gi/o-coupled MOR agonist ME (0.8 µM, 1 min) were selected to perform the 
concentration-effect curves for sulprostone. Moreover, proper drug perfusion was tested with 
GABA (1 mM, 1 min), which has been shown to fully inhibit the firing rate through GABAA 
ionotropic receptors. Thus, overnight treatment of the slices with PTX shifted by 6 fold to 
the right the concentration-effect curve for sulprostone (n = 5, P < 0.05), without affecting 
the maximal response or the basal firing rate (Figures 4.5A, D; Table 4.3).  
 
To study the involvement of GIRK channels, we performed concentration-effect curves for 
sulprostone (0.31 nM – 2.56 µM, 2x) in the presence of the non-selective GIRK channel 
blocker BaCl2 or the selective GIRK2 gating inhibitor SCH-23390. Since ME-induced 
inhibitory effect depends on the opening of GIRK channels, ME (0.8 µM, 1 min) was 
previously applied in the presence of the GIRK channel blockers to confirm the blockade 
action. Thus, GIRK channel blockade with Ba2+ (300 μM, 15 min) and SCH-23390 (15 μM, 
30 min) reduced the inhibitory effect of ME by 29.6 ± 6.3% (n = 5, P < 0.05; Figure 4.5B) 
and by 25.2 ± 8.6% (n = 5, P < 0.05; Figure 4.5C), respectively, as previously described158,375. 
Bath perfusion with BaCl2 (300 μM, 15 min) increased the firing rate of LC neurons by 42.6 
± 13.1% (n = 5, P < 0.05 compared to baseline) and shifted by 3 fold to the right the 
concentration-effect curve for sulprostone (n = 5, P < 0.05; Figures 4.5B, D; Table 4.3). 
Likewise, bath administration of SCH-23390 (15 μM, 30 min) increased the firing activity of 
LC neurons by 144 ± 57% (n = 5, P < 0.05 compared to baseline) and shifted by 2 fold to the 
right the concentration-effect curve for sulprostone (n = 5, P < 0.05; Figures 4.5C, D; Table 
4.3). BaCl2 and SCH-23390 slightly reduced the maximal effect of sulprostone, but these 
changes did not reach statistical significances (Table 4.3). These results suggest that EP3 














































































































Figure 4.5. Effect of sulprostone on the firing rate of LC neurons after overnight treatment of the slices with 
the Gi/o inhibitor pertussis toxin (PTX) or in the presence of the GIRK blockers Ba2+ or SCH-23390. 
Representative examples of firing rate recordings of three LC neurons showing the effect of increasing 
concentrations of sulprostone after overnight treatment with PTX (500 ng ml-1) (A) or in the presence of BaCl2 
(300 µM) (B) or SCH-23390 (15 µM) (C). The vertical lines represent the number of spikes recorded every 10 
s and the horizontal bars the period of drug application. Note that the effect of ME (0.8 µM) is reduced compared 
to control (see Figure 4.1) while the inhibitory effect of GABA (1 mM) is maintained (A). (D) Concentration-
effect curves for sulprostone in control (filled squares) or after overnight treatment with PTX (500 ng ml-1, open 
triangles) or in the presence of Ba2+ (300 µM, filled circles) or SCH-23390 (15 µM, open squares). The vertical 
axis expresses the reduction in firing rate of LC as the percentage of the baseline. Data points are the mean ± 
SEM at each sulprostone concentration obtained from n number of experiments. The lines through the data are 
the theoretical curves in each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions. Note that the concentration-effect curve for sulprostone is 





Table 4.3.  Basal firing rate and concentration-effect curve parameters for the inhibitory action of sulprostone on 
LC neurons in the absence (control) or in the presence of PTX, BaCl2, and SCH-23390. 
 __________________________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) Emax (%) pEC50 (M) (EC50, nM) Slope factor  n 
 ______________________________________________________________________________________  
Sulprostone 
 Control  0.84 ± 0.07 100 7.83 ± 0.08 (14.8) 2.39 ± 0.37 9 
 + PTX 500 ng ml-1 1.12 ± 0.18 94.9 7.04 ± 0.15* (90.9) 1.65 ± 0.28 5 
 + BaCl2 300 µM 1.03 ± 0.13 94.6 7.27 ± 0.09* (53.7) 1.37 ± 0.18 5 
 + SCH-23390  15 µM 1.37 ± 0.28 87.5 7.46 ± 0.05* (34.6) 1.56 ± 0.17 5 
 ______________________________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the maximal inhibitory 
effect, and pEC50 is the negative logarithm of the concentration needed to elicit 50% of the Emax. *P < 0.05 when 




4.2 STUDY II – PHARMACOLOGICAL CHARACTERIZATION OF PROSTANOID 
EP2 RECEPTOR IN RAT LOCUS COERULEUS NEURONS IN VITRO 
The results of this study are going to be submitted to the British Journal of Pharmacology. The 
written version of the manuscript has been attached in the section of accompanying 
manuscripts. 
Effect of the EP2 receptor agonist butaprost on the firing rate of LC neurons 
 
In the brainstem, the EP2 receptor is expressed almost exclusively in the LC57, but its 
functional role remains unknown. To investigate the effect of EP2 receptor activation on the 
firing rate of LC neurons, we performed concentration-effect curves for the EP2 receptor 
agonist butaprost (10 nM – 10 µM). Administration of increasing concentrations of butaprost 
(10 nM – 10 μM, 3x, 15 min each) increased the firing rate of LC neurons (from 0.85 ± 0.09 
Hz to 1.38 ± 0.11 Hz; n = 8, P < 0.05) in a concentration-dependent manner with an EC50 
value of 0.45 μM (Figures 4.6A and C; Table 4.4).  
 
To elucidate which EP receptor was mediating the excitatory effect observed with butaprost, 
we constructed concentration-effect curves for this EP2 receptor agonist in the presence of 
the EP2 receptor antagonist PF-04418948 (3 and 10 nM) or a combination of the EP3 receptor 
antagonist L-798,106 (10 nM) and the EP4 receptor antagonist L-161,982 (10 nM). Bath 
application of PF-04418948 (3 and 10 nM) for 30 min did not change the firing rate, but the 
highest concentration (10 nM) shifted by 6 fold (n = 6, P < 0.05) to the right the 
concentration-effect curve for butaprost without affecting the maximal effect significantly  
(Figures 4.6B and C; Table 4.4). The calculated affinity for the EP2 receptor antagonist (pKB) 
was 8.39 ± 0.16 (n = 11). On the other hand, perfusion with a combination of L-798,106 and 
L-161,982 (10 nM each) for 30 min did not change the firing activity or shift to the right the 
concentration-effect curve for butaprost (Figures 4.7A and B; Table 4.4). There was a trend 
for the Emax to be higher after the combination of L-798,106 and L-161,982, but this increase 
was not significant (Figure 4.7B; Table 4.4). Altogether, these results suggest that butaprost 






Figure 4.6. Effect of the EP2 receptor agonist butaprost on the firing rate of LC neurons in the absence or 
presence of the EP2 receptor antagonist PF-04418948. (A, B) Representative examples of firing rate recordings 
of LC neurons showing the effect of increasing concentrations of butaprost in the absence (A) and presence of 
PF-04418948 (10 nM) (B). The vertical lines represent the number of spikes recorded every 10 s and the 
horizontal bars the period of drug application. (C) Concentration-effect curves for butaprost in control (filled 
circles) and in the presence of PF-04418948 (3 nM, open squares or 10 nM, filled squares). The horizontal axis 
shows the butaprost concentration on a semi-logarithmic scale. The vertical axis expresses the increase in firing 
rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at each butaprost 
concentration obtained from n number of experiments (see Table 4.4). The lines through the data are the 
theoretical curves in each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions. Note that the concentration-effect curve for butaprost is 




Figure 4.7. Effect of the EP2 receptor agonist butaprost on the firing rate of LC neurons in the presence of a 
combination of the EP3 receptor antagonist L-798,106 and EP4 receptor antagonist L-161,982. (A) 
Representative example of the firing rate recording of an LC neuron showing the effect of increasing 
concentrations of butaprost in the presence of L-798,106 and L-161,982 (10 nM each). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug application. (B) 
Concentration-effect curves for butaprost in control (filled circles) and in the presence of L-798,106 and L-
161,982 (10 nM each, open diamonds). The horizontal axis shows the butaprost concentration on a semi-
logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons as the percentage of the 
baseline. Data points are the mean ± SEM at each butaprost concentration obtained from n number of 
experiments (see Table 4.4). The lines through the data are the theoretical curves in each group constructed 








Table 4.4.  Basal firing rate and concentration-effect curve parameters for the excitatory action of the EP2 receptor 
agonists butaprost and treprostinil on LC neurons in the absence (control) or in the presence of the EP2 (PF-
04418948) or a combination of the EP3 (L-798,106) and EP4 (L-161,982) receptor antagonists. 
 __________________________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing  Emax (%)  pEC50 (M) (EC50, μM) Slope factor  n 
  rate (Hz) 
 __________________________________________________________________________________  
Butaprost 
Control  0.85 ± 0.09 74.3 ± 11.6 6.35 ± 0.10 (0.45) 1.65 ± 0.41 8 
+ PF-04418948    3 nM 0.87 ± 0.12 82.1 ± 18.4 5.98 ± 0.15 (1.05) 1.55 ± 0.30 5 
     10 nM 0.73 ± 0.08 105 ± 15 5.57 ± 0.08* (2.67) 1.55 ± 0.41 6 
+ L-798,106     10 nM 
   L-161,982     10 nM 0.67 ± 0.11 135 ± 29 6.25 ± 0.07 (0.56) 1.27 ± 0.14 5 
Treprostinil 
Control  0.68 ± 0.07 81.3 ± 6.5 6.27 ± 0.15 (0.54) 0.95 ± 0.12 6 
+ PF-04418948    10 nM 0.78 ± 0.13 42.8 ± 8.1* 6.55 ± 0.19 (0.28) 1.29 ± 0.34 6 
+ L-798,106      10 nM 
   L-161,982      10 nM 0.80 ± 0.12 144 ± 8* 6.34 ± 0.12 (0.46) 1.20 ± 0.09 5 
 _________________________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the maximal excitatory 
effect, and pEC50 is the negative logarithm of the concentration needed to elicit 50% of the Emax. *P < 0.05 when 








Effect of the PGI2 analog treprostinil on the firing rate of LC neurons 
 
To further study the effect of EP2 receptor activation in the LC, we used the PGI2 analog 
treprostinil, a clinically relevant drug that shows high affinity for the EP2 receptor in binding 
studies358. Thus, administration of increasing concentrations of treprostinil (30 nM – 10 μM, 
3x, 15 min each concentration) induced an excitatory effect on the firing rate of LC neurons 
in a concentration-dependent manner (from 0.68 ± 0.07 Hz to 1.22 ± 0.17 Hz; n = 6, P < 
0.05). The EC50 value for the concentration-effect curve for treprostinil was 0.54 μM (Figures 
4.8A and C; Table 4.4).  
 
Considering that treprostinil has a high affinity for other prostanoid receptors, we assessed 
whether the observed excitatory response was produced by the activation of the EP2 receptor 
by using the specific EP2 (PF-04418948), EP3 (L-798,106), or EP4 (L-161,982) receptor 
antagonists at 10 nM. Perfusion with PF-04418948 (10 nM) for 30 min did not modify the 
firing rate or the EC50 of the concentration-effect curve for treprostinil. However, the EP2 
receptor antagonist decreased by 47.4% the Emax value of the concentration-effect curve for 
treprostinil (n = 6, P < 0.05; Figures 4.8B and C; Table 4.4). Given the apparent non-
competitive binding, the affinity value of PF-04418948 for the EP2 receptor was calculated 
from the double reciprocal plot of equieffective agonist concentrations in the presence and 
absence of the antagonist369. Thus, the estimated pKB for PF-04418948 using treprostinil as 
an agonist was 8.34 (95% CI: 8.29 – 8.38). In addition, bath application of a combination of 
L-798,106 and L-161,982 did not produce any rightward shift but increased the Emax value 
of the concentration-effect curve for treprostinil by 77.7% (n = 5, P < 0.05; Figures 4.9A and 
B; Table 4.4). Thus, these results suggest that the treprostinil-induced stimulation of LC 






Figure 4.8. Effect of the EP2 receptor agonist treprostinil on the firing rate of LC neurons in the absence or 
presence of the EP2 receptor antagonist PF-04418948. (A, B) Representative examples of firing rate recordings 
of two LC neurons showing the effect of increasing concentrations of treprostinil in the absence (A) and 
presence of PF-04418948 (10 nM) (B). The vertical lines represent the number of spikes recorded every 10 s 
and the horizontal bars the period of drug application. (C) Concentration-effect curves for treprostinil in control 
(filled circles) and in the presence of PF-04418948 (10 nM, filled squares). The horizontal axis shows the 
treprostinil concentration on a semi-logarithmic scale. The vertical axis expresses the increase in firing rate of 
LC neurons as the percentage of the baseline. Data points are the mean ± SEM at each treprostinil concentration 
obtained from n number of experiments (see Table 4.4). The lines through the data are the theoretical curves in 
each group constructed from the mean of the individual concentration-effect curve parameters, as estimated by 




Figure 4.9. Effect of the EP2 receptor agonist treprostinil on the firing rate of LC neurons in the presence of a 
combination of the EP3 receptor antagonist L-798,106 and the EP4 receptor antagonist L-161,982. (A) 
Representative example of the firing rate recording of an LC neuron showing the effect of increasing 
concentrations of treprostinil in the presence of L-798,106 and L-161,982 (10 nM each). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug application. (C) 
Concentration-effect curves for treprostinil in control (filled circles) and in the presence of L-798,106 and L-
161,982 (10 nM each, open diamonds). The horizontal axis shows the treprostinil concentration on a semi-
logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons as the percentage of the 
baseline. Data points are the mean ± SEM at each treprostinil concentration obtained from n number of 
experiments (see Table 4.4). The lines through the data are the theoretical curves in each group constructed 










Study of cationic currents and cAMP/PKA signaling pathway involvement in EP2 receptor 
activation in LC neurons 
 
It is known that PGE2 increases a sodium current via activation of the EP2 receptor in neurons 
from different CNS areas such as the cerebellum376 or the spinal dorsal horn300. In the LC, 
NA cells are stimulated by a cAMP/PKA-induced inward sodium current327. Therefore, to 
test the putative involvement of sodium current in the butaprost-induced stimulation of LC 
cells, we used a low sodium-containing aCSF, in which 80% of the sodium had been replaced 
by TRIS328,329. Switching from the regular aCSF to a low-sodium aCSF (TRIS 80%) reduced 
the spontaneous activity of LC neurons by 66.5 ± 2.3% (from 1.11 ± 0.34 to 0.35 ± 0.11; n = 
7, P < 0.05; Figure 4.10A) and completely blocked the excitation caused by butaprost (1 μM) 
(n = 7, P < 0.05 vs. control; Figures 4.10A and B). This suggests that the excitatory effect of 
the EP2 receptor agonist butaprost is dependent on a sodium current. Next, to further describe 
the ion channel responsible for this sodium current, we tested whether the cation-permeable 
transient receptor potential (TRP) channel could be involved in the butaprost-induced effect. 
This family of channels has been reported to participate in the hypercapnic response of the 
LC213. Perfusion with the non-selective TRP channel blocker 2-APB (30 μM) reduced the 
LC cell firing rate by 40.2 ± 4.9% (from 0.76 ± 0.09 to 0.46 ± 0.07, n = 5, P < 0.05), but did 
not block the excitatory effect caused by butaprost (1 μM) (Figure 4.10C). Thus, the TRP 
channels do not appear to mediate the sodium current induced by the EP2 receptor agonist 
butaprost. Excitatory effects on the LC cell firing activity have also been reported to be 
elicited by the inhibitory ATP-sensitive K+ channels (the Kir6.2)344. Therefore, we tested the 
Kir6.2 channel blocker glibenclamide (3 μM), which administration for 15 min failed to 
affect the excitatory response induced by butaprost (1 μM) (n = 5, P > 0.05 vs. control; Figure 
4.10C). This suggests that the ATP-dependent K+ channels are not involved in the excitatory 







Figure 4.10. Effect of cationic current blockers on the butaprost-induced excitatory effect on LC neurons. (A) 
Representative example of the firing rate recording of an LC neuron showing the effect of butaprost (1 μM, 15 
min) in the presence of low-sodium aCSF (TRIS 80%, 5 min). The vertical lines represent the number of spikes 
recorded every 10 s and the horizontal bars the period of drug application. Note that TRIS 80% abolishes the 
stimulatory effect of butaprost. (B, C) Bar graphs showing the excitatory effect of butaprost (1 μM, 15 min) as 
the increase in the number of spikes per 10 s in the absence (control) and in the presence of TRIS 80% (n = 7) 
(B) or 2-APB (30 μM, black bar) or glibenclamide (3 μM, hatched bar) (both n = 5) (C). Bars are the mean ± 
SEM of n experiments. *P < 0.05 when compared to the control group (unpaired Student’s t-test).  
 
 
Then, to test whether the butaprost-induced activation of a sodium current is mediated by the 
cAMP/PKA pathway, we used 8-Br-cAMP (1 mM), a non-hydrolyzable cell-permeable 
cAMP analog that activates the PKA377 and sodium currents327. In the case that activation of 
the EP2 receptor by butaprost depended on the cAMP/PKA pathway, prior administration of 
a saturating concentration of 8-Br-cAMP would occlude the excitatory effect of butaprost. 
As expected from previous reports327, perfusion with 8-Br-cAMP (1 mM) for 8 min produced 
a 2-fold increase in the firing activity of LC neurons (from 0.71 ± 0.06 Hz to 1.40 ± 0.14 Hz; 
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n = 5, P < 0.05) (Figures 4.11A and B). However, administration of butaprost (1 μM, 15 min) 
in the presence of 8-Br-cAMP further increased the firing activity of LC cells (from 1.40 ± 
0.14 Hz to 1.97 ± 0.18 Hz; n = 5, P < 0.05) (Figures 4.11A and B), which suggests that the 
effect of butaprost was not occluded by 8-Br-cAMP. Therefore, the excitatory effect of the 
EP2 receptor agonist does not seem to depend on the cAMP/PKA pathway. To confirm it, 
we studied the effect of butaprost in the presence of the PKA inhibitor H-89. Bath application 
of H-89 (10 µM) for 20 min increased the LC firing rate by 18.0 ± 5.5% (from 0.87 ± 0.11 
Hz to 1.02 ± 0.14 Hz; n = 5, P < 0.05). However, H-89 did not change the parameters of the 
concentration-effect curve for butaprost (0.3 – 3 μM, 3x). Thus, the Emax value in the 
presence of H-89 was 86.3 ± 7.1% and the pEC50 was 6.19 ± 0.07 (EC50=0.64 μM; Figure 
4.11C), not different from those obtained in control (n = 5, P > 0.05; see Table 4.4). Hence, 
these data rule out the implication of the PKA in the excitatory effect of butaprost. On the 
other hand, a cationic current has been reported to be activated directly by increased levels 
of cAMP299,378 or the Gβγ subunits379 via activation of HCN channels without the involvement 
of PKA. In fact, HCN channels play a functional role in some responses of LC cells378 and 
to PGE2 in other CNS307 and peripherical neurons380. Then, to analyze whether the HCN 
channels may be involved in the stimulatory effect of butaprost, we perfused the EP2 receptor 
agonist in the presence of the HCN blocker ZD7288. Perfusion of ZD7288 (30 µM) for 20 
min increased the spontaneous firing rate of LC neurons by 77.0 ± 14.1% (from 0.70 ± 0.09 
Hz to 1.20 ± 0.09 Hz; n = 5, P < 0.05). However, the HCN blocker did not change the 
concentration-effect curve for butaprost (0.3 – 3 μM, 3x) (Emax = 64.4 ± 17.1%, pEC50 = 
6.40 ± 0.06, and EC50 = 0.40 μM; n = 5, P > 0.05 vs. control; see Table 4.4) (Figure 4.11C). 
Thus, the EP2 receptor activation does not seem to regulate LC neurons through the 








Figure 4.11. Effect of blocking the cAMP/PKA pathway and HCN channels on the butaprost-induced 
excitatory effect on LC neurons. (A) Representative example of the firing rate recording of an LC neuron 
showing the effect of butaprost (1 μM, 15 min) in the presence of 8-Br-cAMP (1 mM, 8 min). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug application. Note 
that 8-Br-cAMP increases the spontaneous discharge of the LC neuron and that butaprost produce an additional 
stimulatory effect. (B) Bar graph showing the increase in the number of spikes per 10 s caused by butaprost (1 
μM, white bar), 8-Br-cAMP (1 mM, black bar), butaprost in the presence of 8-Br-cAMP (hatched bar), and the 
arithmetic sum of the effects of butaprost and 8-Br-cAMP (black and white bar). Application of butaprost in 
the presence of 8-Br-cAMP further increased the excitatory effect caused by 8-Br-cAMP (paired Student’s t-
test). Note that application of 8-Br-cAMP does not occlude the excitatory response to butaprost since no 
difference was found between the effect of butaprost in the presence of 8-Br-cAMP and the sum of effects 
(unpaired Student’s t-test). Bars are the mean ± SEM of n experiments. (C) Concentration-effect curves for 
butaprost in control (filled circles, n = 8) and in the presence of the PKA inhibitor H-89 (10 μM, open circles) 
or the HCN channel blocker ZD7288 (30 μM, open triangles). The horizontal axis shows the butaprost 
concentration on a semi-logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons 
as the percentage of the baseline. Data points are the mean ± SEM at each butaprost concentration obtained 
from n number of experiments (n = 5 in all experimental groups). The lines through the data are the theoretical 
curves in each group constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. 
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Study of the involvement of Gαs and Gβγ subunits and presynaptic mechanisms on EP2 
receptor activation in LC neurons 
 
The EP2 receptor has been described to couple to Gs protein58. Therefore, we addressed 
whether the Gαs and Gβγ subunits would be involved in the stimulatory effect of butaprost. 
For this purpose, we used the Gαs-dependent signaling inhibitor NF449347 and the Gβγ-
dependent signaling inhibitor gallein. Administration of NF449 (10 μM) for 30 min did not 
modify the spontaneous firing activity of LC neurons. To verify that NF449 was effectively 
blocking the Gαs subunit, we used VIP (0.5 µM) as a positive control, given that VIP excites 
LC neurons via Gs-dependent activation of a sodium current172. Perfusion of VIP (0.5 μM, 5 
min) increased the firing rate by 82.5 ± 16.6% (from 0.69 ± 0.09 Hz to 1.24 ± 0.16 Hz; n = 
5, P < 0.05; Figure 4.12A). In the presence of NF449, the VIP-induced excitatory effect was 
reduced by 53% (n = 5, P < 0.05 vs. control; Figure 4.12A), which indicates that NF449 was 
readily blocking the Gαs-dependent signaling. However, unlike VIP, the excitatory effect of 
butaprost (1 µM) was not modified in the presence of NF449 (n = 6, P > 0.05 vs. control; 
Figure 4.12A). This result indicates that the effect of butaprost on LC neurons does not appear 
to require the Gαs signaling proteins. On the other hand, slice incubation with the Gβγ-
signaling inhibitor gallein (20 μM, 120 min) reduced the basal firing rate of LC neurons 
compared to baseline in controls before the administration of butaprost (0.85 ± 0.09 Hz in 
controls vs. 0.47 ± 0.10 Hz after gallein incubation; n = 7, P < 0.05) and reduced to nearly 
the half the excitatory effect of butaprost (1 µM) (n = 7, P < 0.05 vs. control; Figure 4.12B). 
In light of these results, the Gβγ subunits may be involved in the excitatory effect induced by 
the EP2 receptor agonist butaprost on LC neurons. 
 
Finally, to investigate whether a presynaptic mechanism could be involved in the excitatory 
effect of butaprost on the LC, we blocked the main inhibitory and excitatory receptors 
regulating the firing rate of LC cells: GABA and glutamate receptors. Perfusion with a 
combination of the GABAA channel blocker picrotoxin (100 μM), the non-NMDA receptor 
antagonist CNQX (30 μM), the NMDA receptor antagonist d-AP5 (100 μM), and the 
metabotropic receptor antagonist RS-MCPG (500 μM) increased the activity of NA cells by 
110 ± 14.3% (from 0.69 ± 0.10 Hz to 1.41 ± 0.14 Hz; n = 6, P < 0.05), as previously 
described349. However, blockade of presynaptic mechanisms did not reduce the excitation 
caused by butaprost (1 μM) but further potentiated it (n = 6, P < 0.05; Figure 4.12C). Thus, 
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these results suggest that the butaprost-induced excitatory effect on LC neurons is not caused 
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Figure 4.12. Effect of blocking the Gαs and Gβγ-dependent signaling and the presynaptic afferences on the 
butaprost-induced excitatory effect on LC neurons. (A, B) Bar graphs showing the excitatory effect of butaprost 
(1 μM, 15 min) as the increase in the number of spikes per 10 s in the absence (control, n = 8) and in the presence 
of NF449 (10 μM, 30 min, n = 6) (A) or gallein (20 μM, 120 min, n = 7) (B). VIP (0.5 μM, 5 min) was used as 
a positive control to demonstrate that NF449 was effectively blocking the Gαs subunits (both n = 5). (C) Bar 
graph showing the excitatory effect of butaprost in control (white bar) and after the administration of the 
synaptic blockers: Picrotoxin (100 μM), CNQX (30 μM), d-AP5 (100 μM), and RS-MCPG (500 μM) for 10 
min (n = 6). Bars are the mean ± SEM of n experiments. *P < 0.05 when compared to their respective control 




4.3 STUDY III – PHARMACOLOGICAL CHARACTERIZATION OF PROSTANOID 
EP4 RECEPTOR IN RAT LOCUS COERULEUS NEURONS IN VITRO 
The results of this study are going to be submitted to the British Journal of Pharmacology. The 
written version of the manuscript has been attached in the section of accompanying 
manuscripts. 
 
Effect of the EP4 receptor agonists rivenprost and TCS 2510 on the firing rate of LC neurons 
 
In situ hybridization studies have shown mRNA expression for the EP4 receptor in the LC57. 
Moreover, c-fos immunoreactivity is increased in response to a systemic pro-inflammatory 
cytokine in brain areas expressing the EP4 receptor, including the LC57. To study the role of 
the EP4 receptor in the regulation of the firing rate of LC neurons, we performed concentration-
effect curves for the EP4 receptor agonists rivenprost and TCS 2510. Increasing concentrations 
of rivenprost (0.01 – 100 nM, 3x, 10 min each) increased the firing rate of LC cells (from 0.70 
± 0.09 Hz to 1.14 ± 0.13 Hz; n = 6, P < 0.05) with an EC50 value of 1.4 nM and Emax of 83.7 
± 13.3% (Figures 4.13A and C; Table 4.5).  
To determine the EP receptor involved in the rivenprost-induced excitatory effect, the specific 
EP4 receptor antagonist L-161,982 (3, 30 and 300 nM), the EP2 receptor antagonist PF-
04418948 (300 nM), and the EP3 receptor antagonist L-798,106 (300 nM) were used. Bath 
application of L-161,982 (3, 30, and 300 nM, 30 min) did not change the firing rate of LC cells 
but 30 nM and 300 nM produced a 4-fold and 8-fold shift in the concentration-effect curve for 
rivenprost, respectively (n = 5, P < 0.05 for both 30 and 300 nM; Figures 4.13B and C; Table 
4.5). On the other hand, perfusion with PF-04418948 (300 nM) and L-798,106 (300 nM) did 
not change the firing rate and failed to shift the concentration-effect curve for rivenprost 
(Figures 4.14A and B; Table 4.5). These results suggest that the excitatory effect of rivenprost 
was mediated by EP4 receptor activation.  
The antagonist affinity of L-161,982 for the EP4 receptor (pKB) was estimated to be 8.06 ± 
0.18 (mean ± SEM, n = 14) when calculated with the Gaddum/Schild equation and assumed a 
Schild slope of unity381. However, the calculated pKB values were variable depending on the 
concentration of L-161,982 employed, resulting in a higher pKB value with 3 nM in comparison 
with 30 or 300 nM (8.84 ± 0.13 for 3 nM different from 7.94 ± 0.24 for 30 nM or 7.40 ± 0.08 
for 300 nM; n = 5, P < 0.05, one-way ANOVA followed by Bonferroni’s Multiple Comparison 
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Test). Therefore, we performed the Schild plot analysis and the resultant pA2 was 8.69 (95% 
CI: 15.96-7.92) with a Schild slope of 0.39 (95% CI: 0.05-0.72) different from unity (n = 5, P 
< 0.05) (Figure 4.13D). This means that, despite the rightward shift of the concentration-effect 
curve for rivenprost by L-161,982 (Figure 4.13C), the Schild slope was found different from 
1, which suggest a non-competitive condition for L-161,982 (see discussion). 
On the other hand, administration of the structurally different EP4 receptor agonist TCS 2510 
(0.20 nM – 2 μM, 3x, 10 min each) increased the firing rate of LC cells (from 0.71 ± 0.08 to 
1.55 ± 0.12 Hz; n = 6, P < 0.05), with an EC50 value of 18.0 nM and Emax of 98.4 ± 8.1% 
(Figures 4.15A and C; Table 4.5). Administration of the EP4 receptor antagonist L-161,982 
(300 nM) for 30 min decreased the maximal effect by 38% (n = 5, P < 0.05) and increased the 
slope steepness by 2 fold (n = 5, P < 0.05) (Figures 4.15B and C; Table 4.5), suggesting that 
the excitatory effect caused by TCS 2510 is mediated by EP4 receptor activation. Considering 
that the Emax reduction for TCS 2510 by L-161,982 may support the non-competitive behavior 
of the antagonist, we plotted double equieffective concentrations of TCS 2510 in the absence 
and presence of L-161,982 (300 nM) by the Gaddum method369, which yielded a pKB yielded 
of 7.69 (95% CI: 7.61 – 7.76). Overall, these results indicate that the activation of EP4 receptors 





Figure 4.13. Effect of the EP4 receptor agonist rivenprost on the firing rate of LC neurons in the absence or 
presence of the EP4 receptor antagonist L-161,982. (A, B) Representative examples of firing rate recordings of 
two LC neurons showing the effect of increasing concentrations of rivenprost in the absence (A) and presence of 
L-161,982 (300 nM) (B). The vertical lines represent the number of spikes recorded every 10 s and the horizontal 
bars the period of drug application. (C) Concentration-effect curves for rivenprost in control (filled circles) and in 
the presence of L-161,982 (3 nM, open circles; 30 nM, full triangles; and 300 nM, open triangles). The horizontal 
axis shows the rivenprost concentration on a semi-logarithmic scale. The vertical axis expresses the increase in 
firing rate of LC neurons as the percentage of the baseline. Data points are the mean ± SEM at each rivenprost 
concentration obtained from n number of experiments (see Table 4.5). The lines through the data are the theoretical 
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curves in each group constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. Note that the concentration-effect curve for rivenprost is shifted to the right by 
the EP4 receptor antagonist. (D) Schild plot for the three concentrations of L-161,982 obtained in the presence of 
rivenprost. The concentration ratio (CR) calculated from the EC50 of rivenprost in the presence of the antagonist 
divided by the EC50 of the agonist alone. The slope for the regression line was different from unity (0.39; 95% 
confidence limits between 0.05 and 0.72, and the correlation coefficient r2 = 0.996).  
 
Figure 4.14. Effect of the EP4 receptor agonist rivenprost on the firing rate of LC neurons in the absence or 
presence of a combination of the EP2 receptor antagonist PF-04418948 and EP3 receptor antagonist L-798,106. 
(A) Representative example of the firing rate recording of an LC neuron showing the effect of increasing 
concentrations of rivenprost in the presence of PF-04418948 and L-798,106 (300 nM each). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug application. (B) 
Concentration-effect curves for rivenprost in control (filled circles) and in the presence of PF-04418948 and L-
798,106 (300 nM each, filled squares). The horizontal axis shows the rivenprost concentration on a semi-
logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons as the percentage of the 
baseline. Data points are the mean ± SEM at each rivenprost concentration obtained from n number of experiments 
(see Table 4.5). The lines through the data are the theoretical curves in each group constructed from the mean of 
the individual concentration-effect curve parameters, as estimated by nonlinear regressions. 
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Table 4.5.  Basal firing rate and concentration-effect curve parameters for the excitatory action of the EP4 receptor 
agonists rivenprost and TCS 2510 on LC neurons in the absence (control) or in the presence of the EP4 (L-161,982) 
or a combination of the EP2 (PF-04418948) and EP3 (L-798,106) receptor antagonists.  
 __________________________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing  Emax (%)  pEC50 (M) (EC50, nM) Slope factor  n 
  rate (Hz) 
 __________________________________________________________________________________  
Rivenprost 
Control  0.70 ± 0.09 83.7 ± 13.3 8.84 ± 0.10 (1.43) 0.70 ± 0.17 6 
+ L-161,982     3 nM 0.80 ± 0.12 67.3 ± 14.2 8.43 ± 0.13 (3.72) 1.43 ± 0.43 5 
   30 nM 0.70 ± 0.07 62.2 ± 5.0 8.23 ± 0.08* (5.92) 0.97 ± 0.15 5 
 300 nM 0.82 ± 0.05 62.5 ± 7.5 7.93 ± 0.12* (11.8) 0.83 ± 0.10 5 
+ L-798,106 300 nM  
PF-04418948 300 nM 0.75 ± 0.09 80.6 ± 13.0 8.47 ± 0.16 (3.38) 0.81 ± 0.11 5 
TCS 2510 
Control  0.78 ± 0.07 98.4 ± 8.1 7.74 ± 0.19 (18.0) 0.67 ± 0.05 6 
+ L-161,982 300 nM 0.94 ± 0.08 61.0 ± 6.9* 7.43 ± 0.11 (37.5) 1.29 ± 0.25* 5 
 _________________________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the maximal excitatory 
effect, and pEC50 is the negative logarithm of the concentration needed to elicit a 50% of the Emax. *P < 0.05 
when compared to the control group of rivenprost (one-way ANOVA followed by a Dunnett’s post hoc test) or 






Figure 4.15. Effect of the EP4 receptor agonist TCS 2510 on the firing rate of LC neurons in the absence or 
presence of the EP4 receptor antagonist L-161,982. (A, B) Representative examples of firing rate recordings of 
two LC neurons showing the effect of increasing concentrations of TCS 2510 in the absence (A) and presence of 
L-161,982 (300 nM) (B). The vertical lines represent the number of spikes recorded every 10 s and the horizontal 
bars the period of drug application. (C) Concentration-effect curves for TCS 2510 in control (filled circles) and in 
the presence of L-161,982 (300 nM, open triangles). The horizontal axis shows the TCS 2510 concentration on a 
semi-logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons as the percentage of 
the baseline. Data points are the mean ± SEM at each TCS 2510 concentration obtained from n number of 
experiments (see Table 4.5). The lines through the data are the theoretical curves in each group constructed from 
the mean of the individual concentration-effect curve parameters, as estimated by nonlinear regressions. Note that 
the Emax of TCS 2510 decreases in the presence of the EP4 receptor antagonist. 
 
 81 
Study of cationic currents and cAMP/PKA signaling pathway involvement in EP4 receptor 
activation in LC neurons 
 
In cerebellar neurons, PGE2 has been described to elicit a sodium current via activation of 
Gs-coupled EP4 receptors and in a cAMP/PKA-mediated pathway376. In the LC, activation 
of the cAMP/PKA pathway is known to drive the spontaneous pacemaker activity149,382 
through the opening of an inward sodium current327. Therefore, to test the involvement of 
sodium current in the excitatory effect of rivenprost, we used a low sodium-containing aCSF, 
in which the 80% of the sodium had been replaced by TRIS (TRIS 80%)328,329. Perfusion 
with TRIS 80% reduced the spontaneous activity of LC neurons by 63.6 ± 2.6% (from 0.92 
± 0.31 to 0.34 ± 0.08; n = 6, P < 0.05) and completely blocked the excitatory effect caused 
by rivenprost (30 nM) (n = 6, P < 0.05; Figures 4.16A and B). This result implies that the 
excitatory effect of the EP4 receptor agonist rivenprost is dependent on a sodium current. 
Next, to characterize the molecular substrate for this sodium current, we checked whether the 
cation-permeable transient receptor potential (TRP) channel was involved. PGE2 has been 
reported to increase the activity of these channels in EP4 receptor-expressing cells383. 
Administration of the non-selective TRP channel blocker 2-APB (30 μM) reduced the LC 
cell firing activity by 41.7 ± 6.1% (from 0.74 ± 0.09 Hz to 0.45 ± 0.11 Hz; n = 5, P < 0.05) 
but it failed to alter the excitatory effect induced by rivenprost (30 nM) (Figure 4.16B). 
Therefore, the TRP channels do not appear to mediate the sodium current induced by the EP4 
receptor agonist rivenprost.  
 
Next, to test whether the cAMP/PKA pathway is involved in the EP4 receptor agonist effect, 
we perfused rivenprost in the presence of 8-Br-cAMP, a non-hydrolyzable cell-permeable 
cAMP analog that activates the PKA enzyme377. Thus, if rivenprost exerted its effect through 
the cAMP cascade, prior administration of a saturating concentration of 8-Br-cAMP would 
occlude the excitatory effect induced by rivenprost. As expected from previous reports327 
(see study II), PKA activation with 8-Br-cAMP (1 mM, 8 min) increased by 2 fold the firing 
rate of LC neurons (from 0.73 ± 0.06 Hz to 1.42 ± 0.12 Hz; n = 5, P < 0.05) (Figure 4.16C). 
However, administration of rivenprost (30 nM, 10 min) in the presence of 8-Br-cAMP further 
increased the firing activity of LC cells (from 1.42 ± 0.12 Hz to 2.02 ± 0.13 Hz; n = 5, P < 
0.05) (Figure 4.16C), which suggests that the effect of rivenprost was not occluded by 8-Br-
cAMP. Therefore, the excitatory effect of the EP4 receptor agonist does not apparently 
depend on the cAMP/PKA pathway. To further test this hypothesis, we studied the effect of 
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rivenprost (30 nM) in the presence of the PKA inhibitor H-89 (10 μM). Bath application of 
H-89 (10 µM) for 20 min increased the LC firing rate by 8.99 ± 3.36% (from 0.62 ± 0.06 Hz 
to 0.68 ± 0.08 Hz; n = 5, P < 0.05). However, H-89 did not change the magnitude of 
rivenprost-induced excitation (Figure 4.16D). Hence, these data indicate that the effect of the 
EP4 receptor agonist rivenprost on the LC is dependent on a sodium current but independent 
of the cAMP/PKA pathway.  
 
Figure 4.16. Effect of blocking a sodium current and the cAMP/PKA pathway on the rivenprost-induced 
excitatory effect on LC neurons. (A) Representative example of the firing rate recording of an LC neuron 
showing the effect of rivenprost (30 nM, 10 min) in the presence of low-sodium aCSF (TRIS 80%, 5 min). The 
vertical lines represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. Note that TRIS 80% abolishes the stimulatory effect of rivenprost. (B) Bar graph showing the 
increase in the number of spikes per 10 s caused by rivenprost (30 nM) in the absence (control, n = 6) and in 
the presence of TRIS 80% (black bar, n = 6) or 2-APB (30 μM, hatched bar, n = 5). (C) Bar graph showing the 
increase in the number of spikes per 10 s by rivenprost (30 nM, white bar, n = 6), 8-Br-cAMP (1 mM, black 
bar, n = 5), rivenprost in the presence of 8-Br-cAMP (hatched bar, n = 5), and the arithmetic sum of the effects 
of rivenprost and 8-Br-cAMP (black and white bar). Application of rivenprost in the presence of 8-Br-cAMP 
further increased the excitatory effect caused by 8-Br-cAMP (paired Student’s t-test). Note that 8-Br-cAMP 
does not occlude the excitatory response to rivenprost since no difference was found between the effect of 
rivenprost in the presence of 8-Br-cAMP and the arithmetic sum of effects (unpaired Student’s t-test). (D) Bar 
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graph showing the excitatory effect of rivenprost (30 nM, n = 6) in the presence of the PKA inhibitor H-89 (10 
μM, n = 5) compared to control. Bars are the mean ± SEM of n experiments. *P < 0.05 when compared to the 
control group (unpaired Student’s t-test). 
 
We have previously shown that the effect of the EP2 receptor agonist butaprost is also 
dependent on a sodium current but independent of the cAMP/PKA pathway (see Study II). 
Therefore, we studied whether the administration of butaprost at a submaximal concentration 
would occlude the following stimulatory effect of rivenprost. As previously described, 
administration of butaprost (1 μM, 15 min) increased the firing rate of LC neurons by 61.4 ± 
9.7% (from 0.74 ± 0.10 Hz to 1.19 ± 0.17 Hz; n = 5, P < 0.05) (Figures 4.17A and B). However, 
in the presence of butaprost, rivenprost (30 nM) further increased the LC cell firing activity 
(from 1.19 ± 0.17 Hz to 1.51 ± 0.22 Hz; n = 5, P < 0.05) (Figures 4.17A and B), indicating that 
the excitatory effect of rivenprost was not occluded by butaprost. These data suggest that the 
EP2 and EP4 receptors do not share the same signaling pathway to excite the activity of LC 
neurons. 
 
Figure 4.17. Effect of butaprost on the rivenprost-induced excitatory effect on LC neurons. (A) Representative 
example of the firing rate recording of an LC neuron showing the effect of rivenprost (30 nM, 10 min) in the 
presence of butaprost (1 μM, 15 min). The vertical lines represent the number of spikes recorded every 10 s and 
the horizontal bars the period of drug application. (B) Bar graph showing the increase in the number of spikes 
per 10 s caused by rivenprost (30 nM, white bar, n = 6), butaprost (1 μM, black bar, n = 5), rivenprost in the 
presence of butaprost (hatched bar, n = 5), and the arithmetic sum of the effects of rivenprost and butaprost 
(black and white bar). Application of rivenprost in the presence of butaprost further increased the excitatory 
effect caused by butaprost (paired Student’s t-test). Note that application of butaprost does not occlude the 
excitatory response to rivenprost since no difference was found between the effect of rivenprost in the presence 




Study of the involvement of Gαs and Gβγ subunits, and PI3K and PKC signaling mechanisms 
in EP4 receptor activation in LC neurons 
 
The EP4 receptor is described to be coupled to Gs protein in cerebellar neurons376. In order to 
study whether the Gαs protein mediated the effect of rivenprost on the LC, we used the specific 
Gαs-dependent signaling inhibitor NF449. Administration of NF449 (10 μM) for 20 min did 
not change the firing activity of LC neurons, but blunted by 42.1% the excitatory effect induced 
by rivenprost (30 nM) (n = 6, P < 0.05 vs. control; Figures 4.18A and B), suggesting that the 
effect of rivenprost was mediated by the Gαs protein. In addition, we studied the involvement 
of the Gβγ subunits by testing the effect of rivenprost in the presence of the selective inhibitor 
gallein. Bath incubation with gallein (20 μM) for 120 min did not change the rivenprost-
induced excitation (n = 5, P > 0.05 vs. control; Figure 4.18A). These results indicate that the 
Gβγ subunits are not involved in the excitatory effect of rivenprost on LC cells. 
In addition to Gαs protein, the EP4 receptor has been described to be coupled to the PI3K 
signaling pathway in cultured cells81,352 and microglia384. Furthermore, PI3K signaling is 
needed for the leptin-induced excitatory effect in hypothalamic neurons355. Therefore, we 
tested the effect of rivenprost in the presence of the PI3K inhibitor wortmannin. Administration 
of wortmannin (100 nM) for 20 min did not change the spontaneous activity of LC cells and 
failed to block the excitatory effect of rivenprost (30 nM), suggesting that the stimulatory effect 
of rivenprost was not mediated by the PI3K. In fact, in the presence of wortmannin, the effect 
of rivenprost was increased by 58.3% (n = 5, P < 0.05 vs. control; Figure 4.18C). On the other 
hand, PKC activity is required for the PGE2-induced modulation of sodium currents in sensory 
neurons385 and the PGE2-induced hypernociception in vivo386. Therefore, we examined the 
involvement of PKC by testing the effect of rivenprost in the presence of the PKC inhibitor 
chelerythrine. Bath perfusion of chelerythrine (10 μM) for 30 min did not change the firing 
activity of LC neurons and failed to prevent the increase in excitability of LC neurons caused 
by rivenprost (30 nM). Furthermore, the rivenprost-induced excitatory effect was increased by 
2 fold in the presence of chelerythrine (n = 5, P < 0.05 vs. control; Figure 4.18C). In light of 
this result, the PKC does not seem to mediate the rivenprost-induced excitation. In summary, 
the excitatory effect observed upon EP4 receptor activation seems to be mediated by the Gαs 
subunits, whereas the Gβγ subunits and the PK3K and PKC signaling pathways are not 






Figure 4.18. Effect of blocking the Gαs and Gβγ-dependent signaling, and the PI3K and PKC enzymes on the 
rivenprost-induced excitatory effect on LC neurons. (A) Representative example of the firing rate recording of 
an LC neuron showing the effect of rivenprost (30 nM, 10 min) in the presence of NF449 (10 µM, 20 min). The 
vertical lines represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. Note that NF449 hinders the stimulatory effect of rivenprost. (B, C) Bar graphs showing the 
increase in the number of spikes per 10 s caused by rivenprost (30 nM, 10 min) in the absence (control, n = 6) 
or in the presence of NF449 (10 μM, black bar, n = 6) or gallein (20 μM, hatched bar, n = 5) (B) or the PI3K 
inhibitor wortmannin (100 nM, black bar, n = 5) or the PKC inhibitor chelerythrine (10 μM, hatched bar, n = 






4.4 STUDY IV – INTERACTION BETWEEN OPIOIDS AND PROSTAGLANDIN E2 
IN THE INSPIRATION-GENERATING PREBÖTZINGER COMPLEX 
The results of this study are going to be submitted to The Journal of Physiology. The written 
version of the manuscript has been attached in the section of accompanying manuscripts.  
Effect of the MOR agonist DAMGO on the cellular activity and network connectivity of the 
preBötC in vitro 
 
The rhythmic cellular activity of the preBötC is directly related to the respiratory frequency236, 
so its neuronal hyperpolarization can lead to apneas in vivo265. Moreover, it is considered 
indispensable for the opioid-induced respiratory depression255, as the majority of the NK1R+ 
cells (i.e., respiratory neurons) in the preBötC co-express MOR119. Therefore, to determine the 
effect of opioids in preBötC cells in vitro, we applied the high-affinity MOR agonist DAMGO 
(0.5 – 5 μM) for 15 min to organotypic slices and measured Ca2+ fluctuations. DAMGO (0.5 
µM) did not modify the Ca2+ transient amplitude or frequency at any time (n = 7) but the highest 
concentration of DAMGO (5 µM) reduced by 17.2 ± 7.8% the relative amplitude and by 21.7 
± 6.8% the frequency of Ca2+ transients within 5 min (n = 7, P < 0.05 compared to baseline; 
Figures 4.19A, B, C, and D, Table 4.6). Furthermore, within the first 5 min of recording, the 
effect of the highest concentration of DAMGO (5 µM) was greater than that of DAMGO 0.5 
µM (n = 7, P < 0.05 compared to DAMGO 0.5 µM; Figures 4.19B and C) and more cells were 
inhibited (75.3 ± 11.0% vs. 46.9 ± 14.5%, respectively; n = 7 each, P < 0.05; Figure 4.19D). 
The inhibitory effect of DAMGO (5 µM) persisted throughout the experiment (15 min) 
(Figures 4.19B and C) showing a small recovery in the Ca2+ oscillatory frequency during the 
last 5 min of application (n = 7, P < 0.05 when compared to the previous 5 min period; Figure 
4.19C), possibly due to MOR desensitization387. Furthermore, NK1R+ neurons showed a 
similar inhibition in the Ca2+ transient relative amplitude and frequency to the whole cell 
population (Figure 4.19A, Table 4.6), and possibly suggesting that the effect on respiratory 
neurons might define the behavior of the whole network. In light of these results, the opioid 
agonist DAMGO reduced the Ca2+ oscillatory activity of respiratory neurons in preBötC 
organotypic cultures. 
 
During an inflammatory state or at birth, there is an endogenous release of PGE2388, which has 
been shown to increase the frequency of gasps and sighs at low concentrations99 via activation 
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of the Gi/o-coupled EP3 receptor in the preBötC97. Furthermore, a mutual dependency on the 
cAMP pathway has been suggested for both opioids and prostanoids324. Thus, to study the 
possible interaction between the prostanoid and the opioid systems, we analyzed the effect of 
DAMGO in mice genetically modified to lack the PGE2-EP3 receptor (Ptger3-/-) and compared 
them to wild-type mice (WT). Administration of DAMGO (5 µM) in Ptger3-/- mice did not 
inhibit Ca2+ transient amplitude and produced a delayed effect on the oscillatory frequency, as 
it did not change within the first 10 min, and required 15 min to inhibit to the same extent than 
WT mice did within 5 min (17.0 ± 13.4% reduction within 15 min in Ptger3-/- mice; n = 8, P < 
0.05 compared to baseline; Figures 4.19B and C). This result means that the DAMGO-induced 
reduction in Ca2+ transient frequency was more gradual in mice lacking the EP3 receptor, but 
equal in magnitude as in WT mice. Furthermore, this trend held for respiratory neurons, which 
showed a decrease in Ca2+ signaling frequency only within 15 min of DAMGO (5 µM) 
administration. Thus, showing that the modification in Ca2+ transient amplitude induced by 
DAMGO (5 µM) was hindered in Ptger3-/-. Overall, this delayed effect of opioids in mice 
lacking the EP3 receptor suggests an interaction between the opioid and the prostanoid systems. 
 
PreBötC pacemaker neurons have synchronized activity mediated by gap junctions and 
excitatory synaptic interactions262,275. This synchronized activity between interconnected cells 
is crucial for driving the inspiratory output262. According to the algorithm employed, two cells 
are defined as connected if their correlation coefficient exceeds the set cut-off278. 
Administration of DAMGO (5 µM) reduced the mean correlation above cut-off values in WT 
mice (from 0.74 ± 0.06 to 0.59 ± 0.07; n = 7, P < 0.05; Figure 4.19E) thus suggesting a reduced 
interconnectivity among cells. Furthermore, DAMGO (5 µM) administration reduced the 
number of correlations per active cell (from 33 ± 21 to 6 ± 3; n = 7, P < 0.05), suggesting a 
reduced functional coupling. Likewise, Ptger3-/- mice displayed similar reductions in the mean 
correlation above cut-off (from 0.86 ± 0.04 to 0.67 ± 0.10; n = 8, P < 0.05) and the number of 
correlations per active cell (from 61 ± 35 to 28 ± 18; n = 8, P < 0.05) upon DAMGO (5 µM) 
application. These results suggest that the opioid receptor agonist DAMGO reduced the 
network synchronization of preBötC cells in organotypic slices and that this effect was not 
altered in mice lacking the EP3 receptor. 
 
Synchronized bursting activity depends on the network topology389 and preBötC neurons 
organize into clusters interconnected by hubs resembling the small-world architecture97,276.  
Thereby, neighboring cells in a network are wired with a few migratory outputs that reduce the 
 
 89 
average path length between nodes277,278, and thus providing efficient transmission of 
information371. These networks are defined by the parameters: mean clustering coefficient (σ), 
mean shortest path length (λ), and small-world parameter (γ= σ/λ). DAMGO (0.5 – 5 µM) 
increased the σ within 5 min in WT mice (n = 7, both P < 0.05 compared to baseline; Figure 
4.19F) and then it returned to baseline, suggesting increased segregation into clusters and 
tendency towards local connections during the first 5 min. Similarly, DAMGO (0.5 – 5 µM) 
increased the γ parameter (n = 7, both P < 0.05 compared to baseline; Figure 4.19F), indicating 
an enhancement of small-world features. Furthermore, the highest concentration of DAMGO 
(5 µM) increased λ by 11.8 ± 6.7% (n = 7, P < 0.05 compared to baseline; Figure 4.19F) and 
produced a higher increase in σ and γ than with DAMGO (0.5 µM) (n = 7, both P < 0.05; 
Figure 4.19F). Likewise, DAMGO (5 µM) increased σ and γ in Ptger3-/- mice within the same 
period (5 min) (Figure 4.19F) and did not change any further afterward. However, the 
DAMGO-induced effect on σ and γ was lower in Ptger3-/- than in WT mice (σ by 71.7% and γ 
by 75.5%; n = 8, both P < 0.05 compared to WT; Figure 4.19F). This result suggests that the 
effect of DAMGO on the network parameters may be hindered in mice lacking the EP3 
receptor. Overall, these data insinuate that DAMGO reduced the synchronicity of the network 
by promoting segregation and local connections within a cluster with a reduction in the 
outgoing information. 
 
Finally, to ascertain whether the observed effects induced by DAMGO were mediated by MOR 
activation, we tested the effect of DAMGO (5 µM) in the presence of the MOR antagonist 
naloxone. Administration of naloxone (5 µM) for 10 min did not change the Ca2+ signaling 
activity but completely abolished the DAMGO-induced reduction in Ca2+ transient frequency 
or relative amplitude in the whole network and respiratory neurons (P < 0.05 compared to 
control in the absence of naloxone; Table 4.6). Furthermore, naloxone blocked the DAMGO-
induced modifications of the network parameters and connectivity. These results suggest that 
MOR activation mediates the inhibitory effect induced by DAMGO in preBötC cellular activity 





Figure 4.19. DAMGO modulates preBötC network activity and connectivity. (A) Localization of the preBötC in 
a sagittal drawing of the brainstem and in the coronal slice, which also contains the nucleus ambiguus (NA), the 
nucleus tractus solitarius (NTS), and the nucleus hypoglossus (XII) (Adapted from 97). Effect of DAMGO (5 µM) 
administration on representative Ca2+ traces as ΔF/F0 from regular cells (black; #1 and 2) and NK1R+ cells 
(respiratory neurons; #3 and 4 in blue) and their localization in a single frame of the Ca2+ signaling recording from 
a WT mouse (top right). (B) Inhibitory effect of DAMGO (0.5 – 5 µM) on Ca2+ transient relative amplitude and 
frequency (C) as a percentage of the baseline value in WT (circles) and Ptger3-/- (diamonds). (D) Cells that showed 
a decrease in Ca2+ transient frequency within 5 min of DAMGO (5 µM) administration as a percentage (gray filled 
circles) and their subsequent behavior over time, in comparison with the non-sensitive cells. Note that sensitive 
cells displayed a higher baseline frequency. (E) Graphical depiction of the network structure on top of NK1R-
labelled cells. Each line represents the correlation coefficient above the set cut-off for the cell pairs, and warmer 
colors are a stronger correlation between the cells connected by the line. Administration of DAMGO (5 µM) 
decreased the number of correlated cells and the correlation coefficient. (F) Network parameter values revealing 
a small-world topology during baseline and upon DAMGO (0.5 – 5 µM) administration in WT and Ptger3-/- mice. 
Note that the highest concentration of DAMGO caused more effect than the lowest. Data are presented as means 
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± SD. * P < 0.05 compared to baseline (paired Student’s t-test) and # P < 0.05 when compared among groups 
(paired Student’s t-test in D and ANOVA followed by a Dunnett’s post hoc test in the rest). A.U.: arbitrary units. 
Scale bars: 100 µm. 
 
Table 4.6. Inhibitory effect of DAMGO (5 µM) within 5 min on the Ca2+ transient frequency and amplitude of 
preBötC cells (network) and respiratory neurons (NK1R+) in vitro in the absence and presence of naloxone (5 
µM). N: number of slices, n: number of cells. Data are presented as mean ± SD. *P < 0.05 when compared to their 
respective baseline values. Note that the effect on the respiratory networks resembled the effect of the whole 
network.  
 Relative amplitude (ΔF/F0) Mean frequency (mHz) 
 Cells Sample size Baseline +DAMGO (5 μM) Baseline +DAMGO (5 μM) 
Control network N=7, n=977 31.1 ± 3.0 25.6 ± 1.2* 55.6 ± 3.6 43.3 ± 2.9* 
 NK1R+ N=7, n= 110 32.6 ± 6.4 25.4 ± 1.9* 54.8 ± 3.9 43.1 ± 2.5* 
Naloxone (5 µM) network N=8, n=1300 31.1 ± 3.9 30.7 ± 5.2 56.0 ± 7.3 54.7 ± 5.9 
 NK1R+ N=6, n=95 30.3 ± 4.4 29.3 ± 6.8 55.4 ± 7.5 50.3 ± 9.3 
 
 
Effect of PGE2 and its interaction with DAMGO on the cellular activity and network 
connectivity of the preBötC in vitro 
 
Prostaglandins have been reported to inhibit the inspiratory nerve discharge in brainstem-spinal 
cord preparations324 and to increase the frequency of sighs in vivo97. This effect may be 
particularly threatening in neonates, as high levels of PGE2 metabolite in neonatal 
cerebrospinal fluid has been associated with severe perinatal asphyxia104. Furthermore, 
activation of EP3 receptors in the preBötC has been shown to decrease the Ca2+ transient 
frequency97. Here, we aimed to understand whether prostaglandins and opioids may interact to 
produce major respiratory depression. Thus, we examined the effect of PGE2 in preBötC 
organotypic cultures and then tested the effect of DAMGO in the presence of PGE2. 
Administration of PGE2 (10 – 100 nM) for 5 min did not modify the relative Ca2+ transient 
amplitude but reduced the Ca2+ transient frequency in WT mice (n = 12 and n = 10, 
respectively, both P < 0.05 compared to baseline; Table 4.7; Figures 4.20A and B). This PGE2-
induced inhibitory effect was not observed in Ptger3-/- mice (n = 9 and n = 10, respectively, 
both P < 0.05 compared to WT; Table 4.7; Figure 4.20A), which suggests that EP3 receptor 
activation mediates the inhibition of network activity caused by PGE2 in the preBötC in vitro, 
as already described97. Further, the effect of the highest concentration of PGE2 (100 nM) was 
greater than that of PGE2 (10 nM) (n = 10 and n = 12, respectively, P < 0.05; Table 4.7; Figures 
4.20A and B) and more cells were inhibited (72.3 ± 8.5% vs. 58.3 ± 13.8%; n = 10 and n = 12, 
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respectively, P < 0.05; Figure 4.20B). Notably, during PGE2 (100 nM) administration, the Ca2+ 
transient frequency reduction in NK1R+ cells was similar to the whole cell population (Table 
4.7), thus suggesting that preBötC respiratory neurons were sensitive to PGE2, in accordance 
with previous studies97. 
 
Next, we assessed the possible interaction between opioids and prostaglandins by applying 
DAMGO in the presence of PGE2. Thus, the lowest concentration of DAMGO (0.5 µM) in the 
presence of PGE2 (10 nM) did not further change Ca2+ transient amplitude or frequency (from 
53.5 ± 5.8 mHz to 51.8 ± 5.1 mHz in WT, before and after DAMGO administration; n = 12, P 
> 0.05 compared to the frequency during PGE2 administration; Figures 4.20A and B). 
Similarly, bath perfusion with the highest concentration of DAMGO (5 µM) in the presence of 
PGE2 (100 nM) did not further inhibit the Ca2+ transient frequency, but decreased the amplitude 
of the whole network and NK1+ cells (n = 10, P < 0.05 compared to baseline; Table 4.7, Figures 
4.20A and B). Furthermore, the DAMGO-induced reduction in Ca2+ transient frequency was 
smaller in the presence of PGE2 than in the absence in WT but not in Ptger3-/- (P < 0.05 
compared to controls in the absence of PGE2), which suggest that the inhibitory effect of 
DAMGO was prevented by prior administration of PGE2 in an EP3 receptor-dependent 
manner. Overall, these data indicate that the onset of PGE2-induced inhibitory effect on Ca2+ 
oscillatory activity prevented any further reduction caused by DAMGO. Thus, EP3 receptor 
activation apparently occluded the effect of DAMGO and therefore, both EP3 and MOR 
receptor activation seems to share a similar signaling pathway, as elsewhere mentioned324. 
 
Table 4.7. Inhibitory effect of PGE2 (100 nM) within 5 min on the Ca2+ transient frequency of preBötC cells 
(network) and respiratory neurons (NK1R+) in vitro and effect of subsequent DAMGO (5 µM) administration in 
the presence of PGE2 (100 nM). N: number of slices, n: number of cells. Data are presented as mean ± SD. * P < 
0.05 when compared to their respective baseline values. Note that the effect on the respiratory networks resembled 
the effect of the whole network and that the inhibitory effect of PGE2 was absent in slices from Ptger3-/- mice. 
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + PGE2 (100 nM) + DAMGO (5 μM) 
WT network N=10, n=1460 59.9 ± 5.2 48.2 ± 6.1* 50.9 ± 7.4*  
 NK1R+ N=8, n= 43 59.2 ± 7.4 51.6 ± 8.6* 52.6 ± 5.7  
Ptger3-/- network N=10, n=1938 55.1 ± 5.3 50.9 ± 9.5 47.8 ± 5.1*  





Analysis of the network Ca2+ activity revealed that PGE2 (10 nM) did not modify any 
parameter, but PGE2 (100 nM) decreased the mean correlation above cut-off values in WT 
(from 0.74 ± 0.13 to 0.62 ± 0.10; n = 10, P < 0.05 compared to baseline; Figure 4.20C) and 
Ptger3-/- mice (from 0.77 ± 0.14 to 0.59 ± 0.15; n = 10, P > 0.05 compared to WT). These 
results suggest a decreased network synchronicity induced by PGE2, which was not apparently 
mediated by the EP3 receptor. However, PGE2 (100 nM) reduced the number of correlations 
per active cell in WT (from 36 ± 16 to 21 ± 17; n = 10, P < 0.05 compared to baseline) but not 
in Ptger3-/- mice, which implies that EP3 receptor activation may reduce the functional 
interconnectivity among cells. Overall, these data indicate that PGE2 reduces the network 
connectivity and synchronicity of preBötC cells and that this effect may be partly mediated by 
EP3 receptor activation.  
 
Intriguingly, DAMGO (5 µM) in the presence of PGE2 (100 nM) increased the mean 
correlation above cut-off values (from 0.62 ± 0.10 to 0.82 ± 0.09; n = 10, P < 0.05 compared 
to the decrease observed during PGE2 administration; Figure 4.20C) in WT but not in Ptger3-/- 
mice. Additionally, DAMGO (5 µM) administration in the presence of PGE2 (100 nM) 
reversed the number of correlations per active cell to baseline conditions (from 21 ± 17 to 34 
± 26; n = 10, P < 0.05 compared to the decrease observed during PGE2 administration) in WT 
but not in Ptger3-/- mice. These data suggest that DAMGO in the presence of PGE2 increased 
the cellular activity synchronization, which was exactly the opposite behavior than in the 
absence of PGE2 (see above). These could be due to an inhibitory effect of DAMGO on a 
broader number of cells, and then a network resynchronization (see discussion). 
 
Finally, regarding the small-world topology, PGE2 (100 nM) increased σ and γ in WT mice (n 
= 10, P < 0.05 compared to baseline; Figure 4.20D), suggesting segregation into stronger local 
connections and small-worldness. On the other hand, this effect was not observed in Ptger3-/- 
mice or with the lowest concentration of PGE2 (10 nM) (n = 12, P > 0.05 compared to baseline; 
Figure 4.20D). Thus, suggesting that activation of EP3 receptors mediated the increase of 
segregation and small-world properties caused by PGE2 application. In addition, subsequent 
administration of DAMGO (0.5 – 5 µM) in the presence of PGE2 (10 – 100 nM) did not change 
any further the network parameters in WT (n = 10, P < 0.05 compared to baseline; Figure 
4.20D) and Ptger3-/- mice. This result suggests that activation of EP3 receptors mediated by 





Figure 4.20. PGE2 (10 – 100 nM) reduces preBötC network activity and connectivity in WT but not in Ptger3-/- 
mice and occludes the subsequent inhibitory effect induced by DAMGO (0.5 – 5 µM). (A) Representative Ca2+ 
traces as ΔF/F0 from regular cells (top black) and NK1R+ cells (respiratory neurons, bottom blue) in WT (left) and 
Ptger3-/- mice (right). (B) Effect of PGE2 (10 and 100 nM) and DAMGO (0.5 and 5 µM) administration on Ca2+ 
transient amplitude (left) and frequency (center) as a percentage of the baseline value in WT. Note that DAMGO 
in the presence of PGE2 did not produce a further inhibitory effect on the Ca2+ transient frequency. At the right: 
cells that showed a decrease in Ca2+ transient frequency within 5 min of PGE2 (100 nM) administration as a 
percentage (gray filled circles) and their subsequent behavior over time, in comparison with the non-sensitive cells. 
Note that PGE2-sensitive cells displayed a higher baseline frequency and that DAMGO administration did not 
change the Ca2+ transient frequency in those cells, but decreased that of the PGE2 non-sensitive cells. (C) Graphical 
depiction of the network structure on top of NK1R-labelled cells. Each line represents the correlation coefficient 
above the set cut-off for the cell pairs, and warmer colors are a stronger correlation between the cells connected 
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by the line. Administration of PGE2 (100 nM) decreased the number of correlated cells and the correlation 
coefficient in WT mice, and this effect was reversed by DAMGO (5 µM). (F) Network parameter values revealing 
a small-world topology during baseline and upon PGE2 (10 – 100 M) administration in WT. Note that the highest 
concentration of PGE2 produced a greater effect. Subsequent administration of DAMGO (5 µM) in the presence 
of PGE2 (100 nM) did not change the network parameters any further. Data are presented as means ± SD. * P < 
0.05 compared to baseline (paired Student’s t-test) and # P < 0.05 when compared among groups (paired Student’s 
t-test in A and unpaired in D). A.U.: arbitrary units. Scale bars: 100 µm. 
 
Involvement of the cAMP/PKA pathway in the inhibitory effect caused by PGE2 and DAMGO 
on the cellular activity and network connectivity of the preBötC in vitro  
 
Both MOR and EP3 receptor activation has been described to couple to Gi/o protein286,373, which 
is known to decrease the production of cAMP. Further, a previous study made in isolated 
brainstem-spinal cord preparations has reported that pharmacological elevation of cAMP levels 
reversed the PGE1- and opioid-induced inhibition of the respiratory nerve discharge324. To 
assess whether the proposed common mechanism converges on the cAMP pathway in the 
preBötC, we utilized the phosphodiesterase 4 (PDE4) inhibitor rolipram (5 µM), which 
potentially increases cAMP pathway signaling by blocking cAMP degradation. Then, we tested 
the effect of DAMGO (5 µM) and PGE2 (100 nM) in the presence of rolipram. Bath perfusion 
of rolipram (5 µM) for 10 min increased relative Ca2+ transient amplitude within the first 5 min 
(n = 8, P < 0.05 compared to baseline), returning back to baseline levels after these 5 min 
(Figures 4.21A and B) and decreased the Ca2+ transient frequency within 10 min (n = 8, P < 
0.05 compared to baseline; Table 4.8, Figures 4.21A and B). On the other hand, upon rolipram 
administration, respiratory neurons showed a similar tendency in the Ca2+ oscillatory activity 
than the whole network, but it did not reach statistical significance (P > 0.05 compared to 
baseline; Table 4.8, Figure 4.21B). Given that a low number of slices were dyed for the NK1R 
in this group (Table 4.8), we pooled the NK1R+ data of rolipram administration from before 
PGE2 and DAMGO to test whether the respiratory neurons would reflect the response observed 
in the whole network. Thus, pooling the NK1R+ data resulted in significant changes in Ca2+ 
transient relative amplitude within 5 min (from 26.5 ± 3.8 to 30.6 ± 4.4; n = 12, P < 0.05 
compared to baseline) and frequency within 10 min (from 57.7 ± 6.0 to 51.1 ± 7.2; n = 12, P < 
0.05 compared to baseline). This result indicates that blocking the degradation of cAMP 
increased the relative Ca2+ transient amplitude, but decreased the Ca2+ transient frequency of 




Next, we tested the effect of DAMGO after these modifications in Ca2+ oscillatory relative 
amplitude and frequency induced by rolipram. Administration of rolipram (5 µM) completely 
blocked the DAMGO (5 µM)-induced changes in Ca2+ transient relative amplitude and 
frequency in the whole network (n = 8, P < 0.05 compared to control in the absence of rolipram, 
Table 4.8; Figures 4.21A, B, and C) and NK1R+ cells (n = 5, P < 0.05 compared to control in 
the absence of rolipram) (Figures 4.21A and B; Table 4.8). These results indicate that the cAMP 
pathway may have a role in the inhibitory effect caused by DAMGO in the cellular activity of 
the respiratory network and respiratory neurons of the preBötC. 
 
Likewise, rolipram (5 µM) prevented the reduction in Ca2+ transient frequency induced by 
PGE2 (100 nM) in the whole network (P < 0.05 compared to control in the absence of rolipram; 
Table 4.8, Figures 4.21A, B, and C). Further, this blockade was also observed in respiratory 
neurons, which did not display any further decrease in the Ca2+ transient frequency upon PGE2 
administration (P > 0.05 compared to the previous 5 min period in the presence of rolipram; 
Table 4.8; Figure 4.21B). However, this effect was not different from NK1R+ cells in controls 
(P > 0.05 compared to control in the absence of rolipram). These results indicate that inhibition 
of the cAMP degradation reverted the modification in the respiratory network activity induced 
by PGE2, but not that observed in respiratory neurons. Overall, these data suggest that the levels 
of cAMP may modulate the respiratory depression observed with opioids and prostaglandins, 
as previously suggested324, and thus, that the cAMP pathway may be the endpoint of the 
presumed common signaling mechanism. 
 
Table 4.8. Inhibitory effect of rolipram (5 µM) within 10 min on the Ca2+ transient frequency of preBötC cells 
(network) and respiratory neurons (NK1R+) in vitro and effect of subsequent DAMGO (5 µM) or PGE2 (100 nM) 
administration in the presence of rolipram (5 µM). N: number of slices, n: number of cells. Data are presented as 
mean ± SD. * P < 0.05 when compared to their respective baseline values. N.S.: not significant when the group of 
DAMGO or PGE2 was compared to the previous 5 min period in the presence of rolipram. Note that once rolipram 
had decreased the Ca2+ transient frequency, neither DAMGO nor PGE2 induced any further modification. 
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + rolipram (5 µM) + DAMGO or PGE2 
DAMGO  network N=8, n=1943 57.3 ± 4.6 52.8 ± 3.1* 50.9 ± 2.7* N.S. 
(5 µM) NK1R+ N=5, n= 78 52.2 ± 3.7 46.3 ± 4.6 49.2 ± 5.4 N.S. 
PGE2 network N=8, n=1796 57.3 ± 3.1 53.3 ± 3.4* 52.0 ± 5.2* N.S. 





Regarding the network circuitry, administration of rolipram (5 µM) reduced the mean 
correlation above cut-off within 10 min (from 0.74 ± 0.04 to 0.65 ± 0.08; n = 8, P < 0.05 
compared to baseline; Figure 4.21D) and hindered the DAMGO (5 µM)-induced modification 
in the mean correlation above cut-off (from 0.65 ± 0.08 to 0.68 ± 0.06; n = 8, P < 0.05 compared 
to control in the absence of rolipram; Figure 4.21D). These results suggest that rolipram may 
reduce the interconnectivity among cells but prevented that caused by DAMGO. Furthermore, 
rolipram administration did not change the number of correlations per active cell but blocked 
the reduction caused by DAMGO (from 14 ± 14 to 12 ± 15; n = 8, P > 0.05 compared to 
baseline before DAMGO). However, this effect was not different from that observed under 
control conditions (n = 8, P > 0.05 compared to control in the absence of rolipram), possibly 
due to the high variability. These data suggest that inhibition of cAMP degradation partially 
hampered the effect of DAMGO on the network configuration. Furthermore, administration of 
rolipram (5 µM) for 10 min did not modify σ, γ or λ, but abolished the DAMGO-induced 
changes in small-world features (n = 8, P < 0.05 compared to control in the absence of rolipram; 
Figure 4.21E). Thus, these results suggest that the cAMP pathway seems to mediate the 
decrease in network synchronicity and connectivity caused by DAMGO in the preBötC. 
 
Furthermore, bath perfusion of rolipram (5 µM) reduced the mean correlation above cut-off 
within 10 min (from 0.80 ± 0.06 to 0.71 ± 0.11; n = 8, P < 0.05 compared to baseline; Figure 
4.21D) and blocked the reduction in the mean correlation above cut-off induced by PGE2 (100 
nM) (from 0.71 ± 0.11 to 0.68 ± 0.11; n = 8, P < 0.05 compared to control in the absence of 
rolipram; Figure 4.21D). Additionally, PGE2 in the presence of rolipram did not alter the 
number of correlations per active cell (from 12 ± 13 to 5 ± 5; n = 8, P > 0.05 compared to 
baseline before PGE2) but this effect was not different from that observed under control 
conditions (n = 8, P > 0.05 compared to control in the absence of rolipram). These data suggest 
that the cAMP pathway seems to be partially involved in the effect of PGE2 on the network 
configuration. Further, PGE2 (100 nM) in the presence of rolipram did not change σ or γ (n = 
8, P > 0.05 compared to baseline before PGE2; Figure 4.21E). However, this effect was not 
different from that observed in controls (n = 8, P > 0.05 compared to control in the absence of 
rolipram), possibly due to the high variability. Thus, these data reveal that blockade of cAMP 
degradation with rolipram hindered the inhibitory effect of PGE2 on Ca2+ transient frequency 
and network synchronicity, but it did not seem to intervene in the small-world topology 
modification caused by PGE2. As a whole, the cAMP pathway seemed to be involved in both 





Figure 4.21. Administration of rolipram (5 µM) prevented both DAMGO (5 µM)- and PGE2 (100 nM)-induced 
reduction in preBötC network activity and connectivity. (A) Effect of rolipram (5 µM) and subsequent 
administration of DAMGO (5 µM) or PGE2 (100 nM) on Ca2+ transient relative amplitude (top) and frequency 
(bottom). Note that neither DAMGO nor PGE2 modified the Ca2+ transient relative amplitude or frequency after 
administration of rolipram. (B) Representative Ca2+ traces showing the effect of rolipram and subsequent DAMGO 
or PGE2 administration as ΔF/F0 from regular cells (top black) and NK1R+ cells (respiratory neurons, bottom blue). 
(C) Effect of DAMGO (5 µM) or PGE2 (100 nM) in the presence of rolipram (5 µM) on Ca2+ transient frequency 
compared to their respective control in the absence of rolipram. The effects were normalized to their baseline in 
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control or baseline in the presence of rolipram). (D) Graphical depiction of the network structure. Each line 
represents the correlation coefficient above the set cut-off for the cell pairs, and warmer colors are a stronger 
correlation between the cells connected by the line. Administration of rolipram (5 µM) decreased the correlation 
coefficient in WT mice, and subsequent application of DAMGO (5 µM) (top) or PGE2 (100 nM) (bottom) did not 
decrease the mean correlation any further. (E) Rolipram (5 µM) prevented the increase in network parameter 
values induced by DAMGO (5 µM), but not that of PGE2 (100 nM). The experimental values were normalized to 
their respective baseline. Data are presented as means ± SD. * P < 0.05 compared to baseline (paired Student’s t-
test) and # P < 0.05 when compared among groups (unpaired Student’s t-test).  
 
Involvement of GIRK channel activation in the inhibitory effect caused by PGE2 and DAMGO 
on the cellular activity of the preBötC in vitro 
 
Opioid-induced respiratory depression in vivo is thought to be mediated by GIRK channels290. 
Thus, to verify the involvement of GIRK channels in the inhibitory effect caused by DAMGO 
or PGE2 in vitro, we incubated the organotypic slices with the GIRK channel blocker SCH-
23390 (15 µM) for 30 min during Fluo-8 loading, and then, we tested the effect of DAMGO 
(5 µM) or PGE2 (100 nM) by time-lapse Ca2+ imaging. Incubation with SCH-23390 (15 µM) 
did not alter the basal Ca2+ transient amplitude (baseline ΔF/F0 without SCH-23390 = 31.3 ± 
3.0 vs. with SCH-23390 = 27.5 ± 3.4; n = 8, P > 0.05) nor frequency (baseline without SCH-
23390 = 55.6 ± 3.6 mHz vs. with SCH-23390 = 57.3 ± 5.5 mHz; n = 8, P > 0.05) compared to 
baseline values before DAMGO (5 µM) administration in controls. However, GIRK channel 
blockade with SCH-23390 completely prevented the inhibitory effect of DAMGO (5 µM) on 
Ca2+ transient amplitude and frequency in the whole network and NK1R+ cells (n = 8, P < 0.05 
compared to control in the absence of SCH-23390; Table 4.9, Figures 4.22A and B). This result 
indicates that GIRK channel activation is involved in the opioid-induced inhibition of 
respiratory network and respiratory neurons in vitro. 
 
Next, we determined whether SCH-23390 would hinder as well the PGE2-induced inhibition 
in Ca2+ oscillatory frequency. Thus, upon SCH-23390 (15 µM) incubation, PGE2 (100 nM) did 
not reduce the Ca2+ transient frequency in the whole network and respiratory neurons (P < 0.05 
compared to control in the absence of SCH-23390; Table 4.9, Figures 4.22A and B). This result 
suggests that GIRK channel activation seemed to participate in both the opioid- and PGE2-





Regarding the network connectivity, slice incubation with SCH-23390 (15 µM) did not change 
the baseline values of mean correlation above cut-off (without SCH-23390: 0.74 ± 0.06 vs. 0.80 
± 0.09 with SCH-23390; n = 8, P > 0.05 compared to baseline values before DAMGO 5 µM 
administration in controls). However, SCH-23390 hampered DAMGO (5 µM)-induced 
reduction in the mean correlation above cut-off (from 0.80 ± 0.09 to 0.70 ± 0.09; n = 8, P < 
0.05 compared to control in the absence of SCH-23390; Figure 4.22C) and the number of 
correlations per active cell (from 23 ± 15 to 16 ± 15; n = 8, P < 0.05 compared to control in the 
absence of SCH-23390). Therefore, GIRK channel activation seemed to contribute to the 
asynchronous network activity caused by DAMGO in the preBötC. Further, incubation with 
SCH-23390 (15 µM) did not change the σ, γ or λ parameters compared to control (n = 8, P < 
0.05 compared to control in the absence of SCH-23390). However, SCH-23390 blocked the 
DAMGO (5 µM)-induced modification of small-world features, as it prevented the increase in 
σ and γ parameters caused by DAMGO (n = 8, P < 0.05 compared to control in the absence of 
SCH-23390; Figure 4.22D). Therefore, in view of these data, GIRK channel activation was 
involved in the reduction of cellular calcium activity produced by DAMGO, and also in the 
modification of the network synchronicity and small-world topology of preBötC cells in vitro.   
 
On the other hand, after slice incubation with SCH-23390 (15 µM), PGE2 (100 nM) did not 
significantly reduce the mean correlation above cut-off (from 0.79 ± 0.08 to 0.75 ± 0.09; n = 9, 
P > 0.05 compared to baseline; Figure 4.22C) but this effect was not different from that 
observed under control conditions (n = 9, P > 0.05 compared to control in the absence of SCH-
23390). Furthermore, GIRK channel blockade with SCH-23390 did not prevent the reduction 
in the number of correlations per active cell caused by PGE2 (100 nM) (from 30 ± 23 to 4 ± 2; 
n = 9, P < 0.05 compared to baseline and P > 0.05 vs. control in the absence of SCH-23390). 
Thus, GIRK channel activation was not apparently involved in the PGE2-induced reduction of 
the network synchronicity. Further, PGE2 (100 nM) administration after slice incubation with 
SCH-23390 did not increase the σ and γ parameters (Figure 4.22D), and this effect was not 
different from control in the absence of SCH-23390 (n = 9; P > 0.05 compared to control). 
Thus, blocking the GIRK channel activation did not seem to prevent the asynchronous network 
activity and small-world topology caused by PGE2 in preBötC organotypic cultures. Overall, 
these data indicate that GIRK channel activation seems to mediate the opioid- and PGE2-
induced inspiratory frequency inhibition, but it does not apparently intervene in the network 






Figure 4.22. Administration of SCH-23390 (15 µM) prevented both DAMGO (5 µM)- and PGE2 (100 nM)-
induced reduction in preBötC network activity. (A) Representative Ca2+ traces showing the effect of SCH-23390 
and subsequent DAMGO or PGE2 administration as ΔF/F0 from regular cells (top black) and NK1R+ cells 
(respiratory neurons, bottom blue). Note that neither DAMGO nor PGE2 modified the Ca2+ transient relative 
amplitude or frequency after administration of rolipram. (B) Effect of DAMGO (5 µM) or PGE2 (100 nM) after 
incubation SCH-23390 (15 µM) on Ca2+ transient frequency compared to their respective control in the absence 
of SCH-23390. The effects were normalized to their respective baseline. (C) Graphical depiction of the network 
structure. Each line represents the correlation coefficient above the set cut-off for the cell pairs, and warmer colors 
are a stronger correlation between the cells connected by the line. Incubation with SCH-23390 (15 µM) prevented 
the decrease in the number of correlated cells and the correlation coefficient induced by DAMGO (5 µM), but not 
that induced by PGE2 (100 nM). (D) SCH-23390 (15 µM) prevented the increase in network parameter values 
induced by DAMGO (5 µM), but not that of PGE2 (100 nM). The experimental values were normalized to their 
respective baseline. Data are presented as means ± SD. * P < 0.05 compared to baseline (paired Student’s t-test) 






Table 4.9. Effect of SCH-23390 (15 µM) incubation on the Ca2+ transient frequency of preBötC cells (network) 
and respiratory neurons (NK1R+) in vitro and effect of subsequent DAMGO (5 µM) or PGE2 (100 nM) 
administration in the presence of SCH-23390 (15 µM). N: number of slices, n: number of cells. Data are presented 
as mean ± SD. N.S.: not significant when the group of DAMGO or PGE2 was compared to their respective baseline.  
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + DAMGO or PGE2 
DAMGO (5 µM) network N=8, n=755 57.3 ± 5.5 55.2 ± 7.6 N.S. 
 NK1R+ N=5, n=72 54.6 ± 7.4 55.9 ± 4.6 N.S. 
PGE2 (100 nM) network N=9, n=1000 59.0 ± 6.8 53.8 ± 5.2 N.S. 







5.1 STUDY I – INHIBITION OF RAT LOCUS COERULEUS NEURONS VIA 
PROSTAGLANDIN E2 EP3 RECEPTOR: PHARMACOLOGICAL 
CHARACTERIZATION IN VITRO 
The present work was undertaken to characterize the functional role of EP3 receptors in LC 
neurons in rat brain slices. Our results show that the EP3 receptor agonists sulprostone, PGE2, 
and misoprostol inhibits in a concentration-dependent manner the neuronal activity of LC 
cells in vitro. This inhibitory effect was blocked by the selective EP3 receptor antagonist L-
798,106, but not by the EP2 or EP4 receptor antagonists, indicating that the observed effect 
was mediated by EP3 receptor activation. Furthermore, sulprostone-induced inhibition of the 
firing rate was hindered by pretreatment with the Gi/o protein inhibitor PTX and the GIRK 
blockers BaCl2 and SCH-23390. Thus, our results suggest that the EP3 receptor activation 
inhibits the firing activity of LC neurons, presumably by its coupling to Gi/o proteins and the 
subsequent opening of GIRK channels.  
 
Dense EP3 receptor immunoreactivity has been found by double immunofluorescence in the 
neuropil and in a few cell bodies of the LC65, where there is also strong expression of EP3 
receptor mRNA63. Furthermore, the LC contains constitutive COX-2, the rate-limiting 
enzyme for prostaglandin synthesis21, suggesting the presence of endogenous prostaglandins 
in this nucleus. In our study, we assessed the functional role of EP3 receptors by using 
extracellular recordings in vitro and application of EP3 receptor agonists. Sulprostone was 
selected as an EP3 receptor agonist based on its more than 300-fold higher affinity for the 
EP3 than for the EP1 receptor357. Sulprostone was perfused at similar concentrations 
previously used to study EP3 receptor-mediated effects in rodent brain slices from the 
cortex318 and the LC338. We also assessed the biological relevance of the endogenous 
prostanoid system by perfusing PGE2, which has high affinity for all the EP receptors but 
especially for the EP3 receptor (EP3 ≥ EP4 > EP2 > EP1)357. Moreover, we tested the PGE1 
analog, commercially available misoprostol, which has higher selectivity for the EP3 receptor 
(affinity: EP3 > EP4 > EP2)357. On the other hand, we used as EP3 receptor antagonist L-
798,106, which is highly selective for the EP3 receptor compared to the EP4 receptor361.  
Finally, the EP2 receptor antagonist has no affinity for the EP3 receptor at the concentrations 





In the present study, sulprostone, PGE2, and misoprostol completely inhibited the firing 
activity of LC neurons. The inhibitory effect was blocked by an EP3 receptor antagonist but 
not by EP2 or EP4 receptor antagonists, ruling out the involvement of EP2 or EP4 receptors 
in this inhibition. EP1 receptor-mediated effects may be unlikely in our system because low 
EP1 receptor mRNA expression has been reported in the brainstem54. In our study, the 
determined EC50 values of the concentration-effect curves for sulprostone, misoprostol, and 
PGE2 and the rank order of potency found for firing activity inhibition (sulprostone > 
misoprostol > PGE2) were consistent with preceding data in rodent brain cortex slices, where 
the same agonists inhibited the NA release with 0.4-1.0 fold higher pIC50 values (8.22, 8.00, 
and 7.74, respectively318). Furthermore, in guinea-pig aorta comparable EC50 values were 
found for the sulprostone-induced vasoconstriction (23 nM)390. The pKB value for the EP3 
receptor antagonist L-798,106 herein reported was equivalent when either sulprostone or 
misoprostol were used as standard agonist (5.8 – 5.9), which supports the evidence for the 
activation of a common EP3 receptor. However, when PGE2 was used as an agonist, the pKB 
value was 0.4 units higher, suggesting that PGE2 may also activate interfering non-EP3 
receptors. In this regard, in the presence of PF-04418948 and L-161,982, the concentration-
effect curve for PGE2 was shifted to the left, which could suggest that PGE2 may also activate 
Gs protein-coupled EP2 and EP4 receptors counteracting the EP3 receptor-mediated 
inhibition. Other authors have estimated a 2 units higher pKB value for L-798,106 when 
sulprostone and PGE2 were used as standard agonists in peripheral tissues, such as guinea-
pig smooth muscle339,391. This disparity could be due to the high lipophilicity of L-798,106, 
which determines the equilibration kinetics and the pKB calculation339, or to the different 
tissues (muscle vs. brain slices) and species employed (guinea-pig vs. rat). In summary, EP3 
receptor activation by selective agonists inhibits the firing rate of LC neurons. 
 
In line with our results, c-fos expression, an indicator of neuronal activity, is increased in the 
LC from morphine-dependent rats and this enhancement is reversed by EP3 receptor agonists 
administered centrally120, suggesting that the neuronal activity of LC cells is inhibited by EP3 
receptor activation. Furthermore, a single concentration of sulprostone has recently been 
shown to hyperpolarize LC neurons in slices from mice338. Likewise, other 
electrophysiological studies have demonstrated an EP3 receptor-mediated inhibition of 
central neurotransmission in other brain regions. Thus, EP3 receptor activation by PGE2 
reduces glutamatergic transmission in the dorsolateral periaqueductal gray301, GABAergic 
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transmission in the paraventricular nucleus of the hypothalamus392, and network activity in 
the neocortex305. In contrast to our results, a neuronal activity increase has been described 
upon PGE2 administration in serotonergic neurons of the dorsal raphe nucleus, but the exact 
mechanism has not been fully elucidated393. 
 
EP3 receptor activation has been described to be coupled to Gi/o proteins 373. In our research, 
the sulprostone-induced inhibitory effect was reduced by the Gi/o signaling inhibitor PTX394, 
indicating that EP3 receptor activation leads to cell inhibition by stimulation of Gi/o proteins. 
Gi/o-mediated effects have been previously described for the EP3 receptor in other brain 
regions, such as in the hippocampus, where PTX blocks the EP3 receptor-induced ischemic 
excitotoxicity373. Inhibition of firing activity of LC neurons has been described to occur after 
opening of GIRK channels by Gi/o-protein βγ subunits166, such as upon activation of Gi/o 
protein-coupled µ-opioid receptors and α2 adrenoceptors375,395. Barium and SCH-23390 are 
effective GIRK channel blockers396 that have been reported to stimulate the firing rate of LC 
cells397. Indeed, in our study, administration of barium and SCH-23390 increased the firing 
rate of LC neurons and prevented the effect of sulprostone, supporting an involvement of 
GIRK channels in the EP3 receptor-mediated effect in the LC. Similarly, in sympathetic 
neurons, PGE2 activates GIRK channels probably through a Gi/o-dependent mechanism374.  
 
Our results show that EP3 receptor activation inhibits the activity of LC neurons in rat brain 
slices, likely through opening of postsynaptic Gi/o-coupled GIRK channels. This inhibitory 
effect on the LC may regulate NA release throughout projection areas of the CNS and thus 
add to the local inhibitory EP3 receptors on nerve terminals regulating NA release318,320. The 
prostanoid system in the LC could play a role in the regulation of pain. Thus, the LC exerts 
a supraspinal descending control of pain135 and activation of a neuronal subpopulation of the 
LC evokes an anti-nociceptive response135. One possible consequence would be that EP3 
receptor activation in the LC may lead to a hyperalgesic effect. In line with this hypothesis, 
inflammatory stimuli reduce the analgesic effect induced by opioids in the LC197. Likewise, 
in the PAG, EP3 receptor activation exerts pro-nociceptive actions115. Prostaglandin release 
and EP3 receptor activation in the LC may also modulate the neuroinflammatory response 
and febrile response. In this regard, c-Fos expression is increased in the LC by inflammatory 
insults through the prostanoid synthesis180 and the febrigenic effect of PGE2, which involves 
EP3 receptors91, is mediated by a neuronal network including the LC204. Finally, EP3 
receptors in the LC may be relevant for some neuropsychiatric diseases. Thus, enhanced 
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expression of EP3 receptor has been found around amyloid plaques in LC-projecting areas 
in Alzheimer’s disease398. Furthermore, lesions of the LC enhance both pro-inflammatory 
cytokines232 and amyloid-β deposition in the hippocampus of a mouse model of Alzheimer’s 
disease198. Regarding psychiatry, stimulation of prefrontal-projecting neurons in the LC 
results in anxiety-like behavior136, thereby reduction of LC-noradrenergic cell activity by the 
EP3 receptor could attenuate anxiety, as shown by a previous study in which sulprostone 
infusion into the LC produced anxiolytic effects338. In conclusion, the prostaglandin system 
in the LC would play a relevant role in the regulation of central physiology, and the EP3 
receptor in this nucleus might be a suitable pharmacological target for the development of 
novel treatments for different neuropsychiatric disorders. 
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5.2 STUDY II – PHARMACOLOGICAL CHARACTERIZATION OF PROSTANOID 
EP2 RECEPTOR IN RAT LOCUS COERULEUS NEURONS IN VITRO 
Our study was aimed to pharmacologically characterize the EP2 receptor in LC neurons from 
rat brain slices by extracellular electrophysiological techniques. We found that the EP2 receptor 
agonists butaprost and treprostinil increase the firing activity of LC neurons in vitro. This 
excitatory effect was blocked by the EP2 receptor antagonist PF-04418948, but not by the EP3 
or EP4 receptor antagonists (L-798,106 and L-161,982, respectively), indicating that it was 
mediated by EP2 receptor activation. The butaprost-induced increase in the firing rate of LC 
cells was prevented in the presence of low sodium-containing aCSF and the Gβγ-signaling 
inhibitor gallein. However, blockers of the Gαs/cAMP/PKA pathway or TRP and Kir6.2 
channels failed to change the butaprost-induced stimulatory effect. These results suggest that 
activation of the EP2 receptor stimulates the neuronal activity of LC cells, presumably by its 
coupling to Gβγ proteins and an inward sodium current. 
In our study, we assessed the functional role of EP2 receptors in LC neurons by using 
extracellular electrophysiology in vitro and application of EP2 receptor agonists. Butaprost 
was selected as an EP2 receptor agonist since its free acid form shows an 18-fold higher 
affinity for the EP2 than for the EP3 receptor357 and has been previously used at similar 
concentrations to explore EP2 receptors in brain slices93. We also assessed the effect of 
treprostinil, a clinically used PGI2 analog that has high affinity for several prostanoid 
receptors, especially high for the EP2 receptor (EP2=DP1>IP>EP1>EP4>EP3)358. On the 
other hand, we used PF-04418948 as EP2 receptor antagonist since it has very low affinity 
for any other prostanoid receptor341. L-161,982 has much higher affinity for the EP4 than for 
EP3 receptors362, while L-798,106 shows higher affinity for the EP3 than for the EP4 or other 
EP receptors361. 
In the current study, butaprost and treprostinil increased the neuronal activity of LC cells and 
generated similar parameters of the concentration-effect curves (EC50 and Emax), suggesting 
equivalent efficacy and potency in the LC. Furthermore, the EC50 of the concentration-effect 
curve for butaprost was in accordance with that found in other systems (0.64 µM)399. In our 
work, the excitatory effect caused by butaprost and treprostinil was blocked by PF-04418948, 
and not by L-798,106 or L-161,982. In fact, PF-04418948 displaced to the right the 
concentration-effect curve for butaprost, whereas it reduced the Emax for treprostinil without 
any rightward shift. This difference could be explained by additional activation of other 
receptors or mechanisms by treprostinil, such as the phylogenetically related Gs-coupled DP1 
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receptor358,400. However, the blockade of the treprostinil-induced effect with PF-04418948 
supports the involvement of, at least, the EP2 receptor. Alternatively, one could speculate that 
a slow dissociation rate of PF-04418948 from the EP2 receptor and a higher receptor reserve369 
for butaprost than for treprostinil could account for the differences observed with butaprost and 
treprostinil in the presence of PF-04418948. In any case, the calculated pKB of PF-04418948 
for the EP2 receptor was equivalent when obtained by butaprost or by treprostinil. Furthermore, 
similar pKB values for PF-04418948 are obtained when PGE2 is used in other tissues341. These 
data indicate that the excitatory effect observed with butaprost and treprostinil in LC neurons 
was mediated by EP2 receptor activation.  
EP2 receptor activation in neurons has been described to elicit a sodium current through the 
cAMP/PKA pathway376. In our work, the butaprost-induced excitatory effect was completely 
abolished by replacement of 80% of the extracellular sodium by TRIS, indicating the 
involvement of sodium current. In agreement, PGE2 elicits a sodium current in cerebellar376 
and spinal neurons300, leading to neuronal depolarization in the latter case. In the LC, sodium 
currents could be generated by TRP channels, as previously reported in response to CO2213. In 
our study, perfusion with the non-selective TRP channel blocker 2-APB at concentrations 
previously used in other brain regions in vitro401 failed to change the butaprost-induced 
excitatory effect. On the other hand, inhibition of Kir6.2 channels has been shown to contribute 
to excitatory responses in LC neurons, which could be hindered by the Kir6.2 channel blocker 
glibenclamide344. However, in our study, glibenclamide did not affect the butaprost-induced 
excitatory response. Therefore, our data indicate that sodium current is a final downstream 
effector of EP2 receptor activation, and Kir6.2 or TRP channels do not seem to be involved in 
this effect. 
In LC noradrenergic neurons, inward sodium currents are activated by the cAMP/PKA 
pathway327. In our research, the butaprost-induced excitatory effect was not mediated by the 
cAMP/PKA/HCN pathway as the PKA activator 8-Br-cAMP, the PKA inhibitor H-89 or the 
HCN channel blocker ZD7288 failed to modify the stimulatory effect caused by butaprost. Our 
results contrast with the main signaling mechanism described for excitatory responses mediated 
by the EP2 receptor in other brain regions. Thus, PGE2 increases the hypothalamic neuronal 
activity3 and hippocampal synaptic transmission26 via EP2 receptor-mediated activation of the 
cAMP/PKA pathway. However, other authors have previously suggested that 
cAMP/PKA/HCN is not involved in EP2 receptor-mediated responses. Thus, in nodose 
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ganglion neurons, PGE2 elicits a sodium current by EP2 receptors without the intervention of 
the cAMP/PKA pathway402.  
The EP2 receptor has been published to be coupled to Gs proteins58. However, NF449, a 
selective inhibitor of the association between Gαs and GTP347, failed to reduce the butaprost-
induced excitation, while it blocked the effect of VIP, which increases the firing rate of LC 
cells by a Gαs/cAMP/PKA-dependent sodium current173. This means that butaprost effect is not 
mediated by Gαs proteins. On the other hand, the excitation caused by butaprost was prevented 
by the Gβγ-signaling inhibitor gallein, which binds to the “hot spot” of the Gβ subunit403. In our 
study, gallein did not modify the inhibitory effect of the µ opioid receptor agonist ME on the 
LC, which is mediated by Gi/o protein βγ subunits404. Likewise, other authors have described 
that a gallein analog fails to affect Gi/o protein βγ-mediated effects in other systems405, 
suggesting diversity and selectivity of the Gβγ subunits for different downstream signaling 
mechanisms. Furthermore, a direct binding of Gβγ subunits to voltage-gated sodium channels 
(Nav) have been reported in cell cultures406,407. In LC neurons, tetrodotoxin (TTX)-sensitive 
Nav contribute to the pacemaker activity150, although a TTX-resistant current has also been 
described150. Furthermore, EP2 receptor activation has been associated with the enhancement 
of TTX-resistant sodium current in ganglion neurons402. However, in our study, we cannot 
conclude that the Nav channel mediates the effect of EP2 receptors on sodium currents and 
whether it is directly modulated by EP2 receptor-activated Gβγ subunits.  
Finally, in our research, blockade of GABAergic or glutamatergic transmission in the LC did 
not decrease but rather enhanced the butaprost-induced stimulatory effect. These results are 
congruent with the presence of EP2 receptors enhancing inhibitory GABAergic regulation of 
noradrenergic cells or glutamatergic afferents, which blockade would increase the butaprost-
induced excitatory effect. However, the neuronal subpopulation expressing the EP2 receptor is 
yet to be characterized in the brain. 
In conclusion, our work supports the existence of functional postsynaptic EP2 receptors in LC 
neurons, which activation results in a concentration-dependent increase of the spontaneous 
firing rate in vitro. The underlying mechanism may require Gβγ subunits and sodium currents, 
but it does not involve a Gαs, TRP or cAMP/PKA-dependent pathway. According to previous 
data from our laboratory, the endogenous PGE2 has a preferential inhibitory effect on LC 
neurons mediated by EP3 receptor activation (see Study I), and herein, we demonstrate the 
functional role of EP2 receptors in the regulation of the firing rate. Since the LC has been 
shown to contribute to the affective processing of nociception by promoting anxiogenic-like 
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behavior during chronic pain408, EP2 receptor activation in the LC may be of relevance in the 
integration of pain stimuli by enhancing NA release throughout the CNS. This suggestion is 
supported by the cognitive impairment observed in mice lacking the EP2 receptor409. 
Furthermore, both β-adrenoreceptor and EP2 receptor activation elicit anti-inflammatory 
effects in microglial cells198,351. Therefore, it may be reasonable to suggest that the EP2 receptor 
in the LC could further tune the inflammatory response to PGE2 in the brain. An 
immunomodulatory effect of EP2 receptors may be relevant for the pathophysiology of 
Alzheimer’s disease, and the prevention of neuronal death upon amyloid β-peptide exposure410. 
Consequently, the EP2 receptor signaling in the LC could become a novel therapeutic target 







5.3 STUDY III – PHARMACOLOGICAL CHARACTERIZATION OF PROSTANOID 
EP4 RECEPTOR IN RAT LOCUS COERULEUS NEURONS IN VITRO 
The purpose of this study was to characterize the functional role of EP4 receptors in LC neurons 
by extracellular electrophysiological techniques. We found that the EP4 receptor agonists 
rivenprost and TCS 2510 increase the neuronal activity of LC cells in vitro. This excitatory 
effect was blocked by the EP4 receptor antagonist L-161,982, but not by the EP2 or EP3 
receptor antagonists PF-04418948 and L-798,106, respectively, indicating an EP4 receptor-
mediated effect. The increase in firing rate of LC neurons caused by rivenprost was blocked by 
extracellular sodium replacement and a Gαs signaling inhibitor, but not by blockers of the 
cAMP/PKA pathway, TRP channels, Gβγ subunits, PI3K or PKC signaling. Thus, these results 
suggest that EP4 receptor activation stimulates the neuronal activity of LC cells, presumably 
by its coupling to Gαs proteins and an inward sodium current. 
In our study, we characterized the functional role of EP4 receptors in LC neurons by using 
extracellular electrophysiology in vitro, EP4 receptor agonists, and EP receptor antagonists. 
The concentrations of the EP4 receptor agonists rivenprost and TCS 2510 used herein were 
based on the affinity data demonstrated in radioligand binding experiments, which show that 
rivenprost has 80-fold higher affinity for the EP4 than for EP3 or EP2 receptors359 and TCS 
2510 fails to have affinity at the tested concentration range for non-EP4 receptors360. 
Furthermore, the involvement of the EP4 receptor was demonstrated with the specific 
antagonist L-161,982, which shows a more than 200-fold higher affinity for the EP4 than for 
EP3 receptors362. The EP2 receptor antagonist PF-04418948 does not show antagonistic 
affinity for any other EP receptor341, while L-798,106 has much higher affinity for the EP3 than 
for EP4 receptors361. 
In the present study, administration of rivenprost or TCS 2510 increased the firing rate of LC 
neurons. In the case of rivenprost, the EC50 value (1.43 nM) was similar to its Ki value measured 
in cell membranes (0.7 nM)359, whereas the EC50 value for TCS 2510 (18.0 nM) was higher 
than that of rivenprost, but at the same range as that described in other tissues (e.g., isolated 
smooth muscle, pIC50: 7.6)411. The excitatory effect of rivenprost or TCS 2510 was mediated 
by EP4 receptor activation since it was only blocked by L-161,982, but not by perfusion with 
L-798,106 or PF-04418948. In our work, L-161,982 shifted to the right the concentration-effect 
curve for rivenprost but reduced the Emax for TCS 2510 without any rightward shift. This 
disparity of effects was unlikely to be caused by activation of other EP receptors, given the 
high selectivity of these ligands for the EP4 receptor. Furthermore, the Schild slope for L-
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161,982 was less than unity when calculated with rivenprost and furthermore different pKB 
values were found for various concentrations of L-161,982. According to different authors, a 
slow dissociation rate of the antagonist and a higher receptor reserve for one of the agonist369 
(i.e., rivenprost) could explain the different pharmacological profiles observed with rivenprost 
and TCS 2510 in the presence of L-161,982. Moreover, the calculated pKB of L-161,982 for 
the EP4 receptor resulted in 7.69 by double equieffective concentrations of TCS 2510, which 
was at similar concentration ranges to the pKB obtained for L-161,982 with rivenprost (7.67). 
Furthermore, the result obtained in our study for L-161,982 was akin to its Ki value (32 nM) 
measured by binding assays in cell cultures with PGE2 as an agonist362. Overall, these data 
indicate that the observed excitatory effect of rivenprost or TCS 2510 was mediated by EP4 
receptor activation. 
Activation of Gs-coupled EP4 receptors modulates sodium currents in brain neurons (e.g., 
cerebellar granule cells376). In our work, the blockade of the rivenprost-induced stimulation of 
LC cells by extracellular sodium replacement reveals the involvement of sodium currents. In 
agreement, PGE2 has been shown to enhance sodium currents via EP4 receptors in cerebellar376 
and nodose ganglion neurons402. Furthermore, EP4 receptor activation increases the firing rate 
of supraoptic neurons, which has been suggested to be mediated by non-selective cation 
channels303. In the LC, sodium currents can be elicited by non-selective cation TRP channels 
in response to hypercapnia213. However, in our study, the TRP channel blocker 2-APB did not 
prevent the excitatory effect induced by rivenprost, which indicates that the TRP channel is not 
involved in the rivenprost-induced excitatory effect. 
EP4 receptor activation elicits a sodium current via activation of Gs proteins and cAMP/PKA 
pathway376. In the current study, the rivenprost-induced stimulation was blocked by the Gαs 
signaling inhibitor NF449, but not by the Gβγ signaling inhibitor gallein, which suggests that 
the EP4 receptor is coupled to Gαs proteins in the LC. However, the rivenprost-induced 
excitatory effect was not mediated by the cAMP/PKA pathway as it was not occluded by the 
PKA activator 8-Br-cAMP nor blocked by the PKA inhibitor H-89, which were perfused at the 
same concentrations used in other brain areas in vitro173,345. Although these results are in 
contrast with the signaling mechanism described for the EP4 receptor in neurons412, some other 
authors have pointed out a cAMP-independent pathway for EP4 receptor-mediated effects. For 
example, chronic exposure to PGE2 downregulates the EP4 receptor-mediated cAMP/PKA 
pathway activation in cultured DRG neurons413 and TCS 2510 fails to raise cAMP levels in 
mast cells368. Likewise, activation of the EP2 receptor, which also induces excitatory responses 
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in LC neurons, is not dependent on the cAMP/PKA pathway (see Study II). Since both EP2 
and EP4 receptors activate sodium currents in the LC via a non cAMP/PKA pathway, in the 
present work, we compared the effect of rivenprost with or without administration of the EP2. 
Thus, the excitatory effect of rivenprost was not occluded by butaprost effect, which suggests 
an uncommon signaling pathway for both EP2 and EP4 receptors. This divergence could be 
explained by phylogenetic differences, as they only share a 31% amino acid identity in mice61. 
Overall, these data indicate that EP4 receptor activation in LC neurons is coupled to a Gαs 
protein and a sodium current, but not dependent on cAMP/PKA and Gβγ subunit signaling. 
On the other hand, EP4 receptor activation has been linked to the PI3K signaling pathway in 
cell cultures81,352 and DRG neurons82. In the latter case, activation of the PI3K promotes the 
externalization of the EP4 receptor, which could enhance the nociceptive transmission82. 
However, according to our data, the PI3K inhibitor wortmannin did not block the excitatory 
effect of rivenprost in LC cells but rather potentiated it. It has been shown that EP4 receptor 
activation stimulates the PI3K pathway via Gi/o proteins in cultured cells81. Furthermore, the 
EP4 receptor can couple to both Gs and Gi/o proteins in cell cultures, with the degree of 
activation of Gs and Gi/o protein depending on the functional selectivity of EP4 receptor 
agonists414. In our system, we cannot exclude a simultaneous coupling of the EP4 receptor to 
the Gi/o/PI3K pathway in LC cells, which would counteract the excitatory effect of EP4-Gαs 
and would be unmasked in the presence of wortmannin. In addition to the PI3K, a PKC-
dependent pathway has been described for EP4 receptor-mediated effects, such as in DRG 
neurons353. However, in our work, the PKC inhibitor chelerythrine did not block the excitatory 
effect of rivenprost but further enhanced it, which rules out the implication of this enzyme in 
the rivenprost-induced stimulation. 
In summary, our work supports the existence of functional EP4 receptors in LC neurons, which 
activation results in a concentration-dependent increase in the spontaneous firing rate. The 
underlying mechanism may involve the Gαs protein and a sodium current, but it does not seem 
to involve Gβγ, TRP, cAMP/PKA, PI3K, or PKC-dependent pathways. Further studies will be 
carried out to test whether the coupling of EP4-Gαs and sodium currents is a direct mechanism. 
According to previous data from our laboratory, the endogenous PGE2 has a preferential 
inhibitory effect on LC neurons mediated by EP3 receptor activation (see Study I). We have 
also described a stimulatory effect of LC neurons caused by EP2 receptor activation (see Study 
II). In this study, we demonstrate the presence of EP4 receptors in the LC, which could further 
tune the inflammatory response to PGE2 in the brain. Thus, EP4 receptor signaling in the LC 
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may gain relevance during inflammatory states, since peripheral inflammation has been 
reported to upregulate EP4 receptor expression in DRG107 and brain catecholaminergic 
neurons57. This suggestion is also supported by the rise in c-Fos immunoreactivity in response 
to an inflammatory insult in brain regions expressing the EP4 receptor57. Furthermore, chronic 
inflammatory pain, which is known to release PGE2, has been shown to enhance anxiety-like 
behaviors in rodents415 and the LC mediates some of the affective events involved in the 
processing of nociception by promoting anxiogenic-like behavior during chronic pain408. It is 
therefore tempting to speculate that EP4 receptor activation in the LC may be of relevance in 
the integrative reaction to pain stimuli possibly by enhancing NA release throughout the CNS. 
Therefore, the prostaglandin system and the EP4 receptor in the LC might be suitable 




5.4 STUDY IV – INTERACTION BETWEEN OPIOIDS AND PROSTAGLANDIN E2 
IN THE INSPIRATION-GENERATING PREBÖTZINGER COMPLEX 
The purpose of this study was to assess whether the opioid-induced respiratory depression was 
intensified under inflammatory conditions (i.e., those caused by PGE2) by time-lapse calcium 
imaging in brainstem organotypic cultures. In the preBötC cellular network, we found that both 
MOR agonist DAMGO and EP3 receptor agonist PGE2 reduced Ca2+ oscillatory activity. The 
effect of DAMGO was blocked by naloxone, whereas deletion of the EP3 receptor abolished 
the PGE2-induced effect and delayed that of DAMGO. The reduction in Ca2+ oscillatory 
activity caused by DAMGO was occluded by prior administration of PGE2, which suggested a 
common signaling pathway. Indeed, both DAMGO and PGE2-induced modification in Ca2+ 
activity was prevented by blocking cAMP degradation and GIRK channel activation. 
Furthermore, both DAMGO and PGE2 reduced the number of connections among cells and the 
synchronicity. 
Recently, we have developed brainstem organotypic slice cultures containing the preBötC that 
allow the study of the respiratory brainstem activity in vitro97. These cultured slice preparations 
maintain the respiratory-related rhythm97,252 identical to acute slices252 while preserving the 
cytoarchitecture97. These features, along with the tissue flattening over time97,252, create an 
optimal model for the activity evaluation of a broad population of cells by calcium imaging 
techniques and their synchronicity by means of cross-correlation analysis278. Furthermore, 
preBötC respiratory neurons in vitro preserve rhythmic Ca2+ transients in phase with the 
inspiratory motor output measured on the hypoglossal XII nerve239, and therefore, the observed 
calcium oscillatory activity in our study is representative of the respiratory rhythm. The 
PreBötC was identified in our slices with the fluorescent ligand TMR-SP, which labels the 
NK1R-positive cells and thereby, the respiratory neurons119. In our study, we measured the 
effect of DAMGO as MOR agonist since it has high affinity and selectivity for the MOR416. 
The effect of DAMGO was antagonized by using naloxone, which shows high affinity for all 
opioid receptors, but especially for the MOR416. The endogenous inflammatory response was 
mimicked by using PGE2, a non-selective EP receptor agonist that shows high affinity for the 
EP3 receptor357. Finally, the fluorescent dye employed here was non-ratiometric, so the 
described amplitude data is relative to its baseline, and no intracellular Ca2+ concentration could 
be inferred.  
In the current study, DAMGO and PGE2 reduced Ca2+ transient frequency in what seemed a 
concentration-dependent fashion, as we tested two different concentrations of each and the 
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highest concentration produced a greater inhibition in the frequency than the lowest. 
Furthermore, the DAMGO (5 µM)-induced reduction in Ca2+ transient frequency of the whole 
population (22%) was similar to that observed with PGE2 (100 nM) (19%), and further, similar 
to the breathing frequency reduction (18%) in vivo caused by microinjection of DAMGO into 
the preBötC described elsewhere253. An improvement in the data analysis allowed us to know 
how single cells behaved over time and how many of them varied their frequency compared to 
their baseline. By using this script, 75% of the cells showed a marked frequency reduction of 
34% upon DAMGO, and similarly, 72% of the cells displayed a frequency reduction with PGE2 
of 32%. Moreover, NK1R+ data revealed that the reduction in Ca2+ transient frequency in 
respiratory neurons upon DAMGO and PGE2 is representative of the whole population, which 
may suggest that the respiratory neurons define the activity of the entire network. This result is 
in agreement with previous reports in similar brainstem slice culture preparations, which 
observed Ca2+ oscillatory activity only from neurons and not from glial cells252. Furthermore, 
previous data from our laboratory demonstrated that NK1R+ cells respond to PGE2 in the 
preBötC97 and co-express EP3 receptor in medullary sections at the preBötC level38. In line, 
other studies showed a co-expression of MOR and NK1R in the preBötC119,253, and 
accordingly, preBötC respiratory neurons have been considered fundamental for the opioid-
induced respiratory depression254.  
In our study, the DAMGO-induced reduction in Ca2+ transient frequency was prevented by the 
application of the MOR antagonist naloxone and delayed by deleting the EP3 receptor. Thus, 
in Ptger3-/- mice, DAMGO (5 µM) needed 15 min instead of 5 min to cause the same magnitude 
of effect as in WT mice, suggesting a hindered effect of DAMGO in Ptger3-/- mice. 
Interestingly, this late effect was similar to that observed with the lowest concentration of 
DAMGO (0.5 µM) in WT mice. Furthermore, the PGE2-induced frequency decrease was 
absent in mice lacking the EP3 receptor, in agreement with previous results from our 
laboratory97. These results highlight the functional relevance of the EP3 receptor in the 
preBötC. Similarly, activation of the EP3 receptor has been shown to have inhibitory actions 
in other brain regions, for example, it inhibits the network frequency in the neocortex305 and 
the neuronal activity of the central chemosensitive LC cells (see Study I). In contrast with our 
study, PGE2 has shown to increase the fictive sigh frequency in preBötC acute slices, and even 
increase the eupnoeic frequency at higher concentrations than those employed in our study99. 
These differences could be due to a loss of selectivity at higher concentrations of PGE2, given 
that it has a high affinity for many other prostanoid receptors, and the receptor mediating this 
effect was not determined in that study.  
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In the present work, the onset of the PGE2-induced inhibitory effect occluded any further 
reduction in Ca2+ oscillatory activity caused by DAMGO. Furthermore, this result is congruent 
with the attenuation of the morphine-induced respiratory depression observed in a neuropathic 
pain model417, where the involvement of PGE2 is widely known418. This occlusion could be 
caused by the reach of a maximum reduction in Ca2+ transient frequency, considering the 
ongoing Ca2+ dynamics that are partly regulated by intracellular stores, and thus a basal Ca2+ 
fluctuation. However, a common signaling pathway was elsewhere mentioned324, so we tested 
whether it would be plausible. The nature of the proposed common mechanism would be the 
result of a signaling pathway convergence in either the cAMP or the GIRK channels, based on 
previous data290,324. In our study, administration of the blocker of cAMP degradation rolipram 
prevented the DAMGO- and PGE2-induced reduction in Ca2+ oscillatory activity. This result 
agrees with previous studies showing that rolipram restores the inspiratory-related rhythm after 
DAMGO-induced inhibition in acute slices288 and that high cAMP levels reverse the DAMGO- 
and PGE1-induced respiratory depression in brainstem-spinal cord preparations324. On the other 
hand, incubation with the GIRK channel blocker SCH-23390 prevented the reduction in Ca2+ 
transient frequency caused by both DAMGO and PGE2 in our study. These data agree with 
previous reports in vivo, describing that the respiratory rate decrease produced by 
microperfusion of DAMGO into the preBötC is blocked by a GIRK channel inhibitor290. 
Furthermore, immunohistochemical techniques have demonstrated that NK1R+ cells in the 
preBötC co-express GIRK channels289, which suggests that these channels are present in 
respiratory neurons, and thus, that may intervene in the opioid- and PGE2-induced respiratory 
depression. Overall, the inhibitory actions of PGE2 and DAMGO on the cellular Ca2+ transient 
frequency seems to be mutually dependent on cAMP levels and GIRK channels. 
The respiratory rhythmogenesis is thought to be driven by preBötC cellular activity 
coordination into a group pacemaker mediated by glutamatergic transmission and electrical 
coupling262,275. Thus, the study of the network synchronization may be key for understanding 
the mechanism of opioid- and prostaglandin-induced respiratory depression. Herein, both 
DAMGO and PGE2 reduced the mean correlation above cut-off and the number of correlations 
per active cell, suggesting a reduction in the network circuitry and synchronization. In line with 
our results, elimination of correlated population activity and desynchronization of Ca2+ activity 
have been observed in the preBötC in vitro after blockade of gap junctions97 and glutamatergic 
synaptic transmission262. It is therefore tempting to speculate that the DAMGO- and PGE2-
induced respiratory depression may be caused by the lack of integrated group pacemaker 
activity. Intriguingly, in our results, DAMGO restored the baseline values of mean correlation 
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and number of correlations per active cell after the reduction caused by PGE2. This means that 
the effect of DAMGO in the presence of PGE2 was the opposite than in the absence, suggesting 
that DAMGO administration might affect a broader number of cells that reconfigure the circuit, 
possibly through an additional mechanism. Furthermore, synchronized bursting activity 
depends on the network topology389, and the preBötC is organized into a small-world 
architecture97,276, where the neuronal connections are favored within clusters, in comparison 
with across clusters276. In fact, in our work, both DAMGO and PGE2 increased the clustering 
coefficient and small-world parameter, suggesting segregation into local clusters and a shift 
towards a more regular topology, which is less synchronizable than the small-world 
composition277. Similar alterations of small-world structures have been observed in patients 
with Alzheimer’s disease and neuromyelitis optica419,420, where the global activity integration 
may be compromised, leading to a weaker population bursting in a computational model389. 
Overall, the opioid-induced asynchronous network seems to be mediated by MOR activation 
with the involvement of the cAMP pathway and GIRK channels; while the PGE2-induced 
asynchrony seemed to be partly mediated by the EP3 receptor and the cAMP pathway. These 
results may suggest a different mechanism for PGE2-induced disruption of network 
organization, possibly mediated by persistent sodium current and gap junctions as previously 
suggested for other effects caused by PGE2 in the preBötC97,99.   
In conclusion, PGE2 modulates preBötC activity in vitro and it seems to interact with the 
opioid-induced inhibitory effect, so a common signaling pathway was proposed, with the 
apparent involvement of the cAMP pathway and GIRK channels. Furthermore, both opioids 
and prostaglandins seem to disrupt the structural integrity of the network, leading to less wiring 
and synchronicity. Thus, the current study supports that preBötC inspiratory neurons mediate 
the opioid- and PGE2-induced respiratory depression by reducing their activity and 
synchronization. However, it remains unknown the possible implication of other areas of the 
breathing brainstem421,422, such as the recently discovered postinspiratory complex (PiCo)261, 
that may shape the in vivo opioid response into a quantal slowing of the respiratory rhythm323. 
The endogenous release of PGE2 during inflammation and the concurrent treatment with 
opioids may condition the ventilatory behavior, which may be of relevance in post-operative 
states. Moreover, the pediatric population should receive special consideration given the 
endogenous release of PGE2 at birth388 and the implication of PGE2 in neonatal breathing 
disorders98,423, which may ultimately lead to apneas during infections by attenuating the 




1. EP3 receptor activation inhibits LC neuron firing activity in rat brain in vitro with a 
rank order of agonist potencies being: sulprostone > misoprostol > PGE2. An EP3 
receptor antagonist, but not EP2 or EP4 receptor antagonists, causes rightward shifts of 
the concentration-effect curves for the EP3 receptor agonists. These results indicate that 
acute administration of sulprostone, PGE2 or misoprostol induces an inhibitory effect 
on the LC neuron activity via EP3 receptor activation. 
 
2. The concentration-effect curve for sulprostone is shifted to the right by the blocker of 
the Gi/o protein-dependent pathway pertussis toxin. Furthermore, GIRK channel 
blockers prevent the sulprostone-induced inhibitory effect. This shows that the EP3 
receptor may be coupled to Gi/o proteins and its activation may lead to the opening of 
GIRK channels, causing an inhibition of the firing activity of LC neurons. 
 
3. The EP2 receptor agonists butaprost and treprostinil increase LC neuron firing activity 
in rat brain in vitro. An EP2 receptor antagonist, but not EP3 or EP4 receptor 
antagonists causes a rightward shift of the concentration-effect curve for butaprost and 
reduces the maximal excitatory effect caused by treprostinil. These results suggest that 
butaprost and treprostinil increase LC neuron activity via EP2 receptor activation. 
 
4. The butaprost-induced excitatory effect is blocked by a decrease in the extracellular 
concentration of sodium, which suggests that the excitation caused by EP2 receptors 
depends on a sodium current. According to pharmacological assays, this sodium current 
is not mediated by TRP, HCN or potassium Kir6.2 channels. Furthermore, the 
butaprost-induced excitatory effect is not prevented by manipulation of the cAMP/PKA 
pathway, inhibition of synaptic transmission or blockade of Gαs subunits. Only Gβγ-
signaling inhibition reduces the excitatory effect caused by butaprost, thus revealing a 
role for the Gβγ subunits. These data suggest that EP2 receptor activation 
postsynaptically may excite LC neuron activity via a sodium current and Gβγ-dependent 
pathway, but not through the Gαs/cAMP/PKA pathway.  
 
5. The EP4 receptor agonists rivenprost and TCS 2510 increase LC neuron firing activity 
in rat brain in vitro. This excitatory effect is prevented by an EP4 receptor antagonist, 
as it induces a shift to the right in the concentration-effect curve for rivenprost and 
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reduces the maximal excitatory effect caused by TCS 2510. These results suggest that 
rivenprost and TCS 2510 may increase LC neuron activity via EP4 receptor activation. 
 
6. The rivenprost-induced excitatory effect is blocked by a decrease in the extracellular 
concentration of sodium, which suggests that the excitation caused by EP4 receptors 
depends on a sodium current. According to pharmacological assays, this sodium current 
does not seem to be mediated by TRP channels or the cAMP/PKA pathway. 
Furthermore, the rivenprost-induced excitatory effect is not changed by blockers of the 
PI3K, PKC, and Gβγ signaling. Previous administration of the EP2 receptor agonist 
butaprost does not occlude the excitatory effect caused by rivenprost, suggesting a 
divergent signaling pathway for both receptors. Inhibition of Gαs signaling reduces the 
excitatory effect induced by rivenprost. These data reveal that EP4 receptor activation 
may excite LC neuron activity via Gαs-dependent trigger of a sodium current, but not 
by the cAMP/PKA, PI3K or PKC pathways. 
 
7. The MOR agonist DAMGO and the PGE2 reduce the Ca2+ transient frequency of 
preBötC cells and respiratory neurons in organotypic slices. The effect of DAMGO is 
blocked by previous administration of the MOR antagonist naloxone and delayed on 
time by deleting the Ptger3 gene (Ptger3-/- mice). These results suggest that the 
inhibitory effect on Ca2+ oscillatory activity caused by DAMGO is mediated by MOR 
activation and that there may be an interaction between MOR and EP3 receptors. On 
the other hand, the effect of PGE2 is absent in Ptger3-/- mice, which indicates that the 
PGE2-induced effect is mediated by EP3 receptor activation.  
 
8. The inhibitory effect of DAMGO on Ca2+ transient frequency is occluded by previous 
administration of PGE2, suggesting that PGE2 interferes with the opioid-induced 
respiratory depression. Blockers of the cAMP degradation and GIRK channels prevent 
both DAMGO- and PGE2-induced reductions in Ca2+ oscillatory activity, suggesting a 
convergence on the cAMP pathway and GIRK channels in preBötC cells.  
 
9. Furthermore, DAMGO and PGE2 reduce the cellular connectivity and synchronicity of 
the respiratory network, which alters the small-world features. The effect of DAMGO 
is abolished by naloxone and blockers of the cAMP degradation and GIRK channels, 
while the effect of PGE2 is partially hindered by Ptger3 gene deletion (Ptger3-/- mice) 
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and blockers of the cAMP degradation. These data suggest that the DAMGO-induced 
asynchrony may be mediated by MOR activation, GIRK channel opening, and possibly 
also by inhibition of the cAMP pathway. On the other hand, the PGE2-induced 
asynchrony seems to be only partially mediated by EP3 receptor activation and 
inhibition of the cAMP pathway. 
 
 
Taken together, these results provide functional data regarding the role of the prostanoid 
system in modulating the cellular activity of the LC and the preBötC in vitro. In addition, 
our results highlight the signaling mechanism downstream of EP receptors. Our data 
support an inhibitory and excitatory regulation of the firing activity of LC neurons in 
vitro by EP3, EP2, or EP4 receptors. EP3 receptor-mediated inhibition of LC neurons 
may occur through Gi/o proteins and GIRK channels, whereas EP2 and EP4 receptor-
mediated excitation of LC neurons appear to be mediated through Gβγ and Gαs-dependent 
activation of sodium currents, respectively. On the other hand, PGE2 inhibits the preBötC 
cellular activity and interferes with the opioid-induced respiratory depression. Given the 
role of the LC and the preBötC in the regulation of nociception and its affective 
component, as well as in the induction of fever, anxious states, and the inspiratory 
pattern, the presence of the prostanoid system in these brain areas may constitute a 
suitable target for the treatment of neuropsychiatric or breathing disorders triggered or 
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Bullet point summary 
What is already known: 
- PGE2, inflammatory mediator involved in pain and fever, modulates the activity of 
brain neurons 
- EP3 receptor agonist sulprostone activation hyperpolarizes mice LC neurons 
 
What this study adds: 
- Endogenous PGE2 reduces the neuronal activity of rat LC cells through EP3 receptors  
- EP3 receptor activation inhibits LC neurons via Gi/o proteins and GIRK channels 
Clinical significance: 
- The LC, the main noradrenergic nucleus, is susceptible to inflammatory mediators 
- Prostanoid system in the LC might be a pharmacological target against inflammation-
mediated neuropsychiatric processes 
 
Abstract 
BACKGROUND AND PURPOSE: Prostaglandin E2 (PGE2) is an inflammatory mediator 
synthesized by the brain constitutive cyclooxygenase (COX) enzyme. PGE2 binds to G protein-
coupled EP1-4 receptors (EP1 to Gq, EP2 and EP4 to Gs, and EP3 to Gi/o). The EP2, EP3, and 
EP4 receptors are expressed in the locus coeruleus (LC), the main noradrenergic nucleus in the 
brain. EP3 receptors have been extensively studied in the CNS, although its role regulating the 
LC neuronal activity is unclear. Our aim was to pharmacologically characterize the EP3 
receptor in the LC. 
 
EXPERIMENTAL APPROACH: We studied the effect of EP3 receptor agonists on the firing 
activity of LC cells in rat brain slices by single-unit extracellular electrophysiology. 
 
KEY RESULTS: The EP3 receptor agonist sulprostone (0.15 nM – 1.28 µM), the endogenous 
PGE2 (0.31 nM – 10.2 µM), and the PGE1 analogue misoprostol (0.31 nM – 2.56 µM) inhibited 
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the firing rate of LC neurons in a concentration-dependent manner (EC50=15 nM, 51 nM, and 
110 nM, respectively). The EP3 receptor antagonist L-798,106 (10 µM), but not the EP2 (PF-
04418948 10 µM) or EP4 (L-161,982 10 µM) receptor antagonists, caused a more than 8-fold 
rightward shift in the concentration-effect curves for the EP3 receptor agonists. Sulprostone-
induced effect was attenuated by the Gi/o-protein blocker pertussis toxin (PTX, 500 ng ml-1) 
and the inhibitors of inwardly rectifying potassium channels (GIRK) BaCl2 (300 µM) and 
SCH-23390 (15 µM). 
 
CONCLUSIONS AND IMPLICATIONS: LC neuronal firing activity is regulated in an 
inhibitory manner by EP3 receptors, presumably by a Gi/o protein and GIRK-mediated 
mechanism. 
 
Keywords: locus coeruleus; PGE2; EP3 receptor; firing; slice; prostanoid 
 
Introduction  
Prostaglandins, as pain and inflammatory mediators, are synthesized from membrane 
phospholipids on demand, which are transformed into arachidonic acid, and then into a 
common precursor by the rate-limiting enzyme cyclooxygenase (COX). Nonsteroidal anti-
inflammatory drugs (NSAIDs), widely used as analgesic, antipyretic, and anti-inflammatory 
drugs, act by blocking COX and thereby suppressing the synthesis of prostaglandins. In 
human and animal brain, both COX-1 and COX-2 isoforms are constitutively expressed 
under non-inflammatory conditions (Hétu and Riendeau, 2005; Kirkby et al., 2016). 
Moreover, the COX-2 is found in specific brain areas such as the cortical dendritic spines 
(Kaufmann et al., 1996), supporting the idea that prostaglandins play an essential role in 
regulating the function of the central nervous system (CNS). Indeed, prostaglandin E2 
(PGE2), the main final product of this pathway, modulates synaptic transmission in the 
hippocampus (Sang et al., 2005), the periaqueductal grey (Lu et al., 2007), and the 
paraventricular nucleus of the hypothalamus (Khazaeipool et al., 2018). The variety of PGE2 
actions are believed to be the result of four PGE2 receptor subtypes (EP1-4) which are 
coupled to different G-protein pathways, primarily EP1 to Gq, EP2 and EP4 to Gs, and EP3 
to Gi/o. The EP2, EP3, and EP4 receptors are widely expressed in the CNS, including the 
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hypothalamus and the locus coeruleus (LC) (Zhang and Rivest, 1999; Ek et al., 2000). Among 
all EP receptors, the functional role of the EP3 receptor has been one of the most extensively 
studied in the brain. Thus, EP3 receptor activation mediates the response to hypercapnia in 
the chemosensitive parafacial respiratory group (Forsberg et al., 2016), weakens the long-
term potentiation in the hippocampus (Maingret et al., 2017), depolarizes serotonergic 
neurons in the dorsal raphe nucleus (Momiyama et al., 1996), and leads to hyperalgesia in 
the periaqueductal gray (Drake et al., 2016). 
 
The LC, the main source of noradrenaline (NA) in the brain, is involved in the regulation of 
numerous functions, such as sleep-wake cycle, arousal, cognition, pain, and reward behavior. 
Several pieces of evidence have associated the LC with the EP3 receptor. First, in situ 
hybridization and immunohistochemistry techniques have shown the presence of a high 
density of the EP3 receptor or its mRNA in the LC (Ek et al., 2000; Nakamura et al., 2001). 
Second, LC neurons also possess the enzymatic machinery to synthesize prostaglandins such 
as the constitutive COX-2 (Yamaguchi and Okada, 2009). Third, a very recent 
electrophysiological study has shown that administration of a single EP3 receptor agonist 
hyperpolarizes LC neurons in mice (Mulvey et al., 2018). In addition, behavioral studies have 
demonstrated that administration of an EP3 receptor agonist reverses naloxone-induced c-fos 
expression in the LC from morphine-dependent rats (Nakagawa et al., 2000). Finally, 
presynaptic EP3 receptors mediate the inhibition of NA release in the main projection areas 
of the LC, including the cortex and the hippocampus (Exner and Schlicker, 1995; Günther et 
al., 2010). 
 
Despite evidence suggesting a functional role for the EP3 receptor in the LC, it remains to be 
pharmacologically examined in this nucleus. Therefore, the aim of our research was to 
characterize pharmacologically the EP3 receptor and to study the signaling mechanism 




Animals and ethics statement 
87 male adult Sprague-Dawley rats (200-300 g) were used in this study. Experiments were 
performed in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and 
Lilley, 2015) and with the recommendations made by the British Journal of Pharmacology. 
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Rats were obtained from the animal unit of the University of the Basque Country (Leioa, 
Spain) and housed under standard environmental conditions (22 ºC, 12:12 h light/dark cycles) 
with free access to food and water. One slice was taken from each animal and, unless stated 
otherwise, only one experiment was performed in each slice. The number of experiments in 
each group was typically five to nine, depending on the level of variability. Treatments and 
controls were performed in parallel in a randomized manner. As electrophysiological 
outcomes were collected in situ, data recording could not be blinded to the operator. 
However, the data analysis performed by the experimenter was confirmed separately by an 
additional researcher. All the experiments were carried out according to EU Directive 
2010/63 on the protection of animals used for scientific purposes and approved by the local 
Ethical Committee for Research and Teaching of the University of the Basque Country 
(UPV/EHU, Spain) and the Department of Sustainability and Natural Environment of 
Provincial Council from Bizkaia (ref. CEEA M20-2015-152; CEEA M20-2018-026). All the 
efforts were made to minimize the animal suffering and to reduce the number of animals 
used. 
 
Brain slice preparation 
Animals were anesthetized with chloral hydrate (400 mg kg-1, i.p.) and decapitated 
(Mendiguren and Pineda, 2007). The brain was rapidly extracted and a block of tissue 
including the brainstem was immersed in an ice-cold modified artificial cerebrospinal fluid 
(aCSF) where NaCl was equiosmolarly substituted for sucrose to improve neuronal viability. 
Coronal slices of 500-600 μm thickness containing the LC were cut using a vibratome (Leica 
VT1200 S, Leica Biosystems, Nussloch, Germany). The tissue was allowed to recover from 
the slicing for 90 min, placed on a nylon mesh, and incubated at 33 ± 1ºC on a modified 
Haas-type interface chamber which provided excellent perfusion to the slice. The tissue was 
continuously perfused with aCSF saturated with 95% O2/ 5% CO2 (final pH = 7.34) at a flow 
rate of 1.5 ml min-1 and left for equilibration before recordings were made. The aCSF 
contained (in mM): NaCl 130, KCl 3, NaH2PO4 1.25, D-glucose 10, NaHCO3 21, CaCl2 2 
and MgSO4 2. The LC was recognized visually in the rostral pons as a dark oval area on the 
lateral borders of the central gray and the fourth ventricle, at or just anterior to the genu of 






Single-unit extracellular recordings of LC noradrenergic cells were made as previously 
described (Mendiguren and Pineda, 2004; 2007). The recording electrode consisted of an 
Omegadot glass micropipette pulled (Sutter Instruments, Novato, CA, USA) and filled with 
50 mM NaCl. The tip of the electrode was broken back to a size of 2 – 5 μm (3 – 5 MΩ) and 
positioned in the LC. The extracellular signal from the electrode was passed through a high-
input impedance amplifier (Axoclamp 2B, Molecular devices, Union City, CA, USA) and 
monitored with an audio-amplifier and also on an oscilloscope (Aumon 14, Cibertec S.A., 
Madrid, Spain). Individual neuronal spikes were isolated from the background noise with a 
window discriminator (PDV 225, Cibertec S.A.). The firing rate (FR) was continuously 
recorded and analyzed before, during, and after experimental manipulations by a PC-based 
custom-made program which generated consecutive 10 s bin histogram bars of the 
cumulative number of spikes (HFCP®, Cibertec S.A., Madrid, Spain). Noradrenergic cells in 
the LC were identified by their spontaneous and regular discharge activities, the slow FR and 
the long-lasting biphasic positive-negative waveforms (Andrade and Aghajanian, 1984). We 
only recorded cells that showed stable FRs between 0.5 and 1.5 Hz for at least 3-5 min and 
inhibitory responses to [Met]enkephalin (ME 0.8 μM, 1 min) higher than 80% (Pablos et al., 
2015), which was used as control for the perfusion system.  
 
Pharmacological procedures  
The firing rate of LC neurons was recorded for several minutes before drug applications to 
obtain the baseline activity and then, during and after drug perfusion. To study the effect of 
EP3 receptor agonists on the firing rate of LC neurons, we perfused increasing concentrations 
of the EP3 receptor agonist sulprostone (0.15 nM – 1.28 µM, 2x), PGE2 (0.31 nM – 10.2 µM, 
2x) or the PGE1 analogue misoprostol (0.31 nM – 2.56 µM, 2x). Concentrations were based 
on previous studies in brain slices (Exner and Schlicker, 1995; Mulvey et al., 2018). Each 
concentration of the EP receptor agonists was perfused for enough time to reach its plateau 
effect and each agonist was used up to concentrations that achieved the maximal effect of the 
drug. To identify the subtype of EP receptor involved in the effect of sulprostone, PGE2, and 
misoprostol, concentration-effect curves for these agonists were performed in the presence 
of different EP receptor subtype selective antagonists. First, for sulprostone, the EP2 receptor 
antagonist PF-04418948 (3 and 10 µM), the EP3 receptor antagonist L-798,106 (3 and 10 
µM), and the EP4 receptor antagonist L-161,982 (3 and 10 µM) were used at the 
concentrations previously reported (Jones et al., 2011). Next, for PGE2 and misoprostol, the 
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EP3 receptor antagonist L-798,106 at 10 µM and a combination of the aforementioned EP2 
and EP4 receptor antagonists at 10 µM were used. All the antagonists were perfused for 30 
min before performing the concentration-effect curves for the EP receptor agonists.  
Based on its pharmacological profile sulprostone was selected to further characterize the 
molecular mechanism underlying EP3 receptor activation. In order to study the involvement 
of Gi/o proteins, concentration-effect curves for sulprostone were made after overnight 
incubation of the slices with the irreversible Gi/o protein inhibitor pertussis toxin (PTX, 500 
ng ml-1, 18 h) in an oxygenated glass beaker at room temperature (modified from Chessell et 
al., 1996). In order to verify that PTX had effectively blocked the Gi/o protein, the effect of 
the Gi/o-coupled MOR agonist ME was tested. Thus, only cells with a reduced inhibitory 
effect of ME (inhibiton <80% of basal FR) were considered to perform the concentration-
effect curve for sulprostone. In those cells, proper drug perfusion was assessed with GABA 
(1 mM, 1 min). To confirm the involvement of inwardly rectifying potassium channels 
(GIRK), concentration-effect curves for sulprostone were performed in the presence of the 
GIRK blocker BaCl2 (300 µM, 15 min) or the selective GIRK2 gating inhibitor SCH-23390 
(15 µM, 30 min) at the concentrations previously used (Pineda and Aghajanian, 1997; Chee 
et al., 2011).  
 
Analysis and statistics of electrophysiological data 
The data and statistical analysis were carried out with the computer programs GraphPad 
Prism (version 5.0 for Windows, GraphPad Software, Inc., San Diego, CA, USA) and SPSS 
(version 22.0 for Windows, SPSS Inc, Chicago, IL, USA) and comply with the 
recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018). 
The inhibitory effect of GABA (1 mM, 1 min) and ME (0.8 µM, 1 min) was normalized to 
the initial FR in each cell as follows: E (%) = (FRbasal - FRpost) · 100/FRinitial, where FRinitial 
is the average basal FR of each neuron calculated for 60 s at the beginning of the recording 
and FRbasal is the average FR of each pre-agonist condition calculated for 60 s immediately 
before drug application. FRpost is the average FR after the drug application calculated for 60-
90 s. Whereas in the case of the EP3 receptor agonists, the effect of each concentration of the 
drug was normalized to the FRbasal. The intervals were chosen to integrate the whole period 
of maximal effect of each drug administration (Medrano et al., 2017). Normalization to 
FRinitial or FRbasal was made to obtain comparable measures across groups. 
To construct concentration-effect curves for the EP3 receptor agonists, fitting analysis was 
performed to obtain the best simple nonlinear fit to the following three-parameter logistic 
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equation: E = Emax[A]n / (EC50n + [A]n), where E and [A] are the observed effect and the 
concentration of the agonist, respectively; Emax is the maximal effect of the EP3 receptor 
agonist with the Emax being constrained to 100% in all those neurons in which the observed 
effect reached a full cessation of the FR. EC50 is the concentration of the agonist required to 
promote the 50% of Emax, and n represents the slope factor of the function. These parameters 
were determined in individual assays by the nonlinear analysis and then averaged to obtain 
the theoretical parameters in each group. For comparison purposes, the EC50 values were 
converted and expressed as negative logarithm (pEC50) which adjusted the variable into a 
Gaussian distribution (Pineda et al., 1997).  
The antagonist affinity value was calculated as the negative logarithm of the equilibrium 
dissociation constant of the antagonist-receptor complex (pKB). The pKB value was estimated 
using the Gaddum/Schild equation modified for global fitting of the curves using GraphPad 
Prism 5.0 (Lazareno and Birdsall, 1993; Säfholm et al., 2013), where the minimum and 
maximum effects were constrained to 0 and 100%, respectively, and the Schild slope was 
constrained to 1.0 in accordance with previous reports (Lazareno and Birdsall, 1993; Säfholm 
et al., 2013). 
Data are expressed as the mean ± SEM of n number of slices. Statistical analyses were 
performed by a two-tailed paired Student’s t-test when the response values were compared 
before and after drug applications within the same cell, and by a two-tailed two-sample 
Student’s t-test when the FRs, responses or parameters were two independent experimental 
conditions. Statistical comparison of the results among more than two experimental 
conditions (including a control group) were done by one-way analysis of variance (ANOVA) 
followed by a post hoc pairwise comparisons with a Dunnett’s test or a Bonferroni’s Multiple 
Comparison test and only if F achieved the necessary level of statistical significance (i.e. P 
< 0.05) and there was no significant variance inhomogeneity. Dunnett’s procedure was used 
for comparisons with a control group and Bonferroni’s test, for comparisons among all the 
groups. The threshold of significance was set at P = 0.05 and only one level of probability (P 
< 0.05) is reported.  
 
Materials and drugs 
For electrophysiological recordings, the following drugs were used (drug source): BaCl2 
(Sigma-Aldrich Química S.A., Madrid, Spain), γ-aminobutyric acid (GABA, Sigma-
Aldrich), L-161,982 (Tocris Bioscience, Bristol, UK), L-798,106 (Tocris Bioscience), ME 
acetate salt (Bachem, Weil am Rhein, Germany), misoprostol free acid (Cayman Chemical, 
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Ann Arbor, MI, USA), pertussis toxin (Tocris Bioscience), PF-04418948 (Tocris 
Bioscience), prostaglandin E2 (PGE2) (Tocris Bioscience), SCH-23390 (Tocris Bioscience), 
and sulprostone (Cayman Chemical). Stock solutions of L-161,982, L-798,106, PF-
04418948, and PGE2 were first prepared in pure DMSO and then diluted in aCSF to obtain a 
final concentration of DMSO lower than 0.1%, which does not affect the firing activity of 
LC neurons in vitro (Pineda et al., 1996). Misoprostol and sulprostone were purchased 
already dissolved in methyl acetate and the final concentrations were obtained by diluting it 
in the aCSF at the moment of the experiment. Control assays were performed with equivalent 
volumes of the vehicles in which the drugs were dissolved. The final concentration of methyl 
acetate in the aCSF was < 0.01%. Stock solutions of the rest of the drugs were first prepared 
in Milli-Q water and then diluted 1000- to 10000-fold in aCSF for the desired concentration. 
Final solutions were freshly prepared just before each experiment and stock solutions were 
kept at -20 ºC.  
 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 






Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons 
 
EP3 receptors are expressed in catecholaminergic neurons of the brain, including the LC 
(Nakamura et al., 2001). To investigate the effect of EP3 receptor activation on the firing rate 
of LC neurons, we performed concentration-effect curves for sulprostone, an EP3 receptor 
agonist that shows more than 300-fold higher affinity for the EP3 receptor than for the EP1 
receptor (Abramovitz et al., 2000). Increasing concentrations of sulprostone (1.25 – 320 nM, 
2x, 1 min each) inhibited the neuronal activity of LC cells in a concentration-dependent 
manner with an EC50 value in the nanomolar range (Figures 1A and C; Table 1). Complete 
inhibition of the firing rate of noradrenergic cells was achieved at the highest concentration 
of sulprostone used (20 – 320 nM) and persisted for 265 ± 53 s on average (n = 9).  
 
In order to study the EP receptor involved in the sulprostone-induced inhibitory effect, 
concentration-effect curves for sulprostone (0.15 nM – 1.28 µM) were performed in the 
presence of the EP3 receptor antagonist (L-798,106), the EP2 receptor antagonist (PF-
04418948) or the EP4 receptor antagonist (L-161,982) at 3 and 10 µM. Perfusion with L-
798,106 (3 µM) for 30 min did not significantly change the firing rate of LC neurons, but 
reduced the steepness of the concentration-effect curve for sulprostone (Figure 1C; Table 1). 
Moreover, a higher concentration of L-798,106 (10 μM, 10 min) reduced by 17.7 ± 3.8 % 
within the same cell the firing rate of LC neurons (n = 6, P < 0.05 compared to baseline) 
(data not shown) and shifted by 8 fold to the right the concentration-effect curve for 
sulprostone (Figures 1B and C; Table 1). The apparent affinity of L-798,106 for the EP3 
receptor (pKB) was calculated to be 5.77 ± 0.10 (n = 12). On the other hand, the EP2 receptor 
antagonist PF-04418948 (3 µM) failed to cause significant changes in the firing rate or any 
rightward shift in the concentration-effect curve for sulprostone (Figure 2B; Table 1). Indeed, 
unexpectedly, the highest concentration of PF-04418938 (10 µM) caused a 4-fold leftward 
shift in the concentration-effect curve for sulprostone (Figures 2A and B; Table 1). Similar 
to the EP2 receptor antagonist, perfusion with the EP4 receptor antagonist L-161,982 (3 and 
10 µM) failed to change the firing rate or to shift to the right the concentration-effect curve 




Altogether, these results suggest that the inhibitory effect of sulprostone on the firing rate of 
LC neurons is mainly mediated by the EP3 receptor. 
 
Effect of PGE2 and the PGE1 analog misoprostol on the firing rate of LC neurons 
 
To study whether the endogenous PGE2 and the PGE1 synthetic analog misoprostol mimic 
the inhibitory effect observed with sulprostone on the firing rate of LC cells, we performed 
concentration-effect curves for PGE2 and misoprostol. PGE2 (0.31 nM – 1.28 µM, 2x, 1 min 
each) concentration-dependently inhibited the firing rate of LC neurons with an EC50 value 
in the nanomolar range (Figures 3A and C; Table 2). Likewise, misoprostol (0.31 – 320 nM, 
2x, 1 min each) inhibited the neuronal activity of LC cells with similar potency (Figures 4A 
and C; Table 2).  
 
Perfusion with the EP3 receptor antagonist L-798,106 (10 µM) shifted by 19 and 9 fold, 
respectively, to the right the concentration-effect curves for PGE2 (0.31 nM – 10.2 µM) and 
misoprostol (0.31 nM – 2.56 µM) (Figures 3B and C, 4B and C; Table 2). When PGE2 was 
used as the standard agonist, the pKB value for L-798,106 was higher (pKB = 6.26 ± 0.05; n 
= 5, P < 0.05, one-way ANOVA followed by Bonferroni’s Multiple Comparison test) than 
that with sulprostone (see above). However, the pKB value estimated for L-798,106 with 
misoprostol (pKB = 5.91 ± 0.14; n = 5, P > 0.05) was not different from that obtained with 
sulprostone. On the other hand, administration of a combination of the EP2 receptor 
antagonist PF-04418948 (10 µM) and the EP4 receptor antagonist L-161,982 (10 µM) caused 
a more than 6-fold leftward shift in the concentration-effect curve for PGE2 (Figure 3C; Table 
2). However, both antagonists in combination did not cause any shift in the concentration-
effect curve for misoprostol (Figures 4C; Table 2). Finally, none of these antagonists changed 
the slope of the concentration-effect curves. 
 
As a whole, these results suggest that the endogenous ligand PGE2 and the PGE1 analog 
misoprostol inhibit the activity of LC neurons, preferentially through the EP3 receptor. In 
addition, administration of the EP2 and EP4 receptor antagonists apparently potentiate the 





Molecular mechanisms involved in the effect of EP3 receptor agonists on the firing rate of 
LC neurons 
 
The EP3 receptor has been shown to be coupled to Gi/o proteins (Ikeda-Matsuo et al., 2010) 
and GIRK channels (Ruiz-Velasco and Ikeda, 1998). Thus, to identify the molecular 
mechanisms involved in the EP3 receptor-mediated inhibition of firing activity of LC cells, 
we performed concentration-effect curves for sulprostone (0.31 nM – 1.28 µM, 2x) in slices 
incubated for 18 h with the irreversible Gi/o protein blocker PTX, 500 ng ml-1. In order to 
confirm that PTX had effectively blocked the Gi/o protein, only cells with a reduced inhibitory 
response (inhibition <80% of basal firing rate) to the Gi/o-coupled MOR agonist ME (0.8 µM, 
1 min) were selected to perform the concentration-effect curves for sulprostone (Figure 5A). 
Moreover, proper drug perfusion was tested with GABA (1 mM, 1 min) (Figure 5A), which 
has been shown to fully inhibit the firing rate through GABAA ionotropic receptors 
(Mendiguren and Pineda, 2007). Thus, overnight treatment of the slices with PTX shifted by 
6 fold to the right the concentration-effect curve for sulprostone, without affecting 
significantly the maximal response or the basal firing rate (Figures 5A, D; Table 3).  
 
To study the involvement of GIRK channels, we performed concentration-effect curves for 
sulprostone (0.31 nM – 2.56 µM, 2x) in the presence of the non-selective GIRK channel 
blocker BaCl2 or the selective GIRK2 gating inhibitor SCH-23390. Since ME-induced 
inhibitory effect depends on the opening of GIRK channels, ME (0.8 µM, 1 min) was 
previously applied in the presence of the GIRK channel blockers to confirm the blockade 
action. Thus, GIRK channel blockade with Ba2+ (300 μM, 15 min) and SCH-23390 (15 μM, 
30 min) reduced the inhibitory effect of ME by 29.6 ± 6.3% (n = 5, P < 0.05; Figure 5B) and 
25.2 ± 8.6% (n = 5, P < 0.05; Figure 5C), respectively, as previously described (Torrecilla et 
al., 2002). Bath perfusion with BaCl2 (300 μM, 15 min) increased the firing rate of LC 
neurons by 42.6 ± 13.1% (n = 5, P < 0.05 compared to baseline) and shifted by 3 fold to the 
right the concentration-effect curve for sulprostone (Figures 5B and D; Table 3). Likewise, 
bath administration of SCH-23390 (15 μM, 30 min) increased the firing activity of LC 
neurons by 144 ± 57% (n = 5, P < 0.05 compared to baseline) and shifted by 2 fold to the 
right the concentration-effect curve for sulprostone (Figures 5C and D; Table 3). BaCl2 and 
SCH-23390 slightly reduced the maximal effect of sulprostone, but these changes did not 




These results suggest that EP3 receptor activation inhibits the LC neuronal activity through 
activation of Gi/o proteins and GIRK channels. 
 
Discussion  
The present work was undertaken to characterize the functional role of EP3 receptors in LC 
neurons in rat brain slices. Our results show that the EP3 receptor agonists sulprostone, PGE2, 
and misoprostol inhibits in a concentration-dependent manner the neuronal activity of LC 
cells in vitro. This inhibitory effect was blocked by the selective EP3 receptor antagonist L-
798,106, but not by the EP2 or EP4 receptor antagonists, indicating that the observed effect 
was mediated by EP3 receptor activation. Furthermore, sulprostone-induced inhibition of the 
firing rate was hindered by pretreatment with the Gi/o protein inhibitor PTX and the GIRK 
blockers BaCl2 and SCH-23390. Thus, our results suggest that EP3 receptor activation 
inhibits the firing activity of LC neurons, presumably by its coupling to Gi/o proteins and the 
subsequent opening of GIRK channels. 
 
Dense EP3 receptor immunoreactivity has been found by double immunofluorescence in the 
neuropil and in a few cell bodies of the LC (Nakamura et al., 2001), where there is also strong 
expression of EP3 receptor mRNA (Ek et al., 2000). Furthermore, the LC contains 
constitutive COX-2, the rate-limiting enzyme for prostanoid synthesis (Yamaguchi and 
Okada, 2009), suggesting the presence of endogenous prostaglandins in this nucleus. In our 
study, we assessed the functional role of EP3 receptors by using extracellular recordings in 
vitro and application of EP3 receptor agonists. Sulprostone was selected as an EP3 receptor 
agonist based on its more than 300-fold higher affinity for the EP3 than for the EP1 receptor 
(Abramovitz et al., 2000). Sulprostone was perfused at similar concentrations previously 
used to study EP3 receptor-mediated effects in rodent brain slices from the cortex (Exner and 
Schlicker, 1995) and the LC (Mulvey et al., 2018). We also assessed the biological relevance 
of the endogenous prostanoid system by perfusing PGE2, which has high affinity for all the 
EP receptors but especially for the EP3 receptor (EP3≥EP4>EP2>EP1) (Abramovitz et al., 
2000). Moreover, we tested the PGE1 analog, commercially available misoprostol, which has 
higher selectivity for the EP3 receptor (affinity: EP3>EP4>EP2) (Abramovitz et al., 2000). 
On the other hand, we used as EP3 receptor antagonist L-798,106, which is highly selective 
for the EP3 receptor compared to the EP4 receptor (Su et al., 2008). Finally, the EP2 receptor 
antagonist PF-04418948 has no affinity for the EP3 receptor at the concentrations herein used 
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(Forselles et al., 2011), while L-161,982 shows much higher affinity for the EP4 than for the 
EP3 receptor (Machwate et al., 2001) 
 
In the present study, sulprostone, PGE2, and misoprostol completely inhibited the firing 
activity of LC neurons. This inhibitory effect was blocked by an EP3 receptor antagonist but 
not by EP2 or EP4 receptor antagonists, ruling out the involvement of EP2 or EP4 receptors 
in this inhibition. EP1 receptor-mediated effects may be unlikely in our system because low 
EP1 receptor mRNA expression has been reported in the brainstem (Candelario-Jalil et al., 
2005). In our study, the determined EC50 values of the concentration-effect curves for 
sulprostone, misoprostol, and PGE2 and the rank order of potency found for firing activity 
inhibition (sulprostone > misoprostol > PGE2) were consistent with preceding data in rodent 
brain cortex slices, where the same agonists inhibited the NA release with 0.4-1.0 fold higher 
pIC50 values (8.22, 8.00, and 7.74, respectively; Exner and Schlicker, 1995). Furthermore, in 
guinea-pig aorta, comparable EC50 values were found for the sulprostone-induced 
vasoconstriction (23 nM) (Jones et al., 1998). The pKB value for the EP3 receptor antagonist 
L-798,106 herein reported was equivalent when either sulprostone or misoprostol were used 
as standard agonist (5.8 – 5.9), which supports the evidence for the activation of a common 
EP3 receptor. However, when PGE2 was used as an agonist, the estimated pKB value was 0.4 
units higher, suggesting that PGE2 may also activate interfering non-EP3 receptors. In this 
regard, in the presence of PF-04418948 and L-161,982, the concentration-effect curve for 
PGE2 was shifted to the left, which could suggest that PGE2 may also activate Gs protein-
coupled EP2 and EP4 receptors counteracting the EP3 receptor-mediated inhibition. Other 
authors have estimated a 2 units higher pKB value for L-798,106 when sulprostone and PGE2 
were used as standard agonists in peripheral tissues, such as guinea-pig smooth muscle (Jones 
et al., 2011). This disparity could be due to the high lipophilicity of L-798,106, which 
determines the equilibration kinetics and the pKB calculation (Jones et al., 2011), or to the 
different tissues (muscle vs. brain slices) and species employed (guinea-pig vs. rat). In 
summary, EP3 receptor activation by selective agonists inhibits the firing rate of LC neurons. 
 
In line with our results, c-fos expression, an indicator of neuronal activity, is increased in the 
LC from morphine-dependent rats and this enhancement is reversed by EP3 receptor agonists 
administered centrally (Nakagawa et al., 2000), suggesting that the neuronal activity of LC 
cells is inhibited by EP3 receptor activation. Furthermore, a single concentration of 
sulprostone has recently been shown to hyperpolarize LC neurons in slices from mice 
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(Mulvey et al., 2018). Likewise, other electrophysiological studies have demonstrated an EP3 
receptor-mediated inhibition of central neurotransmission in other brain regions. Thus, EP3 
receptor activation by PGE2 reduces glutamatergic transmission in the dorsolateral 
periaqueductal gray (PAG) (Lu et al., 2007), GABAergic transmission in the paraventricular 
nucleus of the hypothalamus (Khazaeipool et al., 2018), and network activity in the neocortex 
(Koch et al., 2010). In contrast to our results, a neuronal activity increase has been described 
upon PGE2 administration in serotonergic neurons of the dorsal raphe nucleus, but the exact 
mechanism has not been fully elucidated (Momiyama et al., 1996). 
 
EP3 receptor activation has been described to be coupled to Gi/o proteins (Ikeda-Matsuo et 
al., 2010). In our research, the sulprostone-induced inhibitory effect was reduced by the Gi/o 
signaling inhibitor PTX (Mangmool and Kurose, 2011), indicating that EP3 receptor 
activation leads to cell inhibition by stimulation of Gi/o proteins. Gi/o-mediated effects have 
been previously described for the EP3 receptor in other brain regions, such as the 
hippocampus, where PTX blocks the EP3 receptor-induced ischemic excitotoxicity (Ikeda-
Matsuo et al., 2010). Inhibition of firing activity of LC neurons has been described to occur 
after opening of GIRK channels by Gi/o-protein βγ subunits (Albsoul-Younes et al., 2001), 
such as upon activation of Gi/o protein-coupled µ-opioid receptors or α2 adrenoceptors 
(Torrecilla et al., 2002; 2013). Barium and SCH-23390 are effective GIRK channel blockers 
(Kuzhikandathil and Oxford, 2002) that have been reported to increase the firing rate of LC 
cells (Li and Putnam, 2013). Indeed, in our study, administration of barium and SCH-23390 
increased the firing rate of LC neurons and prevented the effect of sulprostone, supporting 
an involvement of GIRK channels in the EP3 receptor-mediated effect in the LC. Similarly, 
in sympathetic neurons, PGE2 activates GIRK channels probably through a Gi/o-dependent 
mechanism (Ruiz-Velasco and Ikeda, 1998).  
 
Our results show that EP3 receptor activation inhibits the activity of LC neurons in rat brain 
slices, likely through opening of postsynaptic Gi/o protein-coupled GIRK channels. This 
inhibitory effect on the LC may regulate NA release throughout projection areas of the CNS 
and thus add to the local inhibitory EP3 receptors on nerve terminals regulating NA release 
(Exner and Schlicker, 1995; Günther et al., 2010). The prostanoid system in the LC could play 
a role in the regulation of pain. Thus, the LC exerts a supraspinal descending control of pain 
(Hickey et al., 2014) and activation of a neuronal subpopulation of the LC evokes an anti-
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nociceptive response (Hickey et al., 2014). One possible consequence would be that EP3 
receptor activation in the LC may lead to a hyperalgesic effect. In line with this hypothesis, 
inflammatory stimuli reduce the analgesic effect induced by opioids in the LC (Jongeling et 
al., 2009). Likewise, in the PAG, EP3 receptor activation exerts pro-nociceptive actions (Drake 
et al., 2016). Prostaglandin release and EP3 receptor activation in the LC may also modulate 
the neuroinflammatory and febrile response. In this regard, c-Fos expression is increased in the 
LC by inflammatory insults through prostanoid synthesis (Xu et al., 2003) and the febrigenic 
effect of PGE2, which involves EP3 receptors (Ushikubi et al., 1998), is mediated by a neuronal 
network including the LC (Almeida et al., 2004). Finally, EP3 receptors in the LC may be 
relevant for some neuropsychiatric diseases. Thus, an enhanced expression of the EP3 receptor 
has been found around amyloid plaques in LC-projecting areas in Alzheimer’s disease (Shi et 
al., 2012). Furthermore, lesions of the LC enhance both pro-inflammatory cytokines (Bharani 
et al., 2017) and amyloid-β deposition in the hippocampus of a mouse model of Alzheimer’s 
disease (Heneka et al., 2010). Regarding psychiatry, stimulation of prefrontal-projecting 
neurons in the LC results in anxiety-like behavior (Hirschberg et al., 2017), thereby reduction 
of LC-noradrenergic cell activity by the EP3 receptor could attenuate anxiety, as shown by a 
previous study in which sulprostone infusion into the LC produced anxiolytic effects (Mulvey 
et al., 2018). In conclusion, the prostaglandin system in the LC would play a relevant role in 
the regulation of central physiology and the EP3 receptor in this nucleus might be a suitable 
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Table 1.  
Basal firing rate and concentration-effect curve parameters for the inhibitory action of the EP3 
receptor agonist sulprostone on LC neurons in the absence (control) or in the presence of the 
EP3 (L-798,106), EP2 (PF-04418948), and EP4 (L-161,982) receptor antagonists. 
 __________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) pEC50 (M) (EC50, nM) Slope factor  n 
 __________________________________________________________________  
Sulprostone 
Control  0.84 ± 0.07 7.83 ± 0.08 (14.8) 2.39 ± 0.37 9 
+ L-798,106 3 µM 0.64 ± 0.11 7.49 ± 0.09 (32.4) 1.39 ± 0.16* 6 
 10 µM 0.87 ± 0.22 6.89 ± 0.11* (128) 1.07 ± 0.12* 6 
+ PF-04418948 3 µM 0.66 ± 0.11 7.63 ± 0.15 (23.5) 1.89 ± 0.14 6 
 10 µM 0.58 ± 0.08 8.49 ± 0.10* (3.25) 1.61 ± 0.21 5 
+ L-161,982 3 µM 0.64 ± 0.11 8.05 ± 0.11 (8.93) 1.92 ± 0.36 5 
 10 µM 0.71 ± 0.12 8.08 ± 0.11 (8.34) 1.49 ± 0.11 5 
 __________________________________________________________________  
 
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Maximal 
effect values were 100% in all cases. pEC50 is the negative logarithm of the concentration 
needed to elicit a 50% of the maximal effect. *P < 0.05 when compared to the control group 






Basal firing rate and concentration-effect curve parameters for the inhibitory action of the EP3 
receptor agonists PGE2 and misoprostol on LC neurons in the absence (control) or in the 
presence of the EP3 (L-798,106) or a combination of the EP2 (PF-04418948) and EP4 (L-
161,982) receptor antagonists. 
 __________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) pEC50 (M) (EC50, nM) Slope factor  n 
 __________________________________________________________________  
PGE2 
Control  0.76 ± 0.10 6.96 ± 0.20 (110) 1.92 ± 0.36 5 
+ L-798,106 10 µM 0.87 ± 0.14 5.68 ± 0.05* (2098) 2.55 ± 0.47 5 
+ PF-04418948 10 µM   
    L-161,982 10 µM 0.83 ± 0.24 7.78 ± 0.19* (16.6) 1.07 ± 0.06 5 
Misoprostol 
Control  0.80 ± 0.12 7.30 ± 0.13 (50.7) 1.85 ± 0.30 5 
+ L-798,106 10 µM 0.67 ± 0.11 6.34 ± 0.12* (455) 1.36 ± 0.28 5 
+ PF-04418948 10 µM   
    L-161,982 10 µM 0.72 ± 0.11 7.31 ± 0.12 (49.5) 1.76 ± 0.33 5 
 __________________________________________________________________  
 
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Maximal 
effect values were 100% in all cases. pEC50 is the negative logarithm of the concentration 
needed to elicit a 50% of the maximal effect. *P < 0.05 when compared to their respective 




Basal firing rate and concentration-effect curve parameters for the inhibitory action of sulprostone 
on LC neurons in the absence (control) or in the presence of PTX, BaCl2, and SCH-23390. 
 _____________________________________________________________________ 
 Concentration-effect curves1 
Drugs Concentration Basal firing rate (Hz) Emax (%) pEC50 (M) (EC50, nM) Slope factor n 
 _____________________________________________________________________ 
Sulprostone 
Control  0.84 ± 0.07 100 7.83 ± 0.08 (14.8) 2.39 ± 0.37 9 
+ PTX 500 ng ml-1 1.12 ± 0.18 94.9 7.04 ± 0.15* (90.9) 1.65 ± 0.28 5 
+ BaCl2 300 µM 1.03 ± 0.13 94.6 7.27 ± 0.09* (53.7) 1.37 ± 0.18 5 
+ SCH-23390  15 µM 1.37 ± 0.28 87.5 7.46 ± 0.05* (34.6) 1.56 ± 0.17 5 
 _____________________________________________________________________ 
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the 
maximal inhibitory effect and pEC50 is negative logarithm of the concentration needed to elicit a 
50% of the Emax. *P < 0.05 when compared to the control group (one-way ANOVA followed by 











Figure 1. Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons in 
the absence or presence of the EP3 receptor antagonist L-798,106. (A, B) Representative 
examples of firing rate recordings of two LC neurons showing the effect of increasing 
concentrations of sulprostone in the absence (A) and presence of L-798,106 (10 µM) (B). 
The vertical lines represent the number of spikes recorded every 10 s and the horizontal bars 
the period of drug application. (C) Concentration-effect curves for sulprostone in control 
(filled squares) and in the presence of L-798,106 (3 µM, open circles or 10 µM, filled circles). 
The horizontal axis shows the sulprostone concentration on a semi-logarithmic scale. The 
vertical axis expresses the reduction in firing rate of LC neurons as the percentage of the 
baseline. Data points are the mean ± SEM at each sulprostone concentration obtained from n 
number of experiments. The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. Note that the concentration-effect curve for sulprostone 
is shifted to the right by the EP3 receptor antagonist. 
Figure 2.  Effect of the EP3 receptor agonist sulprostone on the firing rate of LC neurons in 
the presence of the EP2 receptor antagonist PF-04418948 or the EP4 receptor antagonist L-
161,982. (A, B) Representative examples of firing rate recordings of two LC neurons 
showing the effect of increasing concentrations of sulprostone in the presence of PF-
04418948 (10 µM) (A) or L-161,982 (10 µM) (B). (C, D) Concentration-effect curves for 
sulprostone in control (filled squares) and in the presence of PF-04418948 (3 µM, open 
triangles or 10 µM, filled triangles) (C) or L-161,982 (3 µM, open diamonds or 10 µM, filled 
diamonds) (D). The horizontal axis shows the sulprostone concentration on a semi-
logarithmic scale. The vertical axis expresses the reduction in firing rate of LC neurons as 
the percentage of the baseline. Data points are the mean ± SEM at each sulprostone 
concentration obtained from n number of experiments. The lines through the data are the 
theoretical curves in each group constructed from the mean of the individual concentration-
effect curve parameters, as estimated by nonlinear regressions. 
 
Figure 3.  Effect of PGE2 on the firing rate of LC neurons in the absence or presence of the 
EP3 receptor antagonist L-798,106 or a combination of the EP2 receptor antagonist PF-
04418948 and the EP4 receptor antagonist L-161,982. (A, B) Representative examples of 
firing rate recordings of two LC neurons showing the effect of increasing concentrations of 
 
28 
PGE2 in the absence (A) and presence of L-798,106 (10 µM) (B). The vertical lines represent 
the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (C) Concentration-effect curves for PGE2 in control (filled squares) and in the 
presence of L-798,106 (10 µM, filled circles) or PF-04418948 and L-161,982 (10 µM each, 
half-filled diamonds). The horizontal axis shows the PGE2 concentration on a semi-
logarithmic scale. The vertical axis expresses the reduction in firing rate of LC neurons as 
the percentage of the baseline. Data points are the mean ± SEM at each PGE2 concentration 
obtained from n number of experiments. The lines through the data are the theoretical curves 
in each group constructed from the mean of the individual concentration-effect curve 
parameters, as estimated by nonlinear regressions. Note that the concentration-effect curve 
for PGE2 is shifted to the right by the EP3 receptor antagonist and to the left by the EP2 and 
EP4 receptor antagonists. 
Figure 4. Effect of misoprostol on the firing rate of LC neurons in the absence or presence 
of the EP3 receptor antagonist L-798,106 or a combination of the EP2 receptor antagonist 
PF-04418948 and the EP4 receptor antagonist L-161,982. (A, B) Representative examples of 
firing rate recordings of two LC neurons showing the effect of increasing concentrations of 
misoprostol in the absence (A) and presence of L-798,106 (10 µM) (B). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (C) Concentration-effect curves for misoprostol in control (filled squares) and in 
the presence of L-798,106 (10 µM, filled circles) or PF-04418948 and L-161,982 (10 µM 
each, half-filled diamonds). The horizontal axis shows the misoprostol concentration on a 
semi-logarithmic scale. The vertical axis expresses the reduction in firing rate of LC neurons 
as the percentage of the baseline. Data points are the mean ± SEM at each misoprostol 
concentration obtained from n number of experiments. The lines through the data are the 
theoretical curves in each group constructed from the mean of the individual concentration-
effect curve parameters, as estimated by nonlinear regressions. Note that the concentration-
effect curve for misoprostol is shifted to the right by the EP3 receptor antagonist. 
Figure 5. Effect of sulprostone on the firing rate of LC neurons after overnight treatment of 
the slices with the Gi/o inhibitor pertussis toxin (PTX) or in the presence of the GIRK blockers 
Ba2+ or SCH-23390. Representative examples of firing rate recordings of three LC neurons 
showing the effect of increasing concentrations of sulprostone after overnight treatment with 
PTX (500 ng ml-1) (A) or in the presence of BaCl2 (300 µM) (B) or SCH-23390 (15 µM) (C). 
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The vertical lines represent the number of spikes recorded every 10 s and the horizontal bars 
the period of drug application. Note that the effect of ME (0.8 µM) is reduced compared to 
control (see Figure 4.1) while the inhibitory effect of GABA (1 mM) is maintained (A). (D) 
Concentration-effect curves for sulprostone in control (filled squares) or after overnight 
treatment with PTX (500 ng ml-1, open triangles) or in the presence of Ba2+ (300 µM, filled 
circles) or SCH-23390 (15 µM, open squares). The vertical axis expresses the reduction in 
firing rate of LC as the percentage of the baseline. Data points are the mean ± SEM at each 
sulprostone concentration obtained from n number of experiments. The lines through the data 
are the theoretical curves in each group constructed from the mean of the individual 
concentration-effect curve parameters, as estimated by nonlinear regressions. Note that the 
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Bullet point summary (each bullet max. 15 words, max. 2 bullets per heading) 
 
What is already known: 
- PGE2, an inflammatory mediator involved in pain and fever, modulates the activity of 
brain neurons 
- EP3 receptor activation inhibits locus coeruleus (LC) neurons, which also express EP2 
receptors 
 
What does this study add: 
- EP2 receptor agonists stimulates the neuronal activity of LC noradrenergic cells in vitro  




- The LC, the main noradrenergic nucleus, is susceptible to inflammatory mediators 




BACKGROUND AND PURPOSE: We have shown that the inflammatory mediator 
prostaglandin E2 (PGE2) inhibits locus coeruleus (LC) neurons in vitro via Gi/o-coupled EP3 
receptors. PGE2 also binds to Gq-coupled EP1 and Gs-coupled EP2 and EP4 receptors. In the 
brainstem, the EP2 receptor is expressed almost exclusively in the LC, the main noradrenergic 
nucleus of the brain, but its functional role remains unknown. Thus, we aimed to characterize 
pharmacologically EP2 receptors in LC neurons.  
 
EXPERIMENTAL APPROACH: We studied the effect of EP2 receptor agonists on the LC 
firing activity in rat brain slices by single-unit extracellular electrophysiology. 
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KEY RESULTS: EP2 receptor agonist butaprost (0.01-10 μM) and treprostinil (0.03-10 µM) 
increased the firing rate of LC neurons in a concentration-dependent manner (EC50=0.45 µM 
and 0.54 µM; Emax=74.3% and 81.3%, respectively). The EP2 receptor antagonist PF-
04418948 (10 nM), but not the EP3 (L-798,106, 10 nM) or EP4 receptor antagonists (L-
161,982, 10 nM), hindered the excitatory effect of butaprost and treprostinil. Furthermore, 
extracellular sodium replacement and Gβγ blockade (gallein, 20 μM) prevented the butaprost-
induced stimulation of neuronal activity. However, the excitatory effect caused by butaprost 
was not reduced by a PKA activator (8-Br-cAMP, 1 mM) or PKA inhibitor (H-89, 10 μM), nor 
was it modified by synaptic blockade or by inhibitors of the Gαs subunits (NF449, 10 µM), 
HCN channels (ZD7288, 30 µM), TRP channels (2-APB, 30 µM), and Kir6.2 channels 
(glibenclamide, 3 µM). 
 
CONCLUSIONS AND IMPLICATIONS: activation of postsynaptic EP2 receptor excites LC 
noradrenergic neurons, seemingly through a Gβγ-dependent activation of sodium current. 
Keywords: locus coeruleus; PGE2; EP2 receptor; prostanoid; slice; firing 
 
Introduction  
Prostaglandins are inflammatory mediators synthetized on demand from membrane 
phospholipids, which are transformed into arachidonic acid, and then into a common 
precursor by the rate-limiting enzyme cyclooxygenase (COX). Nonsteroidal anti-
inflammatory drugs (NSAID) are commonly used as analgesic, antipyretic, and anti-
inflammatory drugs as they prevent the synthesis of prostanoids by blocking the enzymatic 
activity of the COX. In mammal brain, the COX enzyme is constitutively expressed under 
non-inflammatory circumstances (Yasojima et al., 1999; Hétu and Riendeau, 2005) 
suggesting a role of prostaglandins on basal conditions. On this premise, COX is found in 
neuronal cell bodies and dendrites (Yasojima et al., 1999), which further highlights the 
implication of the prostanoid system in neuronal physiology. The main final product of COX 
synthesis is the prostaglandin E2 (PGE2), which binds to G protein-coupled receptors: EP1-
EP4. Thus, the EP1 receptor is coupled to Gq, EP3 to Gi/o, and EP2 and EP4 to Gs proteins. 
The EP2, EP3, and EP4 receptors are extensively expressed in the CNS, including the 
hypothalamus and the locus coeruleus (LC) (Zhang and Rivest, 1999; Ek et al., 2000). 
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Activation of these receptors can modulate the neuronal activity, which has been broadly 
studied in the case of the EP2 receptor. For instance, EP2 receptor activation regulates 
synaptic transmission in the hippocampus (Sang et al., 2005) and elicits membrane 
depolarization in neurons from the hypothalamus (Clasadonte et al., 2011) and dorsal horn 
(Baba et al., 2001). Furthermore, PGE2 elicits a sodium current in ganglion (Matsumoto et 
al., 2005) and cerebellar neurons (Fang et al., 2011) via EP2 receptor activation. 
 
The LC, the main source of noradrenaline (NA) in the brain, controls many physiological 
functions, including sleep-wake cycle, arousal, cognition, and pain by sending noradrenergic 
projections to virtually all brain regions. Additionally, the LC receives inputs mainly from 
glutamatergic and GABAergic afferences (Aston-Jones et al., 1986). Some findings have 
suggested a connection between prostaglandins and the LC. First, LC cells possess the 
enzymatic equipment to synthesize prostaglandins, as spinally-projecting LC neurons 
constitutively express COX enzyme (Yamaguchi and Okada, 2009). Thus, NSAID 
administration attenuates the activation of LC cells in response to nociception and 
inflammation (Xu et al., 2003). Second, previous results from our laboratory have shown that 
EP3 receptor activation by the endogenous PGE2 inhibits the neuronal activity of LC cells in 
vitro (Nazabal et al., unpublished results). Finally, in the brainstem, the EP2 receptor is 
almost exclusively expressed in the LC, as demonstrated by in situ hybridization (Zhang and 
Rivest, 1999). However, little is known about the function of the EP2 receptor in LC neurons. 
Thus, we aimed to characterize the EP2 receptor pharmacologically and to study its signaling 




Animals and ethics statement 
97 male adult Sprague-Dawley rats (200-300 g) were used to perform the experiments and 
are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and 
Lilley, 2015) and with the recommendations made by the British Journal of Pharmacology. 
Rats were obtained from the animal house of the University of the Basque Country (Leioa, 
Spain) and housed under standard environmental conditions (22 ºC, 12:12 h light/dark cycles) 
with free access to food and water. One slice was taken from each animal, and unless stated 
otherwise, only one experiment was performed in each slice. The number of experiments in 
each group was typically five to eight, depending on the level of variability. Treatments and 
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controls were performed in parallel in a randomized manner. As electrophysiological 
outcomes were collected in situ, data recording could not be blinded to the operator. 
However, the data analysis performed by the experimenter was confirmed separately by an 
additional researcher in all cases. All the experiments were carried out according to EU 
Directive 2010/63 on the protection of animals used for scientific purposes and approved by 
the local Ethical Committee for Research and Teaching of the University of the Basque 
Country (UPV/EHU, Spain) and the Department of Sustainability and Natural Environment 
of Provincial Council from Bizkaia (ref. CEEA M20-2015-152; CEEA M20-2018-026). All 
the efforts were made to minimize the animal suffering and to reduce the number of animals 
used. 
 
Brain slice preparation 
Animals were anesthetized with chloral hydrate (400 mg kg-1, i.p.) and decapitated 
(Mendiguren and Pineda, 2007). The brain was rapidly extracted, and a block of tissue 
containing the brainstem was immersed in ice-cold modified artificial cerebrospinal fluid 
(aCSF) where NaCl was equiosmolarly substituted for sucrose to improve neuronal viability. 
Coronal slices of 500-600 μm thickness containing the LC were cut using a vibratome (Leica 
VT1200 S, Leica Biosystems, Nussloch, Germany). The tissue was allowed to recover from 
the slicing for 90 min, placed on a nylon mesh, and incubated at 33 ± 1 ºC on a modified 
Haas-type interface chamber. The tissue was continuously perfused with aCSF saturated with 
95% O2/ 5% CO2 (final pH = 7.34) at a flow rate of 1.5 ml min-1. The aCSF contained (in 
mM): NaCl 130, KCl 3, NaH2PO4 1.25, D-glucose 10, NaHCO3 21, CaCl2 2 and MgSO4 2. 
The LC was recognized visually in the rostral pons as a dark oval area on the lateral borders 
of the central gray and the 4th ventricle, at or just anterior to the genu of the facial nerve. 
 
Electrophysiological recordings 
Single-unit extracellular recordings of LC cells were made as previously described 
(Mendiguren and Pineda, 2007). The recording electrode consisted of an Omegadot glass 
micropipette puller (Sutter Instruments, Novato, CA, USA) and filled with 50 mM NaCl. The 
tip was broken back to a size of 2 – 5 μm (3 – 5 MΩ) and positioned in the LC. The 
extracellular signal from the electrode was passed through a high-input impedance amplifier 
(Axoclamp 2B, Molecular Devices, Union City, CA, USA) and monitored on an audio-
amplifier and an oscilloscope (Aumon 14, Cibertec S.A., Madrid, Spain). Individual neuronal 
spikes were isolated from the background noise with a window discriminator (PDV 225, 
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Cibertec S.A.). The firing rate (FR) was continuously recorded and analyzed before, during, 
and after experimental manipulations by a PC-based custom-made program which generated 
consecutive 10 s bin histograms bars of the cumulative number of spikes (HFCP®, Cibertec 
S.A., Madrid, Spain). Noradrenergic cells in the LC were identified by their spontaneous and 
regular discharge activities, the slow FR and the long-lasting biphasic positive-negative 
waveforms (Andrade and Aghajanian, 1984). We only recorded cells that showed stable FRs 
between 0.5 and 1.5 Hz for at least 3-5 min and the inhibitory responses to [Met]enkephalin 
(ME 0.8 μM, 1 min) higher than 80% (Medrano et al., 2017), which was used as a control for 
the perfusion system.  
 
Pharmacological procedures  
The firing rate of LC neurons was recorded for several minutes before drug applications to 
obtain the baseline activity, and then, during and after drug perfusion. To characterize the effect 
of EP2 receptor agonists in LC neurons, we perfused increasing concentrations of the EP2 
receptor agonist butaprost free acid (10 nM – 10 μM, 3x) and the synthetic prostacyclin (PGI2) 
analog treprostinil, which has a high affinity for the EP2 receptor (30 nM – 10 µM, 3x). 
Concentrations were based on other studies made in brain slices (Liu et al., 2005). Each 
concentration of the EP2 receptor agonists was perfused for at least 10 min to reach its plateau 
effect and each agonist was used up to concentrations that achieved the maximal effect of the 
drug. To verify that the EP2 receptor was mediating the effect caused by butaprost and 
treprostinil, concentration-effect curves for these agonists were made in the presence of the 
EP2 receptor antagonist PF-04418948 (3 and 10 nM) or a combination of the EP3 receptor 
antagonist L-798,106 (10 nM) and the EP4 receptor antagonist L-161,982 (10 nM). 
Concentrations of the antagonists were selected according to preceding reports (Forselles et al., 
2011). All the antagonists employed were perfused for 30 min before performing the 
concentration-effect curves for the EP2 receptor agonists.  
Butaprost was used for subsequent characterization of the molecular mechanism involved in 
EP2 receptor activation. Activation of EP2 receptors increases a sodium current in neurons 
from different CNS areas such as the cerebellum (Fang et al., 2011) or the spinal dorsal horn 
(Baba et al., 2001). Then, to investigate the involvement of a sodium current in the butaprost-
mediated effect, a low sodium-containing aCSF was prepared by replacing 80% of the NaCl 
equiosmolarly with Trizma hydrochloride/base (TRIS) (Pineda et al., 1996) and then the effect 
of butaprost was tested. To further describe the involvement of sodium currents, we checked 
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whether the transient receptor potential (TRP) ion channels (Cui et al., 2011) might contribute 
to the effect of butaprost by using the nonselective TRP blocker 2-APB (30 µM, 10 min). 
Finally, to discard the activation of other channels that may mediate excitatory effects in the 
LC neurons (Ugedo et al., 1998), we examined the effect of butaprost in the presence of the 
ATP-sensitive potassium channel (Kir6.2) specific blocker glibenclamide (3 μM, 15 min).  
In the LC, noradrenergic cells are stimulated by a cAMP/PKA-induced inward sodium current 
(Wang and Aghajanian, 1987). To test whether the sodium current was induced by a rise in the 
cAMP levels and the resultant activation of the PKA, we performed an occlusion experiment 
with the non-hydrolyzable cell-permeable cAMP analog 8-Br-cAMP (1 mM, 8 min) (Wang 
and Aghajanian, 1990). Thus, in case EP2 receptor activation depends on the cAMP/PKA 
pathway, administration of a saturating concentration of 8-Br-cAMP would occlude the 
subsequent effect of butaprost. In addition, the cAMP/PKA-dependency was further 
determined by testing butaprost in the presence of the PKA inhibitor H-89 (10 μM, 20 min) 
(Jolas et al., 2000) or the HCN channel blocker ZD7288 (30 μM, 20 min) (Zolles et al., 2006).  
Then, we tested whether the Gαs protein would intermediate in the effect of butaprost by 
application of the blocker of the Gαs-dependent signaling NF449 (10 µM, 30 min) (Hohenegger 
et al., 1998). In these assays, vasoactive intestinal peptide (VIP) (0.5 μM, 5 min) administration 
was used as a positive control to confirm that NF449 was effectively blocking the Gαs protein, 
as previously reported in LC neurons (Wang and Aghajanian, 1990). Finally, to assess the 
involvement of the Gβγ subunits, the effect of butaprost was tested in slices previously 
incubated with gallein (20 µM) in an aluminum foil-covered glass beaker for 120 min 
(Kurowski et al., 2015).  
In order to study the involvement of presynaptic mechanisms in the effect caused by EP2 
receptor activation, butaprost was applied in the presence of the GABAA channel blocker 
picrotoxin (100 μM), the non-NMDA ionotropic glutamate receptor antagonist CNQX (30 
μM), the NMDA receptor antagonist d-AP5 (100 μM), and the non-selective metabotropic 
glutamate receptor antagonist RS-MCPG (500 μM) (Mendiguren and Pineda, 2007). All 
mentioned drugs were bath perfused for at least 10 min before and during testing the effect of 
butaprost. 
Analysis and statistics of electrophysiological data 
The data and statistical analysis were carried out with the computer program GraphPad Prism 
(version 5.0 for Windows, GraphPad Software, Inc., San Diego, CA, USA) and comply with 
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the recommendations on experimental design and analysis in pharmacology (Curtis et al., 
2018). The effect (E) was normalized to baseline (FRbasal) in each cell according to the 
following equation E = (FRbasal – FRpost) · 100/FRbasal, where FRbasal is the average FR of 
each pre-agonist condition calculated for 60 s immediately before drug application, and FRpost 
is the average FR of the last 60 s for each concentration of agonist, once it had reached a 
plateau. In the case of the perfusion test with ME (0.8 µM, 1 min), the inhibitory effect was 
calculated similarly but normalized to the initial FR (FRinitial), being the average FR of each 
neuron calculated for 60 s immediately before drug application and FRpost the average FR 
after drug application for 60-90 s. The intervals were chosen to integrate the whole period of 
maximal effect of each drug administration (Medrano et al., 2017). Normalization to FRbasal 
or FRinitial was used for comparison purposes across groups.  
To construct concentration-effect curves for the EP2 receptor agonists, fitting analysis was 
performed to obtain the best simple nonlinear fit to the following three-parameter logistic 
equation: E = Emax[A]n / (EC50n + [A]n), where E and [A] are the observed effect and the 
concentration of the agonist, respectively; Emax is the maximal excitatory effect of the EP2 
receptor agonist, EC50 is the concentration of the agonist required to promote the 50% of 
Emax, and n represents the slope factor of the function. These parameters were determined in 
individual assays by the nonlinear analysis and then averaged to obtain the theoretical 
parameters in each group. For comparison purposes, the EC50 values were converted and 
expressed as the negative logarithm (pEC50), which adjusted the variable into a Gaussian 
distribution. 
The antagonist affinity value was calculated as the negative logarithm of the equilibrium 
dissociation constant of the antagonist-receptor complex (pKB). The pKB value was estimated 
for parallel shifts by using the modified Gaddum/Schild equation for global fitting of the 
curves using GraphPad Prism 5.0 (Lazareno and Birdsall, 1993), where the minimum and 
maximum effects were constrained to 0 and 100% respectively, and the Schild slope was 
constrained to 1.0 in accordance with previous reports (Lazareno and Birdsall, 1993). In the 
case of treprostinil, the affinity measurement was obtained from the Gaddum method 
(Kenakin et al., 2006) by plotting double equieffective concentrations of treprostinil in the 
absence (ordinates) and presence (abscissae) of the antagonist.  
Data are expressed as the mean ± SEM of n number of rats. Statistical significances were 
obtained by a two-tailed paired Student’s t-test when the response values were compared 
before and after drug applications within the same cell, and by a two-tailed two-sample 
Student’s t-test when the FRs, responses or parameters were two independent experimental 
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conditions. Comparisons among more than two experimental conditions by one-way analysis 
of variance (ANOVA) followed by a Dunnett’s post hoc for comparison with a control group 
and only if F achieved the necessary level of statistical significance (i.e. P < 0.05) and there 
was no significant variance inhomogeneity. The threshold of significance was set at P = 0.05, 
and only one level of probability (P < 0.05) is reported. 
 
Materials and drugs 
For electrophysiological recordings, the following drugs were purchased from Tocris 
Bioscience (Bristol, UK): CNQX, d-AP5, gallein, glibenclamide, H-89, L-161,982, L-
798,106, RS-MCPG, NF449, PF-04418948, and ZD7288. The following drugs were acquired 
from Sigma-Aldrich Química S.A. (Madrid, Spain): picrotoxin and Trizma hydrochloride. 
From Bachem (Weil am Rhein, Germany) were purchased: [Met]enkephalin acetate salt 
(ME) and vasoactive intestinal peptide (VIP). Finally, 8-Bromo-cAMP was from Enzo Life 
Sciences Inc. (New York, USA) and butaprost free acid from Cayman Chemical (Ann Arbor, 
MI, USA). Stock solutions of gallein, glibenclamide, L-161,982, L-798,106, PF-04418948, 
and treprostinil were first prepared in pure DMSO and then diluted in aCSF to obtain a final 
concentration of DMSO lower than 0.1%, which does not affect the LC cell firing responses 
(Pineda et al., 1996). Butaprost free acid was purchased already dissolved in methyl acetate, 
and the final concentrations were obtained by diluting it in the aCSF at the moment of the 
experiment. The final concentration of methyl acetate in aCSF was < 0.03%. Control assays 
were performed with equivalent volumes of the vehicles in which the drugs were dissolved. 
RS-MCPG and picrotoxin were directly dissolved in aCSF the day of the experiment. Stock 
solutions of the rest of the drugs were first prepared in Milli-Q water and then diluted 1000- 
to 10000-fold in aCSF for the desired concentration. Final solutions were prepared freshly 
just before each experiment, and stock solutions were kept at -20 ºC.  
 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 





Effect of the EP2 receptor agonist butaprost on the firing rate of LC neurons 
 
In the brainstem, the EP2 receptor is expressed almost exclusively in the LC (Zhang and 
Rivest, 1999), but its functional role remains unknown. To investigate the effect of EP2 
receptor activation on the firing rate of LC neurons, we performed concentration-effect 
curves for the EP2 receptor agonist butaprost (10 nM – 10 µM). Administration of increasing 
concentrations of butaprost (10 nM – 10 μM, 3x, 15 min each) increased the firing rate of LC 
neurons (from 0.85 ± 0.09 Hz to 1.38 ± 0.11 Hz; n = 8, P < 0.05) in a concentration-dependent 
manner with an EC50 value in the nanomolar range (Figures 1A and D; Table 1).  
 
To elucidate which EP receptor was mediating the excitatory effect observed with butaprost, 
we constructed concentration-effect curves for this EP2 receptor agonist in the presence of 
the EP2 receptor antagonist PF-04418948 (3 and 10 nM) or a combination of the EP3 receptor 
antagonist L-798,106 (10 nM) and the EP4 receptor antagonist L-161,982 (10 nM). Bath 
application of PF-04418948 (3 and 10 nM) for 30 min did not change the firing rate, but the 
highest concentration (10 nM) shifted by 6 fold (n = 6, P < 0.05) to the right the 
concentration-effect curve for butaprost without affecting the maximal effect significantly 
(Figures 1B and D; Table 1). The calculated affinity for the EP2 receptor antagonist (pKB) 
was 8.39 ± 0.16 (n = 11). On the other hand, perfusion with a combination of L-798,106 and 
L-161,982 (10 nM each) for 30 min did not change the firing activity or shift to the right the 
concentration-effect curve for butaprost (Figures 1C and D; Table 1). There was a trend for 
the Emax to be higher after the combination of L-798,106 and L-161,982, but this increase 
was not significant (Figure 1D; Table 1). Altogether, these results suggest that butaprost 
increased the LC neuronal activity via activation of the EP2 receptor. 
 
Effect of the PGI2 analog treprostinil on the firing rate of LC neurons 
 
To further study the effect of EP2 receptor activation in the LC, we used the PGI2 analog 
treprostinil, a clinically relevant drug that shows high affinity for the EP2 receptor in binding 
studies (Whittle et al., 2012). Thus, administration of increasing concentrations of treprostinil 
(30 nM – 10 μM, 3x, 15 min each concentration) induced an excitatory effect on the firing 
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rate of LC neurons in a concentration-dependent manner (from 0.68 ± 0.07 Hz to 1.22 ± 0.17 
Hz; n = 6, P < 0.05), with an EC50 value in the nanomolar range (Figures 2A and D; Table 
1).  
 
Considering that treprostinil has high affinity for other prostanoid receptors, we assessed 
whether the observed excitatory response was produced by the activation of the EP2 receptor 
by using the specific EP2 (PF-04418948), EP3 (L-798,106), or EP4 (L-161,982) receptor 
antagonists at 10 nM. Perfusion with PF-04418948 (10 nM) for 30 min did not modify the 
firing rate or the EC50 of the concentration-effect curve for treprostinil. However, the EP2 
receptor antagonist decreased by 47.4% the Emax value of the concentration-effect curve for 
treprostinil (n = 6, P < 0.05; Figures 2B and D; Table 1). Given the apparent non-competitive 
binding, the affinity value of PF-04418948 for the EP2 receptor was calculated from the 
double reciprocal plot of equieffective agonist concentrations in the presence and absence of 
the antagonist (Kenakin et al., 2006). Thus, the estimated pKB for PF-04418948 using 
treprostinil as an agonist was 8.34 (95% CI: 8.29 – 8.38). In addition, bath application of a 
combination of L-798,106 and L-161,982 did not produce any rightward shift but increased 
the Emax value of the concentration-effect curve for treprostinil by 77.7% (n = 5, P < 0.05; 
Figures 2C and D; Table 1). Thus, these results suggest that the treprostinil-induced 
stimulation of the LC neuronal firing rate is caused, at least in part, by activation of the EP2 
receptor.  
 
Study of cationic currents and cAMP/PKA signaling pathway involvement in EP2 receptor 
activation in LC neurons 
 
It is known that PGE2 increases a sodium current via activation of the EP2 receptor in neurons 
from different CNS areas such as the cerebellum (Fang et al., 2011) or the spinal dorsal horn 
(Baba et al., 2001). In the LC, noradrenergic cells are stimulated by a cAMP/PKA-induced 
inward sodium current (Wang and Aghajanian, 1987). Therefore, to test the putative 
involvement of sodium current in the butaprost-induced stimulation of LC cells, we used a 
low sodium-containing aCSF, in which 80% of the sodium had been replaced by TRIS 
(Alreja and Aghajanian, 1993; Pineda et al., 1996). Switching from the regular aCSF to a 
low-sodium aCSF (TRIS 80%) reduced the spontaneous activity of LC neurons by 66.5 ± 
2.3% (from 1.11 ± 0.34 to 0.35 ± 0.11; n = 7, P < 0.05; Figure 3A) and completely blocked 
the excitation caused by butaprost (1 μM) (n = 7, P < 0.05 vs. control; Figures 3A and B). 
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This suggests that the excitatory effect of the EP2 receptor agonist butaprost is dependent on 
a sodium current. Next, to further describe the ion channel responsible for this sodium 
current, we tested whether the cation-permeable transient receptor potential (TRP) channel 
could be involved in the butaprost-induced effect. This family of channels has been reported 
to participate in the hypercapnic response of the LC (Cui et al., 2011). Perfusion with the 
non-selective TRP channel blocker 2-APB (30 μM) reduced the LC cell firing rate by 40.2 ± 
4.9% (from 0.76 ± 0.09 to 0.46 ± 0.07, n = 5, P < 0.05), but did not block the excitatory effect 
caused by butaprost (1 μM) (Figure 3C). Thus, the TRP channels do not appear to mediate 
the sodium current induced by the EP2 receptor agonist butaprost. Excitatory effects on the 
LC cell firing activity have also been reported to be elicited by the inhibitory ATP-sensitive 
K+ channels (the Kir6.2) (Ugedo et al., 1998). Therefore, we tested the Kir6.2 channel blocker 
glibenclamide (3 μM), which administration for 15 min failed to affect the excitatory 
response induced by butaprost (1 μM) (n = 5, P > 0.05 vs. control; Figure 3C). This suggests 
that the ATP-dependent K+ channels are not involved in the excitatory effect of EP2 receptor 
activation on LC neurons. 
 
Then, to test whether the butaprost-induced activation of a sodium current is mediated by the 
cAMP/PKA pathway, we used 8-Br-cAMP (1 mM), a non-hydrolyzable cell-permeable 
cAMP analog that activates the PKA and sodium currents (Wang and Aghajanian, 1987). In 
the case that activation of the EP2 receptor by butaprost depended on the cAMP/PKA 
pathway, prior administration of a saturating concentration of 8-Br-cAMP would occlude the 
excitatory effect of butaprost. As expected from previous reports (Wang and Aghajanian, 
1987), perfusion with 8-Br-cAMP (1 mM) for 8 min produced a 2-fold increase in the firing 
activity of LC neurons (from 0.71 ± 0.06 Hz to 1.40 ± 0.14 Hz; n = 5, P < 0.05) (Figures 4A 
and B). However, administration of butaprost (1 μM, 15 min) in the presence of 8-Br-cAMP 
further increased the firing activity of LC cells (from 1.40 ± 0.14 Hz to 1.97 ± 0.18 Hz; n = 
5, P < 0.05) (Figures 4A and B), which suggests that the effect of butaprost was not occluded 
by 8-Br-cAMP. Therefore, the excitatory effect of the EP2 receptor agonist does not seem to 
depend on the cAMP/PKA pathway. To confirm it, we studied the effect of butaprost in the 
presence of the PKA inhibitor H-89. Bath application of H-89 (10 µM) for 20 min increased 
the LC firing rate by 18.0 ± 5.5% (from 0.87 ± 0.11 Hz to 1.02 ± 0.14 Hz; n = 5, P < 0.05). 
However, H-89 did not change the parameters of the concentration-effect curve for butaprost 
(0.3 – 3 μM, 3x). Thus, the Emax value in the presence of H-89 was 86.3 ± 7.1% and the 
pEC50 was 6.19 ± 0.07 (EC50=0.64 μM; Figure 4C), not different from those obtained in 
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control (n = 5, P > 0.05; see Table 1). Hence, these data rule out the implication of the PKA 
in the excitatory effect of butaprost. On the other hand, a cationic current has been reported 
to be activated directly by increased levels of cAMP (Momin et al., 2008; Santin and Hartzler, 
2015) or the Gβγ subunits (Grzelka et al., 2017) via activation of HCN channels without the 
involvement of PKA. In fact, HCN channels play a functional role in some responses of LC 
cells (Santin and Hartzler, 2015) and to PGE2 in other CNS (Chen and Bazan, 2005) and 
peripherical neurons (Emery et al., 2011). Then, to analyze whether the HCN channels may 
be involved in the stimulatory effect of butaprost, we perfused the EP2 receptor agonist in 
the presence of the HCN blocker ZD7288. Perfusion of ZD7288 (30 µM) for 20 min 
increased the spontaneous firing rate of LC neurons by 77.0 ± 14.1% (from 0.70 ± 0.09 Hz 
to 1.20 ± 0.09 Hz; n = 5, P < 0.05). However, the HCN blocker did not change the 
concentration-effect curve for butaprost (0.3 – 3 μM, 3x) (Emax = 64.4 ± 17.1%, pEC50 = 
6.40 ± 0.06, and EC50 = 0.40 μM; n = 5, P > 0.05 vs. control; see Table 1) (Figure 4C). Thus, 
the EP2 receptor activation does not seem to regulate LC neurons through the cAMP/PKA 
signaling pathway or the HCN channels.  
 
Study of the involvement of Gαs and Gβγ subunits and presynaptic mechanisms on EP2 
receptor activation in LC neurons 
 
The EP2 receptor has been described to couple to Gs protein (Yano et al., 2017). Therefore, 
we addressed whether the Gαs and Gβγ subunits would be involved in the stimulatory effect 
of butaprost. For this purpose, we used the Gαs-dependent signaling inhibitor NF449 
(Hohenegger et al., 1998) and the Gβγ-dependent signaling inhibitor gallein. Administration 
of NF449 (10 μM) for 30 min did not modify the spontaneous firing activity of LC neurons. 
To verify that NF449 was effectively blocking the Gαs subunit, we used VIP (0.5 µM) as a 
positive control, given that VIP excites LC neurons via Gs-dependent activation of sodium 
current (Wang and Aghajanian, 1990). Perfusion of VIP (0.5 μM, 5 min) increased the firing 
rate by 82.5 ± 16.6% (from 0.69 ± 0.09 Hz to 1.24 ± 0.16 Hz; n = 5, P < 0.05) (Figure 5A). 
In the presence of NF449, the VIP-induced excitatory effect was reduced by 53% (n = 5, P 
< 0.05 vs. control) (Figure 5A), which indicates that NF449 was readily blocking the Gαs-
dependent signaling. However, unlike VIP, the excitatory effect of butaprost (1 µM) was not 
modified in the presence of NF449 (n = 6, P > 0.05 vs. control; Figure 5A). This result 
indicates that the effect of butaprost on LC neurons does not appear to require the Gαs 
signaling proteins. On the other hand, slice incubation with the Gβγ-signaling inhibitor gallein 
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(20 μM, 120 min) reduced the basal firing rate of LC neurons compared to baseline in controls 
before the administration of butaprost (0.85 ± 0.09 Hz in controls vs. 0.47 ± 0.10 Hz after 
gallein incubation; n = 7, P < 0.05) and reduced to nearly the half the excitatory effect of 
butaprost (1 µM) (n = 7, P < 0.05 vs. control; Figure 5B). In light of these results, the Gβγ 
subunits may be involved in the excitatory effect induced by the EP2 receptor agonist 
butaprost on LC neurons. 
 
Finally, to investigate whether a presynaptic mechanism could be involved in the excitatory 
effect of butaprost on the LC, we blocked the main inhibitory and excitatory receptors 
regulating the firing rate of LC cells: GABA and glutamate receptors. Perfusion with a 
combination of the GABAA channel blocker picrotoxin (100 μM), the non-NMDA receptor 
antagonist CNQX (30 μM), the NMDA receptor antagonist d-AP5 (100 μM), and the 
metabotropic receptor antagonist RS-MCPG (500 μM) increased the activity of 
noradrenergic cells by 110 ± 14.3% (from 0.69 ± 0.10 Hz to 1.41 ± 0.14 Hz; n = 6, P < 0.05), 
as previously described (Mendiguren and Pineda, 2007). However, blockade of presynaptic 
mechanisms did not reduce the excitation caused by butaprost (1 μM) but further potentiated 
it (n = 6, P < 0.05; Figure 5C). Thus, these results suggest that the butaprost-induced 
excitatory effect on LC neurons is not caused by presynaptic EP2 receptors. 
 
Discussion  
Our study was aimed to pharmacologically characterize the EP2 receptor in LC neurons from 
rat brain slices by extracellular electrophysiological techniques. We found that the EP2 receptor 
agonists butaprost and treprostinil increase the firing activity of LC neurons in vitro. This 
excitatory effect was blocked by the EP2 receptor antagonist PF-04418948, but not by the EP3 
or EP4 receptor antagonists (L-798,106 and L-161,982, respectively), indicating that it was 
mediated by EP2 receptor activation. The butaprost-induced increase in the firing rate of LC 
cells was prevented in the presence of low sodium-containing aCSF and the Gβγ-signaling 
inhibitor gallein. However, blockers of the Gαs/cAMP/PKA pathway or TRP and Kir6.2 
channels failed to change the butaprost-induced stimulatory effect. These results suggest that 
activation of the EP2 receptor stimulates the neuronal activity of LC cells, presumably by its 
coupling to Gβγ proteins and an inward sodium current. 
 
16 
In our study, we assessed the functional role of EP2 receptors in LC neurons by using 
extracellular electrophysiology in vitro and application of EP2 receptor agonists. Butaprost 
was selected as an EP2 receptor agonist since its free acid form shows an 18-fold higher 
affinity for the EP2 than for the EP3 receptor (Abramovitz et al., 2000) and has been 
previously used at similar concentrations to explore EP2 receptors in brain slices (Liu et al., 
2005). We also assessed the effect of treprostinil, a clinically used PGI2 analog that has high 
affinity for several prostanoid receptors, especially high for the EP2 receptor 
(EP2=DP1>IP>EP1>EP4>EP3) (Whittle et al., 2012). On the other hand, we used PF-
04418948 as EP2 receptor antagonist since it has very low affinity for any other prostanoid 
receptor (Forselles et al., 2011). L-161,982 has much higher affinity for the EP4 than for EP3 
receptors (Machwate et al., 2001), while L-798,106 shows higher affinity for the EP3 than 
for the EP4 or other EP receptors (Su et al., 2008). 
In the current study, butaprost and treprostinil increased the neuronal activity of LC cells and 
generated similar parameters of the concentration-effect curves (EC50 and Emax), suggesting 
equivalent efficacy and potency in the LC. Furthermore, the EC50 of the concentration-effect 
curve for butaprost was in accordance with that found in other systems (0.64 µM) (Fu et al., 
2015). In our work, the excitatory effect caused by butaprost and treprostinil was blocked by 
PF-04418948, and not by L-798,106 or L-161,982. In fact, PF-04418948 displaced to the right 
the concentration-effect curve for butaprost, whereas it reduced the Emax for treprostinil 
without any rightward shift. This difference could be explained by additional activation of other 
receptors or mechanisms by treprostinil, such as the phylogenetically related Gs-coupled DP1 
receptor (Daiyasu et al., 2011; Whittle et al., 2012). However, the blockade of the treprostinil-
induced effect with PF-04418948 supports the involvement of, at least, the EP2 receptor. 
Alternatively, one could speculate that a slow dissociation rate of PF-04418948 from the EP2 
receptor and a higher receptor reserve (Kenakin et al., 2006) for butaprost than for treprostinil 
could account for the differences observed with butaprost and treprostinil in the presence of 
PF-04418948. In any case, the calculated pKB of PF-04418948 for the EP2 receptor was 
equivalent when obtained by butaprost or by treprostinil. Furthermore, similar pKB values for 
PF-04418948 are obtained when PGE2 is used in other tissues (Forselles et al., 2011). These 
data indicate that the excitatory effect observed with butaprost and treprostinil in LC neurons 
was mediated by EP2 receptor activation.  
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EP2 receptor activation in neurons has been described to elicit a sodium current through the 
cAMP/PKA pathway (Fang et al., 2011). In our work, the butaprost-induced excitatory effect 
was completely abolished by replacement of 80% of the extracellular sodium by TRIS, 
indicating the involvement of sodium current. In agreement, PGE2 elicits a sodium current in 
cerebellar (Fang et al., 2011) and spinal neurons (Baba et al., 2001), leading to neuronal 
depolarization in the latter case. In the LC, sodium currents could be generated by TRP 
channels, as previously reported in response to CO2 (Cui et al., 2011). In our study, perfusion 
with the non-selective TRP channel blocker 2-APB at concentrations previously used in other 
brain regions in vitro (Song et al., 2016) failed to change the butaprost-induced excitatory 
effect. On the other hand, inhibition of Kir6.2 channels has been shown to contribute to 
excitatory responses in LC neurons, which could be hindered by the Kir6.2 channel blocker 
glibenclamide (Ugedo et al., 1998). However, in our study, glibenclamide did not affect the 
butaprost-induced excitatory response. Therefore, our data indicate that sodium current is a 
final downstream effector of EP2 receptor activation, and Kir6.2 or TRP channels do not seem 
to be involved in this effect. 
In LC noradrenergic neurons, inward sodium currents are activated by the cAMP/PKA 
pathway (Wang and Aghajanian, 1987). In our research, the butaprost-induced excitatory effect 
was not mediated by the cAMP/PKA/HCN pathway as the PKA activator 8-Br-cAMP, the 
PKA inhibitor H-89 or the HCN channel blocker ZD7288 failed to modify the stimulatory 
effect caused by butaprost. Our results contrast with the main signaling mechanism described 
for excitatory responses mediated by EP2 receptors in other brain regions. Thus, PGE2 
increases the hypothalamic neuronal activity (Clasadonte et al., 2011) and hippocampal 
synaptic transmission (Sang et al., 2005) via EP2 receptor-mediated activation of the 
cAMP/PKA pathway. However, other authors have previously suggested that 
cAMP/PKA/HCN is not involved in EP2 receptor-mediated responses. Thus, in nodose 
ganglion neurons, PGE2 elicits a sodium current by EP2 receptors without the intervention of 
the cAMP/PKA pathway (Matsumoto et al., 2005).  
The EP2 receptor has been published to be coupled to Gs proteins (Yano et al., 2017). However, 
NF449, a selective inhibitor of the association between Gαs and GTP (Hohenegger et al., 1998), 
failed to reduce the butaprost-induced excitation, while it blocked the effect of VIP, which 
increases the firing rate of LC cells by a Gαs/cAMP/PKA-dependent sodium current (Wang and 
Aghajanian, 1990). This means that butaprost effect is not mediated by Gαs proteins. On the 
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other hand, the excitation caused by butaprost was prevented by the Gβγ-signaling inhibitor 
gallein, which binds to the “hot spot” of the Gβ subunit (Lehmann et al., 2008). In our study, 
gallein did not modify the inhibitory effect of the µ opioid receptor agonist ME on the LC, 
which is mediated by Gi/o protein βγ subunits (Connor and Christie, 1999). Likewise, other 
authors have described that a gallein analog fails to affect Gi/o protein βγ-mediated effects in 
other systems (Casey et al., 2010), suggesting diversity and selectivity of the Gβγ subunits for 
different downstream signaling mechanisms. Furthermore, direct binding of Gβγ subunits to 
voltage-gated sodium channels (Nav) have been reported in cell cultures (Ma et al., 1997; 
Mantegazza et al., 2005). In LC neurons, tetrodotoxin (TTX)-sensitive Nav contribute to the 
pacemaker activity (de Oliveira et al., 2010), although a TTX-resistant current has also been 
described (de Oliveira et al., 2010). Furthermore, EP2 receptor activation has been associated 
with the enhancement of TTX-resistant sodium current in ganglion neurons (Matsumoto et al., 
2005). However, in our study, we cannot conclude that the Nav channel mediates the effect of 
EP2 receptors on sodium currents and whether it is directly modulated by EP2 receptor-
activated Gβγ subunits.  
Finally, in our research, blockade of GABAergic or glutamatergic transmission in the LC did 
not decrease but rather enhanced the butaprost-induced stimulatory effect. These results are 
congruent with the presence of EP2 receptors enhancing inhibitory GABAergic regulation of 
noradrenergic cells or glutamatergic afferents, which blockade would increase the butaprost-
induced excitatory effect. However, the neuronal subpopulation expressing EP2 receptors is 
yet to be characterized in the brain. 
In conclusion, our work supports the existence of functional postsynaptic EP2 receptors in LC 
neurons, which activation results in a concentration-dependent increase of the spontaneous 
firing rate in vitro. The underlying mechanism may require Gβγ subunits and sodium currents, 
but it does not involve a Gαs, TRP, or cAMP/PKA-dependent pathway. According to previous 
data from our laboratory, the endogenous PGE2 has a preferential inhibitory effect on LC 
neurons mediated by EP3 receptor activation (Nazabal et al., unpublished results), and herein, 
we demonstrate the functional role of EP2 receptors in the regulation of the firing rate. Since 
the LC has been shown to contribute to the affective processing of nociception by promoting 
anxiogenic-like behavior during chronic pain (Alba-Delgado et al., 2013), EP2 receptor 
activation in the LC may be of relevance in the integration of pain stimuli by enhancing NA 
release throughout the CNS. This suggestion is supported by the cognitive impairment 
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observed in mice lacking the EP2 receptor (Savonenko et al., 2009). Furthermore, both β-
adrenoreceptor and EP2 receptor activation elicit anti-inflammatory effects in microglial cells 
(Heneka et al., 2010; Bonfill-Teixidor et al., 2017). Therefore, it may be reasonable to suggest 
that the EP2 receptor in the LC could further tune the inflammatory response to PGE2 in the 
brain. An immunomodulatory effect of EP2 receptors may be relevant for the pathophysiology 
of Alzheimer’s disease, and the prevention of neuronal death upon amyloid β-peptide exposure 
(Echeverria et al., 2005). Consequently, the EP2 receptor signaling in the LC could become a 
novel therapeutic target for pain and neuroinflammatory diseases. 
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Table 1. Basal firing rate and concentration-effect curve parameters for the excitatory action 
of the EP2 receptor agonists butaprost and treprostinil on LC neurons in the absence (control) 
or in the presence of the EP2 (PF-04418948) or a combination of the EP3 (L-798,106) and 
EP4 (L-161,982) receptor antagonists. 
 ____________________________________________________________________ 
 Concentration-effect curves1 
Drugs Concentration Basal firing Emax (%) pEC50 (M) (EC50, µM) Slope factor  n
  rate (Hz) 
 ____________________________________________________________________ 
Butaprost 
Control  0.85 ± 0.09 74.3 ± 11.6 6.35 ± 0.10 (0.45) 1.65 ± 0.41 8 
+PF-04418948 3 nM 0.87 ± 0.12 82.1 ± 18.4 5.98 ± 0.15 (1.05) 1.55 ± 0.30 5 
 10 nM 0.73 ± 0.08 105 ± 15 5.57 ± 0.08* (2.67) 1.55 ± 0.41 6 
+L-798,106 10 nM  
L-161,982 10 nM 0.67 ± 0.11 135 ± 29 6.25 ± 0.07 (0.56) 1.27 ± 0.14 5 
Treprostinil 
Control   0.68 ± 0.07 81.3 ± 6.5 6.27 ± 0.15 (0.54) 0.95 ± 0.12 6 
+PF-04418948 10 nM 0.78 ± 0.13 42.8 ± 8.1* 6.55 ± 0.19 (0.28) 1.29 ± 0.34 6 
+L-798,106 10 nM 
L-161,982 10 nM 0.80 ± 0.12 144 ± 8* 6.34 ± 0.12 (0.46) 1.20 ± 0.09 5 
 ____________________________________________________________________ 
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the 
maximal excitatory effect, and pEC50 is the negative logarithm of the concentration needed to 
elicit a 50% of the Emax. *P < 0.05 when compared to their respective control group (one-way 




Figure 1. Effect of the EP2 receptor agonist butaprost on the firing rate of LC neurons in the 
absence or presence of the EP2 receptor antagonist PF-04418948 or a combination of the 
EP3 receptor antagonist L-798,106 and EP4 receptor antagonist L-161,982. (A, B, C) 
Representative examples of firing rate recordings of LC neurons showing the effect of 
increasing concentrations of butaprost in the absence (A) and presence of PF-04418948 (10 
nM) (B) or presence of L-798,106 and L-161,982 (10 nM each) (C). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (D) Concentration-effect curves for butaprost in control (filled circles) and in the 
presence of PF-04418948 (3 nM, open squares or 10 nM, filled squares) (left) or in the 
presence of L-798,106 and L-161,982 (10 nM each, open diamonds) (right). The horizontal 
axis shows the butaprost concentration on a semi-logarithmic scale. The vertical axis 
expresses the increase in firing rate of LC neurons as the percentage of the baseline. Data 
points are the mean ± SEM at each butaprost concentration obtained from n number of 
experiments (see Table 1). The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. Note that the concentration-effect curve for butaprost is 
shifted to the right by the EP2 receptor antagonist. 
 
Figure 2. Effect of the EP2 receptor agonist treprostinil on the firing rate of LC neurons in 
the absence or presence of the EP2 receptor antagonist PF-04418948 or a combination of the 
EP3 receptor antagonist L-798,106 and the EP4 receptor antagonist L-161,982. (A, B, C) 
Representative examples of firing rate recordings of LC neurons showing the effect of 
increasing concentrations of treprostinil in the absence (A) and presence of PF-04418948 (10 
nM) (B) or presence of L-798,106 and L-161,982 (10 nM each) (C). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (D) Concentration-effect curves for treprostinil in control (filled circles) and in 
the presence of PF-04418948 (10 nM, filled squares) (left) or in the presence of L-798,106 
and L-161,982 (10 nM each, open diamonds) (right). The horizontal axis shows the 
treprostinil concentration on a semi-logarithmic scale. The vertical axis expresses the 
increase in firing rate of LC neurons as the percentage of the baseline. Data points are the 
mean ± SEM at each treprostinil concentration obtained from n number of experiments (see 
Table 1). The lines through the data are the theoretical curves in each group constructed from 
the mean of the individual concentration-effect curve parameters, as estimated by nonlinear 
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regressions. Note that the Emax of treprostinil decreases in the presence of the EP2 receptor 
antagonist. 
 
Figure 3. Effect of cationic current blockers on the butaprost-induced excitatory effect on 
LC neurons. (A) Representative example of the firing rate recording of an LC neuron 
showing the effect of butaprost (1 μM, 15 min) in the presence of low-sodium aCSF (TRIS 
80%, 5 min). The vertical lines represent the number of spikes recorded every 10 s and the 
horizontal bars the period of drug application. Note that TRIS 80% abolishes the stimulatory 
effect of butaprost. (B, C) Bar graphs showing the excitatory effect of butaprost (1 μM, 15 
min) as the increase in the number of spikes per 10 s in the absence (control) and in the 
presence of TRIS 80% (n = 7) (B) or 2-APB (30 μM, black bar) or glibenclamide (3 μM, 
hatched bar) (both n = 5) (C). Bars are the mean ± SEM of n experiments. *P < 0.05 when 
compared to the control group (unpaired Student’s t-test). 
Figure 4. Effect of blocking the cAMP/PKA pathway and HCN channels on the butaprost-
induced excitatory effect on LC neurons. (A) Representative example of the firing rate 
recording of an LC neuron showing the effect of butaprost (1 μM, 15 min) in the presence of 
8-Br-cAMP (1 mM, 8 min). The vertical lines represent the number of spikes recorded every 
10 s and the horizontal bars the period of drug application. Note that 8-Br-cAMP increases 
the spontaneous discharge of the LC neuron and that butaprost produce an additional 
stimulatory effect. (B) Bar graph showing the increase in the number of spikes per 10 s caused 
by butaprost (1 μM, white bar), 8-Br-cAMP (1 mM, black bar), butaprost in the presence of 
8-Br-cAMP (hatched bar), and the arithmetic sum of the effects of butaprost and 8-Br-cAMP 
(black and white bar). Application of butaprost in the presence of 8-Br-cAMP further 
increased the excitatory effect caused by 8-Br-cAMP (paired Student’s t-test). Note that 
application of 8-Br-cAMP does not occlude the excitatory response to butaprost since no 
difference was found between the effect of butaprost in the presence of 8-Br-cAMP and the 
sum of effects (unpaired Student’s t-test). Bars are the mean ± SEM of n experiments. (C) 
Concentration-effect curves for butaprost in control (filled circles, n = 8) and in the presence 
of the PKA inhibitor H-89 (10 μM, open circles) or the HCN channel blocker ZD7288 (30 
μM, open triangles). The horizontal axis shows the butaprost concentration on a semi-
logarithmic scale. The vertical axis expresses the increase in firing rate of LC neurons as the 
percentage of the baseline. Data points are the mean ± SEM at each butaprost concentration 
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obtained from n number of experiments (n = 5 in all experimental groups). The lines through 
the data are the theoretical curves in each group constructed from the mean of the individual 
concentration-effect curve parameters, as estimated by nonlinear regressions. 
Figure 5. Effect of blocking the Gαs and Gβγ-dependent signaling and the presynaptic 
afferences on the butaprost-induced excitatory effect on LC neurons. (A, B) Bar graphs 
showing the excitatory effect of butaprost (1 μM, 15 min) as the increase in the number of 
spikes per 10 s in the absence (control, n = 8) and in the presence of NF449 (10 μM, 30 min, 
n = 6) (A) or gallein (20 μM, 120 min, n = 7) (B). VIP (0.5 μM, 5 min) was used as a positive 
control to demonstrate that NF449 was effectively blocking the Gαs subunits (both n = 5). (C) 
Bar graph showing the excitatory effect of butaprost in control (white bar) and after the 
administration of the synaptic blockers: Picrotoxin (100 μM), CNQX (30 μM), d-AP5 (100 
μM), and RS-MCPG (500 μM) for 10 min (n = 6). Bars are the mean ± SEM of n experiments. 
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Bullet point summary (each bullet max. 15 words, max. 2 bullets per heading) 
What is already known: 
- PGE2, an inflammatory mediator involved in pain and fever, modulates the 
activity of brain neurons 
- EP2 and EP3 receptor activation regulates LC neuronal activity, which also 
expresses the EP4 receptor 
What does this study add: 
- EP4 receptor agonists stimulate the neuronal activity of LC noradrenergic cells 
in vitro  




- The LC, the main noradrenergic nucleus, is susceptible to inflammatory 
mediators 
- Prostanoid system in the LC might be a pharmacological target against 
inflammation-mediated neuropsychiatric processes 
 
Abstract  
BACKGROUND AND PURPOSE: The inflammatory mediator prostaglandin E2 (PGE2) 
inhibits locus coeruleus (LC) neurons in vitro via Gi/o-coupled EP3 receptors, and EP2 receptor 
activation excites LC neurons via Gβγ-signaling. The LC, the main noradrenergic nucleus in 
the brain, also expresses Gs-coupled EP4 receptors, which functional role is unknown. Thus, 
we aimed to characterize pharmacologically EP4 receptors in LC neurons. 
 
EXPERIMENTAL APPROACH: We studied the effect of EP4 receptor agonists on the LC 
firing activity in rat brain slices by single-unit extracellular electrophysiology. 
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KEY RESULTS: EP4 receptor agonists rivenprost (0.01 nM–1 µM) and TCS 2510 (0.20 nM–
2 µM) increased the firing rate of LC cells in a concentration-dependent manner (EC50=1.43 
nM and 18.0 nM; Emax=83.7% and 98.4%, respectively). EP4 receptor antagonist L-161,982 
(30 and 300 nM), but not EP2 (PF-04418948, 300 nM) or EP3 receptor antagonists (L-798,106, 
300 nM), hindered the excitatory effect caused by rivenprost and TCS 2510. Furthermore, 
extracellular sodium replacement and Gαs blockade (NF449, 10 μM) prevented the rivenprost-
induced stimulation of neuronal activity. However, it was not attenuated by a PKA activator 
(8-Br-cAMP, 1 mM) or inhibitor (H-89, 10 µM), nor was it reduced by blockers of the PI3K 
(wortmannin, 100 nM), PKC (chelerythrine, 10 µM), and Gβγ signaling (gallein, 20 µM). 
Furthermore, the rivenprost-induced stimulation was not occluded by the previous 
administration of butaprost (EP2 receptor agonist, 1 µM), suggesting different signaling 
pathways for EP2 and EP4 receptors. 
 
CONCLUSIONS AND IMPLICATIONS: EP4 receptors activation excites LC noradrenergic 
neurons, seemingly through Gαs-dependent activation of sodium current. 
 
Keywords: locus coeruleus; PGE2; EP4 receptor; prostanoid; firing; slice 
 
Introduction  
Prostaglandins, as inflammatory mediators are synthesized on demand from membrane 
phospholipids, which are transformed into arachidonic acid, and then into a common 
precursor by the rate-limiting enzyme cyclooxygenase (COX). Nonsteroidal anti-
inflammatory drugs (NSAID) are commonly used as analgesic, antipyretic, and anti-
inflammatory drugs act by preventing the synthesis of prostanoids by blocking the enzymatic 
activity of the COX. Despite the involvement of prostaglandins in inflammation, COX 
enzyme is found constitutively in the human and animal brain under non-inflammatory 
circumstances (Yasojima et al., 1999; Hétu and Riendeau, 2005), suggesting that the 
prostanoids may be playing a role under normal conditions. In line with this hypothesis, COX 
is detected in the soma and dendrites of neurons, indicating that the main final enzymatic 
product, the prostaglandin E2 (PGE2) may contribute to neuronal physiology. The PGE2 
exerts its actions by binding to G protein-coupled EP1-EP4 receptors (EP1 to Gq, EP2 and 
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EP4 to Gs, and EP3 to Gi/o). The EP2, EP3, and EP4 receptors are widely expressed in the 
CNS (Zhang and Rivest, 1999; Ek et al., 2000). In particular, high EP4 receptor expression 
levels have been found in the supraoptic nucleus of the hypothalamus, the cerebellum, and 
the locus coeruleus (LC), among other brain areas (Zhang and Rivest, 1999). However, in 
response to peripheral inflammation, its expression is upregulated in neurons from the dorsal 
root ganglion (DRG) (Lin et al., 2006) and brain catecholaminergic regions (Zhang and 
Rivest, 1999), where it may stimulate the neuronal activity (Zhang and Rivest, 1999). In fact, 
EP4 receptor activation excites supraoptic neurons (Shibuya et al., 2002) and results in 
membrane depolarization of preganglionic neurons (Miura et al., 2002). Furthermore, PGE2 
elicits a sodium current in ganglion (Matsumoto et al., 2005) and cerebellar neurons (Fang et 
al., 2011) via EP4 receptor activation. 
 
The LC is the main source of noradrenaline (NA) in the brain and controls many 
physiological functions, including sleep-wake cycle, arousal, cognition, and pain. Some 
findings have associated the LC with the prostaglandin system. First, LC cells possess the 
enzymatic equipment to synthesize prostaglandins, as spinally-projecting LC neurons 
constitutively express COX enzyme (Yamaguchi and Okada, 2009). Thus, NSAID 
administration hinders the activation of LC cells in response to nociception and inflammation 
(Xu et al., 2003). Second, previous results from our laboratory have shown that activation of 
the EP3 receptor by the endogenous PGE2 inhibits the neuronal activity of LC cells in vitro 
(Nazabal et al., unpublished results), whereas it was stimulated by activation of the EP2 
receptor (Nazabal et al., unpublished results). Finally, the expression of EP4 receptor mRNA 
in the LC has been demonstrated by in situ hybridization techniques (Zhang and Rivest, 
1999). However, little is known about the functional role of the EP4 receptor in LC neurons. 
Thus, we aimed to characterize pharmacologically the EP4 receptor and to study its signaling 




Animals and ethics statement 
84 male adult Sprague-Dawley rats (200-300 g) were used to perform the experiments and 
are reported in compliance with the ARRIVE (Kilkenny et al., 2010; McGrath and Lilley, 
2015) and with the recommendations made by the British Journal of Pharmacology. Rats 
were obtained from the animal facility of the University of the Basque Country (Leioa, Spain) 
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and housed under standard environmental conditions (22 ºC, 12:12 h light/dark cycles) with 
free access to food and water. One slice was taken from each animal, and unless stated 
otherwise, only one experiment was performed in each slice. The number of experiments in 
each group was typically five to six, depending on the level of variability. Treatments and 
controls were performed in parallel in a randomized manner. As electrophysiological 
outcomes were collected in situ, data recording could not be blinded to the operator. 
However, the data analysis performed by the experimenter was confirmed separately by an 
additional researcher in all cases. All the experiments were carried out according to EU 
Directive 2010/63 on the protection of animals used for scientific purposes and approved by 
the local Ethical Committee for Research and Teaching (CEID) of the University of the 
Basque Country (UPV/EHU, Spain) and the Department of Sustainability and Natural 
Environment of Provincial Council from Bizkaia (ref. CEEA M20-2015-152; CEEA M20-
2018-026). All the efforts were made to minimize the animal suffering and to reduce the 
number of animals used. 
 
Brain slice preparation 
Animals were anesthetized with chloral hydrate (400 mg kg-1, i.p.) and decapitated 
(Mendiguren and Pineda, 2007). The brain was rapidly extracted, and a block of tissue 
containing the brainstem was immersed in ice-cold modified artificial cerebrospinal fluid 
(aCSF) where NaCl was equiosmolarly substituted for sucrose to improve neuronal viability. 
Coronal slices of 500-600 μm thickness containing the LC were cut using a vibratome (FHC 
Inc., Brunswick, USA). The tissue was allowed to recover from the slicing for 90 min, placed 
on a nylon mesh, and incubated at 33 ± 1 ºC on a modified Haas-type interface chamber. The 
tissue was continuously perfused with aCSF saturated with 95% O2/ 5% CO2 (final pH = 
7.34) at a flow rate of 1.5 ml min-1. The aCSF contained (in mM): NaCl 130, KCl 3, NaH2PO4 
1.25, D-glucose 10, NaHCO3 21, CaCl2 2 and MgSO4 2. The LC was identified visually in 
the rostral pons as a dark oval area on the lateral borders of the central gray and the 4th 
ventricle, at or just anterior to the genu of the facial nerve. 
 
Electrophysiological recordings 
Single-unit extracellular recordings of LC cells were made as previously described 
(Mendiguren and Pineda, 2004, 2007). The recording electrode consisted of an Omegadot 
glass micropipette puller (Sutter Instruments, Novato, CA, USA) and filled with 50 mM 
NaCl. The tip was broken back to a size of 2 – 5 μm (3 – 5 MΩ) and positioned in the LC. 
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The extracellular signal from the electrode was passed through a high-input impedance 
amplifier (Axoclamp 2B, Molecular Devices, Union City, CA, USA) and monitored on an 
audio-amplifier and an oscilloscope (Aumon 14, Cibertec S.A., Madrid, Spain). Individual 
neuronal spikes were isolated from the background noise with a window discriminator (PDV 
225, Cibertec S.A.). The firing rate (FR) was continuously recorded and analyzed before, 
during, and after experimental manipulations by a PC-based custom-made program which 
generated consecutive 10 s bin histogram bars of the cumulative number of spikes (HFCP®, 
Cibertec S.A., Madrid, Spain). Noradrenergic cells in the LC were identified by their 
spontaneous and regular discharge activities, the slow FR and the long-lasting biphasic 
positive-negative waveforms (Andrade and Aghajanian, 1984). We only recorded cells that 
showed stable FRs between 0.5 and 1.5 Hz for at least 3-5 min and the inhibitory effect 
induced by [Met]enkephalin (ME 0.8 μM, 1 min) was higher than 80% (Medrano et al., 2017) 
as a control for the perfusion system. 
 
Pharmacological procedures  
The firing rate of LC neurons was recorded for several minutes before drug applications to 
obtain the baseline activity, and then, during and after drug perfusion. To characterize the 
effect of EP4 receptor agonists in LC neurons, we perfused increasing concentrations of the 
EP4 receptor agonist rivenprost (0.01 – 100 nM, 3x) and TCS 2510 (0.20 nM – 2 µM, 3x) 
for at least 8 min each concentration, until a plateau effect was reached and based on previous 
studies (Bonfill-Teixidor et al., 2017). To pinpoint the EP receptor involved in the observed 
effect, concentration-effect curves for rivenprost were made in the presence of the EP4 
receptor antagonist L-161,982 (3, 30, and 300 nM), the EP2 receptor antagonist PF-04418948 
(300 nM), and the EP3 receptor antagonist L-798,106 (300 nM). In the case of TCS 2510, 
concentration-effect curves were made in the presence of a single concentration of L-161,982 
(300 nM). All the antagonists were perfused for 30 min at the concentrations based on other 
studies (Machwate et al., 2001) before performing the concentration-effect curves for the 
EP4 agonists.  
Rivenprost was used for subsequent characterization of the molecular mechanism involved 
in EP4 receptor activation.  Excitatory responses of LC neurons are described to consist of a 
cAMP/PKA-induced opening of a non-selective cation current (Wang and Aghajanian, 
1987). Then, to investigate the involvement of a sodium current in the rivenprost-mediated 
effect, low sodium-containing aCSF (TRIS 80%) was prepared by replacing 80% of the NaCl 
equiosmolarly with Trizma hydrochloride/base (TRIS) (Pineda et al., 1996) and then the 
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effect of rivenprost was tested. To further describe the involvement of sodium currents, we 
checked whether the transient receptor potential (TRP) ion channels (Cui et al., 2011) might 
contribute to the effect of rivenprost by using the nonselective TRP blocker 2-APB (30 µM, 
10 min). Next, to test whether the cation current was induced by a rise in the cAMP levels, 
we used the cAMP analog 8-Br-cAMP (1 mM, 8 min) (Wang and Aghajanian, 1990). Thus, 
in case EP4 receptor activation depends on the cAMP/PKA pathway, administration of a 
saturating concentration of 8-Br-cAMP would occlude the subsequent effect of rivenprost. 
In addition, the cAMP/PKA-dependency was further determined by testing butaprost in the 
presence of the PKA inhibitor H-89 (10 μM, 20 min) (Jolas et al., 2000). Considering the 
similarities between the effects of EP2 and EP4 receptor activation (Nazabal et al., 
unpublished results), we performed an occlusion experiment in the presence of a submaximal 
concentration of butaprost (1 µM, 15 min) to examine the possible convergence of both 
signaling pathways. In addition, the effect of rivenprost was tested in the presence of  Gαs-
dependent signaling blocker NF449 (10 µM, 30 min) (Hohenegger et al., 1998) or the Gβγ-
dependent signaling blocker gallein (20 µM, 120 min incubation in an aluminum foil-covered 
glass) (Kurowski et al., 2015) to further characterize the G-protein subunits involved. Finally, 
since the EP4 receptor has been described to couple to the PI3K and PKC signaling pathways 
(Fujino et al., 2005; Fujino and Regan, 2006; Eijkelkamp et al., 2010), the PI3K inhibitor 
wortmannin (100 nM, 20 min) and the cell-permeable PKC inhibitor chelerythrine (10 µM, 
30 min) were used at previously tested concentrations (Bailey et al., 2004; Hill et al., 2008).  
Except otherwise stated, all mentioned drugs were bath perfused for at least 10 min before 
testing the effect of rivenprost.  
 
Analysis and statistics of electrophysiological data 
The data and statistical analysis were carried out with the computer program GraphPad Prism 
(version 5.0 for Windows, GraphPad Software, Inc., San Diego, CA, USA) and comply with 
the recommendations on experimental design and analysis in pharmacology (Curtis et al., 
2018). The effect (E) was normalized to baseline (FRbasal) in each cell according to the 
following equation E = (FRbasal – FRpost) · 100/FRbasal, where FRbasal is the average FR for 60 
s immediately before the prostanoid agonist administration, and FRpost is the average FR of 
the last 60 s for each concentration of agonist, once it had reached a plateau. In the case of 
the perfusion test with ME (0.8 µM, 1 min), the inhibitory effect was calculated similarly but 
normalized to the initial FR (FRinitial), being the average FR of each neuron calculated for 60 
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s immediately before drug application and FRpost the average FR after drug application for 
60-90 s. Normalization to FRbasal or FRinitial was used for comparison purposes across groups.  
To construct the concentration-effect curves for the EP4 receptor agonists, fitting analysis 
was performed to obtain the best simple nonlinear fit to the following three-parameter logistic 
equation: E = Emax[A]n / (EC50n + [A]n), where E and [A] are the observed effect and the 
concentration of the agonist, respectively; Emax is the maximal excitatory effect of the EP4 
agonist. EC50 is the concentration of the agonist required to promote the 50% of Emax, and n 
represents the slope factor of the function. These parameters were determined in individual 
assays by the nonlinear analysis and then averaged to obtain the theoretical parameters in 
each group. For comparison purposes, the EC50 values were converted and expressed as the 
negative logarithm (pEC50), which adjusted the variable into a Gaussian distribution (Pineda 
et al., 1997). 
The antagonist affinity value was calculated as the negative logarithm of the equilibrium 
dissociation constant of the antagonist-receptor complex (pKB). The pKB value was estimated 
for parallel shifts by using the modified Gaddum/Schild equation for global fitting of the 
curves using GraphPad Prism 5.0 (Lazareno and Birdsall, 1993), where the minimum and 
maximum effects were constrained to 0 and 100% respectively, and the Schild slope was 
constrained to 1.0. In the case of TCS 2510, the affinity measurement was obtained from the 
Gaddum method (Kenakin et al., 2006) by plotting double equieffective concentrations of 
TCS 2510 in the absence (ordinates) and presence (abscissae) of the antagonist. 
Data are expressed as the mean ± SEM of n number of rats. Statistical significances were 
obtained by a two-tailed paired Student’s t-test when the response values were compared 
before and after drug applications within the same cell, and by a two-tailed two-sample 
Student’s t-test when the FRs, responses or parameters were two independent experimental 
conditions. Statistical comparison of the results among more than two experimental 
conditions (including a control group) were done by one-way analysis of variance (ANOVA) 
followed by a post hoc pairwise comparisons with a Dunnett’s post hoc test or Bonferroni’s 
Multiple Comparison test only if F achieved the necessary level of statistical significance 
(i.e. P < 0.05) and there was no significant variance inhomogeneity. Dunnett’s method is 
used for comparison with a control group and Bonferroni’s test for comparison among all the 
groups. The threshold of significance was set at P = 0.05 and only one level of probability (P 





Materials and drugs 
For electrophysiological recordings, the following drugs were purchased from Tocris 
Bioscience (Bristol, UK): gallein, H-89, L-161,982, L-798,106, NF449, PF-04418948, and 
TCS 2510. The following drug was acquired from Sigma-Aldrich Química S.A. (Madrid, 
Spain): Trizma hydrochloride. From Bachem (Weil am Rhein, Germany) was purchased: 
[Met]enkephalin acetate salt (ME). Finally, 8-Bromo-cAMP was from Enzo Life Sciences 
Inc. (New York, USA) and rivenprost from Cayman Chemical (Ann Arbor, MI, USA). 
Rivenprost and TCS 2510 were purchased already dissolved in methyl acetate and anhydrous 
ethanol, respectively, so the required volume was directly extracted from the vial and 
incorporated to aCSF at the moment of the experiment. The final concentration of methyl 
acetate in aCSF was < 0.0005% and < 0.015% for anhydrous ethanol. Stock solutions of 
gallein, L-161,982, L-798,106, PF-04418948 were first prepared in pure DMSO and then 
diluted in aCSF to obtain a final concentration of DMSO lower than 0.1%, which does not 
affect the LC cell firing responses (Pineda et al., 1996). Control assays were performed with 
equivalent volumes of the vehicles in which the drugs were dissolved. Stock solutions of the 
rest of the drugs were first prepared in Milli-Q water and then diluted 1000- to 10000-fold in 
aCSF for the desired concentration. Final solutions were prepared freshly just before each 
experiment and stock solutions were kept at -20 ºC.  
 
Nomenclature of targets and ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 






Effect of the EP4 receptor agonists rivenprost and TCS 2510 on the firing rate of LC neurons 
In situ hybridization studies have shown mRNA expression for the EP4 receptor in the LC 
(Zhang and Rivest, 1999). Moreover, c-fos immunoreactivity is increased in response to a 
systemic pro-inflammatory cytokine in brain areas expressing the EP4 receptor, including the 
LC (Zhang and Rivest, 1999). To study the role of the EP4 receptor in the regulation of the 
firing rate of LC neurons, we performed concentration-effect curves for the EP4 receptor 
agonists rivenprost and TCS 2510. Increasing concentrations of rivenprost (0.01 – 100 nM, 3x, 
10 min each) increased the firing rate of LC cells (from 0.70 ± 0.09 Hz to 1.14 ± 0.13 Hz; n = 
6, P < 0.05) with an EC50 value in the nanomolar range (Figures 1A and D; Table 1).  
To determine the EP receptor involved in the rivenprost-induced excitatory effect, the specific 
EP4 receptor antagonist L-161,982 (3, 30 and 300 nM), the EP2 receptor antagonist PF-
04418948 (300 nM), and the EP3 receptor antagonist L-798,106 (300 nM) were used. Bath 
application of L-161,982 (3, 30, and 300 nM, 30 min) did not change the firing rate of LC cells 
but 30 nM and 300 nM produced a 4-fold and 8-fold shift in the concentration-effect curve for 
rivenprost, respectively (n = 5, P < 0.05 for both 30 and 300 nM; Figures 1B and D; Table 1). 
On the other hand, perfusion with PF-04418948 (300 nM) and L-798,106 (300 nM) did not 
change the firing rate and failed to shift the concentration-effect curve for rivenprost (Figures 
1C and D; Table 1). These results suggest that the excitatory effect of rivenprost was mediated 
by EP4 receptor activation.  
The antagonist affinity of L-161,982 for the EP4 receptor (pKB) was estimated to be 8.06 ± 
0.18 (mean ± SEM, n = 14) when calculated with the Gaddum/Schild equation and assumed a 
Schild slope of unity (Kenakin, 1982). However, the calculated pKB values were variable 
depending on the concentration of L-161,982 employed, resulting in a higher pKB value with 
3 nM in comparison with 30 or 300 nM (8.84 ± 0.13 for 3 nM different from 7.94 ± 0.24 for 
30 nM or 7.40 ± 0.08 for 300 nM; n = 5, P < 0.05, one-way ANOVA followed by Bonferroni’s 
Multiple Comparison Test). Therefore, we performed the Schild plot analysis and the resultant 
pA2 was 8.69 (95% CI: 15.96-7.92) with a Schild slope of 0.39 (95% CI: 0.05-0.72) different 
from unity (n = 5, P < 0.05). This means that, despite the rightward shift of the concentration-
effect curve for rivenprost by L-161,982 (Figure 1D), the Schild slope was found different from 




On the other hand, administration of the structurally different EP4 receptor agonist TCS 2510 
(0.20 nM – 2 μM, 3x, 10 min each) increased the firing rate of LC cells (from 0.71 ± 0.08 to 
1.55 ± 0.12 Hz; n = 6, P < 0.05), with an EC50 value in the nanomolar range (Figures 2A and 
C; Table 1). Administration of the EP4 receptor antagonist L-161,982 (300 nM) for 30 min 
decreased the maximal effect by 38% (n = 5, P < 0.05) and increased the slope steepness by 2 
fold (n = 5, P < 0.05) (Figures 2B and C; Table 1), suggesting that the excitatory effect caused 
by TCS 2510 is mediated by EP4 receptor activation. Considering that the Emax reduction for 
TCS 2510 by L-161,982 may support the non-competitive behavior of the antagonist, we 
plotted double equieffective concentrations of TCS 2510 in the absence and presence of L-
161,982 (300 nM) by the Gaddum method (Kenakin et al., 2006), which yielded a pKB yielded 
of 7.69 (95% CI: 7.61 – 7.76). Overall, these results indicate that the activation of EP4 receptors 
by the selective agonists rivenprost and TCS 2510 stimulated LC neuronal activity in vitro. 
 
Study of cationic currents and cAMP/PKA signaling pathway involvement in EP4 receptor 
activation in LC neurons 
In cerebellar neurons, PGE2 has been described to elicit a sodium current via activation of 
Gs-coupled EP4 receptors and in a cAMP/PKA-mediated pathway (Fang et al., 2011). In the 
LC, activation of the cAMP/PKA pathway is known to drive the spontaneous pacemaker 
activity (Alreja and Aghajanian, 1991, 1995) through the opening of an inward sodium 
current (Wang and Aghajanian, 1987). Therefore, to test the involvement of sodium current 
in the excitatory effect of rivenprost, we used a low sodium-containing aCSF, in which the 
80% of the sodium had been replaced by TRIS (TRIS 80%) (Alreja and Aghajanian, 1993; 
Pineda et al., 1996). Perfusion with TRIS 80% reduced the spontaneous activity of LC 
neurons by 63.6 ± 2.6% (from 0.92 ± 0.31 to 0.34 ± 0.08; n = 6, P < 0.05) and completely 
blocked the excitatory effect caused by rivenprost (30 nM) (n = 6, P < 0.05; Figures 3A and 
B). This result implies that the excitatory effect of the EP4 receptor agonist rivenprost is 
dependent on a sodium current. Next, to characterize the molecular substrate for this sodium 
current, we checked whether the cation-permeable transient receptor potential (TRP) channel 
was involved. PGE2 has been reported to increase the activity of these channels in EP4 
receptor-expressing cells (Moriyama et al., 2005). Administration of the non-selective TRP 
channel blocker 2-APB (30 μM) reduced the LC cell firing activity by 41.7 ± 6.1% (from 
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0.74 ± 0.09 Hz to 0.45 ± 0.11 Hz; n = 5, P < 0.05) but it failed to alter the excitatory effect 
induced by rivenprost (30 nM) (Figure 3B). Therefore, the TRP channels do not appear to 
mediate the sodium current induced by the EP4 receptor agonist rivenprost.  
 
Next, to test whether the cAMP/PKA pathway is involved in the EP4 receptor agonist effect, 
we perfused rivenprost in the presence of 8-Br-cAMP, a non-hydrolyzable cell-permeable 
cAMP analog that activates the PKA enzyme (Poppe et al., 2008). Thus, if rivenprost exerted 
its effect through the cAMP cascade, prior administration of a saturating concentration of 8-
Br-cAMP would occlude the excitatory effect induced by rivenprost. As expected from 
previous reports (Wang and Aghajanian, 1987; Nazabal et al., unpublished results), PKA 
activation with 8-Br-cAMP (1 mM, 8 min) increased by 2 fold the firing rate of LC neurons 
(from 0.73 ± 0.06 Hz to 1.42 ± 0.12 Hz; n = 5, P < 0.05) (Figure 3C). However, administration 
of rivenprost (30 nM, 10 min) in the presence of 8-Br-cAMP further increased the firing 
activity of LC cells (from 1.42 ± 0.12 Hz to 2.02 ± 0.13 Hz; n = 5, P < 0.05) (Figure 3C), 
which suggests that the effect of rivenprost was not occluded by 8-Br-cAMP. Therefore, the 
excitatory effect of the EP4 receptor agonist does not apparently depend on the cAMP/PKA 
pathway. To further test this hypothesis, we studied the effect of rivenprost (30 nM) in the 
presence of the PKA inhibitor H-89 (10 μM). Bath application of H-89 (10 µM) for 20 min 
increased the LC firing rate by 8.99 ± 3.36% (from 0.62 ± 0.06 Hz to 0.68 ± 0.08 Hz; n = 5, 
P < 0.05). However, H-89 did not change the magnitude of rivenprost-induced excitation 
(Figure 3D). Hence, these data indicate that the effect of the EP4 receptor agonist rivenprost 
on the LC is dependent on a sodium current but independent of the cAMP/PKA pathway.  
 
Study of the involvement of Gαs and Gβγ subunits, and PI3K and PKC signaling mechanisms 
in EP4 receptor activation in LC neurons 
We have previously shown that the effect of the EP2 receptor agonist butaprost is also 
dependent on a sodium current but independent of the cAMP/PKA pathway (Nazabal et al., 
unpublished results). Therefore, we studied whether the administration of butaprost at a 
submaximal concentration would occlude the following stimulatory effect of rivenprost. As 
previously described, administration of butaprost (1 μM, 15 min) increased the firing rate of 
LC neurons by 61.4 ± 9.7% (from 0.74 ± 0.10 Hz to 1.19 ± 0.17 Hz; n = 5, P < 0.05) (Figures 
4A and B). However, in the presence of butaprost, rivenprost (30 nM) further increased the LC 
cell firing activity (from 1.19 ± 0.17 Hz to 1.51 ± 0.22 Hz; n = 5, P < 0.05) (Figures 4A and 
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B), indicating that the excitatory effect of rivenprost was not occluded by butaprost. These data 
suggest that the EP2 and EP4 receptors do not share the same signaling pathway to excite the 
activity of LC neurons. 
 
The EP4 receptor is described to be coupled to Gs protein in cerebellar neurons (Fang et al., 
2011). In order to study whether the Gαs protein mediated the effect of rivenprost on the LC, 
we used the specific Gαs-dependent signaling inhibitor NF449. Administration of NF449 (10 
μM) for 20 min did not change the firing activity of LC neurons, but blunted by 42.1% the 
excitatory effect induced by rivenprost (30 nM) (n = 6, P < 0.05 vs. control; Figure 4C), 
suggesting that the effect of rivenprost was mediated by the Gαs protein. In addition, we studied 
the involvement of the Gβγ subunits by testing the effect of rivenprost in the presence of the 
selective inhibitor gallein. Bath incubation with gallein (20 μM) for 120 min did not change 
the rivenprost-induced excitation (n = 5, P > 0.05 vs. control; Figure 4C). These results indicate 
that the Gβγ subunits are not involved in the excitatory effect of rivenprost on LC cells. 
 
In addition to Gαs protein, the EP4 receptor has been described to be coupled to the PI3K 
signaling pathway in cultured cells (Fujino et al., 2005; Fujino and Regan, 2006) and microglia 
(Shi et al., 2010). Furthermore, PI3K signaling is needed for the leptin-induced excitatory effect 
in hypothalamic neurons (Hill et al., 2008). Therefore, we tested the effect of rivenprost in the 
presence of the PI3K inhibitor wortmannin. Administration of wortmannin (100 nM) for 20 
min did not change the spontaneous activity of LC cells and failed to block the excitatory effect 
of rivenprost (30 nM). In fact, in the presence of wortmannin, the effect of rivenprost was 
increased by 58.3% (n = 5, P < 0.05 vs. control; Figure 4D), suggesting that the stimulatory 
effect of rivenprost was not mediated by the PI3K. On the other hand, PKC activity is required 
for the PGE2-induced modulation of sodium currents in sensory neurons (Gold et al., 1998) 
and the PGE2-induced hypernociception in vivo (Sachs et al., 2009). Therefore, we examined 
the involvement of PKC by testing the effect of rivenprost in the presence of the PKC inhibitor 
chelerythrine. Bath perfusion of chelerythrine (10 μM) for 30 min did not change the firing 
activity of LC neurons and failed to prevent the increase in excitability of LC neurons caused 
by rivenprost (30 nM). Furthermore, the rivenprost-induced excitatory effect was increased by 
2 fold in the presence of chelerythrine (n = 5, P < 0.05 vs. control; Figure 4D). In light of this 
result, the PKC does not seem to mediate the rivenprost-induced excitation. In summary, the 
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excitatory effect observed upon EP4 receptor activation seems to be mediated by the Gαs 
subunits, whereas the Gβγ subunits and the PK3K and PKC signaling pathways are not 
apparently involved.  
 
Discussion 
The purpose of this study was to characterize the functional role of EP4 receptors in LC neurons 
by extracellular electrophysiological techniques. We found that the EP4 receptor agonists 
rivenprost and TCS 2510 increase the neuronal activity of LC cells in vitro. This excitatory 
effect was blocked by the EP4 receptor antagonist L-161,982, but not by the EP2 or EP3 
receptor antagonists PF-04418948 and L-798,106, respectively, indicating an EP4 receptor-
mediated effect. The increase in firing rate of LC neurons caused by rivenprost was blocked by 
extracellular sodium replacement and a Gαs signaling inhibitor, but not by blockers of the 
cAMP/PKA pathway, TRP channels, Gβγ subunits, PI3K or PKC signaling. Thus, these results 
suggest that EP4 receptor activation stimulates the neuronal activity of LC cells, presumably 
by its coupling to Gαs proteins and an inward sodium current. 
In our study, we characterized the functional role of EP4 receptors in LC neurons by using 
extracellular electrophysiology in vitro, EP4 receptor agonists, and EP receptor antagonists. 
The concentrations of the EP4 receptor agonists rivenprost and TCS 2510 used herein were 
based on the affinity data demonstrated in radioligand binding experiments, which show that 
rivenprost has 80-fold higher affinity for the EP4 than for EP3 or EP2 receptors (Yoshida et 
al., 2002) and TCS 2510 fails to have affinity at the tested concentration range for non-EP4 
receptors (Young et al., 2004). Furthermore, the involvement of the EP4 receptor was 
demonstrated with the specific antagonist L-161,982, which shows a more than 200-fold higher 
affinity for the EP4 than for EP3 receptors (Machwate et al., 2001). The EP2 receptor 
antagonist PF-04418948 does not show antagonistic affinity for any other EP receptor 
(Forselles et al., 2011), while L-798,106 has much higher affinity for the EP3 than for EP4 
receptors (Su et al., 2008). 
In the present study, administration of rivenprost or TCS 2510 increased the firing rate of LC 
neurons. In the case of rivenprost, the EC50 value (1.43 nM) was similar to its Ki value measured 
in cell membranes (0.7 nM) (Yoshida et al., 2002), whereas the EC50 value for TCS 2510 (18.0 
nM) was higher than that of rivenprost, but at the same range as that described in other tissues 
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(e.g., isolated smooth muscle, pIC50: 7.6) (Jones et al., 2013). The excitatory effect of rivenprost 
or TCS 2510 was mediated by EP4 receptor activation since it was only blocked by L-161,982, 
but not by perfusion with L-798,106 or PF-04418948. In our work, L-161,982 shifted to the 
right the concentration-effect curve for rivenprost but reduced the Emax for TCS 2510 without 
any rightward shift. This disparity of effects was unlikely to be caused by activation of other 
EP receptors, given the high selectivity of these ligands for the EP4 receptor. Furthermore, the 
Schild slope for L-161,982 was less than unity when calculated with rivenprost and furthermore 
different pKB values were found for various concentrations of L-161,982. According to 
different authors, a slow dissociation rate of the antagonist and a higher receptor reserve for 
one of the agonist (Kenakin et al., 2006) (i.e., rivenprost) could explain the different 
pharmacological profiles observed with rivenprost and TCS 2510 in the presence of L-161,982. 
Moreover, the calculated pKB of L-161,982 for the EP4 receptor resulted in 7.69 by double 
equieffective concentrations of TCS 2510, which was at similar concentration ranges to the 
pKB obtained for L-161,982 with rivenprost (7.67). Furthermore, the result obtained in our 
study for L-161,982 was akin to its Ki value (32 nM) measured by binding assays in cell 
cultures with PGE2 as an agonist (Machwate et al., 2001). Overall, these data indicate that the 
observed excitatory effect of rivenprost or TCS 2510 was mediated by EP4 receptor activation. 
Activation of Gs-coupled EP4 receptors modulates sodium currents in brain neurons (e.g., 
cerebellar granule cells (Fang et al., 2011)). In our work, the blockade of the rivenprost-induced 
stimulation of LC cells by extracellular sodium replacement reveals the involvement of sodium 
currents. In agreement, PGE2 has been shown to enhance sodium currents via EP4 receptors in 
cerebellar (Fang et al., 2011) and nodose ganglion neurons (Matsumoto et al., 2005). 
Furthermore, EP4 receptor activation increases the firing rate of supraoptic neurons, which has 
been suggested to be mediated by non-selective cation channels (Shibuya et al., 2002). In the 
LC, sodium currents can be elicited by non-selective cation TRP channels in response to 
hypercapnia (Cui et al., 2011). However, in our study, the TRP channel blocker 2-APB did not 
prevent the excitatory effect induced by rivenprost, which indicates that the TRP channel is not 
involved in the rivenprost-induced excitatory effect. 
EP4 receptor activation elicits a sodium current via activation of Gs proteins and cAMP/PKA 
pathway (Fang et al., 2011). In the current study, the rivenprost-induced stimulation was 
blocked by the Gαs signaling inhibitor NF449, but not by the Gβγ signaling inhibitor gallein, 
which suggests that the EP4 receptor is coupled to Gαs proteins in the LC. However, the 
rivenprost-induced excitatory effect was not mediated by the cAMP/PKA pathway as it was 
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not occluded by the PKA activator 8-Br-cAMP nor blocked by the PKA inhibitor H-89, which 
were perfused at the same concentrations used in other brain areas in vitro (Wang and 
Aghajanian, 1990; Jolas et al., 2000). Although these results are in contrast with the signaling 
mechanism described for EP4 receptors in neurons (Wise, 2006), some other authors have 
pointed out a cAMP-independent pathway for EP4 receptor-mediated effects. For example, 
chronic exposure to PGE2 downregulates the EP4 receptor-mediated cAMP/PKA pathway 
activation in cultured DRG neurons (Malty et al., 2016) and TCS 2510 fails to raise cAMP 
levels in mast cells (Kay et al., 2013). Likewise, activation of the EP2 receptor, which also 
induces excitatory responses in LC neurons, is not dependent on the cAMP/PKA pathway 
(Nazabal et al., unpublished results). Since both EP2 and EP4 receptors activate sodium 
currents in the LC via a non cAMP/PKA pathway, in the present work, we compared the effect 
of rivenprost with or without administration of the EP2. Thus, the excitatory effect of rivenprost 
was not occluded by butaprost effect, which suggests an uncommon signaling pathway for EP2 
and EP4 receptors. This divergence could be explained by phylogenetic differences, as they 
only share a 31% amino acid identity in mice (Sugimoto and Narumiya, 2007). Overall, these 
data indicate that EP4 receptor activation in LC neurons is coupled to a Gαs protein and a 
sodium current, but not dependent on cAMP/PKA and Gβγ subunit signaling. 
On the other hand, EP4 receptor activation has been linked to the PI3K signaling pathway in 
cell cultures (Fujino et al., 2005; Fujino and Regan, 2006) and DRG neurons (Ma and St-
Jacques, 2018). In the latter case, activation of the PI3K promotes the externalization of EP4 
receptors, which could enhance the nociceptive transmission (Ma and St-Jacques, 2018). 
However, according to our data, the PI3K inhibitor wortmannin did not block the excitatory 
effect of rivenprost in LC cells but rather potentiated it. It has been shown that EP4 receptor 
activation stimulates the PI3K pathway via Gi/o proteins in cultured cells (Fujino and Regan, 
2006). Furthermore, the EP4 receptor can couple to both Gs and Gi/o proteins in cell cultures, 
with the degree of activation of Gs and Gi/o protein depending on the functional selectivity of 
EP4 receptor agonists (Leduc et al., 2009). In our system, we cannot exclude a simultaneous 
coupling of EP4 receptors to the Gi/o/PI3K pathway in LC cells, which would counteract the 
excitatory effect of EP4-Gαs and would be unmasked in the presence of wortmannin. In addition 
to the PI3K, a PKC-dependent pathway has been described for EP4 receptor-mediated effects, 
such as in DRG neurons (Eijkelkamp et al., 2010). However, in our work, the PKC inhibitor 
chelerythrine did not block the excitatory effect of rivenprost but further enhanced it, which 
rules out the implication of this enzyme in the rivenprost-induced stimulation. 
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In summary, our work supports the existence of functional EP4 receptors in LC neurons, which 
activation results in a concentration-dependent increase in the spontaneous firing rate. The 
underlying mechanism may involve the Gαs protein and a sodium current, but it does not seem 
to involve Gβγ, TRP, cAMP/PKA, PI3K, or PKC-dependent pathways. Further studies will be 
carried out to test whether the coupling of EP4-Gαs and sodium currents is a direct mechanism. 
According to previous data from our laboratory, the endogenous PGE2 has a preferential 
inhibitory effect on LC neurons mediated by EP3 receptor activation (Nazabal et al., 
unpublished results). We have also described a stimulatory effect of LC neurons caused by EP2 
receptor activation (Nazabal et al., unpublished results). In this study, we demonstrate the 
presence of EP4 receptors in the LC, which could further tune the inflammatory response to 
PGE2 in the brain. Thus, EP4 receptor signaling in the LC may gain relevance during 
inflammatory states, since peripheral inflammation has been reported to upregulate EP4 
receptor expression in DRG (Lin et al., 2006) and brain catecholaminergic neurons (Zhang and 
Rivest, 1999). This suggestion is also supported by the rise in c-Fos immunoreactivity in 
response to an inflammatory insult in brain regions expressing the EP4 receptor (Zhang and 
Rivest, 1999). Furthermore, chronic inflammatory pain, which is known to release PGE2, has 
been shown to enhance anxiety-like behaviors in rodents (Parent et al., 2012) and the LC 
mediates some of the affective events involved in processing of nociception by promoting 
anxiogenic-like behavior during chronic pain (Alba-Delgado et al., 2013). It is therefore 
tempting to speculate that EP4 receptor activation in the LC may be of relevance in the 
integrative reaction to pain stimuli possibly by enhancing NA release throughout the CNS. 
Therefore, the prostaglandin system and the EP4 receptor in the LC might be suitable 
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Basal firing rate and concentration-effect curve parameters for the excitatory action of the EP4 
receptor agonists rivenprost and TCS 2510 on LC neurons in the absence (control) or in the 
presence of the EP4 (L-161,982) or a combination of the EP2 (PF-04418948) and EP3 (L-
798,106) receptor antagonists. 
 ____________________________________________________________________  
 Concentration-effect curves1 
Drugs Concentration Basal firing Emax (%) pEC50 (M) (EC50, nM) Slope factor  n 
  rate (Hz) 
 ____________________________________________________________________  
Rivenprost 
Control  0.70 ± 0.09 83.7 ± 13.3 8.84 ± 0.10 (1.43) 0.70 ± 0.17 6 
+L-161,982 3 nM 0.80 ± 0.12 67.3 ± 14.2 8.43 ± 0.13 (3.72) 1.43 ± 0.43 5 
 30 nM 0.70 ± 0.07 62.2 ± 5.0 8.23 ± 0.08* (5.92) 0.97 ± 0.15 5 
 300 nM 0.82 ± 0.05 62.5 ± 7.5 7.93 ± 0.12* (11.8) 0.83 ± 0.10 5 
+L-798,106 300 nM 
PF-04418948 300 nM 0.75 ± 0.09 80.6 ± 13.0 8.47 ± 0.16 (3.38) 0.81 ± 0.11 5 
TCS 2510 
Control   0.78 ± 0.07 98.4 ± 8.1 7.74 ± 0.19 (18.0) 0.67 ± 0.05 6 
+L-161,982 300 nM 0.94 ± 0.08 61.0 ± 6.9* 7.43 ± 0.11 (37.5) 1.29 ± 0.25* 5 
 ____________________________________________________________________  
1Values are expressed as mean ± SEM obtained by nonlinear regression of n cells. Emax is the 
maximal excitatory effect, and pEC50 is the negative logarithm of the concentration needed to 
elicit 50% of the Emax. *P < 0.05 when compared to the control group of rivenprost (one-way 
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ANOVA followed by a Dunnett’s post hoc test) or TCS 2510, respectively (unpaired Student’s 
t-test). 
Figure legends 
Figure 1. Effect of the EP4 receptor agonist rivenprost on the firing rate of LC neurons in the 
absence or presence of the EP4 receptor antagonist L-161,982 or a combination of the EP2 
receptor antagonist PF-04418948 and EP3 receptor antagonist L-798,106. (A, B, C) 
Representative examples of firing rate recordings of two LC neurons showing the effect of 
increasing concentrations of rivenprost in the absence (A) and presence of L-161,982 (300 nM) 
(B) or presence of PF-04418948 and L-798,106 (300 nM each) (C). The vertical lines represent 
the number of spikes recorded every 10 s and the horizontal bars the period of drug application. 
(D) Concentration-effect curves for rivenprost in control (filled circles) and in the presence of 
L-161,982 (3 nM, open circles; 30 nM, full triangles; and 300 nM, open triangles) (left) or in 
the presence of PF-04418948 and L-798,106 (300 nM each, filled squares) (right). The 
horizontal axis shows the rivenprost concentration on a semi-logarithmic scale. The vertical 
axis expresses the increase in firing rate of LC neurons as the percentage of the baseline. Data 
points are the mean ± SEM at each rivenprost concentration obtained from n number of 
experiments (see Table 1). The lines through the data are the theoretical curves in each group 
constructed from the mean of the individual concentration-effect curve parameters, as 
estimated by nonlinear regressions. Note that the concentration-effect curve for rivenprost is 
shifted to the right by the EP4 receptor antagonist.  
 
Figure 2. Effect of the EP4 receptor agonist TCS 2510 on the firing rate of LC neurons in 
the absence or presence of the EP4 receptor antagonist L-161,982. (A, B) Representative 
examples of firing rate recordings of two LC neurons showing the effect of increasing 
concentrations of TCS 2510 in the absence (A) and presence of L-161,982 (300 nM) (B). The 
vertical lines represent the number of spikes recorded every 10 s and the horizontal bars the 
period of drug application. (C) Concentration-effect curves for TCS 2510 in control (filled 
circles) and in the presence of L-161,982 (300 nM, open triangles). The horizontal axis shows 
the TCS 2510 concentration on a semi-logarithmic scale. The vertical axis expresses the 
increase in firing rate of LC neurons as the percentage of the baseline. Data points are the 
mean ± SEM at each TCS 2510 concentration obtained from n number of experiments (see 
Table 1). The lines through the data are the theoretical curves in each group constructed from 
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the mean of the individual concentration-effect curve parameters, as estimated by nonlinear 
regressions. Note that the Emax of TCS 2510 decreases in the presence of the EP4 receptor 
antagonist. 
 
Figure 3. Effect of blocking a sodium current and the cAMP/PKA pathway on the rivenprost-
induced excitatory effect on LC neurons. (A) Representative example of the firing rate 
recording of an LC neuron showing the effect of rivenprost (30 nM, 10 min) in the presence 
of low-sodium aCSF (TRIS 80%, 5 min). The vertical lines represent the number of spikes 
recorded every 10 s and the horizontal bars the period of drug application. Note that TRIS 
80% abolishes the stimulatory effect of rivenprost. (B) Bar graph showing the increase in the 
number of spikes per 10 s caused by rivenprost (30 nM) in the absence (control, n = 6) and 
in the presence of TRIS 80% (black bar, n = 6) or 2-APB (30 μM, hatched bar, n = 5). (C) 
Bar graph showing the increase in the number of spikes per 10 s by rivenprost (30 nM, white 
bar, n = 6), 8-Br-cAMP (1 mM, black bar, n = 5), rivenprost in the presence of 8-Br-cAMP 
(hatched bar, n = 5), and the arithmetic sum of the effects of rivenprost and 8-Br-cAMP 
(black and white bar). Application of rivenprost in the presence of 8-Br-cAMP further 
increased the excitatory effect caused by 8-Br-cAMP (paired Student’s t-test). Note that 8-
Br-cAMP does not occlude the excitatory response to rivenprost since no difference was 
found between the effect of rivenprost in the presence of 8-Br-cAMP and the arithmetic sum 
of effects (unpaired Student’s t-test). (D) Bar graph showing the excitatory effect of 
rivenprost (30 nM, n = 6) in the presence of the PKA inhibitor H-89 (10 μM, n = 5) compared 
to control. Bars are the mean ± SEM of n experiments. *P < 0.05 when compared to the 
control group (unpaired Student’s t-test). 
 
Figure 4. Effect of butaprost and effect of blocking the Gαs and Gβγ-dependent signaling, and 
the PI3K and PKC enzymes on the rivenprost-induced excitatory effect on LC neurons. (A) 
Representative example of the firing rate recording of an LC neuron showing the effect of 
rivenprost (30 nM, 10 min) in the presence of butaprost (1 μM, 15 min). The vertical lines 
represent the number of spikes recorded every 10 s and the horizontal bars the period of drug 
application. (B) Bar graph showing the increase in the number of spikes per 10 s caused by 
rivenprost (30 nM, white bar, n = 6), butaprost (1 μM, black bar, n = 5), rivenprost in the 
presence of butaprost (hatched bar, n = 5), and the arithmetic sum of the effects of rivenprost 
and butaprost (black and white bar). Application of rivenprost in the presence of butaprost 
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further increased the excitatory effect caused by butaprost (paired Student’s t-test). Note that 
application of butaprost does not occlude the excitatory response to rivenprost since no 
difference was found between the effect of rivenprost in the presence of butaprost and the 
arithmetic sum of effects (unpaired Student’s t-test). (C, D) Bar graphs showing the increase 
in the number of spikes per 10 s caused by rivenprost (30 nM, 10 min) in the absence (control, 
n = 6) or in the presence of NF449 (10 μM, black bar, n = 6) or gallein (20 μM, hatched bar, 
n = 5) (C) or the PI3K inhibitor wortmannin (100 nM, black bar, n = 5) or the PKC inhibitor 
chelerythrine (10 μM, hatched bar, n = 5) (D). Bars are the mean ± SEM of n experiments. 
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Prostaglandin E2 (PGE2), an inflammatory mediator, depresses breathing movements 
seemingly from the pre-Bötzinger Complex (preBötC), the brainstem central pattern generator. 
This inhibitory effect on breathing is mediated by Gi/o-coupled EP3 receptors and may have 
serious complications, particularly in neonates; such as apneas, sudden unexpected postnatal 
collapse or sudden infant death syndrome. PreBötC inspiratory neurons also express µ-opioid 
receptors and mediate opioid-induced respiratory depression. However, the possible interaction 
between PGE2 and opioids to induce major respiratory disruption, e.g., during infections and 
surgery, remains unknown. Therefore, we performed live time-lapse calcium imaging on 
organotypic brainstem slices of wild-type mice (WT) and mice lacking the EP3 receptor 
(Ptger3-/-). DAMGO (0.5 and 5 µM) or PGE2 (10 and 100 nM) reduced Ca2+ transient frequency 
of the whole population and respiratory neurons. Notably, in Ptger3-/-, PGE2-induced effect was 
absent, and that of DAMGO was delayed on time. Application of DAMGO after PGE2 did not 
further reduce the oscillatory Ca2+ frequency, suggesting a signaling pathway convergence. 
Indeed, the phosphodiesterase 4 blocker rolipram and the GIRK channel blocker SCH-23390 
prevented both DAMGO- and PGE2-induced reduction in Ca2+ oscillatory activity. Finally, 
DAMGO and PGE2 reduced the cellular connectivity and synchronicity and increased the 
segregation into local cell clusters. This effect of DAMGO was abolished by rolipram and 
SCH-23390, whereas that of PGE2 was partially hindered by rolipram. Overall, DAMGO and 
PGE2 reduce the respiratory-related frequency and cellular interconnectivity of the preBötC in 
vitro through a supposedly common signaling pathway, which seems to modulate the cAMP 
and GIRK channels. 
 
Keywords: PGE2; EP3 receptor; opioid; respiratory depression; preBötzinger complex 
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● PGE2: prostaglandin E2 
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Breathing is a complex mechanism that requires the assembly of numerous processes, 
including the rhythmic inspiratory drive. This inspiratory pattern is generated by the 
preBötzinger complex (preBötC), located in the ventrolateral medulla. The preBötC is a highly 
heterogeneous region comprised by glycinergic, GABAergic, and particularly, glutamatergic 
respiratory neurons (Koizumi et al., 2013) whose activity needs to be orchestrated to drive a 
single inspiratory movement. Thus, the majority of preBötC respiratory neurons are 
inspiratory, implying that they fire in phase with the population activity (Zavala-Tecuapetla et 
al., 2014), which is in turn synchronized with the inspiratory motor output in slices (Lieske et 
al., 2000). Consequently, selective ablation of preBötC inspiratory neurons results in disrupted 
breathing rhythm in slices (Wang et al., 2014) and in vivo (Gray et al., 2001). Furthermore, 
preBötC neurons are interconnected into clusters (Hartelt et al., 2008) and resembling a small-
world architecture (Watts & Strogatz, 1998; Forsberg et al., 2016) that allows efficient 
information transfer within the network at low wiring costs (Achard & Bullmore, 2007). 
 
Opioids are potent analgesics widely used in the clinic, with the major drawback of producing 
potentially lethal respiratory depression (Niesters et al., 2013). In the breathing brainstem, the 
preBötC has been considered crucial in the opioid-induced respiratory depression (Montandon 
& Horner, 2014). In fact, preBötC inspiratory neurons express µ-opioid receptor (MOR) (Gray 
et al., 1999) and κ-opioid receptor (KOR) RNA (Hayes et al., 2017), and thus, opioids decrease 
the inspiratory frequency (Gray et al., 1999). The underlying mechanism involves a Gi/o 
protein-dependent (Johnson et al., 1996) decrease of cAMP formation (Ruangkittisakul & 
Ballanyi, 2010) and opening of GIRK channels (Montandon et al., 2016b), which leads to 
neuronal hyperpolarization (Gray et al., 1999). 
 
On the other hand, prostaglandins are inflammatory mediators synthesized on demand during 
inflammatory states or at birth (Mitchell et al., 1978; Beiche et al., 1996) by the rate-limiting 
COX enzyme, which is constitutively found in human and animal brain (Yasojima et al., 1999; 
Hétu & Riendeau, 2005). The main final product is the prostaglandin E2 (PGE2), which 
mediates pain, fever, and inflammation, but also produces respiratory disorders as 
demonstrated by several pieces of evidence. First, PGE2 metabolite concentration in neonatal 
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cerebrospinal fluid correlates positively with asphyxia and the outcome of hypoxic-ischemic 
encephalopathy (Björk et al., 2013). Second, the central administration of PGE2 produces 
irregular breathing and apneas (Siljehav et al., 2012, 2014). Moreover, PGE2 microinjection 
into the preBötC increases the frequency of sighs in vivo and aggravates the gasping response 
to hypoxia in preBötC slices (Koch et al., 2015). PGE2 exerts its effects by activating G protein-
coupled EP receptors: EP1-EP4. Specifically, the PGE2-induced respiratory disruption in vivo 
seems to be mediated by the EP3 receptor (Hofstetter et al., 2007). Further, recent work from 
our laboratory has shown that PGE2 reduces calcium (Ca2+) transient frequency in preBötC 
organotypic slices via the EP3 receptor (Forsberg et al., 2016). The underlying mechanism may 
involve the cAMP pathway, as it has been previously suggested for the PGE1- and opioid-
mediated respiratory depression in brainstem-spinal cord preparations (Ballanyi et al., 1997). 
However, little is known about the possible interaction between PGE2 and opioids in the 
preBötC to cause major respiratory disruption, e.g., during infections and surgery. Thus, we 
aimed to elucidate whether the opioid-induced respiratory depression would be potentiated 
under inflammatory conditions by testing the effect of the MOR agonist DAMGO in 
conjunction with PGE2 on the network activity and connectivity by time-lapse Ca2+ imaging 
on preBötC organotypic slices. 
 
Methods  
Animals and ethics statement 
C57 black (C57BL/6J) inbred mice (Charles River, Wilmington, MA) were utilized in the 
experiments. The eicosanoid prostanoid 3 receptor gene (Ptger3) was selectively deleted in 
knockout mice (Ptger3-/-) with a C57BL/6J background, as described previously (Fleming et 
al., 1998). C57BL/6J mice were then used as experimental controls for Ptger3-/- mice. All 
mice were reared by their mothers under standardized conditions with a 12:12-hr light-dark 
cycle. Food and water were provided ad libitum. The studies were performed in accordance 
with European Community Guidelines and approved by the regional ethic committee. The 
animals were reared and kept at the Department of Comparative Medicine, Karolinska 






Brainstem organotypic cultures 
As previously described in detail (Forsberg et al., 2016), P2-P5 mice pups were used for the 
organotypic brainstem slice cultures. Briefly, the pups were decapitated at the cervical C3–
C4 level. The heads were washed with cold dissection medium and the brain was dissected. 
The brain was sectioned into 300-µm-thick transverse slices by using a McIlwain Tissue 
Chopper (Ted Pella, Inc., Redding, CA, USA). Slices were selected by using anatomical 
landmarks, such as the shape and size of the entire slice and the fourth ventricle, according 
to online references (Ruangkittisakul et al., 2006, 2011, 2014). On the slices, the preBötC is 
located within ventrolateral regions. Selected slices were washed by moving them to brain 
slice medium (55% Dulbecco’s modified Eagle’s medium, 32.5% Hank’s balanced salt 
solution, 0.3% glucose, 10% fetal bovine serum, 1% HEPES buffer and 1% Antibiotic-
Antimycotic [Invitrogen, UK]), after which they were carefully placed on insert membranes 
(Millicell Culture Plate Inserts; Millipore, Billerica, MA, USA) in six-well plates. The 
membranes were coated in advance with poly-L-lysine (0.3 ml; 0.1 mg/ml, Sigma- Aldrich, 
St. Louis, MO, USA). Brain slice medium (1 ml) was placed underneath the membrane, and 
all fluid on top of the membrane was removed in order to avoid impaired oxygenation 
(Frantseva et al., 1999). The brainstem slice cultures were maintained in an incubator (37˚C, 
5% CO2), and the medium was changed every second day. The brainstem slices were kept 
in culture for 7–21 days in vitro (DIV) before live imaging experiments. 
 
Ca2+ time-lapse imaging  
For Ca2+ imaging, Fluo-8 AM (AAT Bioquest, Inc., USA) was added to a solution of pluronic 
acid 1% in DMSO (Invitrogen, UK) and was used at 10 µM in artificial cerebrospinal fluid 
(aCSF, containing in mM: 151.1 Na+, 3 K+, 2 Ca2+, 2 Mg2+, 135 Cl-, 1.1 H2PO4-, 25 HCO3- and 
10 glucose). To localize the preBötC, tetramethylrhodamine-conjugated Substance P (TMR-
SP; Biomol, Oakdale, NY, USA) was used at a final concentration of 3 µM aCSF. The TMR-
SP solution was placed on top of the brainstem slice and incubated for 10 min at 37˚C in an 
atmosphere of 5% CO2. The TMR-SP solution was then replaced with 1 ml of 10 µM Fluo-8 
solution. The Fluo-8 solution was incubated for 30 min (37˚C, 5% CO2). Before imaging, the 
slice was washed with aCSF for 1-5 min (37˚C, 5% CO2). During time-lapse imaging, slices 
were kept in an open chamber perfused with aCSF (1.5 ml/min) by using a peristaltic pump. A 
Chamlide Inline Heater (Live Cell instruments, Seoul, Korea, cat no. IL-H-10) was used for 
temperature control, and a Chamlide AC-PU perfusion chamber for 25-mm coverslips (Live 
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Cell instruments, Seoul, Korea, cat no. ACPU25) was used for perfusion. The aCSF was 
constantly bubbled with 5% CO2 and 95% O2. The temperature of the chamber was set to 32˚C. 
Images were captured by using a Zeiss AxioExaminer D1 microscope equipped with 20x and 
40x water immersion objectives (N.A. 1.0), a Photometrics eVolve EMCCD-camera and filter 
sets 38HE (Zeiss) and et560/hq605 (Chroma, Bellows Falls, VT, USA). For live imaging, a 
frame interval of 0.5 s was used. Exposure time was set to 100 ms. Substances added during 
imaging were [D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin (DAMGO, 0.5 – 5 µM; Sigma-
Aldrich, St. Louis, MO, USA, cat no. E7384), naloxone hydrochloride dihydrate (naloxone, 5 
µM; Sigma-Aldrich, St. Louis, MO, USA, cat no. N7758), R(+)-SCH-23390 hydrochloride 
(SCH-23390 15 µM; Sigma-Aldrich, St. Louis, MO, USA, cat no. D054), prostaglandin E2 
(PGE2, 10 – 100 nM; Sigma-Aldrich, St. Louis, MO, USA, cat no. P5640), and rolipram (5 
µM; Sigma-Aldrich, St. Louis, MO, USA, cat no. R6520). All substances were dissolved in 
aCSF prior to experimentation and added to the chamber by using a continuous flow system. 
SCH-23390 was added to the Fluo-8 solution for the 30-minute incubation. For each 
experiment, a control or baseline period with aCSF was followed by drug application. The drug 
concentrations employed in this investigation are in accordance to those used in previous 
studies in slices (Zamalloa et al., 2009; Ruangkittisakul & Ballanyi, 2010; Chee et al., 2011; 
Forsberg et al., 2016). 
 
Data analysis and statistics 
Ca2+ imaging time traces were analyzed with a recently published method (Malmersjo et al., 
2013; Smedler et al., 2014). Regions of interest (ROI) were marked for all cells based on the 
standard deviation of fluorescence intensity over time, using a semiautomatic, adapted ImageJ 
script kindly provided by Dr. John Hayes (The College of William and Mary, Williamsburg, 
VA, USA, http://physimage.sourceforge.net/). For each frame, the mean intensity value within 
each ROI was measured using ImageJ, along with their coordinates. Then, the fluorescence 
signals were normalized to baseline values. Synchronized activity between cells was measured 
by the Pearson correlation with a custom-made script in MATLAB (version 9.2.0.538062 
R2017a; MathWorks, Natick, MA, USA) and by the mic2net toolbox (Smedler et al., 2014) 
(version 6.12; MathWorks). The calculated pair-wise correlation coefficients resulted in a 
correlation matrix that was converted to an adjacency matrix by applying a cut-off level. The 
cut-off level was selected by calculating the mean of the 99th percentile of correlation 
coefficients for a set of experiments with scrambled signals. Scrambling was performed by 
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randomly translating all traces in the time-domain. The network structure was visualized by 
plotting a line between pairs of cells, where the color of the lines was proportionate to the 
correlation coefficient. The degree of connections within a network (connectivity) was defined 
as the number of cell pairs with a correlation coefficient larger than the cut-off value divided 
by the total number of cell pairs. PreBötC cells are organized in a small-world structure 
(Forsberg et al., 2016) formed by hubs or nodes connected in clusters and allowing high 
connectivity efficiency with a minimal connection cost (Achard & Bullmore, 2007). The 
information travels from one node to another, so that the parameter mean shortest path length 
(λ) could be defined as the minimum number of nodes that must be passed in between. In 
addition, the mean clustering coefficient (σ) is the number of neighbors of a node that are also 
neighbors of each other. Finally, as the small-world parameter (γ) equals σ/λ (Smedler et al., 
2014) these networks are defined by short distance λ and high σ (For further details see figure 
1.11 in the introduction section). The parameters were calculated by using the MATLAB BGL 
library (http://www.mathworks.com/matlabcentral/fileexchange/10922) and compared to the 
corresponding randomized networks. For each ROI a baseline fluorescence was determined 
(F0), which was used to normalize the change in fluorescence as ΔF/F0, where ΔF=F1-F0, 
being F1 is the specific fluorescence intensity at a specific time point, and F0 is the average 
intensity of 30 s before and after F1. A previously published toolbox was used for the frequency 
analysis of time traces by the Fourier transform (Uhlén, 2004). Data were further processed in 
GraphPad Prism 5.01 (GraphPad Software, Inc., USA) to create the figures. 
A heterogeneous population of cells constitutes the preBötC, and some of them were found 
insensitive to DAMGO (Barnes et al., 2007). Thus, the cells were sorted out into two groups 
depending on their behavior within the first 5 minutes of drug application. The behavior was 
defined as either decreased or increased Ca2+ oscillation frequency compared to control. This 
analysis allowed the proportion of cells that were affected by the drug in a certain way to be 
calculated. Then, the behavior of single cells could be followed.  
Experiments were excluded based on the following criteria: low dye loading, the total number 
of cells per slice less than 20, standard deviation (SD) at the control period higher than the 50% 
of the mean frequency, and peaks of maximum amplitude in the Fourier transform of calcium 
oscillation signal above 200 mHz.  
Statistical analysis of paired comparisons was performed by two-sided Student’s t-test. 
Comparisons among more than two experimental conditions by one-way analysis of variance 
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(ANOVA) followed by a Dunnett’s post hoc for comparison with a control group and only if 
F achieved the necessary level of statistical significance (i.e. P < 0.05) and there was no 
significant variance inhomogeneity. All calculations for the statistical tests were conducted 
with Microsoft Excel 2016 (16.0.4639.1000 for Windows), LibreOffice Calc (6.0.7.3 for 
Ubuntu), and GraphPad Prism (5.01 for Windows). In all cases, P < 0.05 was considered 




Effect of the MOR agonist DAMGO on the cellular activity and network connectivity of the 
preBötC in vitro 
The rhythmic cellular activity of the preBötC is directly related to the respiratory frequency 
(Alsahafi et al., 2015), so its neuronal hyperpolarization can lead to apneas in vivo (Huckstepp 
et al., 2016). Moreover, it is considered indispensable for the opioid-induced respiratory 
depression (Montandon & Horner, 2014), as the majority of the NK1R+ cells (i.e., respiratory 
neurons) in the preBötC co-express MOR (Gray et al., 1999). Therefore, to determine the effect 
of opioids in preBötC cells in vitro, we applied the high-affinity MOR agonist DAMGO (0.5 – 
5 μM) for 15 min to organotypic slices and measured Ca2+ fluctuations. DAMGO (0.5 µM) did 
not modify the Ca2+ transient amplitude or frequency at any time (n = 7) but the highest 
concentration of DAMGO (5 µM) reduced by 17.2 ± 7.8% the relative amplitude and by 21.7 
± 6.8% the frequency of Ca2+ transients within 5 min (n = 7, P < 0.05 compared to baseline; 
Figures 1A, B, C, and D, Table 1). Furthermore, within the first 5 min of recording, the effect 
of the highest concentration of DAMGO (5 µM) was greater than that of DAMGO 0.5 µM (n 
= 7, P < 0.05 compared to DAMGO 0.5 µM; Figures 1B and C) and more cells were inhibited 
(75.3 ± 11.0% vs. 46.9 ± 14.5%, respectively; n = 7 each, P < 0.05; Figure 1D). The inhibitory 
effect of DAMGO (5 µM) persisted throughout the experiment (15 min) (Figures 1B and C) 
showing a small recovery in the Ca2+ oscillatory frequency during the last 5 min of application 
(n = 7, P < 0.05 when compared to the previous 5 min period; Figure 1C), possibly due to MOR 
desensitization (Lowe et al., 2013). Furthermore, NK1R+ neurons showed a similar inhibition 
in the Ca2+ transient relative amplitude and frequency to the whole cell population (Figure 1A, 
Table 1), and possibly suggesting that the effect on respiratory neurons might define the 
behavior of the whole network. In light of these results, the opioid agonist DAMGO reduced 
the Ca2+ oscillatory activity of respiratory neurons in preBötC organotypic cultures. 
 
During an inflammatory state or at birth, there is an endogenous release of PGE2 (Mitchell et 
al., 1978), which has been shown to increase the frequency of gasps and sighs at low 
concentrations (Koch et al., 2015) via activation of the Gi/o-coupled EP3 receptor in the 
preBötC (Forsberg et al., 2016). Furthermore, a mutual dependency on the cAMP pathway has 
been suggested for both opioids and prostanoids (Ballanyi et al., 1997). Thus, to study the 
possible interaction between the prostanoid and the opioid systems, we analyzed the effect of 
DAMGO in mice genetically modified to lack the PGE2-EP3 receptor (Ptger3-/-) and compared 
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them to wild-type mice (WT). Administration of DAMGO (5 µM) in Ptger3-/- mice did not 
inhibit Ca2+ transient amplitude and produced a delayed effect on the oscillatory frequency, as 
it did not change within the first 10 min, and required 15 min to inhibit to the same extent than 
WT mice did within 5 min (17.0 ± 13.4% reduction within 15 min in Ptger3-/- mice; n = 8, P < 
0.05 compared to baseline; Figures 1B and C). This result means that the DAMGO-induced 
reduction in Ca2+ transient frequency was more gradual in mice lacking the EP3 receptor, but 
equal in magnitude as in WT mice. Furthermore, this trend held for respiratory neurons, which 
showed a decrease in Ca2+ signaling frequency only within 15 min of DAMGO (5 µM) 
administration. Thus, showing that the modification in Ca2+ transient amplitude induced by 
DAMGO (5 µM) was hindered in Ptger3-/-. Overall, this delayed effect of opioids in mice 
lacking the EP3 receptor suggests an interaction between the opioid and the prostanoid systems. 
 
PreBötC pacemaker neurons have synchronized activity mediated by gap junctions and 
excitatory synaptic interactions (Koshiya & Smith, 1999; Rekling et al., 2000). This 
synchronized activity between interconnected cells is crucial for driving the inspiratory output 
(Koshiya & Smith, 1999). According to the algorithm employed, two cells are defined as 
connected if their correlation coefficient exceeds the set cut-off (Smedler et al., 2014). 
Administration of DAMGO (5 µM) reduced the mean correlation above cut-off values in WT 
mice (from 0.74 ± 0.06 to 0.59 ± 0.07; n = 7, P < 0.05; Figure 1E) thus suggesting a reduced 
interconnectivity among cells. Furthermore, DAMGO (5 µM) administration reduced the 
number of correlations per active cell (from 33 ± 21 to 6 ± 3; n = 7, P < 0.05), suggesting a 
reduced functional coupling. Likewise, Ptger3-/- mice displayed similar reductions in the mean 
correlation above cut-off (from 0.86 ± 0.04 to 0.67 ± 0.10; n = 8, P < 0.05) and the number of 
correlations per active cell (from 61 ± 35 to 28 ± 18; n = 8, P < 0.05) upon DAMGO (5 µM) 
application. These results suggest that the opioid receptor agonist DAMGO reduced the 
network synchronization of preBötC cells in organotypic slices and that this effect was not 
altered in mice lacking the EP3 receptor. 
 
Synchronized bursting activity depends on the network topology (Gaiteri & Rubin, 2011) and 
preBötC neurons are organized into clusters interconnected by hubs resembling the small-
world architecture (Hartelt et al., 2008; Forsberg et al., 2016).  Thereby, neighboring cells in a 
network are wired with a few migratory outputs that reduce the average path length between 
nodes (Watts & Strogatz, 1998; Smedler et al., 2014), and thus providing efficient transmission 
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of information (Achard & Bullmore, 2007). These networks are defined by the parameters: 
mean clustering coefficient (σ), mean shortest path length (λ), and small-world parameter (γ= 
σ/λ). DAMGO (0.5 – 5 µM) increased the σ within 5 min in WT mice (n = 7, both P < 0.05 
compared to baseline; Figure 1F) and then it returned back to baseline, suggesting increased 
segregation into clusters and tendency towards local connections during the first 5 min. 
Similarly, DAMGO (0.5 – 5 µM) increased the γ parameter (n = 7, both P < 0.05 compared to 
baseline; Figure 1F), indicating an enhancement of small-world features. Furthermore, the 
highest concentration of DAMGO (5 µM) increased λ by 11.8 ± 6.7% (n = 7, P < 0.05 
compared to baseline; Figure 1F) and produced a higher increase in σ and γ than with DAMGO 
(0.5 µM) (n = 7, both P < 0.05; Figure 1F). Likewise, DAMGO (5 µM) increased σ and γ in 
Ptger3-/- mice within the same time span (5 min) (Figure 1F) and did not change any further 
afterward. However, the DAMGO-induced effect on σ and γ was lower in Ptger3-/- than in WT 
mice (σ by 71.7% and γ by 75.5%; n = 8, both P < 0.05 compared to WT; Figure 1F). This 
result suggests that the effect of DAMGO on the network parameters may be hindered in mice 
lacking the EP3 receptor. Overall, these data insinuate that DAMGO reduced the synchronicity 
of the network by promoting segregation and local connections within a cluster with a reduction 
in the outgoing information. 
 
Finally, to ascertain whether the observed effects induced by DAMGO were mediated by MOR 
activation, we tested the effect of DAMGO (5 µM) in the presence of the MOR antagonist 
naloxone. Administration of naloxone (5 µM) for 10 min did not change the Ca2+ signaling 
activity but completely abolished the DAMGO-induced reduction in Ca2+ transient frequency 
or relative amplitude in the whole network and respiratory neurons (P < 0.05 compared to 
control in the absence of naloxone; Table 1). Furthermore, naloxone blocked the DAMGO-
induced modifications of the network parameters and connectivity. These results suggest that 
MOR activation mediates the inhibitory effect induced by DAMGO in preBötC cellular activity 
and connectivity in vitro. 
 
Effect of PGE2 and its interaction with DAMGO on the cellular activity and network 
connectivity of the preBötC in vitro 
 
Prostaglandins have been reported to inhibit the inspiratory nerve discharge in brainstem-spinal 
cord preparations (Ballanyi et al., 1997) and to increase the frequency of sighs in vivo (Forsberg 
et al., 2016). This effect may be particularly threatening in neonates, as high levels of PGE2 
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metabolite in neonatal cerebrospinal fluid has been associated with severe perinatal asphyxia 
(Björk et al., 2013). Furthermore, activation of EP3 receptors in the preBötC has been shown 
to decrease the Ca2+ transient frequency (Forsberg et al., 2016). Here, we aimed to understand 
whether prostaglandins and opioids may interact to produce major respiratory depression. 
Thus, we examined the effect of PGE2 in preBötC organotypic cultures and then tested the 
effect of DAMGO in the presence of PGE2. Administration of PGE2 (10 – 100 nM) for 5 min 
did not modify the relative Ca2+ transient amplitude but reduced the Ca2+ transient frequency 
in WT mice (n = 12 and n = 10, respectively, both P < 0.05 compared to baseline; Table 2; 
Figures 2A and B). This PGE2-induced inhibitory effect was not observed in Ptger3-/- mice (n 
= 9 and n = 10, respectively, both P < 0.05 compared to WT; Table 2; Figure 2A), which 
suggests that EP3 receptor activation mediates the inhibition of network activity caused by 
PGE2 in the preBötC in vitro, as already described(Forsberg et al., 2016). Further, the effect of 
the highest concentration of PGE2 (100 nM) was greater than that of PGE2 (10 nM) (n = 10 and 
n = 12, respectively, P < 0.05; Table 2; Figures 2A and B) and more cells were inhibited (72.3 
± 8.5% vs. 58.3 ± 13.8%; n = 10 and n = 12, respectively, P < 0.05; Figure 2B). Notably, during 
PGE2 (100 nM) administration, the Ca2+ transient frequency reduction in NK1R+ cells was 
similar to the whole cell population (Table 2), thus suggesting that preBötC respiratory neurons 
were sensitive to PGE2, in accordance with previous studies(Forsberg et al., 2016). 
 
Next, we assessed the possible interaction between opioids and prostaglandins by applying 
DAMGO in the presence of PGE2. Thus, the lowest concentration of DAMGO (0.5 µM) in the 
presence of PGE2 (10 nM) did not further change Ca2+ transient amplitude or frequency (from 
53.5 ± 5.8 mHz to 51.8 ± 5.1 mHz in WT, before and after DAMGO administration; n = 12, P 
> 0.05 compared to the frequency during PGE2 administration; Figures 2A and B). Similarly, 
bath perfusion with the highest concentration of DAMGO (5 µM) in the presence of PGE2 (100 
nM) did not further inhibit the Ca2+ transient frequency, but decreased the amplitude of the 
whole network and NK1+ cells (n = 10, P < 0.05 compared to baseline; Table 2, Figures 2A 
and B). Furthermore, the DAMGO-induced reduction in Ca2+ transient frequency was smaller 
in the presence of PGE2 than in the absence in WT but not in Ptger3-/- (P < 0.05 compared to 
controls in the absence of PGE2), which suggest that the inhibitory effect of DAMGO was 
prevented by prior administration of PGE2 in an EP3 receptor-dependent manner. Overall, 
these data indicate that the onset of PGE2-induced inhibitory effect on Ca2+ oscillatory activity 
prevented any further reduction caused by DAMGO. Thus, EP3 receptor activation apparently 
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occluded the effect of DAMGO and therefore, both EP3 and MOR receptor activation seems 
to share a similar signaling pathway, as elsewhere mentioned (Ballanyi et al., 1997). 
 
Analysis of the network Ca2+ activity revealed that PGE2 (10 nM) did not modify any 
parameter, but PGE2 (100 nM) decreased the mean correlation above cut-off values in WT 
(from 0.74 ± 0.13 to 0.62 ± 0.10; n = 10, P < 0.05 compared to baseline; Figure 2C) and Ptger3-
/- mice (from 0.77 ± 0.14 to 0.59 ± 0.15; n = 10, P > 0.05 compared to WT). These results 
suggest a decreased network synchronicity induced by PGE2, which was not apparently 
mediated by the EP3 receptor. However, PGE2 (100 nM) reduced the number of correlations 
per active cell in WT (from 36 ± 16 to 21 ± 17; n = 10, P < 0.05 compared to baseline) but not 
in Ptger3-/- mice, which implies that EP3 receptor activation may reduce the functional 
interconnectivity among cells. Overall, these data indicate that PGE2 reduces the network 
connectivity and synchronicity of preBötC cells and that this effect may be partly mediated by 
EP3 receptor activation.  
 
Intriguingly, DAMGO (5 µM) in the presence of PGE2 (100 nM) increased the mean 
correlation above cut-off values (from 0.62 ± 0.10 to 0.82 ± 0.09; n = 10, P < 0.05 compared 
to the decrease observed during PGE2 administration; Figure 2C) in WT but not in Ptger3-/- 
mice. Additionally, DAMGO (5 µM) administration in the presence of PGE2 (100 nM) 
reversed the number of correlations per active cell to baseline conditions (from 21 ± 17 to 34 
± 26; n = 10, P < 0.05 compared to the decrease observed during PGE2 administration) in WT 
but not in Ptger3-/- mice. These data suggest that DAMGO in the presence of PGE2 increased 
the cellular activity synchronization, which was exactly the opposite behavior than in the 
absence of PGE2 (see above). These could be due to an inhibitory effect of DAMGO on a 
broader number of cells, and then a network resynchronization (see discussion). 
 
Finally, regarding the small-world topology, PGE2 (100 nM) increased σ and γ in WT mice (n 
= 10, P < 0.05 compared to baseline; Figure 2D), suggesting segregation into stronger local 
connections and small-worldness. On the other hand, this effect was not observed in Ptger3-/- 
mice or with the lowest concentration of PGE2 (10 nM) (n = 12, P > 0.05 compared to baseline; 
Figure 2D). Thus, suggesting that activation of EP3 receptors mediated the increase of 
segregation and small-world properties caused by PGE2 application. In addition, subsequent 
administration of DAMGO (0.5 – 5 µM) in the presence of PGE2 (10 – 100 nM) did not change 
any further the network parameters in WT (n = 10, P < 0.05 compared to baseline; Figure 2D) 
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and Ptger3-/- mice. This result suggests that activation of EP3 receptors mediated by PGE2 
occluded the following modification of the small-world network features caused by DAMGO.  
 
Involvement of the cAMP/PKA pathway in the inhibitory effect caused by PGE2 and DAMGO 
on the cellular activity and network connectivity of the preBötC in vitro  
 
Both MOR and EP3 receptor activation has been described to couple to Gi/o protein (Johnson 
et al., 1996; Ikeda-Matsuo et al., 2010), which is known to decrease the production of cAMP. 
Further, a previous study made in isolated brainstem-spinal cord preparations has reported that 
pharmacological elevation of cAMP levels reversed the PGE1- and opioid-induced inhibition 
of the respiratory nerve discharge (Ballanyi et al., 1997). To assess whether the proposed 
common mechanism converges on the cAMP pathway in the preBötC, we utilized the 
phosphodiesterase 4 (PDE4) inhibitor rolipram (5 µM), which potentially increases cAMP 
pathway signaling by blocking cAMP degradation. Then, we tested the effect of DAMGO (5 
µM) and PGE2 (100 nM) in the presence of rolipram. Bath perfusion of rolipram (5 µM) for 10 
min increased relative Ca2+ transient amplitude within the first 5 min (n = 8, P < 0.05 compared 
to baseline), returning back to baseline levels after these 5 min (Figures 3A and B) and 
decreased the Ca2+ transient frequency within 10 min (n = 8, P < 0.05 compared to baseline; 
Table 3, Figures 3A and B). On the other hand, upon rolipram administration, respiratory 
neurons showed a similar tendency in the Ca2+ oscillatory activity than the whole network, but 
it did not reach statistical significance (P > 0.05 compared to baseline; Table 3, Figure 3B). 
Given that a low number of slices were dyed for the NK1R in this group (Table 3), we pooled 
the NK1R+ data of rolipram administration from before PGE2 and DAMGO to test whether the 
respiratory neurons would reflect the response observed in the whole network. Thus, pooling 
the NK1R+ data resulted in significant changes in Ca2+ transient relative amplitude within 5 
min (from 26.5 ± 3.8 to 30.6 ± 4.4; n = 12, P < 0.05 compared to baseline) and frequency within 
10 min (from 57.7 ± 6.0 to 51.1 ± 7.2; n = 12, P < 0.05 compared to baseline). This result 
indicates that blocking the degradation of cAMP increased the relative Ca2+ transient 
amplitude, but decreased the Ca2+ transient frequency of preBötC cells and respiratory neurons 
in vitro.  
 
Next, we tested the effect of DAMGO after these modifications in Ca2+ oscillatory relative 
amplitude and frequency induced by rolipram. Administration of rolipram (5 µM) completely 
blocked the DAMGO (5 µM)-induced changes in Ca2+ transient relative amplitude and 
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frequency in the whole network (n = 8, P < 0.05 compared to control in the absence of rolipram, 
Table 3; Figures 3A, B, and C) and NK1R+ cells (n = 5, P < 0.05 compared to control in the 
absence of rolipram) (Figures 3A and B; Table 3). These results indicate that the cAMP 
pathway may have a role in the inhibitory effect caused by DAMGO in the cellular activity of 
the respiratory network and respiratory neurons of the preBötC. 
 
Likewise, rolipram (5 µM) prevented the reduction in Ca2+ transient frequency induced by 
PGE2 (100 nM) in the whole network (P < 0.05 compared to control in the absence of rolipram; 
Table 3, Figures 3A, B, and C). Further, this blockade was also observed in respiratory neurons, 
which did not display any further decrease in the Ca2+ transient frequency upon PGE2 
administration (P > 0.05 compared to the previous 5 min period in the presence of rolipram; 
Table 3; Figure 3B). However, this effect was not different from NK1R+ cells in controls (P > 
0.05 compared to control in the absence of rolipram). These results indicate that inhibition of 
the cAMP degradation reverted the modification in the respiratory network activity induced by 
PGE2, but not that observed in respiratory neurons. Overall, these data suggest that the levels 
of cAMP may modulate the respiratory depression observed with opioids and prostaglandins, 
as previously suggested (Ballanyi et al., 1997), and thus, that the cAMP pathway may be the 
endpoint of the presumed common signaling mechanism. 
 
Regarding the network circuitry, administration of rolipram (5 µM) reduced the mean 
correlation above cut-off within 10 min (from 0.74 ± 0.04 to 0.65 ± 0.08; n = 8, P < 0.05 
compared to baseline; Figure 3D) and hindered the DAMGO (5 µM)-induced modification in 
the mean correlation above cut-off (from 0.65 ± 0.08 to 0.68 ± 0.06; n = 8, P < 0.05 compared 
to control in the absence of rolipram; Figure 3D). These results suggest that rolipram may 
reduce the interconnectivity among cells but prevented that caused by DAMGO. Furthermore, 
rolipram administration did not change the number of correlations per active cell but blocked 
the reduction caused by DAMGO (from 14 ± 14 to 12 ± 15; n = 8, P > 0.05 compared to 
baseline before DAMGO). However, this effect was not different from that observed under 
control conditions (n = 8, P > 0.05 compared to control in the absence of rolipram), possibly 
due to the high variability. These data suggest that inhibition of cAMP degradation partially 
hampered the effect of DAMGO on the network configuration. Furthermore, administration of 
rolipram (5 µM) for 10 min did not modify σ, γ or λ, but abolished the DAMGO-induced 
changes in small-world features (n = 8, P < 0.05 compared to control in the absence of rolipram; 
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Figure 3E). Thus, these results suggest that the cAMP pathway seems to mediate the decrease 
in network synchronicity and connectivity caused by DAMGO in the preBötC. 
 
Furthermore, bath perfusion of rolipram (5 µM) reduced the mean correlation above cut-off 
within 10 min (from 0.80 ± 0.06 to 0.71 ± 0.11; n = 8, P < 0.05 compared to baseline; Figure 
3D) and blocked the reduction in the mean correlation above cut-off induced by PGE2 (100 
nM) (from 0.71 ± 0.11 to 0.68 ± 0.11; n = 8, P < 0.05 compared to control in the absence of 
rolipram; Figure 3D). Additionally, PGE2 in the presence of rolipram did not alter the number 
of correlations per active cell (from 12 ± 13 to 5 ± 5; n = 8, P > 0.05 compared to baseline 
before PGE2) but this effect was not different from that observed under control conditions (n = 
8, P > 0.05 compared to control in the absence of rolipram). These data suggest that the cAMP 
pathway seems to be partially involved in the effect of PGE2 on the network configuration. 
Further, PGE2 (100 nM) in the presence of rolipram did not change σ or γ (n = 8, P > 0.05 
compared to baseline before PGE2; Figure 3E). However, this effect was not different from that 
observed in controls (n = 8, P > 0.05 compared to control in the absence of rolipram), possibly 
due to the high variability. Thus, these data reveal that blockade of cAMP degradation with 
rolipram hindered the inhibitory effect of PGE2 on Ca2+ transient frequency and network 
synchronicity, but it did not seem to intervene in the small-world topology modification caused 
by PGE2. As a whole, the cAMP pathway seemed to be involved in both MOR and EP3 
receptor activation in the preBötC organotypic cultures. 
 
Involvement of GIRK channel activation in the inhibitory effect caused by PGE2 and DAMGO 
on the cellular activity of the preBötC in vitro 
 
Opioid-induced respiratory depression in vivo is thought to be mediated by GIRK channels 
(Montandon et al., 2016b). Thus, to verify the involvement of GIRK channels in the inhibitory 
effect caused by DAMGO or PGE2 in vitro, we incubated the organotypic slices with the GIRK 
channel blocker SCH-23390 (15 µM) for 30 min during Fluo-8 loading, and then, we tested 
the effect of DAMGO (5 µM) or PGE2 (100 nM) by time-lapse Ca2+ imaging. Incubation with 
SCH-23390 (15 µM) did not alter the basal Ca2+ transient amplitude (baseline ΔF/F0 without 
SCH-23390 = 31.3 ± 3.0 vs. with SCH-23390 = 27.5 ± 3.4; n = 8, P > 0.05) nor frequency 
(baseline without SCH-23390 = 55.6 ± 3.6 mHz vs. with SCH-23390 = 57.3 ± 5.5 mHz; n = 8, 
P > 0.05) compared to baseline values before DAMGO (5 µM) administration in controls. 
However, GIRK channel blockade with SCH-23390 completely prevented the inhibitory effect 
 
17 
of DAMGO (5 µM) on Ca2+ transient amplitude and frequency in the whole network and 
NK1R+ cells (n = 8, P < 0.05 compared to control in the absence of SCH-23390; Table 4, 
Figures 4A and B). This result indicates that GIRK channel activation is involved in the opioid-
induced inhibition of respiratory network and respiratory neurons in vitro. 
 
Next, we determined whether SCH-23390 would hinder as well the PGE2-induced inhibition 
in Ca2+ oscillatory frequency. Thus, upon SCH-23390 (15 µM) incubation, PGE2 (100 nM) did 
not reduce the Ca2+ transient frequency in the whole network and respiratory neurons (P < 0.05 
compared to control in the absence of SCH-23390; Table 4, Figures 4A and B). This result 
suggests that GIRK channel activation seemed to participate in both the opioid- and PGE2-
induced inhibition of cellular calcium activity and respiratory neurons in preBötC organotypic 
cultures. 
 
Regarding the network connectivity, slice incubation with SCH-23390 (15 µM) did not change 
the baseline values of mean correlation above cut-off (without SCH-23390: 0.74 ± 0.06 vs. 0.80 
± 0.09 with SCH-23390; n = 8, P > 0.05 compared to baseline values before DAMGO 5 µM 
administration in controls). However, SCH-23390 hampered DAMGO (5 µM)-induced 
reduction in the mean correlation above cut-off (from 0.80 ± 0.09 to 0.70 ± 0.09; n = 8, P < 
0.05 compared to control in the absence of SCH-23390; Figure 4C) and the number of 
correlations per active cell (from 23 ± 15 to 16 ± 15; n = 8, P < 0.05 compared to control in the 
absence of SCH-23390). Therefore, GIRK channel activation seemed to contribute to the 
asynchronous network activity caused by DAMGO in the preBötC. Further, incubation with 
SCH-23390 (15 µM) did not change the σ, γ or λ parameters compared to control (n = 8, P < 
0.05 compared to control in the absence of SCH-23390). However, SCH-23390 blocked the 
DAMGO (5 µM)-induced modification of small-world features, as it prevented the increase in 
σ and γ parameters caused by DAMGO (n = 8, P < 0.05 compared to control in the absence of 
SCH-23390; Figure 4D). Therefore, in view of these data, GIRK channel activation was 
involved in the reduction of cellular calcium activity produced by DAMGO, and also in the 
modification of the network synchronicity and small-world topology of preBötC cells in vitro.   
 
On the other hand, after slice incubation with SCH-23390 (15 µM), PGE2 (100 nM) did not 
significantly reduce the mean correlation above cut-off (from 0.79 ± 0.08 to 0.75 ± 0.09; n = 9, 
P > 0.05 compared to baseline; Figure 4C) but this effect was not different from that observed 
under control conditions (n = 9, P > 0.05 compared to control in the absence of SCH-23390). 
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Furthermore, GIRK channel blockade with SCH-23390 did not prevent the reduction in the 
number of correlations per active cell caused by PGE2 (100 nM) (from 30 ± 23 to 4 ± 2; n = 9, 
P < 0.05 compared to baseline and P > 0.05 vs. control in the absence of SCH-23390). Thus, 
GIRK channel activation was not apparently involved in the PGE2-induced reduction of the 
network synchronicity. Further, PGE2 (100 nM) administration after slice incubation with 
SCH-23390 did not increase the σ and γ parameters (Figure 4D), and this effect was not 
different from control in the absence of SCH-23390 (n = 9; P > 0.05 compared to control). 
Thus, blocking the GIRK channel activation did not seem to prevent the asynchronous network 
activity and small-world topology caused by PGE2 in preBötC organotypic cultures. Overall, 
these data indicate that GIRK channel activation seems to mediate the opioid- and PGE2-
induced inspiratory frequency inhibition, but it does not apparently intervene in the network 
rewiring induced by the latter. 
 
Discussion 
The purpose of this study was to assess whether the opioid-induced respiratory depression was 
intensified under inflammatory conditions (i.e., those caused by PGE2) by time-lapse calcium 
imaging in brainstem organotypic cultures. In the preBötC cellular network, we found that both 
MOR agonist DAMGO and EP3 receptor agonist PGE2 reduced Ca2+ oscillatory activity. The 
effect of DAMGO was blocked by naloxone, whereas deletion of the EP3 receptor abolished 
the PGE2-induced effect and delayed that of DAMGO. The reduction in Ca2+ oscillatory 
activity caused by DAMGO was occluded by prior administration of PGE2, which suggested a 
common signaling pathway. Indeed, both DAMGO and PGE2-induced modification in Ca2+ 
activity was prevented by blocking cAMP degradation and GIRK channel activation. 
Furthermore, both DAMGO and PGE2 reduced the number of connections among cells and the 
synchronicity. 
 
Recently, we have developed brainstem organotypic slice cultures containing the preBötC that 
allow the study of the respiratory brainstem activity in vitro (Forsberg et al., 2016). These 
cultured slice preparations maintain the respiratory-related rhythm (Forsberg et al., 2016; 
Phillips et al., 2016) identical to acute slices (Phillips et al., 2016) while preserving the 
cytoarchitecture (Forsberg et al., 2016). These features along with the tissue flattening over 
time (Forsberg et al., 2016; Phillips et al., 2016) create an optimal model for the activity 
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evaluation of a broad population of cells by calcium imaging techniques and their synchronicity 
by means of cross-correlation analysis (Smedler et al., 2014). Furthermore, preBötC respiratory 
neurons in vitro preserve rhythmic Ca2+ transients in phase with the inspiratory motor output 
measured on the hypoglossal XII nerve (Koizumi et al., 2013), and therefore, the observed 
calcium oscillatory activity in our study is representative of the respiratory rhythm. The 
PreBötC was identified in our slices with the fluorescent ligand TMR-SP, which labels the 
NK1R-positive cells and thereby, the respiratory neurons (Gray et al., 1999). In our study, we 
measured the effect of DAMGO as MOR agonist since it has high affinity and selectivity for 
the MOR (Raynor et al., 1993). The effect of DAMGO was antagonized by using naloxone, 
which shows high affinity for all opioid receptors, but especially for the MOR (Raynor et al., 
1993). The endogenous inflammatory response was mimicked by using PGE2, a non-selective 
EP receptor agonist that shows high affinity for the EP3 receptor (Abramovitz et al., 2000). 
Finally, the fluorescent dye employed here was non-ratiometric, so the described amplitude 
data is relative to its baseline, and no intracellular Ca2+ concentration could be inferred.  
 
In the current study, DAMGO and PGE2 reduced Ca2+ transient frequency in what seemed a 
concentration-dependent fashion, as we tested two different concentrations of each and the 
highest concentration produced a greater inhibition in the frequency than the lowest. 
Furthermore, the DAMGO (5 µM)-induced reduction in Ca2+ transient frequency of the whole 
population (22%) was similar to that observed with PGE2 (100 nM) (19%), and further, similar 
to the breathing frequency reduction (18%) in vivo caused by microinjection of DAMGO into 
the preBötC described elsewhere (Qi et al., 2017). An improvement in the data analysis allowed 
us to know how single cells behaved over time and how many of them varied their frequency 
compared to their baseline. By using this script, 75% of the cells showed a marked frequency 
reduction of 34% upon DAMGO, and similarly, 72% of the cells displayed a frequency 
reduction with PGE2 of 32%. Moreover, NK1R+ data revealed that the reduction in Ca2+ 
transient frequency in respiratory neurons upon DAMGO and PGE2 is representative of the 
whole population, which may suggest that the respiratory neurons define the activity of the 
entire network. This result agrees with previous reports in similar brainstem slice culture 
preparations, which observed Ca2+ oscillatory activity only from neurons and not from glial 
cells (Phillips et al., 2016). Furthermore, previous data from our laboratory demonstrated that 
NK1R+ cells respond to PGE2 in the preBötC (Forsberg et al., 2016) and co-express EP3 
receptor in medullary sections at the preBötC level (Hofstetter et al., 2007). In line, other 
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studies showed a co-expression of MOR and NK1R in the preBötC (Gray et al., 1999; Qi et 
al., 2017) and accordingly, preBötC respiratory neurons have been considered fundamental for 
the opioid-induced respiratory depression (Montandon et al., 2011).  
 
In our study, the DAMGO-induced reduction in Ca2+ transient frequency was prevented by the 
application of the MOR antagonist naloxone and delayed by deleting the EP3 receptor. Thus, 
in Ptger3-/- mice, DAMGO (5 µM) needed 15 min instead of 5 min to cause the same magnitude 
of effect as in WT mice, suggesting a hindered effect of DAMGO in Ptger3-/- mice. 
Interestingly, this late effect was similar to that observed with the lowest concentration of 
DAMGO (0.5 µM) in WT mice. Furthermore, the PGE2-induced frequency decrease was 
absent in mice lacking the EP3 receptor, in agreement with previous results from our laboratory 
(Forsberg et al., 2016). These results highlight the functional relevance of the EP3 receptor in 
the preBötC. Similarly, activation of the EP3 receptor has been shown to have inhibitory 
actions in other brain regions, for example, it inhibits the network frequency in the neocortex 
(Koch et al., 2010) and the neuronal activity of the central chemosensitive LC cells (Nazabal 
et al., unpublished results). In contrast with our study, PGE2 has shown to increase the fictive 
sigh frequency in preBötC acute slices, and even increase the eupnoeic frequency at higher 
concentrations than those employed in our study (Koch et al., 2015). These differences could 
be due to a loss of selectivity at higher concentrations of PGE2, given that it has a high affinity 
for many other prostanoid receptors, and the receptor mediating this effect was not determined 
in that study.  
 
In the present work, the onset of the PGE2-induced inhibitory effect occluded any further 
reduction in Ca2+ oscillatory activity caused by DAMGO. Furthermore, this result is congruent 
with the attenuation of the morphine-induced respiratory depression observed in a neuropathic 
pain model (Kamei et al., 2011), where the involvement of PGE2 is widely known (Ma & 
Quirion, 2008). This occlusion could be caused by the reach of a maximum reduction in Ca2+ 
transient frequency, considering the ongoing Ca2+ dynamics that are partly regulated by 
intracellular stores, and thus a basal Ca2+ fluctuation. However, a common signaling pathway 
was elsewhere mentioned (Ballanyi et al., 1997), so we tested whether it would be plausible. 
The nature of the proposed common mechanism would be the result of a signaling pathway 
convergence in either the cAMP or the GIRK channels, based on previous data (Ballanyi et al., 
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1997; Montandon et al., 2016b). In our study, administration of the blocker of cAMP 
degradation rolipram prevented the DAMGO- and PGE2-induced reduction in Ca2+ oscillatory 
activity. This result is in consonance with previous studies showing that rolipram restores the 
inspiratory-related rhythm after DAMGO-induced inhibition in acute slices (Ruangkittisakul 
& Ballanyi, 2010) and that high cAMP levels reverse the DAMGO- and PGE1-induced 
respiratory depression in brainstem-spinal cord preparations (Ballanyi et al., 1997). On the 
other hand, incubation with the GIRK channel blocker SCH-23390 prevented the reduction in 
Ca2+ transient frequency caused by both DAMGO and PGE2 in our study. These data agree 
with previous reports in vivo, describing that the respiratory rate decrease produced by 
microperfusion of DAMGO into the preBötC is blocked by a GIRK channel inhibitor 
(Montandon et al., 2016b). Furthermore, immunohistochemical techniques have demonstrated 
that NK1R+ cells in the preBötC co-express GIRK channels (Montandon et al., 2016a), which 
suggests that these channels are present in respiratory neurons, and thus, that may intervene in 
the opioid- and PGE2-induced respiratory depression. Overall, the inhibitory actions of PGE2 
and DAMGO on the cellular Ca2+ transient frequency seems to be mutually dependent on 
cAMP levels and GIRK channels. 
 
The respiratory rhythmogenesis is thought to be driven by preBötC cellular activity 
coordination into a group pacemaker mediated by glutamatergic transmission and electrical 
coupling (Koshiya & Smith, 1999; Rekling et al., 2000). Thus, the study of the network 
synchronization may be key for understanding the mechanism of opioid- and prostaglandin-
induced respiratory depression. Herein, both DAMGO and PGE2 reduced the mean correlation 
above cut-off and the number of correlations per active cell, suggesting a reduction in the 
network circuitry and synchronization. In line with our results, elimination of correlated 
population activity and desynchronization of Ca2+ activity have been observed in the preBötC 
in vitro after blockade of gap junctions (Forsberg et al., 2016) and glutamatergic synaptic 
transmission (Koshiya & Smith, 1999). It is therefore tempting to speculate that the DAMGO- 
and PGE2-induced respiratory depression may be caused by the lack of integrated group 
pacemaker activity. Intriguingly, in our results, DAMGO restored the baseline values of mean 
correlation and number of correlations per active cell after the reduction caused by PGE2. This 
means that the effect of DAMGO in the presence of PGE2 was the opposite than in the absence, 
suggesting that DAMGO administration might affect a broader number of cells that reconfigure 
the circuit, possibly through an additional mechanism. Furthermore, synchronized bursting 
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activity depends on the network topology(Gaiteri & Rubin, 2011) and the preBötC is organized 
into a small-world architecture (Hartelt et al., 2008; Forsberg et al., 2016), where the neuronal 
connections are favored within clusters, in comparison with across clusters (Hartelt et al., 
2008). In fact, in our work, both DAMGO and PGE2 increased the clustering coefficient and 
small-world parameter, suggesting segregation into local clusters and a shift towards a more 
regular topology, which is less synchronizable than the small-world composition (Watts & 
Strogatz, 1998). Similar alterations of small-world structures have been observed in patients 
with Alzheimer’s disease and neuromyelitis optica (He et al., 2008; Liu et al., 2012), where 
the global activity integration may be compromised, leading to a weaker population bursting 
in a computational model (Gaiteri & Rubin, 2011). Overall, the opioid-induced asynchronous 
network seems to be mediated by MOR activation with the involvement of the cAMP pathway 
and GIRK channels; while the PGE2-induced asynchrony seemed to be partly mediated by the 
EP3 receptor and the cAMP pathway. These results may suggest a different mechanism for 
PGE2-induced disruption of network organization, possibly mediated by persistent sodium 
current and gap junctions as previously suggested for other effects caused by PGE2 in the 
preBötC (Koch et al., 2015; Forsberg et al., 2016).   
 
In conclusion, PGE2 modulates preBötC activity in vitro and it seems to interact with the 
opioid-induced inhibitory effect, so a common signaling pathway was proposed, with the 
apparent involvement of the cAMP pathway and GIRK channels. Furthermore, both opioids 
and prostaglandins seem to disrupt the structural integrity of the network, leading to less wiring 
and synchronicity. Thus, the current study supports that preBötC inspiratory neurons mediate 
the opioid- and PGE2-induced respiratory depression by reducing their activity and 
synchronization. However, it remains unknown the possible implication of other areas of the 
breathing brainstem (Lalley et al., 2014; Levitt et al., 2015), such as the recently discovered 
postinspiratory complex (PiCo) (Anderson et al., 2016), that may shape the in vivo opioid 
response into a quantal slowing of the respiratory rhythm (Mellen et al., 2003). The endogenous 
release of PGE2 during the course of inflammation and the concurrent treatment with opioids 
may condition the ventilatory behavior, which may be of relevance in post-operative states. 
Moreover, the pediatric population should receive special consideration in view of the 
endogenous release of PGE2 at birth (Mitchell et al., 1978) and the implication of PGE2 in 
neonatal breathing disorders (Siljehav et al., 2014, 2015), which may ultimately lead to apneas 
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Table 1. Inhibitory effect of DAMGO (5 µM) within 5 min on the Ca2+ transient frequency 
and amplitude of preBötC cells (network) and respiratory neurons (NK1R+) in vitro in the 
absence and presence of naloxone (5 µM). N: number of slices, n: number of cells. Data are 
presented as mean ± SD. *P < 0.05 when compared to their respective baseline values. Note 
that the effect on the respiratory networks resembled the effect of the whole network.  
 
 Relative amplitude (ΔF/F0) Mean frequency 
(mHz) 
 Cells Sample size Baseline +DAMGO (5 μM) Baseline +DAMGO (5 
μM) 
Control network N=7, n=977 31.1 ± 3.0 25.6 ± 1.2* 55.6 ± 3.6 43.3 ± 2.9* 
 NK1R+ N=7, n= 110 32.6 ± 6.4 25.4 ± 1.9* 54.8 ± 3.9 43.1 ± 2.5* 
Naloxone network N=8, n=1300 31.1 ± 3.9 30.7 ± 5.2 56.0 ± 7.3 54.7 ± 5.9 
(5 µM) NK1R+ N=6, n=95 30.3 ± 4.4 29.3 ± 6.8 55.4 ± 7.5 50.3 ± 9.3 
 
 
Table 2. Inhibitory effect of PGE2 (100 nM) within 5 min on the Ca2+ transient frequency of 
preBötC cells (network) and respiratory neurons (NK1R+) in vitro and effect of subsequent 
DAMGO (5 µM) administration in the presence of PGE2 (100 nM). N: number of slices, n: 
number of cells. Data are presented as mean ± SD. * P < 0.05 when compared to their respective 
baseline values. Note that the effect on the respiratory networks resembled the effect of the 
whole network and that the inhibitory effect of PGE2 was absent in slices from Ptger3-/- mice. 
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + PGE2 (100 nM) + 
DAMGO (5 μM) 
WT network N=10, n=1460 59.9 ± 5.2 48.2 ± 6.1* 50.9 ± 7.4*  
 NK1R+ N=8, n= 43 59.2 ± 7.4 51.6 ± 8.6* 52.6 ± 5.7  
Ptger3-/- network N=10, n=1938 55.1 ± 5.3 50.9 ± 9.5 47.8 ± 5.1*  
 NK1R+ N=9, n=288 53.8 ± 6.8 53.5 ± 15.1 46.6 ± 5.6*  
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Table 3. Inhibitory effect of rolipram (5 µM) within 10 min on the Ca2+ transient frequency of 
preBötC cells (network) and respiratory neurons (NK1R+) in vitro and effect of subsequent 
DAMGO (5 µM) or PGE2 (100 nM) administration in the presence of rolipram (5 µM). N: 
number of slices, n: number of cells. Data are presented as mean ± SD. * P < 0.05 when 
compared to their respective baseline values. N.S.: not significant when the group of DAMGO 
or PGE2 was compared to the previous 5 min period in the presence of rolipram. Note that once 
rolipram had decreased the Ca2+ transient frequency, neither DAMGO nor PGE2 induced any 
further modification. 
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + rolipram (5 µM) + 
DAMGO or PGE2 
DAMGO  network N=8, n=1943 57.3 ± 4.6 52.8 ± 3.1* 50.9 ± 2.7* N.S. 
(5 µM) NK1R+ N=5, n= 78 52.2 ± 3.7 46.3 ± 4.6 49.2 ± 5.4 N.S. 
PGE2 network N=8, n=1796 57.3 ± 3.1 53.3 ± 3.4* 52.0 ± 5.2* N.S. 
(100 nM) NK1R+ N=7, n=98 61.6 ± 3.6 53.7 ± 6.8* 50.0 ± 7.0* N.S. 
 
 
Table 4. Effect of SCH-23390 (15 µM) incubation on the Ca2+ transient frequency of preBötC 
cells (network) and respiratory neurons (NK1R+) in vitro and effect of subsequent DAMGO (5 
µM) or PGE2 (100 nM) administration in the presence of SCH-23390 (15 µM). N: number of 
slices, n: number of cells. Data are presented as mean ± SD. N.S.: not significant when the 
group of DAMGO or PGE2 was compared to their respective baseline.  
 
 Mean frequency (mHz) 
 Cells Sample size Baseline + DAMGO or PGE2 
DAMGO network N=8, n=755 57.3 ± 5.5 55.2 ± 7.6 N.S. 
(5 µM) NK1R+ N=5, n=72 54.6 ± 7.4 55.9 ± 4.6 N.S. 
PGE2 network N=9, n=1000 59.0 ± 6.8 53.8 ± 5.2 N.S. 






Figure 1. DAMGO modulates preBötC network activity and connectivity. (A) Localization of 
the preBötC in a sagittal drawing of the brainstem and in the coronal slice, which also contains 
the nucleus ambiguus (NA), the nucleus tractus solitarius (NTS), and the nucleus hypoglossus 
(XII) (Adapted from Forsberg et al., 2016). Effect of DAMGO (5 µM) administration on 
representative Ca2+ traces as ΔF/F0 from regular cells (black; #1 and 2) and NK1R+ cells 
(respiratory neurons; #3 and 4 in blue) and their localization in a single frame of the Ca2+ 
signaling recording from a WT mouse (top right). (B) Inhibitory effect of DAMGO (0.5 – 5 
µM) on Ca2+ transient relative amplitude and frequency (C) as a percentage of the baseline 
value in WT (circles) and Ptger3-/- (diamonds). (D) Cells that showed a decrease in Ca2+ 
transient frequency within 5 min of DAMGO (5 µM) administration as a percentage (gray filled 
circles) and their subsequent behavior over time, in comparison with the non-sensitive cells. 
Note that sensitive cells displayed a higher baseline frequency. (E) Graphical depiction of the 
network structure on top of NK1R-labelled cells. Each line represents the correlation 
coefficient above the set cut-off for the cell pairs, and warmer colors are a stronger correlation 
between the cells connected by the line. Administration of DAMGO (5 µM) decreased the 
number of correlated cells and the correlation coefficient. (F) Network parameter values 
revealing a small-world topology during baseline and upon DAMGO (0.5 – 5 µM) 
administration in WT and Ptger3-/- mice. Note that the highest concentration of DAMGO 
caused more effect than the lowest. Data are presented as means ± SD. * P < 0.05 compared to 
baseline (paired Student’s t-test) and # P < 0.05 when compared among groups (paired 
Student’s t-test in D and ANOVA followed by a Dunnett’s post hoc test in the rest). A.U.: 
arbitrary units. Scale bars: 100 µm. 
 
Figure 2. PGE2 (10 – 100 nM) reduces preBötC network activity and connectivity in WT but 
not in Ptger3-/- mice and occludes the subsequent inhibitory effect induced by DAMGO (0.5 – 
5 µM). (A) Representative Ca2+ traces as ΔF/F0 from regular cells (top black) and NK1R+ cells 
(respiratory neurons, bottom blue) in WT (left) and Ptger3-/- mice (right). (B) Effect of PGE2 
(10 and 100 nM) and DAMGO (0.5 and 5 µM) administration on Ca2+ transient amplitude (left) 
and frequency (center) as a percentage of the baseline value in WT. Note that DAMGO in the 
presence of PGE2 did not produce a further inhibitory effect on the Ca2+ transient frequency. 
At the right: cells that showed a decrease in Ca2+ transient frequency within 5 min of PGE2 
(100 nM) administration as a percentage (gray filled circles) and their subsequent behavior over 
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time, in comparison with the non-sensitive cells. Note that PGE2-sensitive cells displayed a 
higher baseline frequency and that DAMGO administration did not change the Ca2+ transient 
frequency in those cells, but decreased that of the PGE2 non-sensitive cells. (C) Graphical 
depiction of the network structure on top of NK1R-labelled cells. Each line represents the 
correlation coefficient above the set cut-off for the cell pairs, and warmer colors are a stronger 
correlation between the cells connected by the line. Administration of PGE2 (100 nM) 
decreased the number of correlated cells and the correlation coefficient in WT mice, and this 
effect was reversed by DAMGO (5 µM). (F) Network parameter values revealing a small-
world topology during baseline and upon PGE2 (10 – 100 M) administration in WT. Note that 
the highest concentration of PGE2 produced a greater effect. Subsequent administration of 
DAMGO (5 µM) in the presence of PGE2 (100 nM) did not change the network parameters 
any further. Data are presented as means ± SD. * P < 0.05 compared to baseline (paired 
Student’s t-test) and # P < 0.05 when compared among groups (paired Student’s t-test in A and 
unpaired in D). A.U.: arbitrary units. Scale bars: 100 µm. 
 
Figure 3. Administration of rolipram (5 µM) prevented both DAMGO (5 µM)- and PGE2 (100 
nM)-induced reduction in preBötC network activity and connectivity. (A) Effect of rolipram 
(5 µM) and subsequent administration of DAMGO (5 µM) or PGE2 (100 nM) on Ca2+ transient 
relative amplitude (top) and frequency (bottom). Note that neither DAMGO nor PGE2 modified 
the Ca2+ transient relative amplitude or frequency after administration of rolipram. (B) 
Representative Ca2+ traces showing the effect of rolipram and subsequent DAMGO or PGE2 
administration as ΔF/F0 from regular cells (top black) and NK1R+ cells (respiratory neurons, 
bottom blue). (C) Effect of DAMGO (5 µM) or PGE2 (100 nM) in the presence of rolipram (5 
µM) on Ca2+ transient frequency compared to their respective control in the absence of 
rolipram. The effects were normalized to their baseline in control or baseline in the presence 
of rolipram). (D) Graphical depiction of the network structure. Each line represents the 
correlation coefficient above the set cut-off for the cell pairs, and warmer colors are a stronger 
correlation between the cells connected by the line. Administration of rolipram (5 µM) 
decreased the correlation coefficient in WT mice and subsequent application of DAMGO (5 
µM) (top) or PGE2 (100 nM) (bottom) did not decrease the mean correlation any further. (E) 
Rolipram (5 µM) prevented the increase in network parameter values induced by DAMGO (5 
µM), but not that of PGE2 (100 nM). The experimental values were normalized to their 
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respective baseline. Data are presented as means ± SD. * P < 0.05 compared to baseline (paired 
Student’s t-test) and # P < 0.05 when compared among groups (unpaired Student’s t-test).  
 
Figure 4. Administration of SCH-23390 (15 µM) prevented both DAMGO (5 µM)- and PGE2 
(100 nM)-induced reduction in preBötC network activity. (A) Representative Ca2+ traces 
showing the effect of SCH-23390 and subsequent DAMGO or PGE2 administration as ΔF/F0 
from regular cells (top black) and NK1R+ cells (respiratory neurons, bottom blue). Note that 
neither DAMGO nor PGE2 modified the Ca2+ transient relative amplitude or frequency after 
administration of rolipram. (B) Effect of DAMGO (5 µM) or PGE2 (100 nM) after incubation 
SCH-23390 (15 µM) on Ca2+ transient frequency compared to their respective control in the 
absence of SCH-23390. The effects were normalized to their respective baseline. (C) Graphical 
depiction of the network structure. Each line represents the correlation coefficient above the 
set cut-off for the cell pairs, and warmer colors are a stronger correlation between the cells 
connected by the line. Incubation with SCH-23390 (15 µM) prevented the decrease in the 
number of correlated cells and the correlation coefficient induced by DAMGO (5 µM), but not 
that induced by PGE2 (100 nM). (D) SCH-23390 (15 µM) prevented the increase in network 
parameter values induced by DAMGO (5 µM), but not that of PGE2 (100 nM). The 
experimental values were normalized to their respective baseline. Data are presented as means 
± SD. * P < 0.05 compared to baseline (paired Student’s t-test) and # P < 0.05 when compared 
among groups (unpaired Student’s t-test). 
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